


PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION 2007 ANNUAL MEETING



ADDRESSING PATIENT NEEDS
ACCESS, PARITY AND HUMANE CARE

160TH ANNUAL MEETING
SAN DIEGO, CALIFORNIA, MAY 19-24, 2007
AMERICAN PSYCHIATRIC
ASSOCIATION

SAN DIEGO, CA ♦ MAY 19-24, 2007

2007 SCIENTIFIC PROGRAM COMMITTEE



Seated (left to right): Drs. Worley, Baron (*Vice Chairperson*), Ruiz (*APA President*), Guynn (*Chairperson*), Foulks, Spitz, **2nd Row Standing (left to right):** Drs. McCarthy, Merikangas, Matorin, Silk, LeMelle, Scully, Boland, Pandya, Hilty, Licinio, Cheong, Alarcon, Kopelowicz, Mancuso, Rothschild, Pi, Marx, **Not Pictured:** Drs. Connor, Heath, Stabinsky, Taylor, Vogel-Scibilia, Zucker-Goldstein.

May 19, 2007

Dear Colleagues and Guests:

Welcome to the 160th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional human values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year's Annual Meeting theme is "Addressing Patient Needs: Access, Parity, and Humane Care." Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., Monday through Wednesday. An entire track of sessions, presented in collaboration with the National Institute on Drug Abuse has been scheduled throughout the meeting.

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in San Diego. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world, and I will present my Presidential Address. I look forward to seeing you there. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented during the Convocation by John F. Nash, Jr., known in popular culture as the subject of the Hollywood movie, *A Beautiful Mind*, about his mathematical genius and his struggles with schizophrenia.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Robert Guynn and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting. Welcome to this terrific meeting.

Sincerely,

Pedro Ruiz, M.D.
APA President



American Psychiatric Association

1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
Telephone: 703.907.7822
Fax: 703.907.1090
E-mail: apa@psych.org

**160th Annual Meeting
San Diego, CA
May 19-24, 2007**

May 19, 2007

President

Pedro Ruiz, M.D.

**Scientific Program Committee
2006-2007**

Robert W. Guynn, M.D.
Chairperson

David Baron, D.O.
Vice-Chairperson

Renato D. Alarcon, M.D.
David A. Baron, D.O.
Joseph A. Cheong, M.D.
Kathryn M. Connor, M.D.
Edward F. Foulks, M.D.
Donald M. Hilty, M.D.
Stephanie LeMelle, M.D.
Julio Licinio, M.D.
Christine E. Marx, M.D.
Anu Matorin, M.D.
Edmond Hsin T. Pi, M.D.
Anthony J. Rothschild, M.D.
Kenneth R. Silk, M.D.
Deborah Spitz, M.D.
Harvey Stabinsky, M.D.
Suzanne F. Vogel-Scibilia, M.D.
Linda L.M. Worley, M.D.

Consultants

Robert J. Boland, M.D.
Marion Zucker Goldstein, M.D.
Alex J. Kopelowicz, M.D.
Donna M. Mancuso, M.D.
Mary K. McCarthy, M.D.
James R. Merikangas, M.D.
Anand Pandya, M.D.
Jasmine P. Taylor, M.D.

**Committee on Commercial
Support**

Spencer Eth, M.D.
Chairperson
Linda Bueno, *Associate Director*
Commercially-Supported
Activities
(703) 907-7841

Office of Scientific Programs

Gary McMillan, *Acting Director*
(703) 907-7808
Karen D. Bolton
Scientific Program Coordinator
(703) 907-7807
Yashica Joyner, *Course Assistant*
(703) 907-7378
Byron D. Phillips
Scientific Program Coordinator
(703) 907-7379
Desta L. Wallace
Scientific Program Coordinator
(703) 907-7805
Elizabeth Rumsey
Administrator, CME Courses
(703) 907-7813

Dear APA Members and Guests:

Welcome to San Diego, and the 160th Annual Meeting of the American Psychiatric Association. I anticipate that this terrific city, and its fantastic weather, will provide a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "Addressing Patient Needs: Access, Parity, and Humane Care," chosen by our President, Dr. Pedro Ruiz. Let me draw your attention to just a few of the many exciting sessions presented this week, including several Presidential Symposia which will be presented Monday-Wednesday, from 2:00 p.m.-5:00 p.m.

The Business Meeting and the Opening Session will be held at the San Diego Convention Center on Sunday, May 20. The Convocation of Distinguished Fellows also will be held there, on Monday evening, May 21, 5:30-6:30 p.m. During the Convocation, Nobel laureate John Nash Jr., Ph.D., will present the William C. Menninger Memorial Lecture.

A great way to begin this year's meeting is to attend the "Advances in Series," which will focus on the latest advances in neuropsychiatry and clinical neurosciences, C-L psychiatry and psychosomatic medicine, geriatric psychiatry, and psychiatric disorders. We have also combined the Master Educator Consultations, Discussion Groups, and Research Consultations into Small Interactive Sessions, consisting of 14 clinically-based seminars with outstanding clinician educators. These sessions are held Monday-Wednesday.

This year, we have a special series of sessions which will be presented in collaboration with the National Institute on Drug Abuse. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and workshops. The APA is extremely appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Once again, welcome to San Diego. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Robert W. Guynn, M.D.

APA 160th ANNUAL MEETING

San Diego, CA, May 19-24, 2007

KEY LOCATIONS

SAN DIEGO CONVENTION CENTER

<i>American Journal of Psychiatry</i> and <i>Psychiatric Services</i>	APPI Bookstore, Hall B, Ground Level
APA Communications center	Room 14 A/B, Mezzanine Level
APA Meetings and Conventions Department	Room 16 A, Mezzanine Level
APA Member Center	Hall B, Ground Level
APA Scientific Programs Office	Room 21, Upper Level
A/V Preview Room	Room 15 B, Mezzanine Level
CME Course Enrollment	Hall A, Ground Level
Computerized Evaluation	Lobby d, Ground Level
<i>Daily Bulletin</i>	Room 14 A/B, Mezzanine Level
Exhibit Office/Show Office	Lobby B, Ground Level
Exhibits/Publishers' Bookfair	Halls B-D, Ground Level
Housing Desk	Lobby A/B, Ground Level
Lost & Found	Room 16 A, Mezzanine Level
Message Center	Lobby, Ground Level
On-Site Job Bank and Placement Center	APA Member Center, Hall B, Ground Level
Registration	Hall A, Ground Level

FIRST AID

Located in Lobby C, Ground Level, San Diego Convention Center. Hours of operation: Tuesday, May 15, through Thursday, May 24, and opens 30 minutes prior to show opening and closes 30 minutes after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 19, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Thursday, May 24, at 6:00 p.m. The San Diego Convention Center will serve as the "hub" for all shuttle bus routes. The Shuttle Bus Desk will be located in Lobby A/B, Ground Level, San Diego Convention Center. A detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city map on page XVII-XI for the location of hotels in relation to the Convention Center.

EXHIBITS

Commercial and educational exhibits will be located in Exhibit Halls B-D, Ground Level, San Diego Convention Center, along with the Publishers' Bookfair and the APA Member Center. For your convenience, the Publishers' Bookfair and APA Member Center will be open Saturday, May 19, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 20, 10:00 a.m.-4:30 p.m.; Monday, May 21, 10:00 a.m.-5:30 p.m.; Tuesday, May 22, 10:00 a.m.-6:00 p.m.; and the final day, Wednesday, May 23, 10:00 a.m.-3:00 p.m.

MESSAGE CENTER

Located in the Lobby A/B, Ground Level, San Diego Convention Center and open during registration hours (with the exception of Thursday, May 24, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Ancillary message centers will also be located in Lobby C, Ground Level and Lobby Room 20 A, Upper Level in the San Diego Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA MEMBER CENTER

Located in Exhibit Hall B, Ground Level, San Diego Convention Center. Hours of operation will be: Saturday, May 19, 10:00 a.m.-5:00 p.m.; Sunday, May 20, 10:00 a.m.-4:30 p.m.; Monday, May 21, 10:00 a.m.-5:30 p.m.; Tuesday, May 22, 10:00 a.m.-6:00 p.m.; and Wednesday, May 23, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, practice management, and APA periodicals.

APA JOB BANK

Visit the APA on-site Job Bank at APA 2007! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE & PRESS ROOM

Located in Room 14 A/B, Mezzanine Level, San Diego Convention Center. Hours of operation: Saturday, May 19, 11:00 a.m.-5:00 p.m.; Sunday-Wednesday, May 20-23, 8:00 a.m.-6:00 p.m.; and Thursday, May 24, 8:00 a.m.-2:00 p.m. **This room is for the use of registered press only and credentialed public relations representatives only.**

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 14 A/B, Mezzanine Level, by 12 noon prior to the date of publication.

RESIDENTS' RESOURCE CENTER

Located in the Columbia Rooms, North Tower, Lobby Level, of the Marriott San Diego Hotel & Marina. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 20, through Wednesday, May 23. Daily activities are scheduled for residents (such as the orientation, Residents Only Discussion Groups, and Resident Summits) and medical students. Meet and network with your colleagues and leaders in psychiatry. Resources specifically for residents and medical students are available here.

AIRPORT AND LUGGAGE CHECK IN

You can now check-in at the San Diego Convention Center and bypass the airport lines! This unique service allows you to check your bags and receive your boarding pass at the Convention Center, leaving you more time to visit the exhibits and attend sessions. It's safe and secure: The first TSA-approved remote skycap service; All agents are highly trained and credentialed to issue boarding passes and print bag tags on demand; **Participating Airlines (Domestic Flights Only):** Alaska, American, Continental, Delta, JetBlue, Northwest and United. Rates: \$10 per passenger. Normal airline baggage constraints apply. Hours of Operation: Wednesday and Thursday, May 23-24, 8:00 a.m.-1:00 p.m., in the main lobby of the San Diego Convention Center. Flights may be checked in anytime the

day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.

TOURS

Stop by the Tour Desk, Lobby A/B, Ground Level to purchase or pick up tickets to local tours.

REGISTRATION

Admission to all sessions by registration badge

Located in Exhibit Hall A, Ground Level, San Diego Convention Center. Hours of operation: Friday, 12 noon-5:00 p.m., Saturday, 7:30 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS

Full-Time Registration (<i>North American Members</i>).....	\$295
Full-Time Registration (<i>International Members</i>).....	\$295-\$520*
Members-in-Training (<i>Member Class MT</i>)	\$ 85
Daily Registration (<i>North American Members</i>).....	\$150
Daily Registration (<i>International Members</i>).....	\$275
Medical Students	no charge

*Fee determined by country's gross national income according to the World Bank.

NONMEMBERS

Full-Time Registration.....	\$880
Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains	\$120
Daily Registration (<i>all Nonmember categories</i>)	\$470
Medical Students	no charge

GUEST REGISTRATION

One only per full-time registrant.....\$120

Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member. ID may be required.*

One-Day Exhibit Hall Only Pass (18 and older).....20.00
(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived **only** for *CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present, except for industry-supported symposium presenters who must pay the fee).*

Nonmember psychiatric residents and other full-time students must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book, APA Member Center Guide, and New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

REGISTRATION BADGES

Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Prctss, Red-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.

Registered exhibitors will receive red badges, which allow access only to his or her exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

Ticket purchase required for CME Courses

Located in Exhibit Hall A, Ground Level, San Diego Convention Center. Hours of operation are the same as registration. Tickets not sold in advance will be available online at the onsite fee after April 20, and onsite at the Course Enrollment Area beginning at 12 noon on May 18. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION

Located in the Lobby D, Ground Level, San Diego Convention Center and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH

Located in the Lobby A/B, Ground Level San Diego Convention Center. Hours of operation: Saturday, May 19, through Wednesday, May 23, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS

Editorial staff of *The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychosomatics*, and APA's CME journal, *Focus* will be on hand to demonstrate online access for subscribers, answer questions regarding submissions, and show the new state-of-the-art website, www.psychiatryonline.com. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of *Psychiatric News* will be available at stands located throughout the Convention Center. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 *AMA PRA Category 1 Credits*.TM Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for *AMA PRA Category 1 Credit*.TM Sessions in the following program formats are designated as category 1:

Advances in... Series, Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Presidential Symposia, Scientific and Clinical Reports, Small Interactive Sessions, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates and New Research Poster Sessions). Scientific sessions are open to all Annual Meeting registrants, except for the Case Conferences which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available (see section on evaluation).

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in *AMA PRA Category 1 Credit*.TM activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. A CME *Certificate of Compliance* is awarded to APA Members who complete the report. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting.

You can receive a parchment **Certificate of Attendance** by returning your completed form (to the Annual Meetings Office, Information Center, or APA Member Center, all located in San Diego Convention Center). A **personalized Certificate of Attendance** will be available by completing the computerized general evaluation in the Lobby D, Ground Level, San Diego Convention Center. Attendees may also access the web-based evaluation from their own computer during or after the meeting, and the program automatically generates a CME certificate. **PLEASE COMPLETE THE GENERAL EVALUATION ONE TIME ONLY.**

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in Lobby A, Ground Level, San Diego Convention Center.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in **designated areas**.



TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2008 May 3-8	Washington, DC
2009 May 16-21	San Francisco, CA
2010 May 22-27	New Orleans, LA
2011 May 14-19	Honolulu, HI

INSTITUTES ON PSYCHIATRIC SERVICES

2007 October 11-14	New Orleans, LA
2008 October 2-5	Chicago, IL
2009 October 8-11	New York, NY
2010 October 14-17	Boston, MA
2011 October 27-30	San Francisco, CA

Preliminary Programs for the 2007 Institute on Psychiatric Services are available in the New Orleans Booth, Ground Level, San Diego Convention Center.

GUIDE TO THE PROGRAM BOOK

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: You can also create your own personal schedule by using the online itinerary planner. Visit APA's homepage www.psych.org and click on the 2007 Annual Meeting link. Then click on the link under the scientific session information heading and follow the instructions.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Programs Office in Room 21, Upper Level, San Diego Convention Center, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

Floor Plans for San Diego Convention Center, Marriott Hotel & Marina, Manchester Grand Hyatt	VI-XII
City Map	XIII-XIV
Local Information.....	XV-XVI
Special Acknowledgments	XVII-XIX
Format Descriptions.....	XX
Disclosure Information.....	XXI-XLII
Audiotape and CD Sales Information.....	XLIII
Saturday Sessions	1-4
Sunday Sessions.....	5-14
Join the APA Today	15
2007 Institute on Psychiatric Service.....	16
Monday Sessions	17-40
Tuesday Sessions.....	41-59
District Branch Ad.....	60
Wednesday Sessions.....	61-78
Thursday Sessions.....	79-87
Call for 2008 Annual Meeting Papers.....	88
Topic Index	89-100
Participant Index	101-108
American Psychiatric Foundation Special Events	109
American Psychiatric Publishing, Inc.	110-111
APA's Online Library of 2007 Annual Meeting Sessions	112
Industry-Supported Symposia	113-128
APA Member Center.....	Back Cover

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in the San Diego Convention Center.


The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

San Diego Convention Center

111 West Harbor Drive, San Diego, California 92101

619-525-5000


Ground Level




Marriott Hotel & Marina

333 West Harbor Drive, San Diego, California 92101
619-234-1500

Lobby Level





American Psychiatric Association May 19 - 24, 2007


SAN DIEGO CITY MAP

Mission Bay & Beaches (8 miles to SDCC)

- 1 Hilton San Diego Resort
- 2 Hyatt Regency Islandia
- 3 The Dana on Mission Bay


Mission Valley (6 miles to SDCC)

- 4 Comfort Inn & Suites/Hotel Circle South
- 5 Comfort Suites Mission Valley
- 6 DoubleTree Hotel San Diego - Mission Valley
- 7 Hilton San Diego Mission Valley
- 8 Holiday Inn San Diego Zoo Area/Hotel Circle
- 9 Marriott Mission Valley
- 10 Mission Valley Resort
- 11 Red Lion Hanalei Hotel
- 12 Sheraton San Diego Mission Valley
- 13 Town & Country Resort & Convention Center




Marriott Hotel & Marina

Level One




Marriott Hotel & Marina

Level Three



Marriott Hotel & Marina


Level Four



Manchester Grand Hyatt


1 Market Place, San Diego, California, 92101

619-232-1234




San Diego Convention Center

Mezzanine Level



Upper Level





SAN DIEGO CITY MAP

American Psychiatric Association
May 19 – 24, 2007

Hotels

Downtown San Diego

- 1 Best Western Bayside Inn
 - 2 Comfort Inn Downtown San Diego
 - 3 Embassy Suites Hotel San Diego Bay - Downtown
 - 4 Hampton Inn by Hilton San Diego Downtown
 - 5 Hilton San Diego Gaslamp Quarter
 - 6 Holiday Inn Express Downtown (formerly Quality Inn & Suites Downtown Harborview)
 - 7 Holiday Inn on the Bay
 - 8 Holiday Inn San Diego Downtown
 - 9 Horton Grand Hotel
 - 10 Manchester Grand Hyatt San Diego
 - 11 Marriott San Diego Hotel & Marina
 - 12 Omni San Diego Hotel
 - 13 Radisson Hotel Harbor View
 - 14 Residence Inn by Marriott San Diego Downtown
 - 15 Sheraton Suites San Diego
 - 16 U.S. Grant Hotel
 - 17 W Hotel San Diego
 - 18 Westgate Hotel
 - 19 Westin Horton Plaza - Downtown
 - 20 Westin San Diego (formerly Wyndham Emerald Plaza Hotel)
- ### Coronado
- 21 Hotel del Coronado
- ### Harbor Island
- 22 Holiday Inn Bayside
 - 23 Hilton San Diego Airport/Harbor Island
 - 24 Sheraton San Diego Hotel & Marina




San Diego Convention Center
 WWW.VISITSANDIEGO.COM
 111 WEST HARBOR DRIVE, SAN DIEGO, CA 92101
 619.525.5000 • FAX 619.525.5005

LOCAL INFORMATION

Weather

San Diego's "sun-sational" climate makes it the ultimate year-round destination. The average daytime temperature on the Convention Center's outdoor terraces is a pleasant 70 degrees Fahrenheit. The average annual rainfall is less than 10 inches.




What to See and Do

San Diego has nearly perfect weather, 70 miles of beaches and 90

golf courses in the area. Everything about San Diego is easy, which you will see by reading the two pages on local information. There is so much to see and do in San Diego. Just steps away from the Convention Center is the city's hottest dining and entertainment district, the **Gaslamp Quarter**. San Diego is one of the

most family friendly cities in the nation, so plan on spending time with Shamu at **SeaWorld San Diego**


www.seaworld.com or spend a day hanging around Monkey Trails and



Forest Tales at the **San Diego Zoo's** newest exhibit


(www.sandiegozoo.org).

At 1,200 acres, lush and green **Balboa Park** (www.balboapark.org) is one of the nation's largest cultural complexes and home to the largest concentration of museums west of the Mississippi. San Diego



also offers its own unique theater scene and world-class opera.

The region also features a historic aircraft carrier museum aboard the **USS Midway** (www.midway.org)



The San Diego District Branch will also host a tour and reception upon the USS Midway, Wednesday, May 23. More information is available from Paula Marguiles, executive director of the San Diego Psychiatric Society, by phone at (858) 279-4586.

Baseball fan? Looking for a fun way to relax? Across the street from the Convention Center is **PETCO Park**, the new home to Major League Baseball's San Diego Padres.



The Padres will be at home during the meeting (May 22-24, tentative). Enjoy a spring evening while supporting the philanthropic work of the APA Foundation. A portion of each ticket sale will benefit the Foundation. Additional information and discounted tickets can be found at www.padres.com/groups. The login is APA and password is PADRES.

LaJolla and Mission Bay are favorites for groups seeing waterfront gatherings. LaJolla is an older, established neighborhood with many new chefs and restaurants and lovely beaches. It spans across seven miles of coastline and has been dubbed "the Rodeo Drive of San Diego." Mission Bay is another seaside spot, with beaches, restaurants, and nightclubs.

An excellent array of **Tours** will be offered during the Annual Meeting. Please refer to pages 22-26 in this booklet for complete information. Attendees are encouraged to use the hotel's concierge services to assist with the local information and dinner reservations. Also, refer to the San Diego website: www.meetmainsandiego.com/apa/.

Airport

San Diego is serviced by the **San Diego International Airport** and is approximately 10 minutes from downtown San Diego. Almost all major domestic airlines service the airport. For terminal and airlinereference call (619) 231-2100 or visit www.san.org.

Airport Shuttle Services

Cloud 9 Airport Shuttle Service
You may reserve a one-way or round trip ticket to and from the airport through Cloud 9 Shuttle. To make a reservation, go to www.cloud9shuttle.com and click on "make a reservation" and enter **APA2007** in the group code field at the bottom of the page.

Downtown San Diego

Downtown San Diego is incredibly compact and convenient. Some of the



city's best hotels, restaurants, shopping districts and galleries are all within walking distance, as are incredible views of

sparkling San Diego Bay. The Convention Center itself is also very easy to navigate.


Airport Transportation - Arrival

If you need a taxi, there are many companies that provide taxicab at the airport. Fares from the airport to the Convention Center range from \$10-\$12. If you would like to rent a car there are several car rental reservation boards located near the baggage claim areas of Terminals 1 and 2. Use the courtesy phones provided to request shuttle transport to the car rental

company of your choice. All car rental agencies are located off-site and car rental shuttles take you to the rental locations. Shuttle vans and buses operated by private companies

are also available. You can find shuttle service at the Transportation Plazas across from Terminals 1 and 2, and curbside at the Commuter Terminal.

In addition, there are a number of public transportation services available to you at any given time when you need to get to and from the airport.



ETS, APA's shuttle bus provider will provide **express shuttle service** from the San Diego Convention Center to the San Diego Airport for \$9.00 per person. The shuttle will depart every half hour on the hour and the half hour according to the following schedule:
Wednesday, May 23 – 10:30 a.m.-4:00 p.m.
Thursday, May 24 – 10:30 a.m.-4:00 p.m.

Make reservations at 1-888-447-4387, online at www.orders@eventtrans.com or stop by the tour desk onsite at the Convention Center.

LOCAL INFORMATION

Special Discount on Car Rentals

Enterprise Car Rental is offering a special discounted rate to APA attendees. Use the APA discount code 32F3221 and AME for the PIN when making your reservations either online at www.enterprise.com or by calling 1-800-736-8227.

Airport and Luggage Check In

You can now check-in at the San Diego Convention Center and bypass the airport lines!

This unique service allows you to check your bags and receive your boarding pass at the Convention Center, leaving you more time to visit the exhibits and attend sessions. It's safe and secure:

- ❖ The first TSA-approved remote skycap service.
- ❖ All agents are highly trained and credentialed to issue boarding passes and print bag tags on demand.
- ❖ Proprietary sophisticated technology is used to ensure accurate, safe and secure multi-airline baggage check-transport to the airport.

Participating Airlines (Domestic Flights Only):

Alaska, American, Continental, Delta, JetBlue, Northwest and United. Rates: \$10 per passenger. Normal airline baggage constraints apply.

Hours of Operation:

Wednesday and Thursday, May 23-24, 8:00 a.m.– 1:00 p.m., in the main lobby of the San Diego Convention Center. Flights may be checked in anytime the day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.

San Diego Area Transportation Metropolitan Transit System, Public Transportation MTS buses, trolleys, and coasters

provide convenient transportation throughout San Diego County, including travel to and from the airport, all shopping centers, attractions, beaches, hotels, and Mexico. Bus schedules differ, but most hotels and attractions have service every 15 to 20 minutes. The San Diego Trolley runs every 15 minutes throughout most of the day and every 30 minutes in the evening. The North County Coaster runs 43 miles along the coast with station stops in downtown San Diego, Old Town, Solana Beach, Encinitas, Carlsbad, and Oceanside. You can also get a free trolley transfer that will take you to Tijuana. All MTS buses, trolleys, and coasters are equipped with wheelchair lifts. Call 619-233-3004 for schedule and fare information.

Metropolitan Transit System Flyer

Route No. 992 is a bus that travels to and from the San Diego Airport and downtown San Diego. The bus stops between Terminals 1 and 2 and the Commuter Terminal and costs \$2.25. The travel time is approximately 10 minutes.


Trolleys operate along two routes. The Blue Line starts near Qualcomm Stadium and runs through Mission/Fashion Valley, Old Town, and Centre City San Diego to the International Border at San Ysidro. The Orange Line runs from Centre City east to El Cajon or Santee. The East line also serves stations on the Bayside extension, at Seaport Village, the San Diego Convention Center, and Gaslamp Quarter.

Taxis from the San Diego International Airport to downtown are approximately \$8–\$10 one way. Five can ride for the price of one! Taxicab stands are located at the airport, most hotels, attractions, and shopping centers. Your fare will be displayed on the meter and will include a flag drop charge plus a per-mile and/or a per-hour charge. All cabs leaving the airport charge the same rate. Rates for all other cab trips may vary from company to company.



Child Care Services

Childcare services are available through Marion's Childcare. This company works independently to provide in-room hotel child care. Advance registrations are required to ensure availability. Please make reservations at least one week in advance for day time care. For rates, further information or to make reservations, please call 1-888-891-5029 (toll free) or 619-303-4379 (Greater San Diego), between 8:30 a.m. and 6:00 p.m. Pacific Time, Monday through Saturday. Feel free to email: amy@hotelchildcare.com, or visit website: www.hotelchildcare.com.



APA does not endorse or guarantee any of the services listed above.

SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 19, 2007, 7:00 p.m.; and support of the Industry-Supported Symposium, "Multiple and Complex Presentations of Bipolar Disorder," Tuesday, May 23, 7:00 p.m.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 20, 2:30 p.m.

American Association of Chairs of Departments of Psychiatry: support of the APA/AACDP Research Mentorship Award.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture, Monday, May 22, 9:00 a.m.

American Psychiatric Association / Hurricane Disaster Relief Fund: Support of the Disaster Psychiatry Fellowship.

American Psychiatric Foundation: support of the APIRE Practice Research Network.; Caucus/Committee of Hispanic Psychiatrists' Forum and Reception, Tuesday, May 22, 5:30 p.m.; Award for Research in Psychiatry, Tuesday, May 22.

Association of Gay and Lesbian Psychiatrists: partial support of the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

Association of Professional Chaplains: partial support of the Oskar Pfister Award Lecture, Monday, May 21, 11:00 a.m.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, Monday, May 22, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 22, 11:00 a.m.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Rethinking Bipolar Disorder: Implications of Comorbidities", Sunday, May 20, 1:30 p.m.; "Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion", Monday/Tuesday, May 21-22, 7:00 a.m.; "When Endocrinology and Psychiatry Collide: What the Clinician Needs to Know about Antipsychotic-induced Endocrine Disturbances", Monday, May 21, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and reception, Tuesday, May 22, 7:00 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 23, 5:30 p.m.; and the APIRE/AstraZeneca Young Minds in Psychiatry Award; Mind Games resident competition, Tuesday May 22, 5:00 p.m.; the George Tarjan Award Lecture, Wednesday, May 24, 9:00 a.m., Resident's Guide to Surviving Psychiatry Residency

Boehringer Ingelheim Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, "Recognition and Management of Restless Legs Syndrome (RLS) in Psychiatric Practice", Saturday, May 19, 12:30 p.m.

Bristol-Myers Squibb Company: support of the Industry-Supported Symposia, "Long-term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models", Sunday, May 20, 8:00 a.m.; "Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?", Sunday, May 20, 7:00 p.m.; "How do Atypicals and Antipsychotics Work?: From Receptors to Reality", Monday/Tuesday, May 21-22, 7:00 a.m.; "Monoamine Oxidize Inhibitors Today: A 21st Century View on the Treatment of Depression", Tuesday, May 22, 7:00 p.m.; support of the President's Dessert and Reception; and the Solomon Carter Fuller Award Lecture, Monday, May 21, 9:00 a.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; APA Fellowship on Public Psychiatry.

Bristol-Myers Squibb Sweden: support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 21, 2:00 p.m.

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients."

Cephalon, Inc.: support of the Industry-Supported Symposia, "The Alcohol Dependent Patient: Improving Outcomes Through Adherence", Sunday, May 20, 7:00 p.m.; and co-support of the Industry-Supported Symposia, "Insights from STAR*D: Are Our Patients' Needs Being Met?", Saturday, May 19, 6:00 p.m.; "Still Sleepy After All These Cures: Hypersomnia in Psychiatry", Sunday, May 20, 8:00 a.m.

Cyberonics, Inc.: support of the Industry-Supported Symposium, "Caring for Our Most Challenging Patients with Depression: An Interactive Forum on Novel Treatments", Sunday, May 20, 1:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Eisai, Inc.: support of the Industry-Supported Symposium, "Optimizing Outcomes Across the Spectrum of Dementia", Sunday, May 20, 1:30 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Improving Depression Treatments: Bridging the Gap Between Research and Clinical Practice", Monday, May 21, 7:00 p.m.; "Understanding the Complexity of Bipolar Mixed Episodes", Tuesday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.; 11:00 a.m.; support of the Adolf Meyer Award Lecture; the APA/Lilly Psychiatric Research Fellowship; the symposium entitled, "Strengthening of Mental Health Systems in Low and Middle Income Countries," Monday, May 22, 2006, 7:00 p.m.; and the APA/Lilly Resident Research Awards.

SPECIAL ACKNOWLEDGMENTS

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Frank Rundle, M.D.: partial support for the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture, Wednesday, May 23, 11:00 a.m.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "Expert Dialogue on Alzheimer's Disease: Diagnostic and Referral Issues, Treatment of the Cognitive Deficits, Ameliorating the Behavior Complications, and Comprehensive Multidisciplinary Care", Saturday, May 19, 12:30 p.m.; "Dark Horizons: Depression and Cognitive Impairment", Sunday, May 20, 8:00 a.m.; "STAR*D Findings: Implications for Patients, Clinicians, and Other Stakeholders", Sunday, May 20, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the registration portfolios.

Gill Foundation: partial support of the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

GlaxoSmithKline: support of the Industry-Supported Symposia, "The Prevailing Predominant Pole of Bipolar Depression", Saturday, May 19, 6:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception.

Harding Foundation: partial support of the Oskar Pfister Award Lecture, Monday, May 21, 11:00 a.m.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutical and Research Foundation: support of the Industry-Supported Symposium, "Planning for Success in Schizophrenia Management", Sunday, May 20, 2007 1:30 p.m.; "Improving Outcomes in Schizophrenia: Prodrome to Remission", Monday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

McNeil Pediatrics Division of McNeil-PPC, Inc.: support of the Industry-Supported Symposium, "Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management", Sunday, May 20, 8:00 a.m.

Merck & Co., Inc.: support of the Industry-Supported Symposium, "Insomnia: Primary Diagnosis or Secondary Symptom?", Saturday, May 19, 6:00 p.m.; support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 23, 2:00 p.m.; and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Special Annual Meeting Program Track.

National Institute on Alcohol Abuse and Alcoholism (NIAAA): support of annual meeting research track, "Rethinking Alcohol Use Disorders: Science, Diagnosis, Treatment, and Policy".

Neurocrine Biosciences, Inc.: co-support of the Industry-Supported Symposium, "Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy," Sunday, May 21, 7:00 p.m.

Novartis Pharmaceuticals Corporation: support of the daily in-house TV program, "APA TV News."

Otsuka America Pharmaceutical, Inc.: co-support of the Industry Supported Symposium, "Long-term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models", Sunday, May 20, 8:00 a.m.; "Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?", Sunday, May 20, 7:00 p.m.; "How do Atypicals and Antipsychotics Work?: From Receptors to Reality", Monday/Tuesday, May 21-22, 7:00 a.m.; "Monoamine Oxidize Inhibitors Today: A 21st Century View on the Treatment of Depression", Tuesday, May 22, 7:00 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the APF Awards for Advancing Minority Mental Health.

Pfizer, Inc.: support of the Industry-Supported Symposia, "Clinical Skills to Clinical Scales: Practical Tools in the Management of Patients with Schizophrenia", Saturday, May 19, 6:00 p.m.; "Navigating the Complex Maze of Bipolar Disorder", Monday, May 21, 7:00 p.m.; "Cigarette Smoking, Smoking Cessation and Psychiatric Illness", Tuesday, May 22, 7:00 p.m.; "Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia", Tuesday, May 22, 7:00 p.m.; "Fibromyalgia: New Insights into the Pathophysiology and Treatment", Wednesday, May 23, 7:00 p.m.; support of the Psychiatric Services Achievement Awards; the "Abstracts-On-Disk" Program; and the APA *Daily Bulletin* newspaper; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the Pfizer Minority Psychiatric Research Fellowship Award; and the APA *Daily Bulletin* newspaper; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.

SPECIAL ACKNOWLEDGMENTS

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and partial support of the Alumni Reception, Tuesday May 22, 6:00 p.m.

Sheppard Pratt Health Services: support of Assembly Warren Williams Speaker's Awards.

Shire US, Inc.: support of the Industry-Supported Symposia, "Clinical Management of ADHD", Saturday, May 19, 12:30 p.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 21, 7:00 a.m.; "How Comorbid is ADHD? Results from epidemiological and clinical Studies", Sunday, May 20, 7:00 p.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 22, 7:00 a.m.; the APA/Shire Child and Adolescent Psychiatry Fellowships; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 19, 7:00 p.m.

Solvay Pharmaceuticals Inc.: co-support of the Industry-Supported Symposia, "Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia", Tuesday, May 22, 7:00 p.m.; "The Ongoing Debate Surrounding Atypicals: Are The Benefits Worth the Risks?", Sunday, May 20, 8:00 a.m.; "Lifting the Burden of Psychiatric Illness: the management of allostatic load, metabolic syndrome, and co-occurring disorders", Monday/Tuesday, May 21-22, 7:00 a.m.; and the support of the coffee service in the exhibit hall.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposium, "Making Every Sheep Count: Evidence-Based Approaches to Treating Insomnia", Sunday, May 20, 1:30 p.m.; the Internet Village; and the APA Shuttle Bus Service.

University of Nebraska: support of the Frank J. Mcnolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Wyeth Pharmaceuticals: co-support of the Industry-Supported Symposia, "Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia", Tuesday, May 22, 7:00 p.m.; "Lifting the Burden of Psychiatric Illness: the management of allostatic load, metabolic syndrome, and co-occurring disorders", Monday/Tuesday, May 21-22, 7:00 a.m.; "Insights from STAR*D: Are Our Patients' Needs Being Met?", Saturday, May 19, 6:00 p.m.; "The Ongoing Debate Surrounding Atypicals: Are The Benefits Worth the Risks?", Sunday, May 20, 8:00 a.m.; support of the APIRE/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 22, 11:00 a.m.

FORMAT DESCRIPTIONS

ADVANCES IN.....SERIES

These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online at www.appi.org

CASE CONFERENCES

During these 90-minute or three-hour sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. Some cases will review the progress of psychotherapy in two successive sessions. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATES

Experts in the field, including psychiatrists and nonpsychiatrists will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

FOCUS LIVE

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussion.

SMALL INTERACTIVE SESSIONS

This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to discuss topics chosen by the expert obtain consultations around problems in research from senior researchers; or hear clinically-based seminars presented by outstanding educators. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this *Program Book*.

WORKSHOPS

Workshops are 90-minute sessions which typically involve brief presentations from individual panel members, followed by the opportunity to apply to home in small groups, practice new techniques to build skills, and for lively and informative discussion. This format provides for highly interactive audience participation. **Media Workshops** are three-hour sessions in which a feature-length film is shown and discussed.

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2007 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page ****, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

Presenter	Manufacturer(s)
Gene G. Abel, M.D.	Abel Screening, Inc. ⁶
Hagop S. Akiskal, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{1,3,5} ; Sanofi-Aventis ^{1,5}
Michael H. Allen, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Alexza MDC ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{1,3}
Jonathan E. Alpert, M.D.	Abbott Laboratories, Inc. ³ ; Alkermes, Inc. ³ ; Aspect Medical Systems ³ ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; Cyberonics, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Johnson & Johnson ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Lichtwer Pharma GmbH ³ ; Lorex Pharmaceuticals ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc. ^{3,5} ; PamLab ^{1,3} ; Pfizer Inc. ³ ; Pharmavite ^{1,3} ; Roche Pharmaceuticals ³ ; Sanofi/Synthelabo ³ ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth-Ayerst Laboratories ³
Lori L. Altshuler, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ^{4,5} ; Bristol-Myers Squibb Company ^{1,4,5} ; Eli Lilly and Company ^{1,4,5} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{4,5} ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ⁴
Sonia Ancoli-Israel, Ph.D.	Acadia Pharmaceuticals Inc. ¹ ; Cephalon, Inc. ^{1,5} ; King Pharmaceuticals, Inc. ^{1,5} ; Merck & Co., Inc. ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Neurogen Corporation ¹ ; NIH Institute ³ ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5} ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
Raymond F. Anton, M.D.	Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ^{1,5} ; Forest Laboratories, Inc. ^{1,3} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
William J. Apfeldorf, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Eisai Inc. ³ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ^{1,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Lesley M. Arnold, M.D.	Cypress Bioscience Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Alan Axelson, M.D.	Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Marion A. Becker, Ph.D.	Eli Lilly and Company ³
Julian Beczhold, M.B.Ch.B.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Janssen-Cilag ⁵
Bernard D. Beitman, M.D.	Bristol-Myers Squibb Company ⁵
Ruth M. Benca, M.D.	GlaxoSmithKline ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5} ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5} ; Wyeth Pharmaceuticals ⁵
Donna S. Bender, Ph.D.	National Institute of Mental Health ³
Susan R. Bergeson, M.B.A.	Abbott Laboratories, Inc. ³

Presenter	Manufacturer(s)
John I. Beyers, M.D.	Avanir Pharmaceuticals ¹ ; Bristol-Myers Squibb Company ^{3,5} ; Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Myriad Genetics, Inc. ³ ; Pfizer Inc. ³
Joseph Biederman, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon, Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3} ; McNeil Consumer Healthcare ^{1,3,5} ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; NRP ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3,5} ; Stanley Medical Research Institute ³ ; UCB Pharma ^{1,5}
Adam Bisaga, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ¹
Donald W. Black, M.D.	Forest Laboratories, Inc. ^{1,3,5} ; Pfizer Inc. ⁵ ; Scirex Corporation ⁵ ; Shire Pharmaceuticals Group plc. ^{1,2,3,5}
Carlos Blanco-Jerez, M.D.	Somaxon Pharmaceuticals ³
Barton J. Blinder, M.D.	Pfizer Inc. ³
Paul B. Bohn, M.D.	Forest Laboratories, Inc. ⁵ ; Pfizer Inc. ⁵ ; Wyeth-Ayerst Laboratories ⁵
Curley L. Bonds, M.D.	Abbott Laboratories, Inc. ⁵ ; Pfizer Inc. ⁵
Howard E. Book, M.D.	American Psychological Association Press ⁴
Charles L. Bowden, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; National Institute of Mental Health ³ ; Parke-Davis ³ ; Pfizer Inc. ⁵ ; Stanley Medical Research Institute ³ ; UCB Pharma ¹
Kathleen T. Brady, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alkermes, Inc. ¹ ; Cephalon, Inc. ¹ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; National Institute on Drug Abuse ^{1,3} ; Ovation Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,5} ; Wyeth Pharmaceuticals ³
Ronald Brenner, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵
Thomas E. Brown, Ph.D.	American Psychiatric Press ⁴ ; Cephalon, Inc. ¹ ; Eli Lilly and Company ^{1,3} ; McNeil Consumer Healthcare ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Shire Pharmaceuticals Group plc. ^{1,3}
Peter F. Buckley, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Alamo Pharmaceuticals ^{1,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ³
Stephen F. Buie, M.D.	Wyeth Pharmaceuticals ⁵
Oscar G. Bukstein	Cephalon, Inc. ¹ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ¹ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Sanofi-Aventis ³ ; Shire Pharmaceuticals Group plc. ^{1,3,5}
Harold L. Burke, Ph.D.	EEG Spectrum International, Inc. ^{2,6}
George Bush, M.D.	Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; McNeil Consumer Healthcare ^{3,5} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ³ ; Shire Pharmaceuticals Group plc. ⁵
Daniel J. Buysse, M.D.	Cephalon, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; Neurocrine Biosciences Inc. ¹ ; Neurogen Corporation ¹ ; Pfizer Inc. ^{1,3} ; Respiroics, Inc. ¹ ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Servier ¹ ; Takeda Pharmaceuticals America, Inc. ^{1,3}
Nancy Byatt, D.O.	AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ³
Joseph R. Calabrese, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ³ ; Teva Pharmaceutical Industries Ltd. ¹
William E. Callahan, Jr., M.D.	Bristol-Myers Squibb Company ⁵ ; Otsuka America Pharmaceutical, Inc. ⁵
William H. Campbell, M.D.	Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵
Joseph Cappelleri	Pfizer Inc. ²
Stanley N. Caroff, M.D.	Bristol-Myers Squibb Company ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
William T. Carpenter, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Cephalon, Inc. ¹ ; Lilly ¹ ; National Institute of Mental Health ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Diana Carter, M.B.B.S.	GlaxoSmithKline ⁵ ; Wyeth Pharmaceuticals ³
Daniel E. Casey, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Janssen Pharmaceutica Products, LP ^{1,5} ; Pfizer Inc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ¹
David A. Casey, M.D.	Abbott Laboratories, Inc. ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵
Alfonso Ceccherini-Nelli, M.D.	GlaxoSmithKline ²
Robert A. Chambers, M.D.	Forest Laboratories, Inc. ⁵ ; National Institute on Drug Abuse ³
Kiki D. Chang, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3} ; Lilly ¹ ; Otsuka America Pharmaceutical, Inc. ³ ; Shire Pharmaceuticals Group plc. ¹

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Joseph A. Cheong, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Allen Childs, M.D.	Abbott Laboratories, Inc. ¹
Lois W. Choi-Kain, M.D.	National Institute of Mental Health ³
Henry Chung, M.D.	National Institute of Mental Health ³ ; Pfizer Inc. ⁵
Leslie L. Citrome, M.D.	Abbott Laboratories, Inc. ^{5,6} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,6} ; Eli Lilly and Company ^{1,3,5,6} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ³ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Merck & Co., Inc. ⁶ ; Pfizer Inc. ^{1,3,5,6}
Daniel J. Clauw, M.D.	Cypress Bioscience Inc. ^{1,6}
Anita L. Clayton, M.D.	Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,5} ; Neuronetics, Inc. ³ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Vela Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Emil F. Coccaro, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Eli Lilly and Company ³ ; Pfizer Inc. ¹
Judith A. Cohen	Department of Health and Human Services ³ ; Guilford Press ⁴ ; National Institute of Mental Health ³
Francesc Colom, Ph.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Lilly ⁵ ; Sanofi-Aventis ⁵
David O. Conant-Norville, M.D.	McNeil Consumer Healthcare ⁵ ; Novartis Pharmaceuticals Corporation ⁵
Daniel F. Connor, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Ram Cooppan, M.B.Ch.B.	Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Novo Nordisk Pharmaceuticals, Inc. ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Gabriela Cora-Locatelli, M.D.	Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Barbara A. Cornblatt, Ph.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ³
Maria R. Corral, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Janssen Pharmaceutica Products, LP ³
Christoph U. Correll, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ¹ ; Healthcare Technology Systems, Inc. ¹ ; Intra-Cellular Therapeutics ¹ ; Janssen Pharmaceutica Products, LP ⁵
Leslie J. Crofford, M.D.	Allergan Inc. ¹ ; Cypress Bioscience Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; Orphan Medical ¹ ; Pfizer Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Jeffrey L. Cummings, M.D.	Abbott Laboratories, Inc. ¹ ; Eisai Inc. ⁵
Daniella David, M.D.	Janssen Pharmaceutica Products, LP ³
Jonathan S. Davine, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Biovail Corporation ⁵ ; Wyeth Pharmaceuticals ⁵
Lori L. Davis, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,5} ; Eisai Inc. ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³
Melissa P. DelBello, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,5}
Pedro L. Delgado, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Concept Therapeutics ³ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3} ; Medtronic, Inc. ³ ; National Institute of Mental Health ^{1,3} ; Neuronetics, Inc. ¹ ; NIH Institute ^{1,3} ; Pfizer Inc. ⁶ ; Wyeth Pharmaceuticals ^{1,5} ; Wyeth-Ayerst Laboratories ⁵
Davangere P. Devanand	Eli Lilly and Company ³ ; Wyeth Pharmaceuticals ³
C. Lindsay DeVane, Pharm.D.	Bristol-Myers Squibb Company ⁵ ; Cyberonics, Inc. ³ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Institute of Mental Health ³ ; NovaDel Pharma Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3}
Mantosh J. Dewan, M.D.	McNeil Consumer Healthcare ³
Ronald J. Diamond, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ^{1,5} ; Pfizer Inc. ¹
Joel Dimsdale, M.D.	Sepracor, Inc. ³
Lisa Dixon, M.D.	Bristol-Myers Squibb Company ³
Robert K. Dolgoff, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵
P. Murali Doriaswamy, M.D.	Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ³ ; Myriad Genetics, Inc. ¹ ; Saegis ¹ ; Sanofi-Aventis ³
Christopher L. Drake, Ph.D.	Cephalon, Inc. ⁵ ; Pfizer Inc. ¹ ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ⁵
Ronald S. Duman, Ph.D.	Eli Lilly and Company ³ ; National Foundation for Mental Health ³ ; Organon Pharmaceuticals Inc. ³ ; Sepracor, Inc. ³
Laura B. Dunn, M.D.	National Institute of Mental Health ³
James M. Ellison, M.D.	Bristol-Myers Squibb Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{3,5} ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵

Presenter	Manufacturer(s)
Raymond A. Faber	Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵
Andrea Fagiolini, M.D.	Bristol-Myers Squibb Company ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ³ ; Pfizer Inc. ³
Warachal E. Faison, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Forest Laboratories, Inc. ^{1,5} ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ^{1,5} ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Organon Pharmaceuticals Inc. ³ ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5}
Stephen V. Faraone, Ph.D.	Cephalon, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3,5} ; McNeil Consumer Healthcare ^{1,3,5} ; National Foundation for Mental Health ³ ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; National Institute on Drug Abuse ³ ; Noven Pharmaceuticals, Inc. ¹ ; Shire Pharmaceuticals Group plc. ^{1,3,5}
Maurizio Fava, M.D.	Abbott Laboratories, Inc. ³ ; Alkermes, Inc. ³ ; Aspect Medical Systems ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bayer Corporation ¹ ; Biovail Corporation ¹ ; Boehringer-Ingelheim Pharmaceuticals ⁵ ; BrainCells, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ^{1,3,5} ; Compellis Pharmaceuticals ^{1,6} ; Cypress Bioscience Inc. ¹ ; Cypress Pharmaceuticals ¹ ; Dov Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,3,5} ; EPIX ¹ ; Fabre Kramer Pharmaceuticals Inc. ¹ ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Grunenthal GmbH ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Knoll Pharmaceutical Company ¹ ; Lichtwer Pharma GmbH ³ ; Lorex Pharmaceuticals ³ ; Lundbeck ¹ ; MedAvante, Inc. ^{1,6} ; Neuronetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Nutrition 21, Inc. ¹ ; Organon Pharmaceuticals Inc. ^{1,3,5} ; PamLab ^{1,3} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,3} ; PharmaStar ^{1,5} ; Pharmavite ^{1,3} ; Roche Pharmaceuticals ^{1,3} ; Sanofi/Synthelabo ^{1,3} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Somaxon Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5} ; Wyeth-Ayerst Laboratories ^{1,3,5}
Jan Fawcett, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ⁵ ; National Institute of Mental Health ³ ; Wyeth Pharmaceuticals ¹
Francisco Fernandez, M.D.	Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ³ ; Esai-Pfizer ³ ; NIH Institute ³ ; Pfizer Inc. ³ ; Sumitomo Pharmaceuticals Co., Ltd ³ ; Wyeth Pharmaceuticals ⁵
Robert L. Findling, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ¹ ; Shire Pharmaceuticals Group plc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Naomi A. Fineberg	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; GlaxoSmithKline ¹
David P. Folsom, M.D.	National Institute of Mental Health ⁴
Timothy W. Fong, M.D.	Forest Laboratories, Inc. ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Reckitt-Benkiser ⁵
Brent P. Forester, M.D.	Abbott Laboratories, Inc. ^{3,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ^{3,5}
Philippe Fossati, M.D.	Eli Lilly and Company ¹ ; Servier ³
Ellen Frank, Ph.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; Forest Research Institute ³ ; Guilford Press ⁴ ; Guilford Pharmaceuticals ¹ ; H. Lundbeck A/S, Guilford Press ⁴ ; Lundbeck ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; Servier ¹
Gordon Frankle, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Fujisawa Pharmaceutical, Co. ³
Nancy Frasure-Smith, Ph.D.	GlaxoSmithKline ³ ; IsodisNatura ³ ; Solvay Pharmaceuticals, Inc. ⁵
Marlene P. Freeman, M.D.	Arizona Disease Control Research Commission ³ ; AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ⁵ ; Pronova Biocare ³ ; Reliant ¹ ; The Institute for Mental Health Research of Arizona ³ ; THER-X ¹ ; U.S. Food and Drug Administration ³
Fred Frese, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹
Robert D. Friedberg, Ph.D.	Guilford Publications ⁴
Joseph I. Friedman, M.D.	Eli Lilly and Company ³
Mark A. Frye, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; American Foundation for Suicide Prevention ³ ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3} ; Indevus Pharmaceuticals, Inc. ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Janssen-Cilag ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Otsuka America Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ³ ; Stanley Medical Research Institute ³ ; Wyeth Pharmaceuticals ¹
Kenneth D. Gadow, Ph.D.	Checkmate Plus ⁶
Wolfgang Gaebel, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ⁵ ; H. Lundbeck A/S ¹ ; Janssen-Cilag ^{1,3,5} ; Lilly ^{1,3,5} ; Lundbeck ^{1,3,5} ; Novartis Pharmaceuticals Corporation ¹ ; Sanofi-Aventis ⁵ ; Wyeth Pharmaceuticals ^{1,3}

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Fred H. Gage, Ph.D.	BrainCells, Inc. ^{1,6} ; Celgene Corporation ⁶ ; Ceregene, Inc. ^{1,6} ; Stem Cells Inc. ^{1,6}
James E. Galvin, M.D.	Eisai Inc. ⁵ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ⁵ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Pfizer Inc. ⁵
Keming Gao, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Mark S. George, M.D.	Aventis Pharmaceuticals, Inc. ¹ ; Biovail Corporation ³ ; Cortex Pharmaceuticals, Inc. ³ ; Cyberonics, Inc. ^{1,3,5} ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ¹ ; National Institute of Health ³ ; Neuronetics, Inc. ^{1,3} ; NeuroPace, Inc. ^{1,3}
Tony P. George, M.D.	Eli Lilly and Company ⁵ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute on Drug Abuse ³ ; Pfizer Inc. ^{1,5} ; Targacept, Inc. ³
Nassir Ghaemi, M.D.	Abbott Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ³
Mona H. Gill, M.D.	Wyeth Pharmaceuticals ⁵
Michael J. Gitlin	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Alexander H. Glassman, M.D.	Pfizer Inc. ⁵
Tasha Glenn, Ph.D.	Chronorecord Association ⁴
Ira D. Glick, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁶ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Pfizer Inc. ⁵ ; Shire Pharmaceuticals Group plc. ^{3,5} ; Solvay Pharmaceuticals, Inc. ^{1,3}
Donald C. Goff, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ³ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Merck & Co., Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ¹
Harold W. Goforth, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Forest Laboratories, Inc. ³ ; Pfizer Inc. ³ ; Sepracor, Inc. ³
Joseph F. Goldberg, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{3,5}
Gabe Goldfeder, M.A.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Myriad Genetics, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ³ ; Sanofi-Aventis ³
Morris B. Goldman, M.D.	National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
Irwin Goldstein	Bayer Corporation ¹ ; Eli Lilly and Company ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Pfizer Inc. ¹ ; Proctor & Gamble Pharmaceuticals, Inc. ¹
Frederick K. Goodwin, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ³
Jon E. Grant, M.D.	Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Somaxon Pharmaceuticals ^{1,3}
Jack A. Grebb, M.D.	Bristol-Myers Squibb Company ^{2,6}
George T. Grossberg, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Janssen-Cilag ¹ ; Lilly ^{1,3} ; Myriad Genetics, Inc. ³ ; National Institute on Aging ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ono Pharmaceuticals, Inc. ³ ; Pfizer Inc. ^{1,3} ; Sanofi-Aventis ¹ ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Linda S. Grossman, Ph.D.	National Institute of Mental Health ³
Heinz Grunze, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ^{1,5} ; Janssen-Cilag ⁵ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,5} ; UCB Pharma ³
Sanjay Gupta, M.D.	Abbott Laboratories, Inc. ^{3,6} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{3,5} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Memory Pharmaceuticals ³ ; Myriad Genetics, Inc. ³ ; Neurochem, Inc. ³ ; Ono Pharmaceuticals, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{3,5} ; Solvay Pharmaceuticals, Inc. ³ ; Somaxon Pharmaceuticals ³
Raquel E. Gur, M.D.	NIH Institute ³
Robert E. Hales	Bristol-Myers Squibb Company ^{3,5}
Martin Harrow, Ph.D.	National Institute of Mental Health ³
Philip D. Harvey, Ph.D.	Solvay Pharmaceuticals, Inc., Pfizer Inc. ¹

Presenter	Manufacturer(s)
David Healy, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Teva Pharmaceutical Industries Ltd. ^{1,4}
David J. Hellerstein, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³
David C. Henderson, M.D.	Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Pfizer Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹
Charles H. Hennekens, M.D.	Amgen, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bayer Corporation ¹ ; Biovail Corporation ¹ ; Bristol-Myers Squibb Company ^{1,5} ; GlaxoSmithKline ¹ ; McNeil Consumer Healthcare ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; TAP Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Jacqueline Henschke, M.D.	AstraZeneca Pharmaceuticals LP ³
Paula L. Hensley, M.D.	Amgen, Inc. ⁴ ; Pfizer Inc. ⁶
Barry K. Herman, M.D.	Pfizer Inc. ⁶
Napoleon B. Higgins, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; McNeil Consumer Healthcare ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Marynell Hinton, M.A.	Professional Risk Management Services, Inc. ²
Max Hirshkowitz, Ph.D.	Aventis Pharmaceuticals, Inc. ³ ; Cephalon, Inc. ⁵ ; GlaxoSmithKline ³ ; Lundbeck ³ ; Merck, Sharp, and Dohme ³ ; National Institute of Health ³ ; Neurocrine Biosciences Inc. ³ ; Respironics, Inc. ³ ; Sanofi-Aventis ^{1,3,5} ; Takeda Pharmaceuticals America, Inc. ^{3,5}
Eric Hollander, M.D.	Abbott Laboratories, Inc. ³ ; Lilly ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; National Institute on Drug Abuse ³ ; Neuropharm ^{1,6} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Somaxon Pharmaceuticals ³ ; U.S. Food and Drug Administration ³ ; UCB Pharma ³
Ray C. Hsiao, M.D.	Bristol-Myers Squibb Company ⁶ ; Pfizer Inc. ⁶
Rona Hu, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ¹
Michael Y. Hwang, M.D.	Janssen Pharmaceutica Products, LP ^{1,5}
Dan V. Iosifescu, M.D.	Aspect Medical Systems ^{1,3} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ⁵
Naveed Iqbal, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Myriad Genetics, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ³ ; Sanofi-Aventis ³
Philip G. Janicak, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Neuronetics, Inc. ³ ; Pfizer Inc. ⁵ ; Solvay Pharmaceuticals, Inc. ³
Geetha Jayaram, M.D.	⁵ ; Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Wyeth Pharmaceuticals ⁵
James W. Jefferson, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{5,6} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{1,5,6} ; Healthcare Technology Systems, Inc. ^{2,4} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ⁵ ; Schwartz Pharma ⁵ ; Shire Pharmaceuticals Group plc. ⁵ ; Solvay Pharmaceuticals, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Dilip V. Jeste, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Hadine Joffe, M.D.	Berlex Inc. ⁴ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁴ ; Sepracor, Inc. ³ ; Wyeth Pharmaceuticals ⁴
Bankole Johnson, M.D.	Alkermes, Inc. ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Intranasal Therapeutics, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Sanofi-Aventis ¹ ; TransOral Pharmaceuticals, Inc. ¹
Bradley R. Johnson, M.D.	Forest Laboratories, Inc. ⁵
Joel P. Johnson, M.D.	GlaxoSmithKline ⁴
Rene Kahn	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; Merck, Sharp, and Dohme ^{1,5} ; Organon Pharmaceuticals Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5}
Thomas A. Kaleita, Ph.D.	Cephalon, Inc. ^{1,3}
Ronald L. Kamm, M.D.	Pfizer Inc. ⁶
Kyle M. Kampman, M.D.	Alkermes, Inc. ³ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵

DISCLOSURE INDEX

Presenter	Manufacturer(s)
John M. Kane, M.D.	Abbott Laboratories, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ^{1,5} ; Johnson and Johnson Pharmaceutical Rsearch and Development ¹ ; Lundbeck ¹ ; MDS Pharma Services ¹ ; MedAvante ⁶ ; Pfizer Inc. ^{1,5} ; Roche Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth-Ayerst Laboratories ¹
Shimi Kang, M.D.	Alkermes, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Janssen Pharmaceutica Products, LP ⁵
Shitij Kapur	Forest Laboratories, Inc. ⁵ ; Schwartz Pharma ⁵
Wayne J. Katon, M.D.	Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁵ ; John A Hartford Foundation ³ ; National Institute of Mental Health ³ ; Wyeth-Ayerst Laboratories ⁴
David J. Katzelnick, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{3,5} ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Lilly ⁵ ; Merck & Co., Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{3,5} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Pharmacia & Upjohn ⁵ ; Robert Wood Johnson Foundation ¹ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ¹
Paul E. Keck, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Memory Pharmaceuticals ¹ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Neurocrine Biosciences Inc. ¹ ; Organon Pharmaceuticals Inc ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Medical Research Institute ³ ; UCB Pharma ³
George A. Keepers, M.D.	Eli Lilly and Company ⁵
Samuel J. Keith, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; Cyberonics, Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen-Cilag ^{1,3,5} ; Merck, Sharp, and Dohme ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ³ ; Wyeth Pharmaceuticals ³
John R. Kelsoe, M.D.	GlaxoSmithKline ⁵ ; Psynomics, Inc. ⁴
Ronald C. Kessler, Ph.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ¹
Terence A. Ketter, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ¹ ; Corcept Therapeutics ¹ ; Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Pfizer Inc. ⁵ ; Shire Pharmaceuticals Group plc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharma ¹ ; Wyeth Pharmaceuticals ^{1,3}
Sabrina J. Khan, M.D.	Eli Lilly and Company ⁶ ; Merck & Co., Inc. ⁶ ; Pfizer Inc. ⁶ ; Schering-Plough Corporation ⁶
Clinton D. Kilts, Ph.D.	Forest Laboratories, Inc. ^{1,3} ; H. Lundbeck A/S ¹ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Solvay Pharmaceuticals, Inc. ¹
David G. Kingdon, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{4,5} ; Guilford Press ⁴ ; Janssen-Cilag ⁵ ; Pfizer Inc. ³
Herbert D. Kleber, M.D.	Alkermes, Inc. ¹ ; Reckitt-Benkiser ^{1,3}
Harold W. Koenigsberg, M.D.	Janssen Pharmaceutica Products, LP ³
George F. Koob, Ph.D.	Addex Pharmaceuticals ¹ ; Alkermes, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Hythiam Inc. ¹
Lorrin M. Koran, M.D.	Cypress Bioscience Inc. ^{1,6} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; Jazz Pharmaceuticals, Inc. ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Somaxon Pharmaceuticals ³
Thomas R. Kosten, M.D.	Alkermes, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Cephalon, Inc. ¹ ; Gerson Lehman Group ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,6} ; Merck, Sharp, and Dohme ¹ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ⁶
Christopher J. Kratochvil, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ¹ ; Boehringer-Ingelheim Pharmaceuticals ¹ ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; McNeil Consumer Healthcare ³ ; National Institute of Mental Health ^{1,3} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Shire Pharmaceuticals Group plc. ^{1,3}
K Ranga Krishnan, M.D.	Abbott Laboratories, Inc. ¹ ; Amgen, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; CeNeRx ¹ ; Cyberonics, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; H. Lundbeck A/S ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ³ ; NPS Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Sepracor, Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Vela Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Meir H. Kryger, M.D.	Cephalon, Inc. ¹ ; National Institute of Health ³ ; Takeda Pharmaceuticals America, Inc. ¹
Andrew D. Krystal, M.D.	King Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ³ ; Neurocrine Biosciences Inc. ^{1,3} ; Neurogen Corporation ¹ ; Pfizer Inc. ^{1,3} ; Respiroics, Inc. ^{1,3} ; Sanofi-Aventis ^{1,3} ; Scpracor, Inc. ^{1,3} ; Somaxon Pharmaceuticals ^{1,3} ; Takeda Pharmaceuticals America, Inc. ¹

Presenter	Manufacturer(s)
John H. Krystal, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Research Foundation ¹ ; Merz Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Takeda Industries ¹
Jayashri Kulkarni, M.B.B.S.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Janssen-Cilag ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Novartis Pharmaceutica Corporation ³ ; Organon Pharmaceuticals Inc ³ ; Sanofi/Synthelabo ³ ; Sanofi-Aventis ³ ; Servier ³ ; Stanley Medical Research Institute ³
Elisabeth J. S. Kunkel, M.D.	Forest Laboratories, Inc. ⁵
Helen H. Kyomen, M.D.	AstraZeneca Pharmaceuticals LP, Bayer Corporation; AstraZeneca Pharmaceuticals LP ¹ ; Bayer Corporation ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; John A Hartford Foundation ³ ; Merck & Co., Inc. ¹ ; Merck & Co; National Institute on Aging ³ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3} ; Roche Pharmaceuticals ^{1,3} ; The John A. Hartford Foundation ³ ; UCB Pharma ^{1,3} ; Veterans Administration ³ ; Wyeth-Ayerst Laboratories ^{1,3}
Samuel J. Langer	Bristol-Myers Squibb Company ²
Alan Langlieb, M.D.	Eli Lilly and Company ^{3,5}
John Lauriello, M.D.	Abel Screening, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Janssen-Cilag ^{1,3,5} ; Pfizer Inc. ^{1,5}
William B. Lawson, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ⁵ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ¹
Arthur L. Lazarus, M.D.	AstraZeneca Pharmaceuticals LP ^{2,6}
Hochang B. Lee, M.D.	GlaxoSmithKline ^{3,5}
Steven J. Lee, M.D.	Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵
Andrew C. Leon, Ph.D.	Cortex Pharmaceuticals, Inc ¹ ; Cyberonics, Inc. ¹ ; MedAvante ⁶ ; Pfizer Inc. ⁴ ; Vanda Pharmaceuticals ⁴
François Lespérance, M.D.	GlaxoSmithKline ^{3,5} ; IsodisNatura ³ ; Lundbeck ⁵ ; Servier ¹ ; Wyeth Pharmaceuticals ⁵
Stefan Leucht, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ^{1,3,5} ; H. Lundbeck A/S ⁵ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,5} ; Lundbeck ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ^{1,3,5}
James L. Levenson, M.D.	Eli Lilly and Company ¹
Frances R. Levin, M.D.	Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Cephalon, Inc. ¹ ; Eli Lilly and Company ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3} ; UCB Pharma ³
Petros Levounis, M.D.	Alkermes, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵ ; Reckitt-Benckiser ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵
Roberto Lewis-Fernandez, M.D.	Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ³
Jeffrey A. Lieberman, M.D.	Acadia Pharmaceuticals Inc ³ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Merck, Sharp, and Dohme ³ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,3} ; Pfizer Inc. ^{1,3} ; Repligen ⁴ ; Sanofi-Aventis ¹
Russell F. Lim, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵
Jean-Pierre Lindenmayer, M.D.	Alamo Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Janssen-Cilag ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ³
Maria D. Llorente, M.D.	Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb Company ⁵ ; Veterans Administration ²
Sheila M. Loboprabhu, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Leslie P. Lundt, M.D.	Cephalon, Inc. ^{1,3,5} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Merck, Sharp, and Dohme ³ ; Pfizer Inc. ^{5,6} ; Sanofi-Aventis ^{3,5} ; Sepracor, Inc. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ³ ; Takeda Pharmaceuticals America, Inc. ^{1,3,5} ; Targacept, Inc. ^{3,5} ; Wyeth Pharmaceuticals ⁵
Shari I. Lusskin, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Wyeth Pharmaceuticals ⁵
Robert B. Lydiard, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; McNeil Consumer Healthcare ³ ; Novartis Pharmaceuticals Corporation ¹ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ^{1,3} ; Wyeth Pharmaceuticals ³
Constantine G. Lyketos, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Eisai Inc. ⁴ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3} ; H. Lundbeck A/S ⁴ ; National Institute of Health ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴
Kathryn J. Macdonald, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5}
Sean Mackey, M.D.	Eli Lilly and Company ⁵ ; Pfizer Inc. ⁵
Vishal Madaan, MD	GlaxoSmithKline ⁴

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Alan S. Maisel, M.D.	Abbott Laboratories, Inc. ³ ; Bayer Corporation ³ ; Johnson and Johnson Pharmaceutical Research and Development ⁵
Catherine L. Mancini, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ³
Christina Mangurian, M.D.	Bristol-Myers Squibb Company ⁴ ; Janssen Pharmaceutica Products, LP ³
Lauren B. Marangell, M.D.	Aspect Medical Systems ¹ ; Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Medtronic, Inc. ¹ ; National Institute of Health ³ ; Neuronetics, Inc. ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; Stanley Medical Research Institute ³
Stephen R. Marder, M.D.	Bristol-Myers Squibb Company ¹ ; GlaxoSmithKline ¹ ; Merck, Sharp, and Dohme ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹
John C. Markowitz, M.D.	National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³
Robert W. Marvin, M.D.	National Institute of Mental Health ³
Prakash S. Masand, M.D.	Abbott Laboratories, Inc. ^{3,5} ; Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5,6} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Guilford Pharmaceuticals ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,5} ; Targacept, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Thomas L. Matthews, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Shire Pharmaceuticals Group plc. ⁵
Helen S. Mayberg, M.D.	Advanced Neuromodulation Systems, Inc. ^{1,4} ; Cyberonics, Inc. ¹
Linda C. Mayes, M.D.	National Institute of Health ³
Thomas H. McGlashan, M.D.	Eli Lilly and Company ³
Keith McBurnett, Ph.D.	Cephalon, Inc. ³ ; McNeil Consumer Healthcare ³ ; NRP ³ ; Shire Pharmaceuticals Group plc. ³
Susan L. McElroy, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{3,4} ; Eisai Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁴ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{3,4} ; Sanofi-Aventis ^{3,4} ; Somaxon Pharmaceuticals ^{3,4} ; Stanley Medical Research Institute ⁴ ; Wyeth Pharmaceuticals ¹
Joseph P. McEvoy, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{1,3} ; Janssen-Cilag ^{3,5} ; Organon Pharmaceuticals Inc ³ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Pharmaceutical Product Development, Inc ³
Patrick D. McGorry, M.D.	AstraZeneca Pharmaceuticals LP, Janssen-Cilag ³ ; Janssen-Cilag ³
Roger S. McIntyre, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Biovail Corporation ^{1,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3,5} ; H. Lundbeck A/S ⁵ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Merck & Co., Inc. ³ ; Merck, Sharp, and Dohme ³ ; Organon Pharmaceuticals Inc ^{1,5} ; Oryx Pharmaceuticals, Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Prestwick Pharmaceuticals, Inc. ^{1,5} ; Servier ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Jacqueline M. Melonas, J.D.	Professional Risk Management Services, Inc. ²
Samantha E. Meltzer-Brody, M.D.	GlaxoSmithKline ³
Matthew A. Menza, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; National Institute of Mental Health ¹ ; National Institute of Neurological Disorders and Stroke ^{1,3} ; Sanofi-Aventis ^{1,3,5} ; Sepracor, Inc. ^{1,3,5} ; Takeda Pharmaceuticals America, Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ³
Jonathan M. Meyer, M.D.	Bristol-Myers Squibb Company ^{1,3,4,5} ; Janssen Pharmaceutica Products, LP ^{1,4,5} ; Pfizer Inc. ^{1,3,4,5}
Eric Mick	McNeil Consumer Healthcare ^{1,3} ; National Institute of Mental Health ³ ; Shire Pharmaceuticals Group plc. ¹
Roumen V. Milev, Ph.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Biovail Corporation ¹ ; Eli Lilly and Company ^{1,3,5} ; H. Lundbeck A/S ³ ; Wyeth Pharmaceuticals ⁵ ; Wyeth-Ayerst Laboratories ⁵
Alexander L. Miller, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; InforMedix, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{1,3,5}
William R. Miller, Ph.D.	National Institute of Health ³ ; National Institute on Drug Abuse ³
Jacobo E. Mintzer, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Capital Research Companies ^{1,5} ; Eisai Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,5} ; Mitsubishi Pharmaceutical Corporation ³ ; National Institute of Health ³ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Neurochem, Inc. ³ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ³ ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5} ; Predix Pharmaceuticals ^{1,5} ; Sanofi-Aventis ^{1,3,5} ; Voyager Pharmaceutical Corp ³

Presenter	Manufacturer(s)
Asha S. Mishra, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵
Shaila Misri, F.R.C.P.C.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ⁵ ; GlaxoSmithKline ^{1,5} ; H. Lundbeck A/S ^{1,3,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Wyeth Pharmaceuticals ^{1,3,5}
Ramin Mojtabai, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3}
Jacques Montplaisir, M.D.	Boehringer-Ingelheim Pharmaceuticals ¹ ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ³ ; Servier ¹
Quinton E. Moss, M.D.	National Institute of Mental Health ³ ; Pfizer Inc. ⁵
David A. Mrazek, M.D.	AssureRx ⁶
Rodrigo A. Munoz, M.D.	Eli Lilly and Company ³
Philip R. Muskin, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{1,5} ; Cephalon, Inc. ^{1,5} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; National Institute of Mental Health ¹ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Pfizer Inc. ^{1,5}
Hugh Myrick, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Forest Laboratories, Inc. ^{3,5} ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
David K. Nace, M.D.	McKesson Corporation, ² ; McKesson Corporation ²
Ziad H. Nahas, M.D.	Cyberonics, Inc. ^{1,3} ; Neuronetics, Inc. ^{1,3}
Joseph C. Napoli, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Meera Narasimhan, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{3,5} ; National Institute of Health ³ ; National Institute on Drug Abuse ^{3,5} ; Pfizer Inc. ⁵
Kenneth C. Nash, M.D.	Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵
Henry A. Nasrallah, M.D.	Abbott Laboratories, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ^{1,5}
Randy J. Nelson	Merck & Co., Inc. ¹ ; National Institute of Mental Health ³
Charles B. Nemeroff, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Acadia Pharmaceuticals Inc. ^{1,6} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; CeNeRx ⁴ ; Cyberonics, Inc. ¹ ; Cypress Bioscience Inc. ^{1,6} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; NovaDel Pharma Inc. ⁶ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Reevax ⁴ ; UCB Pharma ¹ ; Wyeth Pharmaceuticals ^{1,3}
David N. Neubauer, M.D.	Neurocrine Biosciences Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
John W. Newcomer, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Compact Clinicals ⁴ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Sidney R. Baer Foundation ³ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
D. Jeffrey Newport, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ³
Anthony T. Ng, M.D.	Eli Lilly and Company ⁵ ; Pfizer Inc. ⁵ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ^{1,5}
Andrew A. Nierenberg, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cederroth International ³ ; Cyberonics, Inc. ^{3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{3,5} ; Genaissance Pharmaceuticals ¹ ; GlaxoSmithKline ^{1,3,5} ; Innapharma, Inc. ¹ ; Janssen-Cilag ¹ ; Lichtwer Pharma GmbH ³ ; Millenium Pharmaceuticals, Inc. ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ^{1,3} ; Neuronetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,3,5} ; Pfizer Inc. ^{1,3} ; Sepracor, Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Andrei Novac, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Keith H. Nuechterlein, Ph.D.	Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health, Janssen Pharmaceutica Products, LP ³
Edward V. Nunes, M.D.	Alkermes, Inc. ^{1,5} ; Cephalon, Inc. ⁵
H. George Nurnberg, M.D.	Abbott Laboratories, Inc. ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,5} ; Lipha Pharma ³ ; Parke-Davis ³ ; Pfizer Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ^{3,5}

Presenter	Manufacturer(s)
David J. Nutt, D.M.	Asahi ¹ ; Cephalon, Inc. ⁵ ; Cypress Bioscience Inc. ^{1,5} ; Eli Lilly and Company ^{1,5} ; Esteve ¹ ; GlaxoSmithKline ^{1,3,5,6} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Lundbeck ^{3,5} ; MDS Pharma Services ^{1,3,5} ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Organon Pharmaceuticals Inc. ^{1,3,5} ; Passion for Life ¹ ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,5} ; Reckitt-Benkiser ⁵ ; Servier ³ ; Takeda Pharmaceuticals America, Inc. ^{1,5} ; Therasci ¹ ; Wyeth Pharmaceuticals ^{3,5} ; Yamanouchi ³
Mary B. O'Malley, M.D.	Cephalon, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Neurocrine Biosciences Inc. ⁵ ; Pfizer Inc. ⁵ ; Sepracor, Inc. ⁵
Stephanie O'Malley, Ph.D.	Alkermes, Inc. ³
Cheryl A. Oncken, M.D.	National Institute on Drug Abuse ³ ; Pfizer Inc. ^{1,3}
Lewis A. Opler, M.D.	Multi-Health Systems, Inc. ⁴
Urban p. Osby, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ^{1,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; Pfizer Inc. ^{1,5}
David W. Oslin, M.D.	NIH Institute, Robert Wood Johnson Foundation ³
Michael J. Ostacher, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵
Sagar V. Parikh, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ^{1,3} ; Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ³ ; Wyeth Pharmaceuticals ^{1,3}
Lawrence T. Park, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ³ ; Janssen Pharmaceutica Products, LP ³
Joseph J. Parks	Abbott Laboratories, Inc. ³ ; Comprehensive Neurosciences Incorporated ¹ ; Medical Letters and Sciences ⁵
Amita R. Patel, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Cyberonics, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Martin P. Paulus, M.D.	GlaxoSmithKline ¹
Roy H. Perlis, Ph.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Eric D. Peselow, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Francois C. Petitjean, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Janssen-Cilag ^{1,5} ; Sanofi-Aventis ¹
Barbara A. Phillips, M.D.	Boehringer-Ingelheim Pharmaceuticals ¹ ; GlaxoSmithKline ¹
Katharine A. Phillips, M.D.	American Psychiatric Press ⁴ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; UCB Pharma ³
Edmond H. Pi, M.D.	Pfizer Inc. ⁵
Harold A. Pincus, M.D.	Academy of Managed Care Pharmacy (AMCP) Horizons, LLC ⁴ ; American Psychiatric Press ⁴ ; Atlantic Philanthropies ³ ; Bimark Medical Education ⁴ ; Cardinal Health, Inc. ⁴ ; Cisco Systems ¹ ; Columbia University ² ; Community Care Behavioral Health Organization/UPMC Health Plan ¹ ; Comprehensive Neuroscience, Inc., Medical Information Technologies ⁴ ; Current Opinion in Psychiatry/Lippincott, William and Wilkins ⁴ ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; New York-Presbyterian Hospital ² ; RAND Corporation ² ; Raymond John Wean Foundation ³ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ³ ; The Heinz Endowments ³ ; The John A. Hartford Foundation ³ ; The Robert Wood Johnson Foundation ³ ; Veterans Administration ³
Mark H. Pollack, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ¹ ; Sepracor, Inc. ^{1,3} ; UCB Pharma ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,5}
Bruce G. Pollock, M.D.	Forest Laboratories, Inc. ^{1,5} ; Janssen Pharmaceutica Products, LP ³ ; Lundbeck ^{1,5} ; National Institute of Mental Health ³
Marc N. Potenza, M.D.	Gerson Lehman Group ¹ ; GlaxoSmithKline ¹ ; National Institute of Alcohol Abuse and Alcoholism ¹ ; National Institute of Child Health and Human Development ¹ ; National Institute of Neurological Disorders and Stroke ¹ ; National Institute on Drug Abuse ^{1,3} ; NIH Institute ^{1,3} ; Somaxon Pharmaceuticals ¹
Annelle B. Primm, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ¹ ; Pfizer Inc. ¹
Jefferson B. Prince, M.D.	McNeil Consumer Healthcare, Shire Pharmaceuticals Group plc. ¹
Andres J. Pumariega, M.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ⁵
Paul M. Ramirez, Ph.D.	Multi-Health Systems, Inc. ⁴

Presenter	Manufacturer(s)
Mark H. Rapaport, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ³ ; BrainCells, Inc. ¹ ; Cyberonics, Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5,6} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ^{1,3} ; National Institute on Drug Abuse ¹ ; Neurocrine Biosciences Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ³ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; UCB Pharma ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Natalia L. Rasgon, M.Ed.	Abbott Laboratories, Inc. ^{1,3,5} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,5} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ^{1,5}
Lawrence P. Reagan, Ph.D.	Servier ^{1,3}
William E. Reichman, M.D.	Eisai Inc. ³ ; Forest Laboratories, Inc. ^{1,3,5} ; Fujisawa Pharmaceutical, Co. ³ ; Myriad Genetics, Inc. ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ⁵ ; Sanofi-Aventis ³ ; Takeda Pharmaceuticals America, Inc. ³
John A. Renner, M.D.	Alkermes, Inc. ⁵ ; Cephalon, Inc. ⁵ ; Johnson & Johnson ⁶ ; Reckitt-Benckiser ⁵ ; Shire Pharmaceuticals Group plc. ¹
Perry F. Renshaw, M.D.	Eli Lilly and Company ³ ; GlaxoSmithKline ¹ ; Kyowa Hakko ¹ ; Novartis Pharmaceuticals Corporation ¹
Roy O. Resnikoff, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
Victor I. Reus, M.D.	Nabi Pharmaceuticals ³
Charles F. Reynolds, M.D.	Forest Laboratories, Inc. ³
Michelle B. Riba, M.D.	Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Steven Richeimer, M.D.	Merck & Co., Inc. ⁵ ; Pfizer Inc. ⁵ ; Purdue Pharma L.P. ⁵
Elliott Richelson, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ³ ; Neuronetics, Inc. ³ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ¹ ; Somaxon Pharmaceuticals ¹
Paula D. Riggs, M.D.	Eli Lilly and Company ³ ; McNeil Consumer Healthcare ³ ; National Institute on Drug Abuse ³ ; Shire Pharmaceuticals Group plc. ^{1,5}
Trevor Robbins, Ph.D.	CeNeS Pharmaceuticals ⁶ ; Cephalon, Inc. ^{1,5} ; Cortex Pharmaceuticals, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Pfizer Inc. ³ ; Roche Pharmaceuticals ^{1,5}
Delbert G. Robinson, M.D.	Bristol-Myers Squibb Company ³ ; Janssen Pharmaceutica Products, LP ³
Robert G. Robinson, M.D.	Avanir Pharmaceuticals ¹
Steven P. Roose, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ¹ ; Wyeth Pharmaceuticals ^{1,3}
Jerrold F. Rosenbaum	Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ¹ ; Sepracor, Inc. ¹
Cherise Rosen, Ph.D.	National Institute of Mental Health ³
Robert Rosenheck, M.D.	AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP; Wyeth Pharmaceuticals
Richard N. Rosenthal, M.D.	Alkermes, Inc. ¹ ; Cephalon, Inc. ¹ ; Forest Laboratories, Inc. ¹
A. John Rush, M.D.	Advanced Neuromodulation Systems, Inc. ¹ ; Best Practice Project Management, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Cyberonics, Inc. ^{1,5} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,5} ; Gerson Lehman Group ¹ ; GlaxoSmithKline ^{1,5} ; Guilford Publications ⁴ ; Healthcare Technology Systems, Inc. ⁴ ; Jazz Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ^{1,5} ; National Institute of Mental Health ³ ; Neuronetics, Inc. ¹ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ¹ ; Ono Pharmaceuticals, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Personality Disorder Research Corporation ¹ ; Pfizer Inc. ⁶ ; Robert Wood Johnson Foundation ³ ; Stanley Medical Research Institute ³ ; Urban Institute ¹ ; Wyeth Pharmaceuticals ¹ ; Wyeth-Ayerst Laboratories ¹
Deirdre M. Ryan, F.R.C.P.C.	Wyeth Pharmaceuticals ³
Abe M. Rychik, J.D.	Professional Risk Management Services, Inc. ⁴
Perminder Sachdev, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Pfizer Inc. ⁵
Gary S. Sachs, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Memory Pharmaceuticals ¹ ; Merck & Co., Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ⁵ ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Medical Research Institute ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Ihsan M. Salloum, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alkermes, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Cephalon, Inc. ¹ ; Drug Abuse Sciences, Inc ³ ; Forest Laboratories, Inc. ¹ ; Lipha Pharma ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Oy Contral Pharma ³

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Jitender Sareen, M.D.	GlaxoSmithKline ⁵
Norman H. Sartorius, M.D.	Eli Lilly and Company ¹ ; Janssen-Cilag ¹ ; Lilly ¹ ; Lundbeck ¹ ; Wyeth Pharmaceuticals ¹
Ayal Schaffer, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Biovail Corporation ⁵ ; Eli Lilly and Company ^{1,5} ; H. Lundbeck A/S ⁵ ; Sanofi-Aventis ³ ; Servier ³
Alan F. Schatzberg, M.D.	Abbott Laboratories, Inc. ¹ ; Aventis Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3} ; Innapharma, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Neuronetics, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,6} ; Somaxon Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Thomas Schlaepfer	Cyberonics, Inc. ³ ; Medtronics, Inc. ³
Lon S. Schneider, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Lundbeck ⁵ ; Myriad Genetics, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Pfizer Inc. ³ ; Wyeth Pharmaceuticals ¹
Nina R. Schooler, Ph.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Vanda Pharmaceuticals ¹
S. Charles Schulz, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ^{1,3,5}
Gary J. Schummer, Ph.D.	A.D.D. Treatment Centers ²
Michael A. Schwartz, M.D.	AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{3,5} ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Thomas L. Schwartz, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Cephalon, Inc. ^{3,5} ; Cyberonics, Inc. ^{3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ⁵ ; Jazz Pharmaceuticals, Inc. ^{3,5} ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ^{1,5}
Jan L. Scott, M.D.	AstraZeneca Pharmaceuticals LP ^{3,5} ; Eli Lilly and Company ^{3,5} ; Janssen-Cilag ⁵ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Sanofi-Aventis ⁵
David S. Shannahoff-Khalsa	W.W. Norton & Co., Inc. ⁴
Zafar Sharif, M.D.	Bristol-Myers Squibb Company, Janssen Pharmaceutica Products, LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Janssen Pharmaceutica Products, LP ⁵
M. Katherine Shear, M.D.	Forest Laboratories, Inc. ³ ; Pfizer Inc. ¹
David V. Sheehan, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alexza MDC ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Avera Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ^{1,3} ; Cortex Pharmaceuticals, Inc ¹ ; Cypress Bioscience Inc. ¹ ; Eisai Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ^{1,3} ; Layton Biosciences, Inc. ^{1,6} ; Mead Johnson ^{3,5} ; Medical Outcome Systems, Inc. ⁶ ; Merck & Co., Inc. ^{1,3,5} ; Novartis Pharmaceuticals Corporation ³ ; Novo Nordisk Pharmaceuticals, Inc. ⁵ ; Organon Pharmaceuticals Inc ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Parke-Davis ^{3,5} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,5} ; Roche Pharmaceuticals ^{1,5} ; Sanofi-Aventis ¹ ; Schering-Plough Corporation ⁵ ; Shire Pharmaceuticals Group plc. ¹ ; Solvay Pharmaceuticals, Inc. ^{1,5} ; TAP Pharmaceuticals, Inc. ^{1,3,5} ; Warner Chilcott PLC ^{3,5} ; Wyeth Pharmaceuticals ^{1,3,5} ; ZARS Pharma ¹
Richard C. Shelton	Abbott Laboratories, Inc. ^{3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ⁵ ; Wyeth Pharmaceuticals ^{3,5}
Larry J. Siever, M.Ed.	Eli Lilly and Company ^{1,3}
Daphne Simeon, M.D.	National Institute of Health ³
Gregory E. Simon, M.D.	Bristol-Myers Squibb Company ¹ ; Wyeth Pharmaceuticals ¹
Naomi M. Simon, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{3,5} ; Sepracor, Inc. ³ ; UCB Pharma ³
Kelly H. Skelton, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Pfizer Inc. ⁵
Andrew E. Skodol, M.D.	National Institute of Mental Health ³
Gary W. Small	Abbott Laboratories, Inc. ^{1,5} ; Brainstorming Co. ¹ ; Dakim ^{1,6} ; Eisai Inc. ^{1,5} ; Forest Laboratories, Inc. ^{1,5} ; GlaxoSmithKline ³ ; Memory Fitness Institute ^{1,5} ; Myriad Genetics, Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Siemens ^{1,4}
Thomas E. Smith, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Pfizer Inc. ⁵

Presenter	Manufacturer(s)
Joyce C. West, Ph.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ³ ; Wyeth Pharmaceuticals ³
Timothy E. Wilens, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ³ ; NeuroSearch A/S ³ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ^{3,5} ; Pfizer Inc. ¹ ; Saegis ¹ ; Sanofi-Aventis ¹ ; Shire Pharmaceuticals Group plc. ^{3,5}
Jeffery N. Wilkins, M.D.	Alkermes, Inc. ^{1,3} ; CME LLC ¹ ; Forest Laboratories, Inc. ³ ; Hythiam Inc. ^{1,3}
Janet B.W. Williams, D.S.W.	American Psychiatric Press ⁴ ; Columbia University ² ; MedAvante, Inc. ¹
Solomon S. Williams, M.D.	Boehringer-Ingelheim Pharmaceuticals ²
M.E. Jan Wise, M.B.Ch.B.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ⁵
Thomas N. Wise, M.D.	Eli Lilly and Company ¹
Jesse H. Wright III, M.D.	Mindstreet ⁴ ; Pfizer, GlaxoSmithKline ⁵
Aysegul Yildiz-Yesiloglu, M.D.	AstraZeneca Pharmaceuticals LP ³ ; GlaxoSmithKline ³ ; Janssen-Cilag ³ ; Pfizer Inc. ³
Monique Yohanan, M.D.	Elan Pharmaceuticals, Inc. ⁴ ; Johnson and Johnson Pharmaceutical Research and Development ⁶
M. Scott Young, Ph.D.	Eli Lilly and Company ³
Mary C. Zanarini, Ed.D.	Eli Lilly and Company ^{1,3}
Phyllis C. Zee, M.D.	Kyowa Pharmaceuticals ³ ; Neurocrine Biosciences Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
Mark Zimmerman, M.D.	Bristol-Myers Squibb Company ⁵ ; GlaxoSmithKline ⁵ ; Wyeth Pharmaceuticals ⁵
Sidney Zisook, M.D.	Aspect Medical Systems ³ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{1,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Health ³ ; National Institute of Mental Health ³ ; PamLab ³
Joseph Zohar, M.D.	Lundbeck ³ ; Pfizer Inc. ³
Edward Zuzarte, M.D.	Pfizer Inc. ⁵

DISCLOSURE INDEX

Pascale Abadie, M.D.
Amina Abdulla, M.D.
Karen M. Abrams, M.D.
Beth L. Abramson, M.D.
Ronald Abramson, M.D.
Neal H. Adams, M.D.
Dominick Addario, M.D.
Lawrence W. Adler, M.D.
Lenard A. Adler, M.D.
Anna M. Agoston, B.A.
Sergio Aguilar-Gaxiola, M.D.
Abdulbaghi Ahmad, Ph.D.
Iqbal Ahmed, M.D.
Dov Aizenberg, M.D.
Dhatt Ajinder, M.D.
Tsuyoshi Akiyama, M.D.
Sören Akselson, M.D.
Fauzi Alam, M.D.
Renato D. Alarcon, M.D.
Ian E. Alger, M.D.
Yesne Alici-Evcimen, M.D.
Farhana Ali, M.A.
Andrea Allen, Ph.D.
Hanan Alraeesi
Mona H. Al-Sawaf, M.D.
Sharon L.A. Mozian, M.D.
Steven I. Alтчuler, M.D.
Evdokia Anagnostou, M.D.
Allan A. Anderson, M.D.
Naleen N. Andrade, M.D.
Nancy C. Andreasen, M.D.
Linda B. Andrews, M.D.
Jason Andrus, M.D.
Luiz M. Anez, Psy.D.
Emily Ansell, Ph.D.
Francesca C. Antognini, Ph.D.
Joan M. Anzia, M.D.
Paul S. Appelbaum, M.D.
Alan Apter, M.D.
Gisele Apter, M.D.
Julio E. Arboleda-Florez, Ph.D.
Britton A. Arey, M.D.
Albert J. Arias, M.D.
Arnoud Arntz, M.D.
Sanjay Arora, Ph.D.
William Arroyo, M.D.
Nadia Arshad, M.D.
Lori Ashcraft, Psy.D.
Kenneth Ashley, M.D.
Peter Ash, M.D.
Anu Asnaani
Robert W. Atkins, M.D.
R. Robert Auger, M.D.
Lina I. Augius, M.D.
Ron Aviram, Ph.D.
Mary Anne Badaracco, M.D.
Ursula F. Bailer, M.D.
Rahn K. Bailey, M.D.
Sue Bailey, M.D.
Brian Baker, M.D.
Mina Bak, M.D.
Anton van Balkom, Ph.D.
Bruce Ballon, M.D.
Azziza O. Bankole, M.D.
Yoram Barak, M.D.
Howard E. Barbaree, Ph.D.
Russell Barkley, Ph.D.
Nigel Bark, M.D.
Stefano Baroni, Ph.D.
Christina S. Barr, Ph.D.
Ellen F. Barr, L.C.S.W.
Thomas B. Barrett, M.D.
Ruth A. Barron, M.D.
Declan Barry, Ph.D.
Selena Bartlett, Ph.D.
Jennifer Bartz, Ph.D.
Yehuda Baruch, M.D.
Monica R. Basco, Ph.D.
Anthony Bateman, M.D.
Dorothy Bates, M.D.
Eraka Bath, M.D.
Mark S. Bauer, M.D.
Michael Bauer, M.D.
Antonia L. Baum, M.D.
Elizabeth A. Baxter, M.D.
Andreas Bechdorf, M.D.
Daniel F. Becker, M.D.
Deborah R. Becker, M.A.
Judith V. Becker, Ph.D.
Judith S. Beck, Ph.D.
Alan R. Beeber, M.D.
Dennis D. Beedle, M.D.
Aartjan T.F. Beekman
Leo Beem
Edgard Belfort, M.D.
Aysenil Belger
Morris D. Bell, Ph.D.
James D. Belluzzi, Ph.D.
Elissa P. Benedek, M.D.
Michael Berk
Heather Berlin, Ph.D.
Jason Bermak, M.D.
Silvia Bernardi, M.D.
Carol A. Bernstein, M.D.
David P. Bernstein, Ph.D.
Shyam K. Bhat, M.D.
Anjan Bhattacharyya, M.D.
Sarann Bielavitz
O. Joseph Bienvenu, M.D.
Gretchen Biesecker, Ph.D.
Stephen B. Billick, M.D.
Renee L. Binder, M.D.
Aurelia N. Bizamcer, M.D.
Paul Bizouard
Jed E. Black, M.D.
John L. Black, M.D.
Karen Blank, M.D.
Mel Blaustein, M.D.
Dan Blazzer, M.D.
Avi Bleich, M.D.
Hy Bloom, M.D.
Michael Blumenfield, M.D.
Nancee Blum, M.S.W.
Daniel I. Bober, D.O.
Daniela A. Boerescu, M.D.
Kimberley Bogan
Radmila Bogdanich, M.A.
Olivera J. Bogunovic, M.D.
Martin Bohus, M.D.
Vladimir Bokarius, MD, Ph.D.
Robert J. Boland, M.D.
Nicolas R. Bolo, Ph.D.
Antonello Bonci, M.D.
Dorret I. Boomsma, Ph.D.
Andrew Booty, M.D.
Nicolette Borek, Ph.D.
Nashaat N. Boutros, M.D.
Kimberly A. Bower, M.D.
Theron C. Bowers Jr, M.D.
John M. Bradford, F.R.C.P.C.
Douglas Braun-Harvey, M.A.
Farrell H. Brazziel, M.D.
Joel Bregman, M.D.
David H. Brendel, M.D.
Adam M. Brenner, M.D.
Jessica L. Broadway, M.D.
Thomas M. Brod, M.D.
Elizabeth Bromley, M.D.
Beth A. Brooks, M.D.
Richard P. Brown, M.D.
Travis O. Bruce, M.D.
William Bruce
Nancy B. Wallis, Ph.D.
Richard Buccigross
Alec Buchanan, M.D.
Gary T. Buckholz, M.D.
Peter J. Buckley, M.D.
Dinesh Bughra, Ph.D.
Viet Bui, M.D.
Ed T. Bullmore, M.D.
Clayton M. Bullock, M.D.
Ronald M. Burd, M.D.
Tracee Burroughs, M.D.
Harold J. Bursztajn, M.D.
Rami T. Bustami, Ph.D.
Fran Butler-Cohen, M.D.
Jeremy R. Butler, M.D.
Mirrat G. Butt, M.D.
Sarah Byford, Ph.D.
Robert P. Cabaj, M.D.
Claudio O. Cabrejos
Consuelo C. Cagande, M.D.
John Cairney, Ph.D.
Norana Caivano, M.D.
Charles F. Caley, Pharm.D.
Eve Caligor, M.D.
Alvaro Camacho, M.D.
Enrique R. Camarena, M.D.
Herbert L. Campbell, M.D.
Nioaka N. Campbell, M.D.
Ana E. Campo, M.D.
Olivier J. Canceil, Psy.D.
Angel A. Caraballo, M.D.
Robert Cardish, M.D.
Alex A. Cardoni, M.S.
Daniel J. Carlat, M.D.
Vladimir Carli, M.D.
Ian Carroll, M.D.
Matthew F. Carroll, M.D.
Cameron Carter, M.D.
Brady G. Case, M.D.
B.J. Casey, Ph.D.
Daniel Castellanos, M.D.
Mario Catena, M.D.
Samuel Chamberlain, Ph.D.
Frances A. Champagne, Ph.D.
Carlyle H. Chan, M.D.
Redonna K. Chandler, Ph.D.
Jacquelyn Chang, M.D.
Daniel P. Chapman, Ph.D.
Dana Charles, B.A.
Irene Chatoor, M.D.
Haroon R. Chaudhry, M.D.
Allison Chausmer, Ph.D.
Iwona Chelminski, Ph.D.
H. Chen
Tai-Jui Chen, M.D.
Xiangning Chen, Ph.D.
Amy H. Cheung, M.D.
Jeffrey Childers, M.D.
Anna R. Childress, Ph.D.
Austina Cho, M.D.
Wendy S. Chow, M.S.W.
Yujuan Choy, M.D.
Paul S. Ciechanowski, M.D.
Connie Clark, L.P.C.
David Clark, M.D.
Jennifer G. Clarke, M.D.
John F. Clarkin, Ph.D.
Timothy F. Cloughesy, M.D.
Ray E. Clouse, M.D.
Cristinel M. Coconcea, M.D.
C. Edward Coffey, M.D.
Carl I. Cohen, M.D.
Lee S. Cohen, M.D.
Mary Ann Cohen, M.D.
Christopher C. Colenda, M.D.
Nora Cole, M.Fd.
Pamela L. Collins, M.D.
Theodore M. Collins, Pharm.D.
Wilson M. Compton, M.D.
Timothy Condon, Ph.D.
Robert R. Conley, M.D.
Kathryn Connor, M.D.
Kevin P. Conway, M.D.
Jana Cook
Andrew Cooper, B.S.C.
Arnold Cooper, M.D.
Gabriela Cora-Locatelli, M.D.
Cheryl M. Corcoran, M.D.
Jay Corcoran, M.D.
Maurice Corcos, M.D.
Vladimir Coric, M.D.
Jack R. Cornelius, M.D.
Eduardo A. Correa, M.D.
Sara Corya, M.D.
Joan Cottler, M.S.W.
Francine Cournos, M.D.
Keith Courtney, M.D.
Kathleen A. Crapanzano, M.D.
M. Cornelia Cremens, M.D.
Brian Crowley, M.D.
Bernadette Cullen, M.D.
Jennifer Cummings, M.D.
Dina Dadabhoy, M.D.
Alain Dagher, M.D.

DISCLOSURE INDEX

R. Damodoran, Ph.D.
Donald A. Davidoff
Ian Dawe, M.D.
Max Day, M.D.
Anthony de Castella
John M. De Figueiredo, M.D.
Lea E. de Francisci Lis, M.D.
Matty de Wit, Ph.D.
Walter Deberdt, M.D.
Christopher deCharms, Ph.D.
Jack J. Dekker, M.D.
Salvador R. del Rosario, M.D.
Paul F. Dell, Ph.D.
Milagros Demandante, M.D.
Valfrido L. de-Melo-Neto, M.D.
Abhilash K. Desai, M.D.
Durisala Desaiiah, Ph.D.
Teresa Descilo, M.S.W.
Holland C. Detke, Ph.D.
M. Parameshavara Deva, M.D.
Amy R. Dewar, M.D.
Navdeep K. Dhaliwal, M.D.
Esperanza Diaz, M.D.
Daniel L. Dickerson, D.O.
Leah J. Dickstein, M.D.
Carlo DiClemente, Ph.D.
Kathleen Diller, M.D.
Hani Dimassi, Ph.D.
David F. Dinges, Ph.D.
Shilpa P. Diwan, M.D.
Mary I. Dobbins, M.D.
Seetal Dodd
Otto F. Doerr Zegers, M.D.
Karl Doghramji, M.D.
Sonia Dollfus, M.D.
Lourdes M. Dominguez, M.D.
Abigail L. Donovan, M.D.
Dennis M. Donovan, Ph.D.
David J. Dorer, Ph.D.
Carolyn J. Douglas, M.D.
Henry W. Dove, M.D.
John H. Draeger, M.D.
Carolyn M. Drazinic, M.D.
Jack Drescher, M.D.
Laura M. Drury, M.S.W.
Russell F. D'Souza, M.D.
Ken Duckworth, M.D.
Kenneth S. Duckworth, M.D.
Farifteh F. Duffy, Ph.D.
Rascha Dughly, M.D.
Katherine DuHamel, Ph.D.
Kitty Dukakis
Christine Dunn, M.A.
Jeff Dunn
Stephanie S. Durruthy, M.D.
Morris N. Eagle
Kamryn T. Eddy, Ph.D.
Ståle Einarsen, Ph.D.
Harold I. Eist, M.D.
Ahmed M. Elkashef, M.D.
Katherine Elliott, Ph.D.
Igor Elman
Marko Elovainio, Ph.D.
MaryJane England, M.D.
Steven A. Epstein, M.D.
Monique Ernst, M.D.
Javier I. Escobar, M.D.
Kimberly A. Espy, Ph.D.
Susan M. Essock, Ph.D.
Spencer Eth, M.D.
Amit E. Ettekal, M.D.
Karleyton C. Evans, M.D.
William D. Evans, Ph.D.
Harun Evcimen, M.D.
Anita S. Everett, M.D.
George Everly, Ph.D.
Kelvin Exum, M.D.
Anthony Fabio, Ph.D.
Michele Fabrazzo, M.D.
Nima A. Fahimian, M.D.
Rodolfo D. Fahrner, M.D.
Tatiana Falcone, M.D.
Bruno Falissard, Ph.D.
Jin Fan, Ph.D.
Ming-Yu Fan, Ph.D.
Amy H. Farabaugh, Ph.D.
Larry R. Faulkner, M.D.
Robert Faull, B.S.
Jan A. Fawcett, M.D.
John Fayyad, M.D.
Jamie Feldman, M.D.
Theodore Feldmann, M.D.
Antony Fernandez, M.D.
Stephen Ferrando
Frank D. Ferris, M.D.
Donald C. Fidler, M.D.
Robert Fink, M.D.
Michael B. First, M.D.
Lauren Fisher, B.A.
Joanna Fiszdon, Ph.D.
Paul Fitzgerald
Candace M. Fleming, Ph.D.
Heather L. Flett, M.D.
Chris Flood, M.S.C.
Julianne Flynn, M.D.
Laura J. Fochtman, M.D.
Peter Fonagy, Ph.D.
William W. Foote, M.D.
Charles V. Ford, M.D.
Julian D. Ford, Ph.D.
Peter F. Fore, M.D.
Marshall Forstein, M.D.
Edward F. Foulks, M.D.
Joanna S. Fowler, Ph.D.
Andrew J. Francis, M.D.
Frances R. Frankenburg, M.D.
Ryan Franke, M.D.
Guido K. Frank, M.D.
Debra L. Franko, Ph.D.
Joseph Frascella, Ph.D.
Lisa Fredman, Ph.D.
Kenneth F. Freedland, Ph.D.
Rafael C. Freire, M.D.
Kenneth Freundlich, Ph.D.
Larry Fricks
Peter D. Friedmann, M.D.
Rohn S. Friedman, M.D.
Susan H. Friedman, M.D.
Ronna Fried, M.D.
René Frydman
Glen O. Gabbard, M.D.
Geoffrey M. Gabriel, M.D.
William F. Gabrielli Jr, M.D.
Wolfgang Gaebel, M.D.
Cheryl Gagne, Sc.D
Marc Galanter, M.D.
Igor I. Galynker, M.D.
Krauz Ganadjian
B.N. Gangadhar, M.D.
Rohan Ganguli, M.D.
Stephen J. Ganocy, Ph.D.
Daniel Garza, M.D.
Tamara L. Gay, M.D.
Jeffrey L. Geller, M.D.
Patricia L. Gerbarg, M.D.
John A. Gergen, M.D.
Elizabeth V. Getter, M.D.
Kayhan Ghatavi, M.D.
Hamid Ghodse, M.D.
Ludovic Gicquel, M.D.
David A. Gilder, M.D.
David F. Gitlin, M.D.
Penny Glass, Ph.D.
Eric Glessner, L.C.S.W.
William Gnam, M.D.
John Godejahaun, R.N.
James Goertzen, M.D.
John W. Goethe, M.D.
R. Rao Gogineni, M.D.
Jessica Goin, M.D.
Robert M. Goisman, M.D.
David A. Goldberg, M.D.
Liza H. Gold, M.D.
Michael Goldstein, M.D.
Junius J. Gonzales, M.D.
Jose L. González de Rivera, M.D.
Gerardo Gonzalez, M.D.
Jodi M. Gonzalez, Ph.D.
Francisco Gonzalez-Lima, Ph.D.
Karl Goodkin, M.D.
Marianne S. Goodman, M.D.
Mary Jo Good, Ph.D.
Randy B. Goossen, F.R.C.P.C.
Edward Gordon, M.D.
Tracy R. Gordy, M.D.
Bonnie Gorscak
Diane B. Gottlieb, M.D.
Marco Grados, M.D.
Tana A. Grady-Weliky, M.D.
Robert P. Granacher, M.D.
Steven J. Grant, Ph.D.
Kevin F. Gray, M.D.
Laureen Gray, M.S.N.
Roger P. Greenberg, Ph.D.
Melva I. Green, M.D.
Michael F. Green, Ph.D.
Stephen A. Green, M.D.
Carl B. Greiner, M.D.
Denise Gretchen-Doorly, Ph.D.
Seena S. Grewal, M.D.
Dauda A. Griffin, M.D.
Edmund Griffin, M.D.
James L. Griffith, M.D.
Roland R. Griffiths, Ph.D.
Carlos M. Grilo, Ph.D.
Charles S. Grob, M.D.
Bernadette M. Grosjean, M.D.
Cornelius T. Gross, Ph.D.
Theresa Guarino, R.N.
Jon E. Gudeman, M.D.
Rachel G. Guerrero, M.S.W.
Marie-Claude Guertin
Salvador M. Guinjoan
John G. Gunderson, M.D.
Dipak K. Gupta, Ph.D.
Nitin Gupta, M.D.
Thomas G. Gutheil, M.D.
Sheila H. Gray, M.D.
John M. Haggarty, M.D.
Deborah J. Hales, M.D.
Geri R. Hall, Ph.D.
Katherine A. Halmi, M.D.
James P. Halper, M.D.
Scott D. Haltzman
Stephanie Hamarman, M.D.
Ann Hamer, Pharm.D.
Roy H. Hamilton, M.D.
Tom Hamilton, Ph.D.
Paul G. Hammerness, M.D.
Judith Hampel, R.N.
Edward Hanin, M.D.
William F. Haning III, M.D.
Richard K. Harding, M.D.
Larry J. Harmon, Ph.D.
Ansar M. Haroun, M.D.
Elizabeth Harre, M.D.
Alexandra M. Harrison, M.D.
Toi B. Harris, M.D.
David E. Hartman, Ph.D.
Lawrence Hartmann, M.D.
Nael M. Hasan, M.B.Ch.B.
Susan J. Hatters-Friedman, M.D.
Shivkumar S. Hatti, M.D.
Dan Haupt, M.D.
Peter Hauser, M.D.
Rochelle Head-Dunham, M.D.
Timothy Heeren, Ph.D.
Markus Heilig, M.D.
Claire Henderson, M.D.
Grace Hennessy, M.D.
Brian M. Hepburn, M.D.
Laurel H. Herbst, M.D.
Alison M. Heru, M.D.
Alfred Herzog, M.D.
David B. Herzog
Victor Hesselbrock, Ph.D.
Rosario Hidalgo
Napoleon B. Higgins Jr, M.D.
Mike Hill
Donald M. Hilty, M.D.
John Kevin Hines
Alan R. Hirsch, M.D.
Hans W. Hoek, M.D.
Steven K. Hoge, M.D.
Gavi Hollander, D.O.
Sheila C. Hollins, M.B.

DISCLOSURE INDEX

Paul E. Holtzheimer, M.D.
 Tjalling J. Holwerda, M.D.
 Jinger G. Hoop, M.D.
 Mardi Horowitz, M.D.
 Cyril Hoschl, M.D.
 Jouke-Jan Hottenga, M.D.
 Rory P. Houghtalen, M.D.
 Edmund G. Howe, M.D.
 Robert C. Hsiung, M.D.
 Pi-Fem Hsu, Ph.D.
 Liwei L. Hua, M.D.
 David L. Huang, M.D.
 Yueqin Huang, M.D.
 Paul E. Hubley
 Leighton Y. Huey, M.D.
 Robbin Huff-Musgrove, Ph.D.
 Nathalie Huguet, Ph.D.
 Dennis J. Hunt, Ph.D.
 Jon Hunter, M.D.
 Justin B. Hunt, M.D.
 Robin Hurley, M.D.
 Thomas D. Hurwitz, M.D.
 Mustafa M. Husain, M.D.
 Nisba F. Husain, M.D.
 Gerard Hutchinson, M.D.
 Steven E. Hyler, M.D.
 Marco Iacoboni, M.D.
 Chioma Iheagwara, D.O.
 James A. Inciardi, Ph.D.
 David Indest, M.D.
 Thomas R. Insel, M.D.
 Derya I. Akbiyik, M.D.
 Scott A. Irwin, M.D.
 JoAnne Isbey, A.B.
 Waguih W. IsHak, M.D.
 Yukio Ishizuka, M.D.
 Matti K. Isohanni, M.D.
 Yad M. Jabbarpour, M.D.
 Leslie K. Jacobsen, M.D.
 Marc Jacobs, M.D.
 Sandra Jacobson, M.D.
 Kamil Jaghab, M.D.
 Shaily Jain, M.D.
 Vivek Jain, M.D.
 Kay R. Jamison, M.D.
 Arshdeep S. Jawandha, M.D.
 J. Eric Jensen, Ph.D.
 Per Jensen, M.D.
 Robert Jesse
 David C. Jimerson, M.D.
 Thomas H. Jobe, M.D.
 Anja Jochims, M.A.
 Kyle P. Johnson, M.D.
 Shaneek Johnson, M.D.
 Sheri L. Johnson, Ph.D.
 Jari Jokelainen, M.S.C.
 Lynne M. Jones, M.D.
 Peter B. Jones, M.D.
 Linda M. Jorgenson, M.D.
 Robert C. Joseph, M.D.
 Allan M. Josephson, M.D.
 Nalini Juthani, M.D.
 Daniel Kajdasz
 Amir Kalali
 Peter W. Kalivas, M.D.
 Yifrah Kaminer, M.D.
 Gabriel Kaplan, M.D.
 Mark Kaplan, D.P.H.
 Aimee N. Karam, Ph.D.
 Elie G. Karam, M.D.
 Dan H. Karasic, M.D.
 Siegfried Kasper, M.D.
 Marianne Kastrup, MD
 Michael Kaufmann, M.D.
 Walter H. Kaye, M.D.
 Jerald Kay, M.D.
 Bob Kearley
 Kimmy S. Kee, Ph.D.
 John F. Kelly, Ph.D.
 Janet L. Kemp, M.D.
 Kenneth S. Kendler, M.D.
 Patrick J. Kennedy, B.A.
 Robert S. Kennedy
 Karin Kerfoot, M.D.
 Otto F. Kernberg, M.D.
 Matcheri Keshavan, M.D.
 David R. Kessler, M.D.
 Christian Keysers, Ph.D.
 Amir A. Khan, M.D.
 Aaron Kheriaty, M.D.
 Julia Kim-Cohen, Ph.D.
 H. Florence Kim, M.D.
 Jieun Kim, M.D.
 Scott Y. Kim, M.D.
 Thomas J. Kim, M.D.
 Brooks King-Casas, Ph.D.
 Kenneth Kirkby, M.D.
 Paul D. Kirwin, M.D.
 Mika Kivimäki, Ph.D.
 Donald F. Klein, M.D.
 Tara A. Klein, M.D.
 Mitchel A. Kling, M.D.
 Robert L. Klitzman, M.D.
 Raymond J. Kloss, M.D.
 Joachim Klosterkötter
 Joachim Knop, M.D.
 Richard Kogan, M.D.
 Dora D. Kohen, M.D.
 Michelle Koller, M.A.
 Robert Kolodner, M.D.
 Simone Kool, M.D.
 Hannu J. Koponen, M.D.
 Laura C. Kordon, M.D.
 Lorne Korman, Ph.D.
 Jason Kornberg
 Diana Koszycki, Ph.D.
 Kimberly Kotov, Ph.D.
 Athanasios Koukopoulos
 Igor Koutsenok
 Beatrice Kovasznay, M.D.
 Helena C. Kraemer, Ph.D.
 Lois E. Krahn, M.D.
 Milton Kramer, M.D.
 Harvey Kranzler, M.D.
 Louis J. Kraus, M.D.
 Maric-Odile Krebs, Ph.D.
 Mary J. Kreek, M.D.
 Daniel F. Kripke, M.D.
 Richard B. Krueger, M.D.
 Robert F. Krueger, Ph.D.
 Sanjiv Kumra, M.D.
 David J. Kupfer, M.D.
 Ralph Kupka
 Alyson Kuroski-Mazzei, M.D.
 Howard I. Kushner, Ph.D.
 Gary S. Kutcher, Ph.D.
 Alyssa S. Kwon, M.D.
 April S. Ladavac, M.D.
 Jaana Laitinen, M.A.
 Anita Lakatos, Ph.D.
 James Lake, M.D.
 Marc-André Laliberté, M.D.
 Claire Lamas
 Michael J. Lambert, Ph.D.
 H. Richard Lamb, M.D.
 Lucy Lamphere, B.A.
 John K. Lam-Po-Tang, M.B.B.S.
 Alisa J. Land, M.D.
 Joan A. Lang, M.D.
 John H. Langley, M.D.
 Karin Larsen, Ph.D.
 Erika Lauronen, M.D.
 Edward C. Lauterbach, M.D.
 Margo Lauterbach, M.D.
 Ella Lavun, M.D.
 Christopher M. Layne, Ph.D.
 Jose Lazaro
 Stephanie Le Melle, M.D.
 Barry D. Lebowitz
 Laurent Lecardeur
 Eugene Lee, M.D.
 Karen L. Lee, M.A.
 Morven Leese, Ph.D.
 Jennifer Lehto, R.N.
 Hoyle Leigh, M.D.
 Elizabeth LeQuesne, M.D.
 Frances Leslie, Ph.D.
 Patricia Lester, M.D.
 Modyn Leszcz, M.D.
 Philip G. Levensky, Ph.D.
 Hanna Levenson, Ph.D.
 Bennett L. Leventhal, M.D.
 Saul Levine, M.D.
 Stephen B. Levine, M.D.
 Stewart B. Levine, M.D.
 Robert D. Levitan, M.D.
 Teresa Levitin, Ph.D.
 Anthony J. Levitt, M.D.
 Alfred J. Lewy, M.D.
 Karen R. Liaw, M.D.
 Robert P. Liberman, M.D.
 Julio Licinio, M.D.
 Alisa Lincoln, Ph.D.
 Daniel Lin, Ph.D.
 Birgitta Lindelius
 Keng S. Lin, D.M.
 Paul S. Links, M.D.
 Benjamin Liptzin, M.D.
 Sarah H. Lisanby, M.D.
 Ting-Kai Li
 W. John Livesley, M.D.
 Gwenole Loas
 Richard J. Loewenstein, M.D.
 Fernando Lolas, M.D.
 Laura Lomax, Ph.D.
 Fabiana L. Lopes, M.D.
 Eduardo Lopez-Gibson
 Juan J. López-Ibor Jr., Ph.D.
 Lina M. Lopez, M.D.
 Miklos F. Losonczy, M.D.
 Anna Löthman, M.D.
 Robert J. Love, D.O.
 Eugene Lowenkopf, M.D.
 Naser F. Loza, M.D.
 Petra Ludaescher, M.A.
 Fvette Ludman, Ph.D.
 Francis G. Lu, M.D.
 Tanya Luhrmann, Ph.D.
 Maria Lujan, M.D.
 John Luo, M.D.
 Patrick J. Lustman, Ph.D.
 Camilla Lyons, M.D.
 Sandra A. Maass-Robinson, M.D.
 Helen M. Thomson
 Subramoniam Madhusoodanan, M.D.
 Maggie Magee, Psy.D.
 Rajnish Mago
 Olivier Maiza, M.D.
 Mario Maj, M.D.
 Pirjo H. Maki, M.D.
 Dolores Malaspina, M.D.
 Jason Malfait
 Amit Malik, M.B.B.S.
 Craig H. Mallinckrodt
 Carl P. Malmquist, M.D.
 Matthew T. Malone, D.O.
 Carla Mandili, M.D.
 Alan Z. A. Manevitz, M.D.
 Irakli Mania, M.D.
 Deanne Mannelid
 Stephan C. Mann, M.D.
 Gail H. Manos, M.D.
 John Manring, M.D.
 Ann M. Manzardo, Ph.D.
 Donatella Marazziti, M.D.
 Eric R. Marcus, M.D.
 Eve Maremont, M.D.
 Alina Marin, M.D.
 Humberto Marin, M.D.
 Robert S. Marin, M.D.
 Sondra Markle, R.N.
 Yuri Markman, Nuc.E.
 Dimitri D. Markov, M.D.
 Tracey I. Marks, M.D.
 Charles R. Marmar, M.D.
 Moises Martinez, M.D.
 Octavio N. Martinez, M.D.
 Michael J. Martin, M.D.
 Nancy C. Maruyama, M.D.
 Christine E. Marx, M.D.
 Mary Jane Massie, M.D.
 Yogi Matharu, O.C.S.
 Maju Mathews, M.D.
 Steve Mathias, M.D.
 Anu A. Matorin, M.D.
 S.G. Matta

DISCLOSURE INDEX

Yantao Ma, M.D.
Richard Mayeux, M.D.
Bernard Mazoyer, M.D.
Patrick S. Mbaya
Bentson Mc L'arland, M.D.
Thomas W. McAllister
Una D. McCann
Tracy H. McCarthy, M.D.
Diane McDiarmid
David M. McDowell
Shunda McGahce, M.D.
Michael D. McGee, M.D.
Paul R. McHugh, M.D.
J.M. McIntosh
Jack S. McIntyre, M.D.
Tammy F. McKinnon, M.S.W.
Alexandra B. McLean, M.D.
Shelley McMain, Ph.D.
Nancy L. McNaughton, Ed.M.
Laura McNicholas
Roger L. McRoberts
Maria E. Medina-Mora
Sarnoff Mednick, Ph.D.
David Mee-Lee, M.D.
Nadine Melhem, Ph.D.
Cesar Mella Mejias
Lisa Mellman, M.D.
J. Reid Meloy, Ph.D.
Reid Meloy, Ph.D.
Carolyn C. Meltzer, M.D.
Cathy Melvin, Ph.D.
W. Finar Mencl, Ph.D.
Anita Menfi, R.N.
Lara Menzies
Michael Mergener, Pharm.D.
Philip Merideth, M.D.
Kathleen R. Merikangas, Ph.D.
Joseph P. Merlino, M.D.
Robert O. Messing, M.D.
Donald J. Meyer, M.D.
Andreas Meyer-Lindenberg, M.D.
Adam L. Meyers
Marco A. Mezzasalma, M.D.
Danni Michaeli, M.D.
Thomas Mick, M.D.
Christel M. Middeldorp, M.D.
Jouko Miettunen, Ph.D.
Brian P. Mika, M.D.
Eva Mikkelsen, Ph.D.
Roseann Milad, B.S.C.
Gary E. Miller, M.D.
Brian P. Miller
Helen EJ Miller, M.B.Ch.B.
Paul R. Miller, M.D.
Richard D. Milone
Lucinda L. Miner, Ph.D.
David L. Mintz, M.D.
David Mischoulon, M.D.
James E. Mitchell, M.D.
Zeina Mneimneh, M.P.H.
David Mobley
Irma Moilanen, M.D.
Rachel C. Molander, M.D.
Victor A. Molinari, Ph.D.
Catherine Monk, Ph.D.
Read P. Montague, Ph.D.
Palmiero Monteleone, M.D.
Roger M. Montenegro, M.D.
Richard A. Montgomery, M.D.
William Montgomery
Ivan D. Montoya
Mike Monuteaux
Francisco A. Moreno, M.D.
Yannick Morvan, Psy.D.
Fayçal Mouaffak, M.D.
Driss Moussaoui, M.D.
Khalid A. Mufti, M.D.
Loretta Mulcare, B.S.
Franz Müller-Spahn, M.D.
Cheryl C. Munday, Ph.D.
Siham Muntasser, M.D.
Graham Murray, M.D.
Irvin L. Muszynski
Mark G. Myers, Ph.D.
Michael F. Myers, M.D.
Wade C. Myers, M.D.
David D. Myran, M.Fd.
Carol C. Nadelson, M.D.
Bonita Nahoum-Jaros, Ph.D.
Atsuo Nakagawa, M.D.
Gene A. Nakajima, M.D.
Surinder S. Nand, M.D.
Syed S.A. Naqvi, M.D.
Antonio E. Nardi, M.D.
William F. Narrow, M.D.
Isabella Nascimento, M.D.
John Nash Jr., M.D.
Vernon I. Nathaniel, M.D.
Johannes C. Ndlela, M.D.
Ali Nemat, M.D.
Gerald Nestadt, M.D.
Laura Nevill, M.S.N.
Antonia S. New, M.Div.
Cassandra F. Newkirk, M.D.
Thomas S. Newmark, M.D.
Jason Newsom, Ph.D.
Warren Y.K. Ng, M.D.
Saima Niaz, M.D.
Unaiza Niaz, M.D.
Alphonso F. Nichols, M.D.
Elizabeth J. Nickel, M.A.
Isabelle Nicolas
Fokko Nienhuis, M.A.
Caroline M. Nievergelt, Ph.D.
Jessica R. Nittler, M.D.
Billy D. Nix
Frank G. Njenga, M.B.Ch.B.
Richard L. Noel, M.D.
Leo O. Noragbon, M.D.
Grayson S. Norquist
Donna M. Norris, M.D.
Georg Northoff
Malkah T. Notman, M.D.
Richard J. Nunes, M.D.
Joel Oberstar, M.D.
Charles P. O'Brien, M.D.
Kevin Ochsner, Ph.D.
Thomas O'Connor, Ph.D.
Ahmed M. Okasha, M.D.
Tarek A. Okasha, M.D.
Violet A. Okech, M.Med.
John M. Oldham, M.D.
Dost Ongur
Desiree Oosterbaan, Ph.D.
Steven Oppenheim, M.D.
Maria A. Oquendo, M.D.
Patricia I. Ordorica, M.D.
Barbara Orłowski, Ph.D.
Alfredo O. Fragola, M.D.
Candice A. Osborn
Urban P. Osby, M.D.
Thomas O. Osinowo, M.D.
Ossama T. Osman, M.D.
Howard Osofsky, M.D.
Joy Osofsky, Ph.D.
David N. Osser, M.D.
Claes-Göran Östensson, M.D.
Britta Ostermeyer
Michael W. Otto, Ph.D.
Eugene A. Oulvey, Ph.D.
R Kaan Ozbayrak, M.D.
Ozgur Ozturk, M.D.
Sharon Packer, M.D.
Tanveer Padder, M.D.
Maria E. Pagano, Ph.D.
Clare Pain, M.D.
Stefano Pallanti, M.D.
Regina Pally, M.D.
Ilenia Pampaloni
Anand Pandya, M.D.
Rajesh M. Parikh, M.D.
Manuel Paris, Psy.D.
S.L. Parker, M.D.
Suzanna Parker
Grant V.S. Parr, M.D.
Irene Patelis-Siotis, M.D.
Michele T. Pato, M.D.
Beth Patterson, B.S.N.
Robindra K. Paul, M.D.
Rodrigo D. Paz, M.D.
Roger Peele, M.D.
Anna Pejlar
Jennifer D. Pender, M.D.
Maribeth Pender, Ph.D.
Elizabeth C. Penick, Ph.D.
Diane Pennesi
Vicenzio H. Perkins, M.D.
Daniel P. Perl
Claire Perrin
John R. Peteet, M.D.
Allan D. Peterkin
Timothy J. Petersen, Ph.D.
Roger H. Peters, Ph.D.
Roger H. Pfeifferbaum, M.D.
Steven E. Pflanz, M.D.
Bruce M. Pfohl, M.D.
Alexandra Pham-Scottez
Melissa P. Piasecki
Armando Piccinni, M.D.
Kate Pickett, Ph.D.
Claire Pierre, M.D.
Debra A. Pinals, M.D.
Daniel Pine, M.D.
Emil R. Pinta, M.D.
Anthony Pinto, Ph.D.
Scott Pizzarello
Eric M. Plakun, M.D.
Robert M. Plovnick, M.D.
David A. Pollack, M.D.
Jonathan D. Pollock, Ph.D.
Michael Poshkus, M.D.
David E. Post, M.D.
Michael A. Posternak, M.D.
Jerrold M. Post, M.D.
Alejandra Postlethwaite, M.D.
Robert M. Post, M.D.
Anne M. Pot
William Z. Potter, Ph.D.
Seth Powsner, M.D.
Michael Poyurovsky
Aparva Prakash, M.D.
Xavier A. Preud'Homme, M.D.
Julie C. Price, Ph.D.
Marilyn Pricc, M.D.
Stefan Priebe, M.D.
Christina M. Puchalski, M.D.
Derek Puddester
Kenneth R. Pugh, Ph.D.
Tara M. Pundiak, M.D.
Katherine Purnam, Ph.D.
Robert S. Pynoos, M.D.
Adam Quastel, M.D.
Alan Q. Radke, M.D.
Donald S. Rae
Sadeq Rahimi, Ph.D.
Umme S. Rahim, M.D.
Charles J. Rainey
Dilip Ramchandani, M.D.
Luis F. Ramirez, M.D.
Terri L. Randall, M.D.
Sonja Randle
Leah Ranney, Ph.D.
John Ranssen, Ph.D.
Paula Rantakallio, M.D.
Nyapati Rao, M.D.
Shanaya Rathod, M.D.
Varinder Rathore, M.D.
Paula Ravitz, M.D.
Nancy C. Raymond, M.D.
Annick Razafimandimby, Ph.D.
Maryam Razavi, M.D.
Patricia R. Recupero, M.D.
Joan Y. Reede, M.D.
Darrel A. Regier, M.D.
D. Bradford Reich, M.D.
James H. Reich, M.D.
Michele Reid, M.D.
William H. Reid, M.D.
Burton V. Reifler, M.D.
James L. Reilly, Ph.D.
Shauna P. Reinblatt, M.D.
James S. Reinhard, M.D.
Aaron Reliford, M.D.
Peter L. Remijnse
David Scott S. Resch, M.D.
Cynthia I. Resendez, M.D.

DISCLOSURE INDEX


Phillip J. Resnick, M.D.
 Pia Natalya Reyes, M.D.
 Raymond M. Reyes, M.D.
 Signy Reynisdottir, M.Div.
 Karen H. Rhea, M.D.
 Greg Richardson
 William A. Richards
 Josiah D. Rich, M.D.
 Mark A. Riddle, M.D.
 Muhamad Aly Rifai
 Marie-Claude Rigaud, M.D.
 Silvana Riggio, M.D.
 Helena Ring, M.D.
 Carleen A. Riselli, M.S.N.
 Candace B. Risen
 Karen A. Ritchie, Ph.D.
 Eva C. Ritvo, M.D.
 Guillermo C.R. Arroyo, Ph.D.
 Michael J. Rivkin, M.D.
 Diaa Rizk, M.D.
 Marion Robin, M.D.
 Carolyn B. Robinowitz, M.D.
 Beatrice E. Robinson, Ph.D.
 David J. Robinson
 Gail E. Robinson, M.D.
 Jacquelyn A. Robinson, M.D.
 Michael J. Robinson
 Charlotte A.L. Rocker, B.S.
 Patricia F. Rockman
 Gary Rodin, M.D.
 Manuel J. Rodriguez-Abuin, Ph.D.
 Mercedes M. Rodriguez, M.D.
 Jamison E. Rogers, M.D.
 Lodi Rohrer, M.P.H.
 Stephen J. Rojcewicz, M.D.
 John S. Rolland, M.D.
 Sarah E. Romans
 Emilio F. Romero
 Jason G. Roof, M.D.
 Mozhdah Roozegar, M.D.
 Erik Roskes, M.D.
 Marc Rothman, M.D.
 David A. Rothstein, M.D.
 Alec Roy, M.D.
 C. Nathaniel Roybal
 Gualberto Ruano, M.D.
 Maritza Rubio-Stipeç, M.D.
 Christian Rück, M.D.
 Stephen Ruedrich
 Alicia Ruelaz, M.D.
 Camilo J. Ruggero, Ph.D.
 Stephan Ruhmann, M.D.
 Amanda Ruiz
 Katherine G. Ruiz-Mellott, M.D.
 Pedro Ruiz, M.D.
 Rachel R. Rosenberg, M.A.
 L. Mark Russakoff, M.D.
 James Russell, M.D.
 Bret R. Rutherford, M.D.
 Carolyn Rutter, Ph.D.
 Jo-Ellyn M. Ryall, M.D.
 Sufyan Sabri, Ph.D.
 Joel Sadavoy, M.H.S.C.
 Sy A. Saeed, M.D.
 Steven A. Safren, Ph.D.
 Barbara Sahakian, Ph.D.
 Fabian M. Saleh
 Jack F. Samuels, Ph.D.
 Francis M. Sanchez, M.D.
 Charles A. Sanislow, Ph.D.
 George D. Santos, M.D.
 Marco Sarchiapone, M.D.
 Vedat Sar, M.D.
 Ryoko Sato, M.D.
 Erika Saunders, M.D.
 Sanjaya Saxena, M.D.
 Andrew J. Saxon, M.D.
 Kemal Sayar, M.D.
 Martin Schalling, M.D.
 Stephen C. Scheiber, M.D.
 Neil Scheurich, M.D.
 Randolph B. Schiffer
 Steven C. Schlozman, M.D.
 Christian Schmahl
 Chester W. Schmidt, Jr, M.D.
 Ulrike Schmidt, M.D.
 Barbara S. Schneiderman, M.D.
 Michael Schoenbaum, Ph.D.
 Gary R. Schoener, M.A.
 Robert A. Schoevers, Ph.D.
 Nicholas J. Schork, Ph.D.
 Agnes Schrier
 James Q. Schubmehl, M.D.
 Gunter Schumann, M.D.
 Ken Schwartz, M.D.
 Robert P. Schwartz, M.D.
 Andres Sciolla
 Charles L. Scott, M.D.
 Marcia Scott, M.D.
 William C. Scott, B.S.W.
 James H. Scully Jr., M.D.
 Deborah E. Seale, M.A.
 Michael Searls, M.D.
 Harry Sekhon
 Roslyn Seligman, M.D.
 Mark J. Sergi, Ph.D.
 Andreea L. Seritan, M.D.
 Daniel Sewell, M.D.
 Sandra B. Sexson, M.D.
 Amara Shabir
 David Shaffer, M.D.
 Amal Shamsan, M.D.
 Stephen B. Shanfield, M.D.
 Edward R. Shapiro, M.D.
 Steven S. Sharfstein, M.D.
 Santvana Sharma, M.D.
 Sonali Sharma, M.D.
 Burt Sharp, M.D.
 Carla Sharp, Ph.D.
 M. Tracie Shea, Ph.D.
 Shawn C. Shea, M.D.
 Hong Shen, M.D.
 Ramakrishnan Shenoy, M.D.
 Miyuki Shiida, M.S.W.
 Al Shimkunas, Ph.D.
 Ruth S. Shim, M.D.
 Erica Z. Shoemaker, M.D.
 Patrick Shrout, Ph.D.
 Derri Shtasel, M.D.
 Yin Shugart, Ph.D.
 Kenneth I. Shulman, M.D.
 David Shurtleff, Ph.D.
 Lawrence A. Siegel, M.D.
 Richard L. Siegel, M.D.
 Kenneth R. Silk, M.D.
 Ivan Silver, M.D.
 Richard A. Silverman, M.D.
 Suzanne Silverstein, M.A.
 Stuart B. Silver, M.D.
 Asher Simon, M.D.
 Robert I. Simon, M.D.
 Bruce S. Singh, M.D.
 Meeta Singh, M.D.
 Vivek Singh, MD
 Pinkhas Sirota, M.D.
 E. Yusuf Sivrioglu, M.D.
 Eline Slagboom
 James P. Slater, M.D.
 Marcia J. Slattery, M.D.
 William H. Sledge, M.D.
 Theodore A. Slotkin, Ph.D.
 Dana M. Small, Ph.D.
 Patrick Smallwood, M.D.
 Meg Smith, M.D.
 Martina Smit, M.D.
 Hugo A. Solari, M.D.
 Paul H. Soloff, M.D.
 Stephen M. Soltys, M.D.
 Shamsah B. Sonawalla, M.D.
 Latha Soorya, Ph.D.
 Eliot Sorel, M.D.
 Joannette A. Sorokin, M.D.
 Renee M. Sorrentino, M.D.
 Elizabeth R. Sowell, Ph.D.
 Jana Spalding
 Edgar Specer, Ph.D.
 Sean Spence
 Jacob Elliott Sperber, M.D.
 Deborah Spitz, M.D.
 Jorge C. Strabstein, M.D.
 Jagannathan Srinivasaraghavan, M.D.
 Apisamai Srirangson, M.D.
 Harvey Stabinsky, M.D.
 Susan Stabinsky, M.D.
 Jessica Stack
 Laurence R. Stanford, Ph.D.
 Joy E. Stankowski, M.D.
 Barbara H. Stanley, M.D.
 Sergio Starkstein, M.D.
 Amy B. Staub, M.B.A.
 Otto Steinfeldt-Foss, MD
 Marvin Steinberg, Ph.D.
 Harriet C. Stern, M.D.
 Hanna E. Stevens, M.D.
 Lisa Stevenson, Ph.D.
 Andrea Stolar, M.D.
 Alan A. Stone, M.D.
 Nada J. Stotland, M.D.
 Robert L. Stout, Ph.D.
 Norman L. Straker, M.D.
 Stephen M. Strakowski, M.D.
 Joshua L. Straus, M.D.
 David Streiner, Ph.D.
 Meg I. Striepe, Ph.D.
 T. Scott Stroup, M.D.
 Heather Stuart, Ph.D.
 Kenneth L. Subotnik, Ph.D.
 Li-Min Su, M.S.
 Ann Marie T. Sullivan, M.D.
 Mary A. Sullivan, M.D.
 Patrick F. Sullivan, M.D.
 Trey Sunderland, M.D.
 Young H. Sung, M.D.
 Stephen J. Suomi, Ph.D.
 Jillian Sussman, M.D.
 Marnina Swartz-Vanetik, M.D.
 John A. Sweeney, Ph.D.
 Annika Sweetland, M.S.W.
 John Robert Swenson, M.D.
 Ralph W. Swindle
 Bonnie S. Szarek, R.N.
 Eva M. Szigethy, M.D.
 George Szmukler, M.B.B.S.
 Anja Taanila, M.A.
 Caroline C. Tabet, M.A.
 Kavita Tahilani, B.S.
 Zebulon C. Taintor, M.D.
 Jatinder Takhar, M.D.
 John A. Talbott, M.D.
 Mahmoud S. Taman, M.D.
 Tuija Tammelin, M.A.
 Rajesh R. Tampi, M.B.B.S.
 Yoko Tanaka, Ph.D.
 Päiviikki Tanskanen, M.D.
 Allan Tasman, M.D.
 Faye S. Taxman, Ph.D.
 Craig B. Taylor, M.D.
 Lynn E. Taylor, M.D.
 Valerie Taylor, M.D.
 Roclof ten Doesschate, M.D.
 Mugdha E. Thakur, M.D.
 Ole J. Thienhaus, M.D.
 Graham Thornicroft, M.B.B.S.
 Maria L.A. Tiamson-Kassab, M.D.
 Jane G. Tillman, Ph.D.
 Lung Tint, M.D.
 Kay H. Titchenal, S.P.H.R.
 Anthony Tommasini, D.M.A.
 Lowell D. Tong, M.D.
 Jennifer Toomey, R.P.N.
 Sari Tormanen
 Alfonso Tortorella, M.D.
 Wilma L. Townsend, M.S.W.
 Brian C. Trainor, Ph.D.
 Michael R. Trimble
 Nhi-Ha T. Trinh, M.D.
 Carol L. Trippitelli, M.D.
 Susan Tross, Ph.D.
 Manuel Trujillo, M.D.
 Quynh Trzaskoma, M.S.
 Kuan-yi Tsai, M.D.
 Werner Tschan, M.D.
 Kuei-Yuan Tseng, Ph.D.
 Debbie Tsuang
 John W. Tsuang, M.D.

DISCLOSURE INDEX

Ming T. Tsuang
Wilco Tuinebreijer, M.D.
Douglas Turkington, M.D.
Judith A. Turner, Ph.D.
Jeffrey Tuttle, M.D.
Larry Tye
Peter Tyrer, M.D.
Nathalie Tzourio-Mazoyer, M.D.
Pichet Udomratn, M.D.
Jurgen Unutzer, M.D.
John C. Urbaitis, M.D.
Amy Ursano, M.D.
Robert J. Ursano, M.D.
Richard Uwakwe, M.B.B.S.
Ipsit Vahia, M.D.
Jussi Vahtera, Ph.D.
George Vaillant, M.D.
Alexandre M. Valença, M.D.
Eve Valera, Ph.D.
Rene J. Valles, M.D.
Gerda van Aalst, M.D.
Michael A. Van Ameringen, M.D.
Annemarie A. van Elburg, M.D.
Louis T. van Zyl, M.D.
Henricus Van, M.D.
Michael Vanyukov, Ph.D.
Sudeepa Varma, M.D.
James Varrell, M.D.
Monisha R. Vasa, M.D.
Meera Vaswani, Ph.D.
A. Vedamurthachar, Ph.D.
Juha M. Veijola, M.D.
Ricardo M. Vela, M.D.
Maria Velazquez, M.D.
Scott Veldhuizen, B.A.
Vytas Velyvis, M.A.
Jean-Luc Venisse
Joseph Ventura, Ph.D.
Marc Verbraak, Ph.D.
George I. Viamontes, M.D.
Ken Vickery, Ph.D.
Lisa Victor, Ph.D.
Kathy M. Vincent, M.D.
Jacqueline M. Vink, Ph.D.
Kateki Vinod, B.A.
Marianna Virtanen, Ph.D.
Alicia B. Vittone, M.D.
Frank Vocci, Ph.D.
Nora D. Volkow, M.D.
Serena Y. Volpp, M.D.
Charles F. von Gunten, M.D.
Michael Von Korff, Sc.D.
Pathik D. Wadhwa, M.D.
Angela Wagner, M.D.
Carl M. Wahlstrom, M.D.
Milton L. Wainberg
Harold J. Wain, Ph.D.
Marjorie E. Waldbaum, M.D.
Sandra C. Walker, M.D.
Willadene Walker-Schmucker, M.Ed.
Charles J. Wallace, Ph.D.
Chuck Wall, Ph.D.
Gene-Jack Wang, M.D.
Ting Wang, Ph.D.
Ying Wang
G. Scott Waterman, M.D.
Clarence Watson Jr, M.D.
Bruce B. Way, Ph.D.
Tristin Wayte, Ph.D.
Natalie D. Weder, M.D.
Priyanthy Weerasekera, M.D.
Colin A. Weil, Ph.D.
Daniel Weinberger
Richard Weiner
Stevan M. Weine, Ph.D.
Henry C. Weinstein, M.Div.
Richard H. Weisler, M.D.
Lydia E. Weisser, D.O.
David K. Wellisch, Ph.D.
Wan-Chen Weng, M.A.
Joseph J. Westermeyer, M.D.
Michael Westerveld, Ph.D.
Sara G. West, M.D.
Bruce E. Wexler, M.D.
Theodore H. Whitfield, Sc.D.
Paul H. Wick, M.D.
Durk Wiersma, Ph.D.
Denise Wilfley, Ph.D.
Kirsten M. Wilkins, M.D.
Joshua E. Wilk, M.D.
Gonneke Willemsen
Mark I. Willenbring, M.D.
Caroline B. Williams, M.D.
Eric R. Williams, M.D.
John W. Williams, M.D.
Monique M. Williams, M.D.
Marlene A. Wilson, Ph.D.
Sarah A. Wilson
Stephen N. Wilson, M.D.
Andreas Windemuth, Ph.D.
John W. Winkelman, M.D.
Dietmar Winkler, M.D.
Daniel K. Winstead, M.D.
Arnold Winston, M.D.
Jennifer P. Wisdom, Ph.D.
Aron S. Wolf, M.D.
Mary K. Wolfe, O.T.D.
Nicole F. Wolfe, M.D.
Vanessa Wong, M.D.
Stephen B. Woolley, D.Sc.
Jessica L. Worley
Linda L. M. Worley, M.D.
John J. Worthington, M.D.
Janet Wozniak, M.D.
Jeffrey R. Wozniak, Ph.D.
Lawson R. Wulsin, M.D.
Lex Wunderink, M.D.
John D. Wynn, M.D.
Roy Yaari, M.D.
Joel Yager, M.D.
David Yamada, J.D.
Chih-Wei Yang, M.D.
Chih-Yu Yang, Ph.D.
Yi-Hsin Yang, Ph.D.
Alayne Yates, M.D.
Mei-Chu Y. Jean, M.D.
Shirley Yen, Psy.D.
Frank E. Yeomans, M.D.
Albert S. Yeung, M.D.
Agul Yildiz
Tai P. Yoo, M.D.
Diane D. Young, Ph.D.
Jason Young
Keith W. Young, M.D.
Kaan Yucel, M.D.
Stuart C. Yudofsky, M.D.
Sun Y. Yum, M.D.
Deborah Yurgelun-Todd, Ph.D.
Theresa A. Yuschok, M.D.
Paul J. Zak, Ph.D.
Ari E. Zaretsky, F.R.C.P.C.
Gary Zarkin, Ph.D.
Thomas S. Zaubler, M.D.
Fangyi Zhao, Ph.D.
Xianjin Zhou, Ph.D.
Michael G. Ziegler, M.D.
Penelope P. Ziegler, M.D.
Juergen Zielasek, M.D.
Stephanie A. Zisook, M.D.
Beata A. Zolovska, M.D.
Howard V. Zonana, M.D.
Steven J. Zuchowski, M.D.
Allen Zweben, Ph.D.
Patricia Zybert, Ph.D.

American Psychiatric Association

CDs and Audiotapes
Recorded Live!



*High Quality Continues for
the 2007 Annual Meeting ...*

Live recordings will be available
for most of the following:

- Lectures • Advances in... Series
- Presidential Symposia •
- Scientific and Clinical Reports • Symposia
- Small Interactive Sessions
- Advances in Medicine

CDs and tapes may be purchased/ordered on site
at Mobiltape's booth at the San Diego Convention Center

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com

SATURDAY, MAY 19, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 1-4

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12:00 noon
Room 25 B, Upper Level, San Diego Convention Center

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman L. Straker, M.D.

COURSE 2 8:00 a.m.-12:00 noon
Room 25 C, Upper Level, San Diego Convention Center

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND TREATMENT

Director: Russell F. Lim, M.D.
Faculty: Candace Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Johannes C. Ndllela, M.D., Francis G. Lu, M.D., David C. Henderson, M.D.

COURSE 3 8:00 a.m.-12:00 noon
Room 26 A/B, Upper Level, San Diego Convention Center

THE EVALUATION, IDENTIFICATION, AND TREATMENT OF THE MAJOR DEMENTIAS

Co-Directors: Raymond A. Faber, M.D., Kevin F. Gray, M.D.
Faculty: Randolph B. Schiffer, M.D.

COURSE 4 8:00 a.m.-12:00 noon
Room 29 C, Upper Level, San Diego Convention Center

PSYCHIATRIC INTERVENTIONS IN DISASTER AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE

Co-Directors: Anthony T. Ng, M.D., Phebe M. Tucker, M.D.
Faculty: Judith A. Cohen, M.D.

9:00 a.m. Sessions



COURSES 5-9

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.
Room 25 A, Upper Level, San Diego Convention Center

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director: William H. Campbell, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 28 D, Upper Level, San Diego Convention Center

UPDATES IN GERIATRIC PSYCHIATRY 2007

Co-Directors: Rajesh R. Tampi, M.B.B.S., Kirsten M. Wilkins, M.D.
Faculty: Karin Kerfoot, M.D., Solomon S. Williams, M.D., Matthew T. Malone, D.O.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 29 B, Upper Level, San Diego Convention Center

THE CONCEPTUAL BASIS OF PSYCHIATRY

Co-Directors: Nassir Ghaemi, M.D., David H. Brendel, M.D.

COURSE 8 9:00 a.m.-4:00 p.m.
Room 29 D, Upper Level, San Diego Convention Center

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

Co-Directors: Shivkumar S. Hatti, M.D., Arthur L. Lazarus, M.D.
Faculty: Barry K. Herman, M.D., Stuart B. Silver, M.D., Sy A. Saeed, M.D., L. Mark Russakoff, M.D.

COURSE 9 9:00 a.m.-4:00 p.m.
Room 30 A, Upper Level, San Diego Convention Center

NEUROANATOMY OF EMOTIONS: FROM BRAIN TO CLINICAL PRACTICE

Director: Ricardo M. Vela, M.D.
Faculty: Francisco Gonzalez-Lima, Ph.D.

12:30 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 1-3

INDUSTRY SUPPORTED SYMPOSIUM 1

12:30 p.m.-3:30 p.m.

Marina Ballroom, South Tower, Level Three, Marriott

CLINICAL MANAGEMENT OF ADHD

Supported by Shire US, Inc.

Chp: Timothy E. Wilens, M.D.

A Office-Based Diagnosis

Keith McBurnett, Ph.D.

B Effective Psychotherapies for Adults With ADHD

Mary Solanto, Ph.D.

C Addressing Comorbidity in ADHD

Paul G. Hammerness, M.D.

D Addressing Treatment in Special Groups

Christopher J. Kratochvil, M.D.

E Managing Hypertension, Cardiovascular Issues, and SUD in ADHD

Timothy E. Wilens, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 2

12:30 p.m.-3:30 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

EXPERT DIALOGUE ON ALZHEIMER'S DISEASE: DIAGNOSTIC AND REFERRAL ISSUES, TREATMENT OF THE COGNITIVE DEFICITS, AMELIORATING THE BEHAVIOR COMPLICATIONS, AND COMPREHENSIVE MULTIDISCIPLINARY CARE

Supported by Forest Laboratories, Inc.

Chp: George T. Grossberg, M.D.

A Diagnostic and Referral Issues

William E. Reichman, M.D.

B Treating Cognitive Deficits in Patients With Alzheimer's Disease

Pierre N. Tariot, M.D.

C Ameliorating the Behavioral Complications in Patients With Alzheimer's Disease

Jacobo E. Mintzer, M.D.

D Comprehensive Multidisciplinary Care

Warachal E. Faison, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 3

12:30 p.m.-3:30 p.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

RECOGNITION AND MANAGEMENT OF RESTLESS LEGS SYNDROME IN PSYCHIATRIC PRACTICE

Supported by Boehringer Ingelheim Pharmaceuticals, Inc.

Chp: John W. Winkelman, M.D.

A Understanding RLS: Epidemiology and Clinical Features

Barbara A. Phillips, M.D.

B RLS-Associated Psychiatric Symptoms

Hochang B. Lee, M.D.

C Treatment Options for RLS

Jacques Montplaisir, M.D.

D The Psychiatrist's Role in Managing RLS

Jed E. Black, M.D.

E Clinical Pathways

John W. Winkelman, M.D.

1:00 p.m. Sessions



COURSES 10-13

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 10

1:00 p.m.-5:00 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN

Co-Directors: Shailla Misri, F.R.C.P.C., Diana Carter, M.B.B.S.

Faculty: Shari I. Lusskin, M.D., Maria R. Corral, M.D.,

Deirdre M. Ryan, F.R.C.P.C.

COURSE 11

1:00 p.m.-5:00 p.m.

Room 28 E, Upper Level, San Diego Convention Center

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Director: Ziad H. Nahas, M.D.

Faculty: Mark Demitrack, M.D., Frank A. Kozel, M.D., John

O'Reardon, M.D., Shirlene Sampson, M.D.

COURSE 12

1:00 p.m.-5:00 p.m.

Room 29 A, Upper Level, San Diego Convention Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.

COURSE 13 1:00 p.m.-5:00 p.m.

Room 29 C, Upper Level, San Diego Convention Center

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Co-Directors: Jesse H. Wright, M.D., Michael E. Thase, M.D.

Faculty: Monica R. Basco, Ph.D.

6:00 p.m. Sessions

LECTURE 1

6:00 p.m.-7:30 p.m.

San Diego Ballroom B,
North Tower, Lobby Level, Marriott

APA'S SIMON BOLIVAR AWARD LECTURE

Francisco Fernandez, M.D.

Hispanics and AIDS

Chp: Andres J. Pumariega, M.D.

Dr. Fernandez' clinical practice consists of consulting on patients with neurobehavioral disorders, psychiatric complications of cancer and AIDS, psychological factors affecting medical illness and end of life decision making, psychopharmacology, pain management, somatoform disorders, attention deficit disorder, memory dysfunction, Alzheimer's disease and other cognitive disorders. Detailing the psychiatric complications of medical illness such as HIV/AIDS, cancer, and end-stage organ disease requiring organ transplant. His main focus has been to assess effective treatment strategies for HIV-Minor Cognitive-Motor Disorder and HIV-Associated Dementia. Another area of research and clinical interest is that of Thanatology. Dr. Fernandez received his M.D. degree from Tuft's University School of Medicine and completed his psychiatry training at the Massachusetts General Hospital. Nationally, Dr. Fernandez is Chair of the American Psychiatric Association's Committee on AIDS and serves on the Steering Committee of the American Psychiatric Association's-CMHS funded AIDS Education Project. He has served on the American College of Psychiatrists PRITE Editorial Board since 1995 and was Editor-in-Chief from 2000-2005. He now serves on the Board of Regents for the American College of Psychiatrists. Prior to serving as Chair of Psychiatry and Behavioral Medicine at the University of South Florida, from 1997-2002 he was the Chair of the Department of Psychiatry and Behavioral Neurosciences at Loyola University Chicago, Stritch School of Medicine.

THIS SESSION WILL BE AUDIOTAPED.

INDUSTRY SUPPORTED SYMPOSIA 4-7

INDUSTRY SUPPORTED SYMPOSIUM 4

6:00 p.m.-9:00 p.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

INSIGHTS FROM STAR*D: ARE OUR PATIENTS' NEEDS BEING MET?

Supported by Cyberonics, Cephalon, & Wyeth

Chp: Maurizio Fava, M.D.

A Do Antidepressants Work in the Real World and for Whom?

Roy H. Perlis, Ph.D.

B Polypharmacy to Increase the Chances of Remission

Maurizio Fava, M.D.

C Switching Antidepressants: The STAR*D Experience

Michael E. Thase, M.D.

D Augmentation and Combination Strategies in Treatment-Resistant Depression

Alan F. Schatzberg, M.D.

E The Role of Psychotherapy as Adjunctive Treatment in Depression

Amy H. Farabaugh, Ph.D.

INDUSTRY SUPPORTED SYMPOSIUM 5

6:00 p.m.-9:00 p.m.

Marina Ballroom, South Tower, Level Three, Marriott

INSOMNIA: PRIMARY DIAGNOSIS OR SECONDARY SYMPTOM?

Supported by Merck & Co., Inc.

Chp: David J. Nutt, D.M.

A The State of Insomnia: Barriers to Recognition

Ruth M. Benca, M.D.

B Clinical Cross-Fire: Comorbid Insomnia Case Study

Mugdha E. Thakur, M.D., Xavier A. Preud'Homme, M.D.

C Pharmacological Progress in Insomnia

David J. Nutt, D.M.

INDUSTRY SUPPORTED SYMPOSIUM 6

6:00 p.m.-9:00 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

**CLINICAL SKILLS TO CLINICAL SCALES:
PRACTICAL TOOLS IN THE MANAGEMENT OF
PATIENTS WITH SCHIZOPHRENIA**

Supported by Pfizer Inc.

Chp: John M. Kane, M.D.

- A Monitoring Physical Health**
Stephen R. Marder, M.D.
- B Measuring and Managing Agitation**
Michael H. Allen, M.D.
- C Measuring Cognitive and Functional Outcomes in
Schizophrenia: A Practical Guide for Clinicians**
Rona Hu, M.D.
- D Measurement-Based Clinical Decision-Making in
Patients With Schizophrenia**
John M. Kane, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 7

6:00 p.m.-9:00 p.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

**THE PREVAILING PREDOMINANT POLE OF
BIPOLAR DEPRESSION**

Supported by GlaxoSmithKline

Chp: Mark A. Frye, M.D.

- A Neurobiology of Bipolar Depression: Implications for
Treatment**
Robert M. Post, M.D.
- B New Treatment Options for Bipolar Depression**
Marcia L. Verduin, M.D.
- C Clinical Correlates Associated With Treatment-
Emergent Mania**
Mark A. Frye, M.D.
- D The Clinical Interface Between Obesity and Bipolar
Depression**
Susan L. McElroy, M.D.
- E Clinical Challenges of Diagnosing and Treating
Adolescents With Bipolar Depression**
Kiki D. Chang, M.D.

SUNDAY, MAY 20, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 14-19

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 14 8:00 a.m.-12:00 noon

Room 23 A/B/C, Upper Level, San Diego Convention Center

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

COURSE 15 8:00 a.m.-12:00 noon

Room 25 C, Upper Level, San Diego Convention Center

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.

Faculty: Howard E. Book, M.D., Gary R. Schoener, M.A.,
Linda M. Jorgenson, M.A.

COURSE 16 8:00 a.m.-12:00 noon

Room 29 A, Upper Level, San Diego Convention Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.

COURSE 17 8:00 a.m.-12:00 noon

Room 29 B, Upper Level, San Diego Convention Center

PSYCHIATRIC CONSULTATION IN LONG TERM CARE: BASIC

Co-Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

COURSE 18 8:00 a.m.-12:00 noon

Room 29 C, Upper Level, San Diego Convention Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 19 8:00 a.m.-12:00 noon

Room 30 B, Upper Level, San Diego Convention Center

IMPROVING CLINICAL OUTCOMES: A PRACTICAL GUIDE TO EVIDENCE-BASED EMPLOYMENT AND RECOVERY PRACTICES

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.

Faculty: Connie Clark, L.P.C., Michael J. Martin, M.D.,
Shyam K. Bhat, M.D., Vivek Jain, M.D.

INDUSTRY SUPPORTED SYMPOSIA 8-12

INDUSTRY SUPPORTED SYMPOSIUM 8

8:00 a.m.-11:00 a.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

THE ONGOING DEBATE SURROUNDING ATYPICALS: ARE THE BENEFITS WORTH THE RISKS?

Supported by *Sohay Pharmaceuticals* and *Wyeth Pharmaceuticals*

Chp.: Stephen R. Marder, M.D.

A Balancing Between Efficacy and Side Effects
Samuel J. Keith, M.D.

B The Effect of Atypicals on Health Outcomes in Light of Pre-Existing Medical Risks
Henry A. Nasrallah, M.D.

C The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia
Elizabeth Bromley, M.D.

D New Mechanisms and Innovative Pharmacological Strategies
Stephen R. Marder, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 9

8:00 a.m.-11:00 a.m.

Marina Ballroom, South Tower, Level Three, Marriott

STILL SLEEPY AFTER ALL THESE CURES: HYPERSOMNIA IN PSYCHIATRY

Supported by *Cephalon, Inc.*

Chp.: Stephen M. Stahl, M.D.

A The Neurobiology of Hypersomnia
Stephen M. Stahl, M.D.

B The Clinical Spectrum of Hypersomnia
Daniel J. Buysse, M.D.

C Measurement of Hypersomnia
Meeta Singh, M.D.

D Strategies for the Management of Hypersomnia
Leslie P. Lundt, M.D.

E Prevalence and Consequences of Hypersomnia
Christopher L. Drake, Ph.D.

INDUSTRY SUPPORTED SYMPOSIUM 10

8:00 a.m.-11:00 a.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

DECONSTRUCTING ATTENTION AND COGNITION IN ADHD: NEW UNDERSTANDINGS FOR IMPROVED MANAGEMENT

Supported by McNeil Pediatrics and Otsuka America Pharmaceuticals, Inc.

Chp.: Thomas J. Spencer, M.D.

A Overview of ADHD

Thomas J. Spencer, M.D.

B Neurocircuitry in ADHD

George Bush, M.D.

C Neuropsychology in ADHD

Ronna Fried, M.D.

D Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults

Steven A. Safren, Ph.D.

E Pharmacological Treatment of ADHD: Focus on Attention

Timothy E. Wilens, M.D.

F Postactivity Measurement

Thomas J. Spencer, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 11

8:00 a.m.-11:00 a.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

LONG-TERM TREATMENT APPROACHES FOR SCHIZOPHRENIA: COMPARING MAINTENANCE AND RECOVERY MODELS

Supported by Bristol-Myers Squibb Company

Chp.: Peter J. Weiden, M.D.

A Maintenance and Recovery in Schizophrenia

Peter J. Weiden, M.D.

B Optimizing Existing Treatment Strategies: Individualizing Dosing and Adjunctive Pharmacotherapy

Rajiv Tandon, M.D.

C Enhancing Patient Outcomes by Improving Medication Tolerability

Daniel E. Casey, M.D.

D The Role of Cognitive Behavioral Therapy in the Treatment of Schizophrenia

Shanaya Rathod, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 12

8:00 a.m.-11:00 a.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

DARK HORIZONS: DEPRESSION AND COGNITIVE IMPAIRMENT

Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A The Epidemiology of genetic Studies of Depression and Memory

Richard Mayeux, M.D.

C The Biology of Depression and Dementia

Gary W. Small, M.D.

D Vascular Depression and Vascular Dementia

K Ranga R. Krishnan, M.B..

E The Course of Treatment for Patients With Questionable Dementia

Davangere P. Devanand, M.D.

F The Course of Treatment of Patients with Depression and Mild Cognitive Impairment

Roy H. Hamilton, M.D.

9:00 a.m. Sessions



COURSES 20-25

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 20

9:00 a.m.-4:00 p.m.

Room 25 A, Upper Level, San Diego Convention Center

SEEING THE FOREST AND THE TREES: A BIOPSYCHOSOCIAL APPROACH TO THE ORAL BOARD EXAMINATION

Director: William H. Campbell, M.D.

COURSE 21

9:00 a.m.-4:00 p.m.

Room 25 B, Upper Level, San Diego Convention Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.

Faculty: Katherine A. Halmi, M.D., James E. Mitchell, M.D., Denise Wilfley, Ph.D., Joel Yager, M.D.

COURSE 22 9:00 a.m.-4:00 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

**KUNDALINI YOGA MEDITATION TECHNIQUES
FOR MENTAL HEALTH**

Director: David S. Shannahoff-Khalsa, B.A.

COURSE 23 9:00 a.m.-4:00 p.m.

Room 28 D, Upper Level, San Diego Convention Center

**ACHIEVING PSYCHOTHERAPY EFFECTIVENESS:
PRACTICAL APPROACHES FOR CLINICIANS**

Co-Directors: Paula Ravitz, M.D., Melyn Leszcz, M.D.
Faculty: Nancy L. McNaughton, Ed.M., Allan D. Peterkin, M.D.,
Clare Pain, M.D., Jon Hunter, M.D.

COURSE 24 9:00 a.m.-4:00 p.m.

Room 29 D, Upper Level, San Diego Convention Center

**BASIC CONCEPTS IN ADMINISTRATIVE
PSYCHIATRY II**

Co-Directors: Shivkumar S. Hatti, M.D., Arthur L. Lazarus, M.D.
Faculty: William H. Reid, M.D., Robert W. Atkins, M.D.

COURSE 25 9:00 a.m.-4:00 p.m.

Room 30 A, Upper Level, San Diego Convention Center

**INTRODUCTION TO COGNITIVE-BEHAVIORAL
THERAPY**

Co-Directors: Robert M. Goisman, M.D., Philip G.
Levendusky, Ph.D.

12:30 p.m. Session

BUSINESS MEETING

(Voting Members Only*)

12:30 p.m.-1:30 p.m.
Ballroom 6 A, Upper Level, San Diego
Convention Center

CALL TO ORDER

Pedro Ruiz, M.D., *President*

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS

Billy E. Jones, M.D., *Chairperson, Committee of Tellers*

REPORTS TO THE MEMBERSHIP

Secretary-Treasurer: Donna M. Norris, M.D.
Speaker, Assembly: Michael Blumenfield, M.D.
Speaker-Elect, Assembly: Jeffrey Akaka, M.D.
Chairperson, Committee on Bylaws: Ramaswamy Viswanathan, M.D.

Chairperson, Elections Committee: Maria T. Lymberis, M.D.
Chairperson, Membership Committee: Joseph E.V. Rubin, M.D.
Medical Director and CEO: James H. Scully, Jr., M.D.
Chairpersons of Councils (Written Reports Only)

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished
Fellows, Fellows, Life Fellows, Distinguished Life Fellows,
and Life Members. Badge or APA membership card
necessary for admission. No cameras or tape recorders will
be permitted.

1:00 p.m. Sessions



COURSES 26-32

Course descriptions are available in the *CME
Course Brochure* included in your registration
packet. Admission by ticket only.

COURSE 26 1:00 p.m.-5:00 p.m.

Room 23 A/B/C, Upper Level, San Diego Convention
Center

**SLEEP MEDICINE REVIEW AND UPDATE FOR
PSYCHIATRISTS**

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Lois E. Krahn, M.D.

COURSE 27 1:00 p.m.-5:00 p.m.

Room 25 C, Upper Level, San Diego Convention Center

**EEG IN CLINICAL PRACTICE: INDICATIONS AND
LIMITATIONS**

Co-Directors: Nashaat N. Boutros, M.D., Silvana Riggio, M.D.

COURSE 28 1:00 p.m.-5:00 p.m.

Room 28 E, Upper Level, San Diego Convention Center

VAGUS NERVE STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Linda Carpenter, M.D., Bob Howland, M.D.,
Mitchell King, M.D., Mustafa Husain, M.D.

COURSE 29 1:00 p.m.-5:00 p.m.

Room 29 A, Upper Level, San Diego Convention Center

**CLINICIAN ADMINISTERED RATING SCALES FOR
MOOD AND ANXIETY DISORDERS**

Co-Directors: Sagar V. Parikh, M.D., Vytas Velyvis, M.A.

COURSE 30 1:00 p.m.-5:00 p.m.

Room 29 B, Upper Level, San Diego Convention Center

BIOETHICS 2007

Director: Edmund G. Howe, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.

Room 29 C, Upper Level, San Diego Convention Center

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright, M.D.

Faculty: David Kingdon, M.D., Douglas Turkington M.D.

COURSE 32 1:00 p.m.-5:00 p.m.

Room 30 B, Upper Level, San Diego Convention Center

WEB-BASED CADI, BEHAVIORAL HEALTHCARE, AND CMHCS

Director: Paul R. Miller, M.D., Karen H. Rhea, M.D.

Faculty: Charles Chiu, M.D., Linda Rosenberg, M.S.W., Tom Doub, Ph.D., Charles Johnson, Ph.D.

1:30 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 13-17

INDUSTRY SUPPORTED SYMPOSIUM 13

1:30 p.m.-4:30 p.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

PLANNING FOR SUCCESS IN SCHIZOPHRENIA MANAGEMENT

Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Dilip V. Jeste, M.D.

- A Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients**
Peter J. Weiden, M.D.
- B Strategies for Assessing and Managing Adherence**
Dilip V. Jeste, M.D.
- C Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, and Psychosocial Strategies**
Dawn I. Velligan, Ph.D.
- D Case Presentations of Adherence Dilemmas**
David P. Folsom, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 14

1:30 p.m.-4:30 p.m.

Marina Ballroom, South Tower, Level Three, Marriott

MAKING EVERY SHEEP COUNT: EVIDENCE-BASED APPROACHES TO TREATING INSOMNIA

Supported by Takeda Pharmaceuticals North America, Inc.

Chp.: Daniel J. Buysse, M.D.

- A The Clinical Neuroscience of Sleep and Insomnia**
Daniel J. Buysse, M.D.

- B Comorbidity Between Insomnia and Psychiatric Illness**
Meera Narashimhan, M.D.

- C Novel Pharmacological Targets for the Management of Insomnia**
Ruth M. Benca, M.D.

- D Innovative Behavioral Approaches for Treating Insomnia and Comorbid Psychiatric Illness**
Karl Doghramji, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 15

1:30 p.m.-4:30 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

OPTIMIZING OUTCOMES ACROSS THE SPECTRUM OF DEMENTIA

Supported by Eisai, Inc.

Chp.: Pierre N. Tariot, M.D.

- A Blending Science and Best Practice Banner Across the Dementia Spectrum**
Pierre N. Tariot, M.D.
- B An Office-Based Approach to Early and Accurate Diagnosis**
Roy Yaari, M.D.
- C Normal Aging, Amnesic MCI, or AD: Managing and Treating Across the Whole Spectrum**
Pierre N. Tariot, M.D.
- D Management of Behavioral Disturbances in Alzheimer's Disease**
Jeffrey L. Cummings, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 16

1:30 p.m.-4:30 p.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

RETHINKING BIPOLAR DISORDER: IMPLICATIONS OF COMORBIDITIES

Supported by AstraZeneca Pharmaceuticals

Chp.: Gary S. Sachs, M.D.

- A Medical Comorbidities With Bipolar Disorder**
Gary S. Sachs, M.D.
- B Comorbid Substance Abuse in Bipolar Disorder**
Michael J. Ostacher, M.D.
- C Suicidality as a Component of Bipolar Disorder**
Lauren Marangell, M.D.
- D PTSD and Bipolar Disorder: Critical Overlaps and Possible Links in Pathology and Treatment**
Lori L. Davis, M.D.
- E Neuroimaging of Dual Diagnoses**
Stephen M. Strakowski, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 16

1:30 p.m.-4:30 p.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

CARING FOR OUR MOST CHALLENGING PATIENTS WITH DEPRESSION: AN INTERACTIVE FORUM ON NOVEL TREATMENTS*Supported by Cyberonics, Inc.***Chp.:** Charles B. Nemeroff, M.D.

- A Mechanism of Action of Vagus Nerve Stimulation**
Charles B. Nemeroff, M.D.
- B Assessing the Efficacy of Vagus Nerve Stimulation in Patients With Treatment Resistant Depression**
Paul Holtzheimer, M.D.
- C Efficacy of Repetitive Transcranial Magnetic Stimulation and Magnetic Seizure Therapy**
Thomas Schlaepfer, M.D.
- D Mechanism of Action and Efficacy of Deep Brain Stimulation**
Helen Mayberg, M.D.

2:30 p.m. Session**LECTURE 2**

2:30 p.m.-4:00 p.m.

Room 33 A/B/C, Upper Level,
San Diego Convention Center**AAPL/APA'S MANFRED GUTTMACHER
AWARD LECTURE**

Carl P. Malmquist, M.D.

Adolescent Parricide**Chp.:** Patricia R. Recupero, M.D.

Carl P. Malmquist, M.D., M.S., is a psychiatrist, board-certified in Adult Psychiatry, Child and Adolescent Psychiatry, Forensic Psychiatry, and with added qualification in Forensic Psychiatry. He is a Professor of Social Psychiatry at the University of Minnesota, and has also taught in areas of criminology and law. He has also done consultation work for district courts and private law firms.

THIS SESSION WILL BE AUDIOTAPED.**5:00 p.m. Session****OFFICIAL OPENING SESSION**

5:00 p.m.-6:30 p.m.

Ballroom 20, Upper Level, San Diego
Convention Center**CALL TO ORDER**Pedro Ruiz, M.D., *President***INTRODUCTION OF STAGE GUESTS****INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE**

Robert W. Guynn, M.D.

*Chairperson, Annual Meeting Scientific Program Committee***INTRODUCTION OF VISITING****DIGNITARIES** (*Please refer to pages 11-14 for a listing of
the presidents of allied organizations.*)**PRESIDENTIAL ADDRESS**

Pedro Ruiz M.D.

*To be introduced by Jack S. McIntrye, M.D.***RESPONSE OF THE PRESIDENT-ELECT**

Carolyn B. Robinowitz, M.D.

*To be introduced by James H. Scully Jr., M.D.***ADJOURNMENT****7:00 p.m. Sessions****INDUSTRY SUPPORTED SYMPOSIA 18-21****INDUSTRY SUPPORTED SYMPOSIUM 18**

7:00 p.m.-10:00 p.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

**HOW COMORBID IS ADHD? RESULTS FROM
EPIDEMIOLOGICAL AND CLINICAL STUDIES***Supported by Shire US, Inc.***Chp.:** Joseph Biederman, M.D.

- A Patterns of Comorbidity in Longitudinal Sample of Boys and Girls with ADHD**
Joseph Biederman, M.D.
- C Patterns of Comorbidity in a Clinical Sample of Adults with ADHD**
Thomas J. Spencer, M.D.
- D Patterns of Comorbidity in a Community Sample of Adults with ADHD: Results from the National Comorbidity Survey**
Ronald C. Kessler, M.D.

(Continued next page)

E Morphometric Findings in Adults With ADHD With and Without Comorbid Bipolar Disorder
Mike Monuteaux, Sc.D.

F Spectroscopic Findings in Children and Comorbid Bipolar Disorder
Constance M. Moore, Ph.D.

INDUSTRY SUPPORTED SYMPOSIUM 19

7:00 p.m.-10:00 p.m.

Marina Ballroom, South Tower, Level Three, Marriott

**THE ALCOHOL DEPENDENT PATIENT:
IMPROVING OUTCOMES THROUGH ADHERENCE**

Supported by Cephalon, Inc. and Alkermes

Chp.: Robert M. Swift, M.D.

A Patient Adherence in the Treatment of Alcohol Dependence: The Journey of Recovery
Roger D. Weiss, M.D.

B Pharmacotherapeutic Options for the Management of Alcohol Dependence: Importance of Adherence
Robert M. Swift, M.D.

C Patient Readiness: Implications for Adherence and Management of Alcohol Dependence
Carlo C. DiClemente, Ph.D.

D Implementing Adherence-Enhancing Strategies in Clinical Practice: Negotiating Within the Therapeutic Alliance
Albert J. Arias, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 20

7:00 p.m.-10:00 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

WEIGHING THE RISKS AND BENEFITS OF ATYPICAL ANTIPSYCHOTICS: CAN WE HAVE OUR CAKE AND EAT IT TOO?

Supported by Bristol-Myers Squibb Company

Chp.: Henry A. Nasrallah, M.D.

A High Morbidity and Mortality in Schizophrenia and Bipolar Disorder: What, Why, and How?
Quinton E. Moss, M.D.

B Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons from the CATIE Schizophrenia Trial
Donald C. Goff, M.D.

C The Dual Health Jeopardy in Schizophrenia: Highly Prevalent Metabolic Disorders and Low Access to Medical Treatment
Henry A. Nasrallah, M.D.

D Lessons from ATPIII, the ADA, and the APA Workgroup on Antipsychotics and Metabolic Risk
John W. Newcomer, M.D.

E Patient, Provider, and System Level Approaches to Reducing Risk of Poor Health Outcomes in Patients Receiving Antipsychotics
Lisa B. Dixon, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 21

7:00 p.m.-10:00 p.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

STAR*D FINDINGS: IMPLICATIONS FOR PATIENTS, CLINICIANS, AND OTHER STAKEHOLDERS

Supported by Forest Laboratories, Inc.

Chp.: Grayson S. Norquist, M.D.

A Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes
Junius J. Gonzales, M.D.

B STAR*D: Selecting Among First and Second Step Acute Treatments: Level One and Level Two
Marlene P. Freeman, M.D.

C Treatments After the First Two Steps Including Follow-Up: Level Three and Level Four
A. John Rush, M.D.

D The Role of Other Treatment Options in Managing Depression
K Ranga R. Krishnan, M.B..

2007 Presidents of Allied Organizations

Academy of Organizational and Occupational Psychiatry

Steven E. Pflanz, M.D.

Academy of Cognitive Therapy

Robert Leahy, Ph.D.

Algerian Psychiatric Association

Farid Kacha, M.D.

American Academy of Addiction Psychiatry

Michael H. Gendel, M.D.

American Academy of Child and Adolescent Psychiatry

Thomas F. Anders, M.D.

American Academy of Family Physicians

Rick Kellerman, M.D.

American Academy of Neurology

Stephen M. Sergay, M.B.

American Academy of Psychiatry and the Law

Alan R. Felthous, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry

Sherry P. Katz-Bearnot, M.D.

American Association for Emergency Psychiatry

Avrim B. Fishking, M.D.

American Association for Social Psychiatry

Steven S. Sharfstein, M.D.

American Association for the Advancement of Science

David Baltimore, Ph.D.

American Association of Chairs of Departments of Psychiatry

Peter F. Buckley, M.D.

American Association of Community Psychiatrists

Wesley Sowers, M.D.

American Association of Directors of Psychiatric Residency Training

Mark Servis, M.D.

American Association of Practicing Psychiatrists

Janis G. Chester, M.D.

American Association on Mental Retardation

Hank Bersani, Ph.D.

American Board of Psychiatry and Neurology, Inc.

Michael V. Johnston, M.D.

American College of Emergency Physicians

Brian F. Keaton, M.D.

American College of Mental Health Administration

Eric N. Goplerud, Ph.D.

American College of Obstetricians and Gynecologists

Douglas E. Laube, M.D.

American College of Physicians-American Society of Internal Medicine

David C. Dale, M.D.

American College of Psychiatrists

Fawzy I. Fawzy, M.D.

American College of Psychoanalysis

Harriet Wolfe, M.D.

American College of Surgeons

Edward M. Copeland III M.D.

American Group Psychotherapy Association

Elizabeth Knight, M.D.

American Medical Association

William G. Pleased III, M.D.

American Medical Women's Association

Susan Ivey, M.D.

American Neurological Association

Stephen Hauser, M.D.

American Neuropsychiatric Association

Fred Ousiew, M.D.

American Nurses Association

Rebecca Patton, M.S.N

American Orthopsychiatric Association

Diane Willis, M.D.

American Psychiatric Association Alliance

Kay Brada

American Psychoanalytic Association

K. Lynne Moritz, M.D.

American Psychological Association

Sharon Stephens Brehm, Ph.D.

American Psychosomatic Society

William Lorallo, Ph.D.

American Society for Adolescent Psychiatry

Mohan Nair, M.D.

American Society of Addiction Medicine

Michael M. Miller, M.D.

American Society of Clinical Psychopharmacology, Inc.

John M. Kane, M.D.

American Society of Hispanic Psychiatrists

Manuel Trujillo, M.D.

Arab American Psychiatric Association

Abdel F. Amin, M.D.

Arab Gulf Psychiatric Association

Professor Mohamed K. Al-Haddad

Argentinean Association of Psychiatrists

Nestor F. Marchant, M.D.

Armenian Association of Psychiatrists and Narcologists

Professor Marietta Melik-Pashayan

Asociacion Espanola de Neuropsiquiatria

Alberto Fernandez Liria

Association for Academic Psychiatry

Patrick O'Neill, M.D.

Association for Behavioral and Cognitive Therapies

Raymond DiGiuseppe, Ph.D.

2007 Presidents of Allied Organizations

Association of American Medical Colleges

Darrel Kircb, M.D.

Association of Chinese American Psychiatrists

Edmond H. Pi, M.D.

Association of Directors of Medical Student Education in Psychiatry

Theodore B. Feldman, M.D.

Association of Free Psychiatrists of Romania

Professor Aurel Romila

Association of Gay and Lesbian Psychiatrists

Dan H. Karasic, M.D.

Association of Korean American Psychiatrists

Tai Pyung Yoo, M.D.

Association of Psychiatrists in Nigeria

Professor Oye Gureje

Association of Psychiatrists of Tajikistan

Abduvakhid Baibabaev, M.D.

Association of Psychiatrists of Uzbekistan

Ulugbek Alimov

Association of Reformers in Psychiatry

Professor Toma Tomov

Association of Women Psychiatrists

Mary Kay Smith, M.D.

Austrian Association for Psychiatry and Psychotherapy

Christoph Stuppach

Bangladesh Association of Psychiatrists

A.K.M. Nazimuddowla Chowdhury

Barbados Association of Psychiatrists

Gajapathy Asokan, M.D.

Black Psychiatrists of America

Cassandra Newkirk, M.D.

Bolivian Society of Psychiatry

Everth Montano Ferrufino, M.D.

Brazilian Association of Psychiatry

Josimar M.F. Franca

Bulgarian Psychiatric Association

Vladimir Velinov, M.D.

Byelorussian Psychiatric Association

Professor Roman A. Evsegneev

Canadian Psychiatric Association

Manon Charbonneau, M.D.

Caribbean Psychiatric Association

Jacqueline Sharpe, M.D.

Chinese Society of Psychiatry

Professor Dongfeng Zhou

Colombian Psychiatric Association

Carlos A. Felizgola Donado, M.D.

Costa Rican Psychiatric Association

Rigoberto Castro Rojas, M.D.

Council of Medical Specialty Societies

Carol Berkowitz, M.D.

Croatian Psychiatric Association

Ljubomir Holujac

Cyprus Psychiatric Association

Argyris Argyriou, M.D.

Czech Psychiatric Association

Jiri Raboch

Danish Psychiatric Association

Dorte Sestoft, M.D.

Depression and Bipolar Support Alliance

Susan R. Bergeson, M.D.

Dominican Society of Psychiatry

Martha Diaz, M.D.

Ecuadorian Association of Psychiatry

Fabrizio Delgado Campodonico, M.D.

Egyptian Psychiatric Association

Professor Ahmed Okasha

Estonian Psychiatric Association

Andres Lehtmets, M.D.

Ethiopian Psychiatric Association

Mesfin Araya, M.D.

Finnish Psychiatric Association

Professor Matti Joukamaa

Flemish Neurologists and Psychiatrists

J. Peuskens, M.D.

Foundation for Interdisciplinary Investigation of Communication

Professor Miguel Angel Materazzi

Francophone Int'l Federation of Psychiatry

Francois Caroli, M.D.

French Association of Psychiatrists in Private Practice

Jean-Jacques Labouliere

French Association of Psychiatry

Professor Christian C. Vasseur

French Psychiatric Information Society

Nicole Garret-Gloanec, M.D.

Ghana Psychiatric Association

Sammy Hene, M.D.

Group for the Advancement of Psychiatry

Lois Flaherty, M.D.

Guatemalan Psychiatric Association

Edgar R Vasquez Trujillo, M.D.

Hellenic Psychiatric Association

Nikolaos Tzavaras

Hellenic Society of Neurology and Psychiatry

Professor Costas Stefanis

Honduran Society of Psychiatry

Sara Maria Murillo Antunez, M.D.

Hong Kong College of Psychiatrists

Chun Wai Lo, M.D.

Hungarian Psychiatric Association

Ferenc Tury

Icelandic Psychiatric Association

Kristofer Porleifsson, M.D.

2007 Presidents of Allied Organizations

Independent Psychiatric Association of Russia

Professor Yury Savenko

Indian Association for Social Psychiatry

Professor Anil Malhotra

Indo-American Psychiatric Association

Asha S. Mishra, M.D.

Indonesian Psychiatric Association

H.M. Syamsulbadi

International Association for Cognitive Psychotherapy

Robert Leahy, Ph.D.

International Society of Psychopathology of Expression

Guy Roux, M.D.

Iranian Psychiatric Association

Professor Ahmad Jalili

Iraqi Psychiatric Association

Muhammed R Lafta, M.B.B.S.

Irish College of Psychiatrists

Kathleen Ganter, M.D.

Israeli Psychiatric Association

Avi Bleich

Italian Association for Research in Schizophrenia

Professor Carlo L. Cazzullo

Italian Psychiatric Association

Professor Eugenio Aguglia

Italian Psychiatric Society

Mario Maj, M.D.

Ivory Coast Association of Psychiatry

Professor Joseph Delafosse

Jamaican Psychiatric Association

G. Leveridge, M.D.

Japanese Society of Psychiatry and Neurology

Takuya Kojima

Jordan Association of Psychiatrists

Tawfik Daradkeh, M.D.

Kazakh Association of Psychiatrists and Narcologists

Professor Boris Dubinin

Kenya Psychiatric Association

Frank G. Njenga, M.D.

Korean Neuropsychiatric Association

Young Cho Chung

Kuwait Psychiatric Association

Essam A. Al-Ansari

Kyrgyz Science and Practical Comm of Psychiatrists

Professor Valery Solojenkin

Latin American Psychiatric Association

Rafael Navarro, M.D.

Latvian Psychiatric Association/ Medical Academy of Latvia

Raisa Andrezjina

League of Mental Health from Republic of Moldova

Mihail Hotineanu, M.D.

Lebanese Psychiatric Society

Charles Baddoura

Lithuanian Psychiatric Association

Algirdas Dembinskas

Luxembourgese Society of Psych, Neurology and Psychotherapy

Chretien Jacoby, M.D.

Malaysian Psychiatric Association

Professor Maniam Thambu

Mauritius Psychiatric Association

Parmannun Jagannath, M.D.

Medical Psychological Society

Professor J.G. Veyrat

Mexican Psychiatric Association

Jesus Del Bosque Garza

Mexican Society of Neurology Psychiatry

Juan Ignacio Rosales, M.D.

Mongolian Mental Health Association

Bayankbuu Ayushjav, M.D.

Moroccan Society of Psychiatry

Nadia Kadri

National Alliance For Research on Schizophrenia and Depression

Constance E. Lieber, M.D.

National Alliance on Mental Illness

Suzanne Vogel-Scibilia, M.D.

National Association of Psychiatric Health Systems

Diana L. Ramsey, M.D.

National Association of Social Workers, Inc.

Elvira Craig de Silva, D.S.W

National Council for Community Behavioral Healthcare

Linda Rosenberg, M.S.W

National Institute of Mental Health

Thomas R. Insel, M.D.

National Institute on Drug Abuse

Nora D. Volkow, M.D.

National Mental Health Association

David L. Sbern, Ph.D.

Netherlands Psychiatric Association

Professor R.S. Kahn

Nicaraguan Psychiatric Association

Luis Aleman Neyra, M.D.

Norwegian Psychiatric Association

Gerd-Ragna Bloch Thorsen, M.D.

Palestinian Psychiatric Association

Bassam Al Ashhab, M.D.

Panamanian Society of Psych

Jose Calderon, M.D.

Papua New Guinea Psychiatric Association

Monica Hagali, M.D.

Paraguayan Society of Psychiatry

Manuel A Fresco, M.D.

Peruvian Psychiatric Association

Marta Rondon

Philippine Psychiatrists in America

Nestor Riel, M.D.

2007 Presidents of Allied Organizations

Philippines Psychiatric Association

Pureza Trinidad-Onate, M.D.

Polish Psychiatric Association

Professor Jacek Wciorka

Portugese Association of Psychiatry

Jose C. Dias Cordeiro, M.D.

Portugese Association of Psychiatry and Mental Health

Professor Adriano Vaz-Serra

Psychiatric Association of Macedonia

Professor Predag Kirovski

Psychiatric Association for East Europe and the Balkans

George Christodoulou

Psychiatric Association of Bosnia-Herzegovina

Narcisa Pojskic

Psychiatric Association of Guatamala

Ismel Salazar, M.D.

Psychiatric Association of Rio de Janeiro State

Marcos A. Gebara Muraro, M.D.

Psychiatric Association of Serbia and Montenegro

Svetlana Drezgic Vugic

Psychiatric Association of Slovenia

Professor Slavko Ziber

Psychiatric Association of Thailand

Professor Pichet Udomratn

Psychiatric Association of Turkey

Haluk Ozbay

Psychiatric Association of Zimbabwe

S.M. Nhinatiwa, M.D.

Psychiatrists Association of Nepal

Desh Raj Babadur Kunwar, M.D.

Romanian Psychiatric Association

Professor Tudor Udristoiu

Royal Society of Mental Medicine of Belgium

Professor Jean Bertrand

Russian Society of Psychiatrists

Professor Valery Krasnov

Salvadoran Association of Psychiatry

Francisco A. Paniagua Osegueda, M.D.

Singapore Psychiatric Association

Hong Choon Chua, M.D.

Slovak Psychiatric Association

Livia Vavrusova

Society of Flemish Neurologists and Psychiatrists

Bernard Sabbe

Society of Georgian Psychiatrists

George Naneishvili, M.D.

Society of Psychiatry of Rio Grande do Sul

Lais Knjnik, M.D.

Society of Psychiatry of Uruguay

Angel Valmaggia, M.D.

Society Settlement of Physically and Mentally Disabled

Professor Daniel Larbi

South African Society of Psychiatrists

Merryll Vorster

Spanish Society of Psychiatry

Professor Enrique Baca Baldomero

Sri Lanka College of Psychiatrists

Jayan Mendis, M.D.

Sudanese Association of Psychiatrists

Abdullah Abdelrahman, M.D.

Swedish Psychiatric Association

Anna-Maria af Sadeberg, M.D.

Swiss Society of Psychiatry

Hans Kurt, M.D.

Syrian Arab Association of Psychiatrists

Mohamed Adib Essali

Taiwanese Society of Psychiatry

Chiao-Chicy Chen

The Psychiatric Evolution

Yves Thoret, M.D.

The Royal Australian and New Zealand College of Psychiatrists

Ken Kirby M.D.

The Royal College of Psychiatrists

Sheila Hollins, M.D.

Tunisian Society of Psychiatry

Professor Saida Douki Dedieu

Turkish American Neuropsychiatric Association

Erol Ucer, M.D.

Turkish Neuro-Psychiatric Association

Professor R. Peykan Gokalp

Ukraine Scientific Society of Neurologists, Psychiatrists, and Narcologists

Petro V. Voloshyn

Ukrainian Psychiatric Association

Professor Victor Shumlyansky

University Hospital Center-Tirana

Professor Anastas Suli

Venezuelan Society of Psychiatry

Professor Guillermo Ginnari Antich

World Association for Dynamic Psychiatry

Nikolaj Neznanov

Yemen Psychiatrists and Neurologists Association

Professor Abdelmagid S. Al-Khulaidi

YUCO- Association of Psychiatric Institutions of Serbia and Montenegro

Jovan Maric

Yugoslav Psychiatric Association

Professor Mirko Pejovic

Join APA at The Annual Meeting and Qualify for a Rebate

How Do I Qualify?

You may qualify if you:

1. Are a psychiatrist residing in the U.S. or Canada and,
2. Have paid the full-time registration fee for the Annual Meeting (\$895 advance, \$880 on-site).

SAN DIEGO

How Do I Apply?

1. Stop by one of the Membership booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Hall B) to fill out an APA Membership Application. The Application must be submitted on-site during the meeting at one of these locations.
2. Additional documentation (proof of ACGME, AOA, or RCPS(C)-approved psychiatry residency training and a current, valid medical license) must be received by APA no later than June 30, 2007.

How Does The Rebate Work?

1. Your local psychiatric district branch must approve the application no later than September 30, 2007.
2. The difference between the member and non-member rate will be applied toward your pro-rated 2007 national and local dues. The remaining balance of the rebate amount will be sent directly to you or if you choose, we can apply the remaining balance to your 2008 dues.* It's up to you!

Why Should I Join?

Please stop by one of the Membership booths to learn more about the many benefits and privileges of APA membership.

*Outstanding dues from previous years may be deducted in some cases.



New Orleans

OCTOBER 11-14, 2007  NEW ORLEANS MARRIOTT



Save the date now to attend the American Psychiatric Association's 59th Institute on Psychiatric Services, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness. Check out our website at www.psych.org/IPS2007.

This four-day event will feature more than 100 exhibits that complement the educational program, popular networking events, and over 200 expertly-led educational sessions on topics including: Violence, Trauma, and Victimization; Social and Community Psychiatry; Psychopharmacology; Resident and Medical Student Concerns; Disorders; Cross-Cultural and Minority Issues; Psychiatric Administration and Services; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia and Other Psychotic Disorders; and much more...

Who Should Attend?

- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector including state and Veterans Affairs hospitals, community clinics, and jails and prisons
- Psychiatric Administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents (only \$60 for advance registration)
- Nonmember Residents and Advocacy Group Members (only \$85 for advance registration)
- Medical Students (free registration)

Why Should You Attend?

- This activity has been approved for AMA PRA category 1 credit and CEU credit



- Receive a 40% discount on APA member registration fees
- Network with colleagues at receptions and other events
- Industry-supported lunch and dinner symposia

- Valuable exhibit hall prizes drawn each day

How Will You Benefit?

- Learn about the latest updates and acquire new skills in clinical psychiatry, that can be utilized to improve patient care;
- Acquire a deeper understanding of how the current health care system affects patient care;
- Demonstrate and apply new skills useful in clinical and public psychiatry settings;
- Recognize and improve mental health disparities in the community; and
- Understand all aspects of recovery and how this affects families and the community.

Preliminary Program

The Preliminary Program, which includes registration, housing, and travel information will be available in May at www.psych.org/IPS2007 or call 1-888-35-PSYCH and request a copy. Online registration will begin on June 1.



For more information, please contact:
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/IPS2007

MONDAY, MAY 21, 2007

160TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY SUPPORTED BREAKFAST SYMPOSIA 22-24

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 22, PART 1

7:00 a.m.-8:30 a.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS: THE MANAGEMENT OF ALLOSTATIC LOAD, METABOLIC SYNDROME, AND CO-OCCURRING DISORDERS

Supported by Solway Pharmaceuticals-Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

- A The Heart of the Matter: Allostatic Load and Psychiatric Disorders**
Robert B. Lydiard, M.D.
- B Co-occurring Disorders: The Complex Interplay Between Psychiatric Syndromes, Substance Use, and Health**
Kathleen T. Brady, M.D.
- C Psychotropic Medications, Psychiatric Illness, and Weight Gain**
Rohan Ganguli, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 23, PART 1

7:00 a.m.-8:30 a.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

HOW DO ATYPICALS AND ANTIPSYCHOTICS WORK?: FROM RECEPTORS TO REALITY

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

- A Mechanisms of Antipsychotic Efficacy: Linking Pharmacology to Phenomenology**
Shitij Kapur, M.D.
- B Neurobiology of Schizophrenia: From Basic Science to Clinical Practice**
Gordon Frankle, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 24, PART 1

7:00 a.m.-8:30 a.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

TREATING THE SPECTRUM OF BIPOLAR DISORDERS: AN INTERACTIVE CASE DISCUSSION

Supported by AstraZeneca Pharmaceuticals

Chp.: Michael E. Thase, M.D.

A Psychotherapy and Bipolar Depression
Holly Swartz

B Antidepressants in Bipolar Depression: A Two-Sided Story
Michael E. Thase, M.D.

RESIDENTS' SESSION

7:00 a.m.-8:30 a.m.

San Diego Ballroom A, North Tower, Lobby Level, Marriott

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Pedro Ruiz, M.D.

Co-Chp.: Carolyn B. Robinowitz, M.D.

At this breakfast, nationally-recognized experts will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Academic Psychiatry, Addiction Psychiatry, Administrative Psychiatry, Child and Adolescent Psychiatry, Cultural Competency, Ethics, Forensic Psychiatry, Geriatric Psychiatry, Leadership, Neuropsychiatry, Psychodynamic Psychotherapy, Psychosomatic Medicine, Public and Community Psychiatry, Research, and Women's Mental Health.

8:00 a.m. Sessions



COURSES 33-41

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 33 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 34 8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS IN COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.

MONDAY

COURSE 35 8:00 a.m.-12 noon
Molly Room A/B, Second Level, Manchester Grand Hyatt

FAMILY SKILLS FOR THE GENERAL PSYCHIATRIST

Director: Alison M. Heru, M.D.
Faculty: Laura M. Drury, M.S.W.

COURSE 36 8:00 a.m.-12 noon
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Jeremy R. Butler, M.D., Michael B. First, M.D.,
Carol A. Bernstein, M.D.

COURSE 37 8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: Edward C. Lauterbach, M.D., David Clark, M.D.

COURSE 38 8:00 a.m.-12 noon
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

THE EVALUATION AND TREATMENT OF PHYSICIANS INVOLVED IN SEXUAL MISCONDUCT AND/OR SEXUAL HARASSMENT

Co-Directors: Gene G. Abel, M.D., Tracey I. Marks, M.D.
Faculty: Richard B. Krueger, M.D.

COURSE 39 8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 40 8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

FAMILIES COPING WITH MEDICAL ILLNESS: A TREATMENT APPROACH FOR PSYCHIATRY

Director: John S. Rolland, M.D.

COURSE 41 8:00 a.m.-5:00 p.m.
Elizabeth Ballroom G, Second Level, Manchester Grand Hyatt

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Gerardo Gonzalez, M.D., Laura McNicholas, M.D.
Faculty: Andrew J. Saxon, M.D., Eric C. Strain, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 1

9:00 a.m.-10:30 a.m.

Room 23 A/B, Upper Level, San Diego Convention Center

PSYCHODYNAMIC PSYCHOTHERAPY OF BPD

Moderator: Glen O. Gabbard, M.D.

Presenters: John G. Gunderson, M.D., Lois W. Choi-Kain, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.**



COURSES 42-48

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 42 9:00 a.m.-4:00 p.m.
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

ADVANCES IN NEUROPSYCHIATRY

Co-Directors: C. Edward Coffey, M.D., Jeffrey L. Cummings, M.D.
Faculty: Thomas W. McAllister, M.D., Michael R. Trimble, M.D.,
Matthew A. Menza, M.D., Mark S. George, M.D.

COURSE 43 9:00 a.m.-4:00 p.m.
Edward Room C/D, Second Level, Manchester Grand Hyatt

PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

COURSE 44 9:00 a.m.-4:00 p.m.
Gregory Room A/B, Second Level, Manchester Grand Hyatt

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 45 - WITHDRAWN

COURSE 46 9:00 a.m.-4:00 p.m.
Del Mar Room A/B, Third Level, Manchester Grand Hyatt

COGNITIVE THERAPY ON THE FLY

Co-Directors: Ari E. Zaretsky, F.R.C.P.C., Mark Fefergard, M.D.

COURSE 47 9:00 a.m.-4:00 p.m.

Annie Room A/B, Third Level, Manchester Grand Hyatt

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Co-Directors: James Q. Schubmehl, M.D., Alan R. Beeber, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.

Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

LOVE, DESIRE, INTIMACY, AND INFIDELITY

Director: Stephen B. Levine, M.D.

FOCUS LIVE SESSION 1

9:00 a.m.-10:30 a.m.

Room 1 A/B, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.

Presenter: Stephen M. Stahl, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Psychopharmacology, the second session at 11:00 a.m. covers Substance Related Disorders, and the third session at 2:00 p.m. covers Genetics and Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 3-5

LECTURE 3

9:00 a.m.-10:30 a.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center

**APA'S SOLOMON CARTER FULLER
AWARD LECTURE**

David C. Henderson, M.D.

**From Psychopharmacology to
Ethnopsychopharmacology and Back to
Psychopharmacology**

Chp.: Michele Reid, M.D.

David C. Henderson, M.D., is Associate Professor of Psychiatry at Harvard Medical School and Director of the Schizophrenia Diabetes and Weight Reduction Research at Massachusetts General Hospital, both in Boston, Massachusetts. He is the Director of the Clozapine Program at the Erich Lindemann Mental Health Center, and Associate Director of the Schizophrenia Clinical and Research Program and Associate Director, Division of International Psychiatry at Massachusetts General Hospital, Massachusetts General Hospital. He also served as Medical Director for the Harvard Program in Refugee Trauma at Harvard Medical School. Dr. Henderson received his undergraduate degree at Tufts University in Massachusetts and received his medical degree at the University of Massachusetts Medical School. Following his internship at St. Elizabeth's Hospital in Boston, he completed his residency at Massachusetts General Hospital and trained as Chief Resident and Research Fellow of the Freedom Trail Clinic at the Erich Lindemann Mental Health Center, also in Boston. Dr. Henderson's main research interests focus on psychopharmacological and antipsychotic agents in the treatment of schizophrenia, impacts of antipsychotic agents on metabolic anomalies and glucose metabolism, and ethnic and cultural impacts on psychiatry. He also studies the impact of trauma in areas of mass violence and develops programs to assist vulnerable populations which include projects in Rwanda, Cambodia, East Timor, Bosnia, Peru, New Orleans, and New York City. Dr. Henderson has lectured extensively throughout the United States and internationally on schizophrenia, treatment-resistant schizophrenia, metabolic disorders and schizophrenia, psychopharmacology, ethnopsychopharmacology, trauma, and cultural psychiatry. He has published numerous peer review articles, chapters, and reviews including in journals such as the Archives of General Psychiatry, American Journal of Psychiatry, and Biological Psychiatry.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 4

9:00 a.m.-10:30 a.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Congressman Patrick J. Kennedy

The Road to Equity: Marching Toward a Just Treatment of Mental Illness and Addiction in America
Collaborative Session With the National Institute on Drug Abuse

Chp.: James H. Scully Jr., M.D.

Co-Chp.: Nora Volkow, M.D.

Congressman Patrick J. Kennedy has made mental health reform one of the highest priorities of his legislative career. Congressman Kennedy is the lead Democratic House cosponsor of the Paul Wellstone Equitable Treatment Act, which would end insurance discrimination against mental illness. Working with both Democratic and Republican colleagues, he has built a bipartisan majority in favor of the bill three Congresses in a row. He has authored numerous other pieces of mental health legislation, including the *Child Healthcare Crisis Relief Act* to help alleviate the critical shortage of child mental health providers and the *Positive Aging Act* to improve mental health services for seniors. Congressman Kennedy and a bipartisan group of colleagues wrote the *Keeping Families Together Act* to end the abominable practice of states conditioning mental health care for seriously emotionally disturbed children on their parents' relinquishment of custody. In 2004, he co-founded the House Addiction Treatment and Recovery Caucus, which he co-chairs. Since taking his seat on the Appropriations Committee in 2001, Congressman Kennedy has been the leading proponent for mental health funding on the Labor-Health-Education and Science-State-Commerce-Justice Subcommittees. From that position, he has successfully advocated for funding of mental health programs, including increases in the mental health block grant, creation of a new initiative to promote mental health among seniors, and appropriations for a new jail diversion program. Most recently, in 2006, a Kennedy amendment to the Higher Education Act to provide loan forgiveness for child and adolescent mental health professionals passed the House with 373 votes. Kennedy also worked with Democratic and Republican members of the Education and Workforce Committee to add provisions aimed at improving mental health care for seniors to the Older Americans Act. Kennedy speaks frequently on mental health issues and serves on the Advisory Board of the University of Michigan's Depression Center and is an Honorary Board Member of the Mental Health Association of Rhode Island.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 5

9:00 a.m.-10:30 a.m.

Room 33 A/B/C, Upper Level,
San Diego Convention Center

Ronald S. Duman, Ph.D.

A Neurotrophic Hypothesis of Depressions and Antidepressant Response

Chp.: Kathryn Connor, M.D.

Dr. Duman is Professor of Psychiatry and Pharmacology and Director of the Abraham Ribicoff Research Facilities at the Yale University School of Medicine. He received his Ph.D. from the University of Texas Medical School in Neuropharmacology and joined the Yale faculty in 1988. He became tenured in 1997 and was named the Elizabeth Mears and House Jameson Professor of Psychiatry in 2000. Dr. Duman has received several prestigious awards for his work on depression including the Anna-Monika Prize (2001), the Nola Maddox Falcone Prize (2002), the Janssen Prize for Research in Psychopharmacology (2003), a NIMH MERIT Award (2005), a NARSAD Distinguished Investigator Award (2005), and the College of International Neuropsychopharmacology (CINP) Basic Research Award (2006). He is author of over 225 original articles, reviews and chapters and has given over 150 invited lectures. Studies from Dr. Duman's laboratory have contributed to the characterization of the molecular and cellular actions of antidepressants and stress, providing the basis for a neurotrophic hypothesis of depression. This hypothesis is based on work from Dr. Duman's laboratory demonstrating that chronic antidepressant treatment increases the expression of neurotrophic factors, and increases the proliferation of new neurons in the adult brain. Up-regulation of these neurotrophic factors and neurogenesis counteract the atrophy and cell loss that is caused by stress and that is thought to underlie, in part, the pathophysiology of depression. Dr. Duman's work has demonstrated that increased neurotrophic factor expression and neurogenesis contribute to the actions of antidepressant treatment. These findings represent major advances in our understanding of the effects of antidepressants and provide a framework for the development of novel therapeutic agents.

Frontiers of Science Lecture Series**THIS SESSION WILL BE AUDIOTAPED.**

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.

Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

SMALL INTERACTIVE SESSIONS 1-4

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 **Joel Yager, M.D.**, on APA Practice Guidelines on the Treatment of Patients With Eating Disorders and Forthcoming Clinical Manual on Eating Disorders
(*Meet the Authors*)
Room 27 B, Upper Level, San Diego Convention Center
- 2 **Lisa Mellman, M.D.**, on Teaching Psychotherapy: How Relevant Are Psychoanalytic Concepts
Room 29 A/B, Upper Level, San Diego Convention Center
- 3 **Russell F. Lim, M.D.**, on What Does Cultural Competence Mean in the Real World?
Room 31 C, Upper Level, San Diego Convention Center
- 4 **Iqbal Ahmed, M.D.**, on Issues in Geriatric Psychiatry
Room 32 B, Upper Level, San Diego Convention Center

WORKSHOPS**COMPONENTS 1-12****COMPONENT WORKSHOP 1** 9:00 a.m.-10:30 a.m.

Room 2, Upper Level, San Diego Convention Center

A MODEL CURRICULUM FOR TEACHING THE WORKING ALLIANCE AS A CORE PROCESS ACROSS PSYCHOTHERAPIES*APA Committee on Psychotherapy by Psychiatrists***Chp.:** Eric M. Plakun, M.D.**Participants:** Donna M. Sudak, M.D., Bernard D. Beitman, M.D., David A. Goldberg, M.D.**COMPONENT WORKSHOP 2** 9:00 a.m.-10:30 a.m.

Room 2, Upper Level, San Diego Convention Center

REENTRY AFTER PRISON: REJOINING THE COMMUNITY*APA Corresponding Committee on Jails and Prisons***Chp.:** Henry C. Weinstein, M.D.**Participants:** William Arroyo, M.D., Erik Roskes, M.D., H. Richard Lamb, M.D., Cassandra F. Newkirk, M.D., Tom Hamilton, Ph.D.**COMPONENT WORKSHOP 3** 9:00 a.m.-10:30 a.m.

Room 4, Upper Level, San Diego Convention Center

COMMITTING OCCUPATIONAL SUICIDE: A PSYCHIATRIC EMERGENCY*APA Corresponding Committee on Psychiatry in the Workplace***Chp.:** Andrea Stolar, M.D.**Participants:** Marcia Scott, M.D., Marie-Claude Rigaud, M.D., Marilyn Price, M.D., Aron S. Wolf, M.D., Steven E. Pflanz, M.D.**COMPONENT WORKSHOP 4** 9:00 a.m.-10:30 a.m.

Room 5 A, Upper Level, San Diego Convention Center

PROVIDING OPTIMUM CARE FOR PATIENTS WITH MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES IN THE PSYCHIATRIC EMERGENCY ROOM*APA Committee on Developmental Disabilities***Chp.:** Katharine A. Stratigos, M.D.**Participants:** Joel Bregman, M.D., Stephanie Hamarman, M.D., John de Figueiredo, M.D., Ramakrishnan Shenoy, M.D.**COMPONENT WORKSHOP 5** 9:00 a.m.-10:30 a.m.

Room 5 B, Upper Level, San Diego Convention Center

OBESITY IN OUR YOUTH: THE WEIGHT OF MENTAL ILLNESS*APA/SAMHSA Minority Fellowship Selection and Program Corresponding Committee***Co-Chps.:** Jodi E. Star, M.D., Daniel I. Bober, D.O.**Participant:** Ana E. Campo, M.D.**COMPONENT WORKSHOP 6** 9:00 a.m.-10:30 a.m.

Ballroom 6 E, Upper Level, San Diego Convention Center

HOW TO BECOME A MORE CREATIVE TEACHER: WINNING STRATEGIES FOR RESIDENTS AND FACULTY*APA Council on Medical Education and Lifelong Learning***Chp.:** Joan M. Anzia, M.D., Lowell D. Tong, M.D.**Participants:** Margo Lauterbach, M.D., Jerald Kay, M.D., Theodore Feldmann, M.D., Rachel C. Molander, M.D.**COMPONENT WORKSHOP 7** 9:00 a.m.-10:30 a.m.

Room 7 A, Upper Level, San Diego Convention Center

BEYOND POWERPOINT: HOW TECHNOLOGY CAN IMPROVE MENTAL HEALTH TRAINING*APA Ad Hoc Work Group on Information Systems***Co-Chps.:** Seth Powsner, M.D., Sharon Packer, M.D.**Participants:** Thomas J. Kim, M.D., Willadene Walker-Schmucker, M.D.

MONDAY

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.

Room 7 B, Upper Level, San Diego Convention Center

MENTAL HEALTH TRANSFORMATION: IS IT FOR REAL?

APA Committee on Psychiatric Administration and Management

Chp.: L. Mark Russakoff, M.D.

Participants: Sy A. Saeed, M.D., Brian M. Hepburn, M.D., Lydia E. Weisser, D.O.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.

Room 9, Upper Level, San Diego Convention Center

MENTAL HEALTH AND MEN WHO HAVE SEX WITH MEN IN THE AFRICAN-AMERICAN COMMUNITY: CONTROVERSIES ABOUT THE DOWN LOW

APA Committee on Gay, Lesbian, and Bisexual Issues and the APA Committee of Black Psychiatrists

Co-Chps.: Lourdes M. Dominguez, M.D., Napoleon B. Higgins Jr., M.D.

Participants: Kelvin Exum, M.D., Sandra C. Walker, M.D., Saundra A. Maass-Robinson, M.D.

COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m.

Room 11 B, Upper Level, San Diego Convention Center

GENDER AND CULTURE IN ACADEMIC LEADERSHIP: IMPROVING THE CURRENT STATE FOR WOMEN

APA Women Psychiatrists

Chp.: Roslyn Seligman, M.D.

Participants: Vivian Reznik, M.D., Robert Freedman, M.D., Ming T. Tsuang, M.D.

COMPONENT WORKSHOP 11 9:00 a.m.-10:30 a.m.

Room 24 B, Upper Level, San Diego Convention Center

OPTIMIZING DEPRESSION TREATMENT: CLINICAL APPLICATIONS OF MEASUREMENT-BASED CARE

APA American Psychiatric Institute For Research And Education

Co-Chps.: Farifteh F. Duffy, Ph.D., Jack S. McIntyre, M.D.

Participants: David J. Katzelnick, M.D., Henry Chung, M.D., Madhukar H. Trivedi, M.D., Darrel A. Regier, M.D.

COMPONENT WORKSHOP 12 9:00 a.m.-10:30 a.m.

Room 32 A, Upper Level, San Diego Convention Center

REACHING OUT: APPROACHES TO SUICIDE AMONGST THE PHYSICIAN POPULATION

APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: Malkah T. Notman, M.D.

Participants: Derek Puddester, M.D., Penelope P. Ziegler, M.D., Michael F. Myers, M.D.

ISSUES 1-16

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.

Room 23 C, Upper Level, San Diego Convention Center

HEADSPACE THEATRE: AN INNOVATIVE METHOD FOR EXPERIENTIAL LEARNING OF PSYCHIATRIC SYMPTOMATOLOGY USING MODIFIED ROLE-PLAYING AND IMPROVISATIONAL THEATRE TECHNIQUES ASSOCIATION FOR ACADEMIC PSYCHIATRY

Chp.: Bruce Ballon, M.D.

Participants: Ivan Silver, M.D., Donald C. Fidler, M.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.

Room 24 A, Upper Level, San Diego Convention Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE

Co-Chps.: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

Participants: Marynell Hinton, M.A., Donna Vanderpool, J.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.

Room 24 C, Upper Level, San Diego Convention Center

CHILDREN OF PSYCHIATRISTS

Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.

Participants: Jessica Goin, Stephanie A. Zisook, M.D., Jessica L. Worley

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.

Room 25 A, Upper Level, San Diego Convention Center

PSYCHIATRY AND THE MEDICAL HUMANITIES

Co-Chps.: Bret R. Rutherford, M.D., David J. Hellerstein, M.D.

Participant: Kay R. Jamison, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.

Room 25 C, Upper Level, San Diego Convention Center

LESSONS FROM TEACHING INTERVIEWING TO INTERNATIONAL RESIDENTS: INTEGRATING CULTURAL COMPETENCY FROM THE START OF TRAINING

Chp.: Jacob Sperber, M.D.

Participants: Nyapati Rao, M.D., Milton Kramer, M.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.

Room 26 A/B, Upper Level, San Diego Convention Center

GRANTWRITING WORKSHOP: RESEARCH FUNDING OPPORTUNITIES FROM THE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Lucinda L. Miner, Ph.D.

Participants: Joseph Frascella, Ph.D., Teresa Levitin, Ph.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.

Room 27 A, Upper Level, San Diego Convention Center

GENE-ENVIRONMENT-DEVELOPMENT INTERACTIONS: IMPLICATIONS FOR PSYCHIATRIC AND SUBSTANCE ABUSE DISORDERS*Collaborative Session With the National Institute on Drug Abuse***Chp.:** Julia Kim-Cohen, Ph.D.**Participants:** Jonathan D. Pollock, Ph.D., Stephen J. Suomi, Ph.D., Cornelius T. Gross, Ph.D., Frances A. Champagne, Ph.D., Kathleen R. Merikangas, Ph.D.**ISSUE WORKSHOP 8** 9:00 a.m.-10:30 a.m.

Room 28 A, Upper Level, San Diego Convention Center

ASSESSMENT OF CAPACITY: A MULTIMEDIA APPROACH TO ENHANCING CLINICAL SKILLS IN DIFFERENT CULTURAL AND LEGAL SETTINGS*Collaborative Session With the National Institute on Drug Abuse***Co-Chps.:** M.E. Jan Wise, M.B.Ch.B., Julian Beezhold, M.B.Ch.B.**ISSUE WORKSHOP 9** 9:00 a.m.-10:30 a.m.

Room 28 C, Upper Level, San Diego Convention Center

PREVENTION OF BURDEN AND BURNOUT IN CAREGIVERS AT HOME AND HEALTHCARE WORKERS IN LONG-TERM CARE SETTINGS**Chp.:** Sanjay M. Vaswani, M.D.**Participants:** Amita R. Patel, M.D., Chuck Wall, Ph.D.**ISSUE WORKSHOP 10** 9:00 a.m.-10:30 a.m.

Room 28 D/E, Upper Level, San Diego Convention Center

GOING TO THE HEART OF THE MATTER IN PATIENT INTERVIEWS: A FURTHER EXPLORATION**Chp.:** Harold J. Bursztajn, M.D.**Participants:** Max Day, M.D., Thomas G. Gutheil, M.D., Robindra K. Paul, M.D., Beata A. Zolovska, M.D., David Mobley, M.D.**ISSUE WORKSHOP 11** 9:00 a.m.-10:30 a.m.

Room 30 A, Upper Level, San Diego Convention Center

PRACTICAL PHARMACOTHERAPY FOR THE TREATMENT OF ALCOHOL DEPENDENCE**Chp.:** Robert M. Swift, M.D.**Participants:** Roger D. Weiss, M.D., Allen Zweben, D.S.W.**ISSUE WORKSHOP 12** 9:00 a.m.-10:30 a.m.

Room 30 B, Upper Level, San Diego Convention Center

THE TRAUMA OF WAR: UNDERSTANDING INTERVENTIONS IN A DEVELOPMENTAL CONTEXT**Chp.:** Stevan M. Weine, M.D.**Participants:** Lynne M. Jones, M.D., Christopher M. Laync, Ph.D., Patricia Lester, M.D., Alisa J. Land, M.D.**ISSUE WORKSHOP 13** 9:00 a.m.-10:30 a.m.

Room 30 C, Upper Level, San Diego Convention Center

METABOLIC SCREENING OF PATIENTS ON ANTIPSYCHOTIC MEDICATIONS: IMPLEMENTATION OF A QUALITY IMPROVEMENT PROGRAM IN AN URBAN TRAINING CLINIC**Co-Chps.:** Diane B. Gottlieb, M.D., Aurelia N. Bizamcer, M.D.**Participants:** Chioma Ihegwara, D.O., April S. Ladavac, M.D., Shaneek Johnson, M.D., Kathleen Diller, M.D., Jieun Kim, M.D.**ISSUE WORKSHOP 14** 9:00 a.m.-10:30 a.m.

Room 30 D/E, Upper Level, San Diego Convention Center

INTERNET CHILD PORNOGRAPHY AND MENTAL ILLNESS: THE PSYCHIATRIST'S ROLE**Chp.:** Humberto Temporini, M.D.**Participants:** Charles L. Scott, M.D., Vladimir Coric, M.D.**ISSUE WORKSHOP 15** 9:00 a.m.-10:30 a.m.

Room 31 A, Upper Level, San Diego Convention Center

CHALLENGING THE STATUS QUO: CENTRALIZED ASSESSMENTS IN PSYCHIATRIC CLINICAL TRIALS**Chp.:** John M. Kane, M.D.**Participants:** Janet B.W. Williams, D.S.W., Maurizio Fava, M.D., William Z. Potter, Ph.D., Jack A. Grebb, M.D., Andrew C. Leon, Ph.D.**ISSUE WORKSHOP 16** 9:00 a.m.-10:30 a.m.

Room 31 B, Upper Level, San Diego Convention Center

ACHIEVING MEDICATION ADHERANCE BY UNDERSTANDING**Chp.:** Stephen N. Wilson, M.D.**MEDIA 1-2****MEDIA WORKSHOP 1** 9:00 a.m.-12 noon

Room 10, Upper Level, San Diego Convention Center

PERSONAL TRANSFORMATION THROUGH AN ENCOUNTER WITH DEATH: AKIRA KUROSAWA'S IKIRU**Chp.:** Francis G. Lu, M.D.**MEDIA WORKSHOP 2** 9:00 a.m.-12 noon

Room 11 A, Upper Level, San Diego Convention Center

BROKEBACK MOUNTAIN: THE MYTH, THE REALITY, AND THE CONTROVERSY*APA New York County District Branch's Committee on Gay and Lesbian Issues***Chp.:** Kenneth Ashley, M.D.**Participants:** Danni Michaeli, M.D., Daniel Garza, M.D., Steven J. Lee, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH

10:30 a.m.-12:30 p.m.

Ballroom 6A, Upper Level, San Diego Convention Center

RESEARCH ADVANCES IN PSYCHIATRY

Chp.: Herbert Pardes, M.D.

Co-Chp.: Robert W. Guynn, M.D.

Presenters: Jeffrey A. Lieberman, M.D., Karen D. Wagner, M.D., Susan G. Kornstein, M.D., Barnett S Meyers, M.D.

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

ADVANCES IN MEDICINE 1

11:00 a.m.-12:30 p.m.

Room 2, Upper Level, San Diego Convention Center

NEW INTEGRATIVE TREATMENTS FOR PTSD AND CHRONIC FATIGUE, DISORDERS OF AUTONOMIC FUNCTION

Chp.: Patricia L. Gerberg, M.D.

Participant: Richard P. Brown, M.D.

THIS SESSION WILL BE AUDIOTAPED.

FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.

Room 1 A/B, Upper Level, San Diego Convention Center

SUBSTANCE RELATED DISORDERS

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.

Presenter: Thomas R. Kosten, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Substance Related Disorders, the first session at 9:00 a.m. covered Psychopharmacology, and the third session at 2:00 p.m. will cover Genetics and Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 6-7

LECTURE 6

11:00 a.m.-12:30 p.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center

APA'S OSKAR PFISTER AWARD LECTURE

William R. Miller, Ph.D.

Spiritus Contra Spiritum:

The Strange Case of Spirituality and Addiction

Chp.: John R. Peteet, M.D.

Dr. William R. Miller is Emeritus Distinguished Professor of Psychology and Psychiatry at the University of New Mexico, where he joined the faculty in 1976 after receiving his Ph.D. in clinical psychology from the University of Oregon. He served as Director of Clinical Training for UNM's APA-approved doctoral program in clinical psychology and as Co-Director of UNM's Center on Alcoholism, Substance Abuse and Addictions (CASAA). Dr. Miller's publications include 35 books and over 400 articles and chapters. Fundamentally interested in the psychology of change, he has focused in particular on the development, testing, and dissemination of behavioral treatments for addictions. He served as principal investigator for numerous research grants and contracts, founded a private practice group, and served as a consultant to many organizations including the United States Senate, the World Health Organization, the National Academy of Sciences, and the National Institutes of Health. In recognition of his research contributions, Dr. Miller is a recipient of the international Jellinek Memorial Award, a career achievement award from the American Psychological Association, and an Innovators in Combating Substance Abuse award from the Robert Wood Johnson Foundation. He maintains an active interest in pastoral counseling and the integration of spirituality and psychology. The Institute for Scientific Information lists him as one of the world's most cited scientists.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7

11:00 a.m.-12:30 p.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

**APA'S ADMINISTRATIVE PSYCHIATRY
AWARD LECTURE**

Jon E. Gudeman, M.D.

Chp.: L. Mark Rusakoff, M.D.

Jon E. Gudeman, M.D., is Director of the Center for Psychotherapy at Columbia-St. Mary's Hospital and Professor of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin in Milwaukee. Dr. Gudeman earned his bachelor's and medical degrees at Harvard University. After a medical internship at the University of Chicago Hospitals and Clinic, he did his psychiatric residency at the Massachusetts Mental Health Center (Chief Resident 1966-67) and trained at the Boston Psychoanalytic Institute. On behalf of the Massachusetts Mental Health Center he received the Gold Award from the Hospital & Community Psychiatry Division of the American Psychiatric Association. He also received the "Citation for Outstanding Performance" for the Commonwealth of Massachusetts in 1984 and the Hospital Research Award from the APA and Psychiatric Institutes of America. For many years he

served as Center Director at the Massachusetts Mental Health Center and Associate Professor of Psychiatry at Harvard Medical School. In addition to clinical practice and teaching, Dr. Gudeman's major research interests are in depression, psychotherapy and the care and treatment of serious mental illness in the hospital and community. He developed and studied the Day Hospital/Inn model of care and has written extensively on this program. He has authored or coauthored articles on these and related topics including the follow books: *Origins of Alcoholism*, *Staffing the Mental Health Center* and *The Use of Psychiatry in Smaller General Hospitals*. Dr. Gudeman has served in a variety of professional organizations and leadership positions including President of the Massachusetts Psychiatric Society, Chair of the Joint Information Service (1977), and Chairman of the Continuing Medical Committee (1984-'85) of the American Psychiatric Association. He is currently on the Medical Examining Board of Wisconsin. **THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 8

11:00 a.m.-12:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Mary J. Kreek, M.D.

Stress Responsivity, Gene Variants, and the Persistence of Addictions

Collaborative Session With the National Institute on Drug Abuse

Chp.: Edward M. Foulkes, M.D.

Dr. Kreek was part of the original three-member 1964 Rockefeller University team of Drs. Dole, Nyswander, and Kreek that developed methadone maintenance treatment for heroin addiction. In 1983-1984, in collaboration with Dr. Don Des Jarlais, Dr. Kreek identified the problem of HIV infection and AIDS in parenteral drug abusers, as well as the protective value of effective methadone maintenance treatment in opiate addicts. Dr. Kreek has done extensive research with resultant publications on the pharmacology of short-acting versus long-acting opiate drugs, on the changing medical status of addicts in opioid agonist treatment with methadone, and also the major concurrent diseases of hepatitis B, hepatitis C, and HIV-AIDS. For the past twenty years, her research has focused on the molecular and clinical neurobiological, and the molecular genetic bases of specific addictive diseases, as well as other biological correlates of addictive diseases and diseases afflicting the parenteral drug abuser.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-9

SCIENTIFIC AND CLINICAL REPORT SESSION 1

11:00 a.m.-12:30 p.m.

Room 3, Upper Level, San Diego Convention Center

PRESIDENT'S THEME: "ADDRESSING PATIENT NEEDS: ACCESS, PARITY, AND HUMANE CARE"

Chp.: Saul Levine, M.D.

Co-Chp.: Amanda Ruiz, M.D.

11:00 a.m.

2 The Discourse of Health Care Economics

David A. Rothstein, M.D.

11:30 a.m.

3 Medicare Part D Prescription Drug Benefits: Impact on Medication Access and Continuity Among Dual Eligible Patients With Psychiatric Conditions

Joyce C. West, Joshua E. Wilk, Irvin L. Muszynski, Donald S. Rae, William E. Narrow, M.D., Darrel A. Regier, M.D.

12 noon

4 Dealing With Disaster Mental Health

Russell F. D'Souza, Sr., M.D., Pedro Ruiz, Jr., M.D., Kenneth Kirkby II, M.D., Bruce Singh II, M.D., Jack S. McIntyre, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2

11:00 a.m.-12:30 p.m.

Room 4, Upper Level, San Diego Convention Center

COMPULSIVE AND ADDICTIVE BEHAVIORS

Chp.: Igor Koutsenok, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

5 Association of Cannabis Use With Prodromal Features of Psychosis and Behavioral Problems in Adolescents

Juha M. Veijola, M.D., Pirjo H. Maki, M.D., Sari Tormanen, Irma Moilanen, M.D., Erika Lauronen, M.D., Anja Taanila, M.A., Jouko Miettunen, M.A.

11:30 a.m.

6 Paternal Alcoholism Predicts Alcohol Dependence But Not Recovery After 40 Years

Joachim Knop, M.D., Elizabeth C. Penick, Ph.D., Elizabeth J. Nickel, M.A., Per Jensen, M.D., Ann M. Manzardo, Ph.D., Sarnoff Mednick, Ph.D., William F. Gabrielli, Jr., M.D.

12 noon

7 Self-Loathing and Perfectionism: Linking Eating Disorders and Compulsive Exercise

Alayne Yates, M.D., Jason Andrus, M.D., John H. Draeger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3

11:00 a.m.-12:30 p.m.

Room 5 A, Upper Level, San Diego Convention Center

OCD

Chp.: Donatella Marazziti, M.D.

Co-Chp.: Krauz Ganadjian, M.D.

11:00 a.m.

- 8 **Capsulotomy in Refractory OCD: Long-Term Outcome in 25 Patients**

Christian Rück, M.D.

11:30 a.m.

- 9 **Trichotillomania in Youth: A Naturalistic Outcome Study**

Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D.,
Beth Patterson, B.S.N., Roseann Milad, B.S.C.

12 noon

- 10 **OCD in Psychiatric Outpatients: Prevalence, Comorbidity, and Demographic and Clinical Characteristics**

Charlotte A.L. Rocker, B.S., Mark Zimmerman, M.D.,
Iwona Chelminski, Ph.D., Diane D. Young, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m.-12:30 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

METABOLIC DISORDERS AND PSYCHOSIS

Chp.: Mitchel A. A. Kling, M.D.

Co-Chp.: Igor Elman, M.D.

11:00 a.m.

- 11 **Second-Generation Antipsychotics and Diabetes Mellitus: Risk, Number Needed to Harm, and Clinical Impact**

Leslie L. Citrome, M.D.

11:30 a.m.

- 12 **Metabolic Risks of Psychosis in Sweden**

Urban P. Ösby, M.D., Sören Akselson, M.D., Anna Löthman, M.D., Helena Ring, M.D., Signy Reynisdottir, M.D., Martin Schalling, M.D., Claes-Göran Östenson, M.D.

12 noon

- 13 **Effect of Body Weight and Metabolic Complications on Health Related Quality of Life in Swedish Outpatients With Schizophrenia**

Signy Reynisdottir, M.Div., Anna Pejlare, Soren Akselson,
Deanne Mannelid, I Helena Ring, Birgitta Lindelius, Urban P. Osby, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5

11:00 a.m.-12:30 p.m.

Room 9, Upper Level, San Diego Convention Center

LEGAL ISSUES IN PSYCHIATRY

Chp.: Dominick Addario, M.D.

Co-Chp.: Jason R. Kornberg, M.D.

11:00 a.m.

- 14 **Understanding Filicide**

Sara G. West, M.D.

11:30 a.m.

- 15 **Testimonies of APA and ANA Presidents in the Harry Thaw "Brain Storm" Defense: Temporary Insanity One Hundred Years Ago in 1907**

Emil R. Pinta, M.D.

12 noon

- 16 **Correctional Mental Health Care in a Large, Urban Jail: Challenges and Opportunities**

Amina Abdulla, M.D., Michael Searls, M.D., Robert Simon, Jr., M.Psy., Sondra Markle, R.N., John Godejahaun, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.-12:30 p.m.

Room 11 B, Upper Level, San Diego Convention Center

ANXIETY DISORDERS

Chp.: Susan Stabinsky, M.D.

Co-Chp.: Harvey Stabinsky, M.D.

11:00 a.m.

- 17 **Treatment Outcome of Panic Disorder and Agoraphobia in a Naturalistic Clinical Setting**

John K. Lam-Po-Tang, M.B.B.S.

11:30 a.m.

- 18 **Panic Disorder With Social Anxiety Disorder Comorbidity: Difference of Response to Low Versus High Doses of Clonazepam**

Antonio E. Nardi, M.D., Alexandre M. Valença, M.D.,
Isabella Nascimento, M.D., Fabiana L. Lopes, M.D.,
Rafael C. Freire, Valfrido L. de-Melo-Neto, M.D., Marco A. Mezzasalma, M.D.

12 noon

- 19 **The Relationship Between Functional Outcomes and Treatment of Anxious and Painful Somatic Symptoms in Patients With GAD**

David V. Sheehan, M.D., Adam Meyers, Apurva Prakash,
Michael J. Robinson, Ralph W. Swindle, James Russell,
Craig H. Mallinckrodt

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.-12:30 p.m.

Room 24 C, Upper Level, San Diego Convention Center

ATTENTION SPECTRUM DISORDERS**Chp.:** Sanjay Vaswani, M.D.**Co-Chp.:** Vishal Madaan, M.D.

11:00 a.m.

20 Circadian Rhythm Disturbances in ADHDGeorge A. Keepers, M.D., Robert D. Levitan, M.D.,
Kyle P. Johnson, M.D., Alfred J. Lewy, M.D.

11:30 a.m.

21 Is Comorbid Adult ADHD Prevalent in Psychiatric Outpatients?

John A. Gergen, M.D.

12 noon

22 Extended Duration of Action of SPD465, a 16-Hour Mixed Amphetamine Salts Formulation, in the Treatment of Adults With ADHD

Thomas J. Spencer, M.D., Lenard A. Adler, M.D., Richard H. Weisler, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 8**

11:00 a.m.-12:30 p.m.

Room 25 A, Upper Level, San Diego Convention Center

CHILD AND ADOLESCENT PSYCHIATRY**Chp.:** Sonja L. Randle, M.D.**Co-Chp.:** Richard L. Buccigross, M.D.

11:00 a.m.

23 Quality of Care for Children and Adolescents: Access to Psychotherapy

Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., Donald S. Rae, William F. Narrow, M.D., Darrel A. Regier, M.D.

11:30 a.m.

24 Adolescent Depression and Its Relationship to School Dropouts and Accidents on University Campuses

Chih-Wei Yang, M.D., Yi-Hsin Yang, Ph.D., Mei-Chu Yen Jean, M.D., Tai-Jui Chen, M.D., Li-Min Su, M.A.

12 noon

25 Insulin Resistance in Adolescent Subjects at Risk for PsychosisHannu J. Koponen, M.D., Pirjo H. Maki, M.D., Irma Moilanen, M.D., Anja Taanila, M.A., Jaana Laitinen, M.A.,
Tuija Tammelin, M.A., Juha M. Veijola**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 9**

11:00 a.m.-12:30 p.m.

Room 27 A, Upper Level, San Diego Convention Center

PSYCHIATRIC IMPACT OF MEDICAL CONDITIONS**Chp.:** Nitin Gupta, M.D.**Co-Chp.:** Mustafa M. Husain, M.D.

11:00 a.m.

26 Severe Headaches and the Risk of Subsequent Suicidal Thoughts or Behaviors

Stephen B. Woolley, D.Sc., John W. Goethe, M.D., Lisa Fredman, Ph.D., Alisa Lincoln, Ph.D., Timothy Heeren, Ph.D.

11:30 a.m.

27 Modafinil Improves Behavioral Alertness in Patients With Residual Excessive Sleepiness Following Nasal Continuous Positive Airway Pressure (nCPAP)-Treated Obstructive Sleep Apnea

David F. Dinges, Ph.D., Max Hirshkowitz, Ph.D., Sanjay Arora, Ph.D., Jed E. Black

12 noon

28 The Effect of Sildenafil on Erectile Function and Depression: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies in Men With ED and Treated or Untreated Depression

Joseph Cappelleri, H. George Nurnberg, Richard L. Siegel

THIS SESSION WILL BE AUDIOTAPED.**SMALL INTERACTIVE SESSIONS 5-7**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Arnold Cooper, M.D., on American Psychoanalysis Today (*Meet the Author*)**Room 27 B, Upper Level, San Diego Convention Center****6 Sandra Jacobson, M.D., on Treatment of Dementia With Behavioral Disturbance: If Not an Antipsychotic, Then What?****Room 31 C, Upper Level, San Diego Convention Center****7 Otto F. Kernberg, M.D., on Sexuality in the Transference****Room 32 B, Upper Level, San Diego Convention Center**

WORKSHOPS

COMPONENTS 13-22

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.

Room 5 B, Upper Level, San Diego Convention Center

ADVOCACY TRAINING FOR EARLY CAREER PSYCHIATRISTS WITH A FOCUS ON PARITY LEGISLATION

APA Assembly Committee of Early Career Psychiatrists

Chp.: Carol L. Trippitelli, M.D.

Participants: Bob Kearley, M.D., Jason Young, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.

Room 7 A, Upper Level, San Diego Convention Center

UNCOVERING THE SECRET: INTIMATE PARTNER VIOLENCE AMONG ASIAN-AMERICANS

APA Asian-American Psychiatrists

Chp.: Surinder S. Nand, M.D.

Participants: Mina Bak, M.D., Jacquelyn Chang, M.D., Yujuan Choy, M.D., Mona H. Gill, M.D., Eugene Lee, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.

Room 7 B, Upper Level, San Diego Convention Center

CONTROVERSIES IN THE MANAGEMENT OF BEHAVIORAL DISTURBANCE IN DEMENTIA

APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: David A. Casey, M.D.

Participants: Mercedes M. Rodriguez, M.D., Keith R. Stowell, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.

Room 8, Upper Level, San Diego Convention Center

MULTINATIONAL PERSPECTIVES OF PSYCHIATRIC ETHICS

APA Ethics Appeal Board

Co-Chps.: Donna M. Norris, M.D., Driss Moussaoui, M.D.

Participants: Wade C. Myers, M.D. William Arroyo, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.

Room 23 C, Upper Level, San Diego Convention Center

HOW TO TEACH CULTURAL COMPETENCE IN GERIATRIC PSYCHIATRY: ADDRESSING UNMET PATIENT NEEDS

APA Committee on Ethnic Minority Elderly

Co-Chps.: Maria D. Llorente, M.D., Warachal E. Faison, M.D.

Participants: Moises Martinez, M.D., Shunda McGahee, M.D., Vernon I. Nathaniel, M.D., Cynthia I. Resendez, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.

Room 24 A, Upper Level, San Diego Convention Center

PROVIDING SERVICES TO MENTALLY ILL INMATES RETURNING TO THE COMMUNITY

APA Task Force on Forensic Outpatient Services

Chp.: Steven K. Hoge, M.D.

Participants: Alec Buchanan, M.D., Beatrice Kovaszny, M.D.

COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m.

Room 25 C, Upper Level, San Diego Convention Center

BOOT CAMP FOR BURNOUT

APA Representatives of Minority/ Underrepresented Groups

Co-Chps.: Gail F. Robinson, M.D., Altha J. Stewart, M.D.

Participants: Nada L. Stotland, M.D., Tana A. Grady-Weliky, M.D., Melva I. Green, M.D., Eva M. Szigethy, M.D.

COMPONENT WORKSHOP 20 11:00 a.m.-12:30 p.m.

Room 28 A, Upper Level, San Diego Convention Center

THE IMPACT OF VIOLENCE IN LATINO COMMUNITIES

APA Committee of Hispanic Psychiatrists

Co-Chp.: Andres J. Pumariega, M.D., Daniel Castellanos, M.D.

Participants: Esperanza Diaz, M.D., Tatiana Falcone, M.D., Natalie Weder, M.D., Rene J. Valles, M.D.

COMPONENT WORKSHOP 21 11:00 a.m.-12:30 p.m.

Room 28 C, Upper Level, San Diego Convention Center

CONCEPTUALIZING ACCESS TO PSYCHIATRIC CARE

APA Access to Care Work Group

Co-Chps.: Eliot Sorel, M.D., Roger Peele, M.D.

COMPONENT WORKSHOP 22 11:00 a.m.-12:30 p.m.

Room 30 A, Upper Level, San Diego Convention Center

PEARLS AND PITFALLS IN NEGOTIATING YOUR FIRST JOB

APA Committee of Residents and Fellows

Co-Chps.: Justin B. Hunt, M.D., Lea E. DeFrancisci Lis, M.D.

Participant: William H. Campbell, M.D.

ISSUES 17-27

ISSUE WORKSHOP 17 11:00 a.m.-12:30 p.m.

Room 23 A/B, Upper Level, San Diego Convention Center

THE DILEMMA OF WOMEN'S PROFESSIONAL GARMENTS AND PROFESSIONALISM

Co-Chps.: Katharine A. Stratigos, M.D., Leah J. Dickstein, M.D.

Participants: Stephanie Le Melle, M.D., Christina Mangurian, M.D., Lisa Mellman, M.D., Asher Simon, M.D.

ISSUE WORKSHOP 18 11:00 a.m.-12:30 p.m.

Room 24 B, Upper Level, San Diego Convention Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINES

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.

Room 28 B, Upper Level, San Diego Convention Center

FIRST EPISODE MOOD DISORDERS: WHAT HAVE WE LEARNED AND WHERE DO WE GO FROM HERE?

Chp.: Kathryn J. MacDonald, M.D.

Participants: Kaan Yucel, M.D., Valerie Taylor, M.D.

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.

Room 28 D/E, Upper Level, San Diego Convention Center

TEACHING COGNITIVE BEHAVIOR THERAPY TO CHILD AND ADULT RESIDENTS

Chp.: Judith S. Beck, Ph.D.

Participants: Donna M. Sudak, M.D., Jesse H. Wright III M.D., Robert D. Friedberg, Ph.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.

Room 30 A, Upper Level, San Diego Convention Center

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY UPDATE: CERTIFICATION AND MAINTENANCE OF CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chp.: Larry R. Faulkner, M.D.

Participants: Daniel K. Winstead, M.D., Naleen N. Andrade, M.D., Beth Ann Brooks, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D.

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m.

Room 30 B, Upper Level, San Diego Convention Center

ASSESSING CAPACITY TO DRIVE: A PRACTICAL APPROACH TO THE PSYCHIATRIST'S ROLE AND RESPONSIBILITIES

Chp.: Dimitri D. Markov, M.D.

Participants: Clarence Watson Jr, M.D., Marc Rothman, M.D., Elisabeth J.S. Kunkel, M.D.

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.

Room 30 C, Upper Level, San Diego Convention Center

IMPLEMENTING A TELEPSYCHIATRY PROGRAM IN THE KERN COUNTY MENTAL HEALTH SYSTEM IN RURAL CALIFORNIA

Chp.: Tai P. Yoo, M.D.

Participant: Salvador R. del Rosario Jr., M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

WOMEN RESIDENTS AND THEIR NEEDS DURING PSYCHIATRIC TRAINING

Chp.: Anu A. Matorin, M.D.

Participants: Lina M. Lopez, M.D., Toi B. Harris, M.D., Deborah Spitz, M.D., Sandra B. Sexson, M.D.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.

Room 31 A, Upper Level, San Diego Convention Center

THE EARLIEST ENVIRONMENT: PRENATAL STRESS, ANXIETY, AND DEPRESSION AND CHILD OUTCOME

Chp.: Hanna E. Stevens, M.D.

Participants: Catherine Monk, Ph.D., Thomas O'Connor, Ph.D., Zachary N. Stowe, M.D., Pathik D. Wadhwa, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.

Room 31 B, Upper Level, San Diego Convention Center

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.

Participants: Carl M. Wahlstrom, Jr., M.D., David E. Hartman, Ph.D.

ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.

Room 32 A, Upper Level, San Diego Convention Center

MUSIC AS A MEANS OF SURVIVAL: THE SIGNIFICANCE OF MUSIC IN SURVIVING THE HOLOCAUST

Chp.: Andrei Novac, M.D.

Participant: Bonita Nahoum-Jaros VIII, Ph.D.

12 noon Sessions

FORUMS 1-5

FORUM 1 12 noon-1:30 p.m.

Ballroom 6 E, Upper Level, San Diego Convention Center

RESEARCH PLANNING FOR DSM-V

Chp.: Darrel A. Regier, M.D.

Participants: David J. Kupfer, M.D., Eric Hollander, M.D., Helena C. Kraemer, M.D., Joel Dimsdale, M.D., David Shaffer, M.D., Norman Sartorius, M.D.

MONDAY

FORUM 2 12 noon-1:30 p.m.
Room 25 B, Upper Level, San Diego Convention Center

**AUTOBIOGRAPHY/BIOGRAPHY YOUNG ADULT:
METAPHORS FOR PUTTING A FACE ON HUMAN
HISTORY**

Chp.: JoAnne Isbey, ABD
Presenters: Dorothy Bates, Daniel Dickstein, M.D., Leah Dickstein, M.D., Cheryl Munday, Ph.D., Eva Szigethy, M.D., Theresa Yuschok, M.D.

FORUM 3 12 noon-1:30 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

**ON THE FRONTLINE IN AMERICA: TREATING
VIOLENT PATIENTS AND THE ETHICS OF
PROVIDING CARE**

Chp.: Paul S. Appelbaum, M.D.
Presenters: Kenneth Duckworth, M.D., Thomas G. Gutheil, M.D.

FORUM 4 12 noon-1:30 p.m.
Room 29 A/B, Upper Level, San Diego Convention Center

**SUBSTANCE ABUSE IN YOUR PATIENTS: BEYOND
WHAT IS TAUGHT IN YOUR RESIDENCY**

Collaborative Session With the National Institute on Drug Abuse

Chp.: Nora Volkow, M.D.
Presenters: Paula D. Riggs, M.D., Herbert Kleber, M.D., Charles P. O'Brien, M.D., Thomas Kosten, M.D.

FORUM 5 12 noon-1:30 p.m.
San Diego Ballroom B, North Tower, Lobby Level, Marriott

**WEST SIDE STORY AT 50: THE MIND AND MUSIC
OF LEONARD BERNSTEIN**

Chp.: Richard Kogan, M.D.

**NEW RESEARCH YOUNG INVESTIGATORS'
POSTER SESION 2**
9:00 a.m.-10:30 a.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 49-54

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 49 1:00 p.m.-5:00 p.m.
Edward Room A/B, Second Level, Manchester Grand Hyatt

**SPIRITUALITY AND WORLDVIEW IN CLINICAL
PRACTICE**

Director: Allan M. Josephson, M.D.
Faculty: James L. Griffith, M.D., John R. Peteet, M.D.

COURSE 50 1:00 p.m.-5:00 p.m.
Molly Room A/B, Second Level, Manchester Grand Hyatt

**CURRENT CPT CODING AND DOCUMENTATION
REQUIREMENTS**

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Faculty: Allan A. Anderson, M.D., David K. Nace, M.D., Ronald M. Burd, M.D.

COURSE 51 1:00 p.m.-5:00 p.m.
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

**STREET DRUGS AND MENTAL DISORDERS:
OVERVIEW AND TREATMENT**

Director: John W. Tsuang, M.D.
Faculty: Karen Miotto, M.D., Timothy W. Fong, M.D., Stephen Ross, M.D.

COURSE 52 1:00 p.m.-5:00 p.m.
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

**ASSESSING POSITIVE AND NEGATIVE SYMPTOMS
WITH THE POSITIVE AND NEGATIVE SYNDROME
SCALE**

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 53 1:00 p.m.-5:00 p.m.
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

**PSYCHIATRIC CONSULTATION IN LONG TERM
CARE: ADVANCED**

Co-Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

COURSE 54 1:00 p.m.-5:00 p.m.
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

2:00 p.m. Sessions

FOCUS LIVE SESSION 3

2:00 p.m.-3:30 p.m.

Room 1 A/B, Upper Level, San Diego Convention Center

GENETICS AND PSYCHIATRY

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.

Presenter: John Kelsoe, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Genetics and Psychiatry, the first session at 9:00 a.m. covered Psychopharmacology, and the second session at 11:00 a.m. covered Substance Related Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 9-11

LECTURE 9

2:00 p.m.-3:30 p.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center

APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE

Stephen C. Scheiber, M.D.

The American Board of Psychiatry and Neurology Impact on Psychiatric Education: Past, Present and Future

Chp.: Kailie Shaw, M.D.

Stephen C. Scheiber, M.D. completed 20 1/2 years as the chief executive officer of the American Board of Psychiatry and Neurology (ABPN) on June 30th 2006. He continues his professorial teaching appointments at Northwestern University Feinstein School of Medicine and at the Medical College of Wisconsin. He received one of the Inaugural Life Fellowship Awards from the Association for Academic Psychiatry in September 2006, the Distinguished Psychiatrist Service Award from the American College of Psychiatrists in February, 2007 and the Distinguished Service Award from the American Board of Medical Specialties in March, 2007. He also was the recipient of the Distinguished Life and Career Achievement Award from the Medical Alumni Association of the University of Buffalo and the Lifetime Educator Award from the Association for Academic

Psychiatry. He has served as an officer in five national psychiatric organizations. He was on the University of Arizona Medical School faculty from 1970 to 1988 where he was the founding residency training director. Scheiber served as an officer of the USPHS. He was assigned to Sierra Leone in West Africa as a Peace Corps general physician. This deployment occurred after his internship at the Mary Fletcher Hospital in Burlington, Vermont. Upon returning from Africa, he completed a psychiatry residency at the Strong Memorial Hospital in Rochester, New York. He obtained his undergraduate degree at Columbia College in New York City and his M.D. at the State University of Buffalo in Buffalo, N.Y.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 10

2:00 p.m.-3:30 p.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Dolores Malaspina, M.D.

Advancing Paternal Age and Offspring Risks for Psychiatric Disorders: A Translational Perspective

Chp.: Josepha A. Cheong, M.D.

Dolores Malaspina M.D., became the Chairman of Psychiatry at New York University Medical Center in September 2006. She was previously Professor of Clinical Psychiatry at Columbia University Medical Center and a Research Psychiatrist at New York State Psychiatric Institute, where she also completed her postgraduate medical education, a fellowship in clinical research, and an M.P.H. in Epidemiology. She was the founding Unit Chief for its Schizophrenia Research Unit and she later established its prodromal schizophrenia research clinic. Her academic career encompasses a strong focus on the mentoring and career development of beginning clinical investigators, and she has also mentored over a dozen research scientists now engaged in psychiatric research careers, including psychiatrists, obstetricians-gynecologists, psychologists and social workers. She is now in her seventh of ten years of funding by NIMH to mentor young scientists who are beginning clinical research careers. Dr. Malaspina has received numerous awards for her research, including the American Psychiatric Institute for Research and Education Kempf Fund Award for Research and Mentoring in Psychobiological Psychiatry (in 2006), the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill, the National Alliance for Research in Schizophrenia and Affective Disorders Ritter Award, and the annual Research Award from the New York State Office of Mental Health. She was chosen to be a Chief Resident and received the Alumni Association's Horowitz Award for clinical excellence as a resident. She is now a fellow of the American College of Neuropsychopharmacology and is a Distinguished Fellow of the American Psychiatric Association.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 11

2:00 p.m.-3:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Kitty Dukakis and Larry Tye

The Healing Power of ECT

Chp.: Richard Weiner, M.D.
Co-Chp.: Sarah Lisanby, M.D.

Kitty Dukakis, the wife of former Massachusetts governor and 1988 Democratic presidential nominee Michael Dukakis, is a social worker, a founding member of the United States Holocaust Memorial Museum, and an advocate for programs to battle homelessness and promote refugee rights. She revealed her ongoing struggle to overcome depression and her accompanying addictions to alcohol and diet pills in her 1990 memoir, *Now You Know*. Her new book, written with Larry Tye, *Shock: The Healing Power of Electroconvulsive Therapy*, tells the story of her successful treatment with electroconvulsive therapy along with Mr. Tye's meticulous research into the history and evolution of ECT, over 100 interviews with patients who have had the treatment, and detailed descriptions of the treatment in its modern form and when and under what circumstances it is appropriate.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 1-2

PRESIDENTIAL SYMPOSIUM 1

2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

THE ROLE OF ETHICS IN WORLD PSYCHIATRY

APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Darrel A. Regier, M.D.

- A Conflicts of Interest in Psychiatric Practice and Research**
Mario Maj, M.D.
- B Ethics in the Mediterranean Countries**
Juan J. Lopez-Ibor Jr., M.D.
- C From Ethical Mantras to Living Ethics in Psychiatry**
Julio Arboleda-Flores, M.D.

Discussant: Alan A. Stone, M.D.
THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2

2:00 p.m.-5:00 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

WOMEN LEADERS IN THE APA AND BEYOND

APA Committee on Women

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Donna M. Norris, M.D.

- A Women Leaders of the APA and beyond: The Contribution of International Medical Graduates**
Geetha Jayaram, M.D.
- B Women in Leadership: Issues and Challenges**
Ann Marie T. Sullivan, M.D.
- C No Crystal Stair**
Annelle B. Primm, M.D.
- D Getting to the Inner Circle: The Long Hard Trail**
Jo-Ellyn M. Ryall, M.D.
- E Lessons in Leadership: Mentoring our Future Women Leaders**
Patricia I. Ordorica, M.D.

Discussants: Altha J. Stewart, M.D., MaryJane England M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-26

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Room 2, Upper Level, San Diego Convention Center

**SCHIZOPHRENIA WITH COMORBID CONDITIONS:
CLINICAL ISSUES**

Chp.: Michael Y. Hwang, M.D.

- A Diagnostic Issues and Treatment Strategy in Schizophrenia With Depression**
Siegfried Kasper, M.D., Dietmar Winkler, M.D.
- B Schizophrenia With Obsessive-Compulsive and Panic Symptoms: Treatment Issues**
Michael Y. Hwang, M.D.
- C Eating Disorder Comorbidity in Schizophrenia: Clinical Implications for Managing Obesity and Metabolic Disorders**
Sun Y Yum, M.D., Michael Y. Hwang, M.D.
- D Recent Increments in Knowledge About Suicidality in Schizophrenia**
Alec Roy, M.D., Marco Sarchiapone, M.D., Vladimir Carli, M.D., Michael Hwang, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.

Room 3, Upper Level, San Diego Convention Center

**BIOLOGICAL FOUNDATIONS OF BIPOLAR DISORDER:
NEW INSIGHTS AND PROSPECTS FOR TREATMENT**

Chp.: Aysegul Yildiz-Yesiloglu, M.D.

Co-Chp.: Eduard Vieta, M.D.

A Cognition, Neuroplasticity, and Treatment, of Bipolar Disorder
Eduard Vieta, M.D.

B Is the Protein Kinase C Inhibition a Keystone in Treatment of Bipolar Disorder?
Aysegul Yildiz-Yesiloglu, M.D.

C Glial Cell Dysfunction in the Pathophysiology of Bipolar Disorder
Dost Ongur, M.D.

D Genetics of Bipolar Disorder: Recent Advances and Coming Attractions
Jordan W. Smoller, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.

Room 4, Upper Level, San Diego Convention Center

PHYSICAL ILLNESS IN PEOPLE WITH SEVERE MENTAL DISORDERS

Chp.: Norman H. Sartorius, M.D.

Co-Chp.: Mario Maj, M.D.

A Physical Illness and Mental Disorder: Neglected Facts
Norman H. Sartorius, M.D.

B Physical Illness and Schizophrenia: Extensive Review of the Literature
Stefan Leucht, M.D.

C Diabetes and Mental Disorders: What Do We Know About Risks and Linkages?
Michelle B. Riba, M.D.

D Physical Illness in Patients With Mental Disorders Seen in Anambra, Nigeria
Richard Uwakwe, M.B.B.S.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.

Room 5 A, Upper Level, San Diego Convention Center

SUICIDE ACROSS THE LIFE CYCLE: A SPANISH LANGUAGE UPDATE (MANEJO Y TRATAMIENTO DEL PACIENTE SUICIDA EN LAS DISTINTAS ETAPAS DE LA VIDA)

Chp.: Gabriel Kaplan, M.D.

Co-Chp.: Javier I. Escobar, M.D.

A Neurobiological Correlates of Suicide
Pedro L. Delgado, M.D.

B Youth Suicide (Suicidio Infantojuvenil)
Gabriel Kaplan, M.D.

C Suicidal Behavior in Adults

Maria A. Oquendo, M.D.

D Suicidal Behavior in Late Life

Jacobo E. Mintzer, M.D.

E Suicide in the Medically Ill

Humberto Marin, M.D.

Discussant: Javier I. Escobar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.

Room 5 B, Upper Level, San Diego Convention Center

INSIGHTS ON OBESITY AND DRUG ADDICTION FROM BRAIN IMAGING

Collaborative Session With the National Institute on Drug Abuse

Chp.: Joseph Frascella, Ph.D.

Co-Chp.: Nora D. Volkow, M.D.

A Modulators of Orbitofrontal Activation in Response to Food Stimuli
Deborah Yurgelun-Todd, Ph.D.

B Hunger as an Addiction
Alain Dagher, M.D.

C Application of Incentive-Sensitization Theory of Drug Addiction to Overeating
Dana M. Small, Ph.D.

D Neuroimaging Studies of Obesity and Drug Addiction
Gene-Jack Wang, M.D., Nora D. Volkow, M.D., Joanna S. Fowler, Ph.D.

Discussant: Nora D. Volkow, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.

Room 7 A, Upper Level, San Diego Convention Center

TREATMENTS FOR MALADAPTIVE PERSONALITY TRAITS WITH SOME EMPIRICAL SUPPORT

Chp.: James H. Reich, M.D.

A The Effect of Axis II on Outcome of Axis I Disorders
James H. Reich, M.D., Simone Kool, M.D.

B Initial Findings From the Canadian RCT of Dialectical Behavior Therapy for BPD
Paul Links, M.D., Shelley McMMain, Ph.D., Robert Cardish, M.D., William Gnam, M.D., Lorne Korman, Ph.D., Adam Quastel, M.D., Ian Dawe, M.D., David Streiner, Ph.D.

C The STEPPS Model: A Cognitive Group Treatment for BPD
Donald W. Black, M.D.

D Schema Focused Therapy: An Evidence-Based Treatment for BPD
David P. Bernstein, Ph.D., Arnoud Arntz, M.D.

E Pharmacologic Treatment of Personality Disorder Traits
Erika Saunders, M.D., Kenneth R. Silk, M.D.

Discussant: Peter J. Tyrer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.

Room 7 B, Upper Level, San Diego Convention Center

NEUROSCIENCE AND PHENOMENOLOGY OF SCHIZOPHRENIA

Chp.: Michael A. Schwartz, M.D.

Co-Chp.: Rodrigo D. Paz, M.D.

- A **Integrating the Neuroscience and Phenomenology of Schizophrenia: A Challenge for the 21st Century Psychiatry**
Michael A. Schwartz, M.D.
- B **The History of the Phenomenological Method in Clinical Psychiatry**
Otto F. Doerr Zegers, M.D.
- C **Neurodevelopmental Disruption of Hippocampal-prefrontal Cortical Synaptic Connectivity: Implications for Schizophrenia Pathophysiology**
Kuei-Yuan Tseng, Ph.D.
- D **From the Neurobiology of Adolescence to the Neurobiology of Early Schizophrenia**
Rodrigo D. Paz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.

Room 8, Upper Level, San Diego Convention Center

HOW TO PRACTICE SPORT PSYCHIATRY: A DEMONSTRATION

Chp.: Antonia L. Baum, M.D.

- A **The Overview of the Field of Sport Psychiatry**
Ira D. Glick, M.D.
- B **The ADHD Affected Athlete and Role of the Psychiatrist**
David O. Conant-Norville, M.D.
- C **Interviewing the Athlete With a Substance Abuse Problem**
Ronald L. Kamm, M.D.
- D **The Athlete With Depression: Understanding Etiology and Treatment Through the Interview**
Antonia L. Baum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.

Room 9, Upper Level, San Diego Convention Center

CRF-ANTAGONISM FOR TREATMENT OF ALCOHOLISM AND AFFECTIVE DISORDERS

Chp.: Markus Heilig, M.D.

- A **Negative Affect and Excessive Alcohol Drinking Driven by Central CRF Systems: Reversal by the Nvel CRF1 Antagonist MTIP**
Markus Heilig, M.D.

- B **The Dark Side of Alcoholism: Neuroadaptational Mechanisms With the CRF System Critical for Excessive Drinking**

George F. Koob, Ph.D.

- C **Amygdala Protein Kinase C Epsilon Regulates Corticotropin Releasing Factor, Anxiety, and Alcohol Self-Administration**

Robert O. Messing, M.D.

- D **Targeting the Corticotrophin Releasing Factor System for the Treatment of Alcohol Dependence**

Selena Bartlett, Ph.D., Antonello Bonci, M.D.

- E **Genetic Association of the Human Corticotropin Releasing Hormone Receptor 1 With Binge Drinking and Alcohol Intake Patterns in Two Independent Samples**

Gunter Schumann, M.D.

- F **Genetic Variation at the CRH Locus and It's Association With Anxiety and Alcohol Consumption-Lessons From the Macaque**

Christina S. Barr, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.

Room 10, Upper Level, San Diego Convention Center

THE CALIFORNIA MENTAL HEALTH SYSTEMS ACT: TRANSFORMING SYSTEMS OF CARE TO REDUCE MENTAL HEALTH DISPARITIES

Chp.: Francis G. Lu, M.D.

- A **Overview of California Mental Health Service Act**
Rachel G. Guerrero, M.S.W.
- B **The Community Services and Supports Component of the MHSA: Evaluating Efforts to Address Disparities in Mental Health**
Katherine Elliott, Ph.D.
- C **MHSA Workforce and Training: Cultural Competence and Disparities Reduction**
Sergio Aguilar-Gaxiola, M.D.
- D **Prevention and Early Intervention in Underserved Populations: Opportunities for Change**
Katherine G. Ruiz-Mellott, M.D.

Discussant: Robbin Huff-Musgrove, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.

Room 11 A, Upper Level, San Diego Convention Center

ETHICS, HUMAN RIGHTS AND DYNAMIC PSYCHIATRY

Chp.: Joseph P. Merlino, M.D.

- A **Challenge to Medical Ethics: Psychiatrists Participating in the Interrogation of Detainees**
Steven S. Sharfstein, M.D.
- B **Ethical Implications of Big Pharma**
Stephen A. Green, M.D.
- C **A Reorientation Towards Professionalism in Medicine: Our Ethics, Our Future**
Joseph P. Merlino, M.D.
- D **Ethical Issues in Sexual Conversion: Reparative™ Therapies**
Jack Drescher, M.D.
- E **Ethics in Residency**
Lea E. de Francisci Lis, M.D.

Discussant: Spencer Eth, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.

Room 11 B, Upper Level, San Diego Convention Center

EATING DISORDERS 2007: EXPANDING BIOLOGICAL AND CLINICAL PERSPECTIVES

Chp.: Joel Yager, M.D.

Co-Chp.: David B. Herzog, M.D.

- A **Anorexia Nervosa and Obsessive Compulsive Disorder**
Walter H. Kaye, M.D.
- B **How Stable Are Eating Disorder Diagnoses?**
David B. Herzog, M.D., Kamryn T. Eddy, Ph.D., Debra L. Franko, Ph.D., David J. Dorer, Ph.D., Kavita Tahlilani, B.S.
- C **Impulse Control Disorders in Eating Disorder Women**
Katherine A. Halmi, M.D.
- D **Body Image Concerns and the Desire for Plastic Surgery After Bariatric Surgery**
James E. Mitchell, M.D.
- E **Eating Disorders in Late Life**
William J. Apfeldorf, M.D., Joel Yager, M.D., C. Nathaniel Roybal, M.D.

Discussant: Joel Yager, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.

Room 23 A, Upper Level, San Diego Convention Center

DECONSTRUCTING PSYCHOSIS: RESEARCH PLANNING FOR DSM-V

Chp.: Carol A. Tamminga, M.D.

Co-Chp.: Jim Van Os, M.D.

- A **Parsing Endophenotypes Across Psychotic Disorders: Toward a Refined Nosology of Psychoses**
Matcheri Keshavan, M.D.

- B **Delusions in Unipolar and Bipolar Major Depression: Recommendations for the Revision of the DSM-IV**
Mario Maj, M.D.

- C **Deconstructing Psychosis: A Brain Imaging Perspective**
Raquel E. Gur, M.D.

- D **Epidemiological and Psychopathological Approaches towards Psychotic Diagnoses in DSM-V**
Jim Van Os, M.D.

- E **Pharmacology of Psychosis: Contrasting Schizophrenia With Bipolar 1 Disorder**
Carol A. Tamminga, M.D.

Discussant: William T. Carpenter, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

BRIEF THERAPIES: AN UPDATE FOR CLINICIANS

Chp.: Mantosh J. Dewan, M.D.

- A **Useful Tips for Psychotherapists From Research**
Roger P. Greenberg, Ph.D.

- B **Formulation and Intervention in Time-Limited Dynamic Psychotherapy**
Hanna Levenson, Ph.D.

- C **Cognitive Therapy**
Judith Beck, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.

Room 28 D/E, Upper Level, San Diego Convention Center

WHAT IS THE DIRECTIONALITY OF THE ONSET OF COMORBID SUBSTANCE USE AND OTHER PSYCHIATRIC DISORDERS?

Collaborative Sessions With the National Institute on Drug Abuse

Chp.: Kevin P. Conway, M.D.

Co-Chp.: Ivan D. Montoya, M.D.

- A **Methodological Issues in Assessing the Directionality of the Onset of Substance Use and Other Comorbid Psychiatric Disorders**
Helena C. Kraemer, Ph.D.

- B **Evidence of Directionality in Epidemiological Studies of Adults**
Ronald Kessler, Ph.D.

- C **Genetic Factors and the Directionality of Comorbid Disorders**
Michael Vanyukov, Ph.D.

(Continued next page)

MONDAY

D Developmental Models to Explain the Onset and Directionality of Comorbid Disorders
Monique Ernst, M.D.

E Treatment Implications of Determining the Directionality of Comorbid Disorders
Edward V. Nunes, M.D.

Discussant: Kathleen T. Brady, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.

Room 29 A/B, Upper Level, San Diego Convention Center

CATEGORIES AND DIMENSIONS IN CLINICAL AND RESEARCH CONTEXTS OF DIAGNOSTIC CLASSIFICATION FOR *DSM-V*
Collaborative Session With the National Institute on Drug Abuse

Chp.: Helena C. Kraemer, Ph.D.

A Severity is the Most Important Dimension of Depression
Michael E. Thase, M.D.

B Anxiety Disorders
M. Katherine Shear, M.D.

C Dimensional Approaches to Diagnosing Addictive Disorders
Wilson M. Compton, M.D.

D A Dimensional Prototype for BPD
Andrew E. Skodol, M.D., Robert F. Krueger, Ph.D., W. John Livesley, M.D., Patrick Shrout, Ph.D., Yueqin Huang, M.D.

E Dimensional Approach to Major Psychoses
Patricia Suppes, M.D.

Discussant: Maritza Rubio-Stipec, Sc.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.

Room 29 C/D, Upper Level, San Diego Convention Center

THE DISRUPTIVE PHYSICIAN: REHABILITATE OR RETALIATE?

Chp.: Howard E. Book, M.D.

A Managing Disruptive Behaviour in Physicians: The Experience of Ontario's Physician Health Program
Michael Kaufmann, M.D.

B Physician Disruptive Behavior Patterns: Assessment, Intervention and Monitoring
Larry J. Harmon, Ph.D.

C The Forensic Psychiatric Contribution to Assessing and Understanding Disruptive Physician Behaviour
Hy Bloom, M.D.

D Disruptive Docs: How Are They?
Eva C. Ritvo, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.

Room 30 A, Upper Level, San Diego Convention Center

IMPULSIVITY: FROM NEUROPHENOMENOLOGY TO TREATMENT OPTIONS

Chp.: Stefano Pallanti, M.D.
Co-Chp.: Eric Hollander, M.D.

A Treatment of Impulsivity and Compulsivity
Eric Hollander, M.D., Daphne Simeon, Andrea Allen, Ph.D., Thomas Mick, M.D., Heather Berlin, Ph.D., Jennifer Bartz, Ph.D.

B Pharmacological Challenge in Pathological Gambling
Stefano Pallanti, M.D., Silvia Bernardi, M.D., Ilenia Pampaloni, M.D., Eric Hollander, M.D.

C Searching for Endophenotypes in OCD Families: Results From Neuropsychology and Brain Imaging Studies
Naomi A. Fineberg, M.D., Lara Menzies, M.D., Ed Bullmore, M.D.

D Exploring Impulsivity and Compulsivity Using Neurocognitive Probes: Translational Approaches
Samuel Chamberlain, Ph.D., Trevor Robbins, Ph.D., Barbara Sahakian, Ph.D.

Discussant: Lorrin M. Koran, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.

Room 30 B, Upper Level, San Diego Convention Center

THE HIDDEN DIAGNOSES IN PSYCHIATRY: IMPLICATIONS FOR TRAINING, CLINICAL CARE, AND OUTCOMES

Chp.: Leighton Y. Huey, M.D.

A The Importance of Early-Onset Psychiatric Disorders and Developmental Psychopathology for the Psychiatrist
Daniel F. Connor, M.D.

B Dismorphology, Mental Illness, and Learning Disabilities: Genetic Syndromes With Behavioral Phenotypes
Carolyn M. Drazinic, M.D.

C Common Diagnostic Confusions, Addictions, Depression, and ASPD: Which Is Which?
Victor Hesselbrock, Ph.D.

D Recovering the Diagnosis of PTSD in Psychiatric Training
Julian D. Ford, Ph.D.

E Pay Attention: The Impact of ADHD in Adulthood
Leighton Y. Huey, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.

Room 30 C, Upper Level, San Diego Convention Center

PSYCHIATRIC PRACTICE IN THE NURSING HOME

Chp.: Subramoniam Madhusoodanan, M.D.

Co-Chp.: Ronald Brenner, M.D.

A Nursing Home Consultation

Olivera J. Bogunovic, M.D.

B Research in the Skilled Nursing Facility: It Is Different?

Sanjay Gupta, M.D.

C Behavior Management Program

Subramoniam Madhusoodanan, M.D.

Discussant: Ronald Brenner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

CHILDREN OF IMMIGRANTS IN THE CHANGING MOSAIC OF THE U.S.

Chp.: Consuelo C. Cagande, M.D.

A A Personal Introduction

Consuelo C. Cagande, M.D.

B Children of Immigrants: An Overview

R. Rao Gogineni, M.D.

C Balancing Act Between Two Cultural Identities

Alyssa S. Kwon, M.D.

D An Immigrant Parental Journey: Trials, Tribulations, and Triumphs

Dilip Ramchandani, M.D.

E The Second Generation: Risks and Opportunities

Andres J. Pumariega, M.D.

Discussant: Andres J. Pumariega, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.

Room 31 A, Upper Level, San Diego Convention Center

UPDATE ON SUPPORTIVE PSYCHOTHERAPY

Chp.: David J. Hellerstein, M.D.

A Theory of Supportive Psychotherapy

Arnold Winston, M.D., Michael Goldstein, M.D.

B History of Supportive Psychotherapy

Stephen J. Rojcewicz, Jr., M.D.

C Research on Supportive Psychotherapy in the Treatment of BPD

David J. Hellerstein, M.D., Barbara H. Stanley, M.D., Kimberly Kotov, Ph.D., Ron Aviram, Ph.D.

D Use of Supportive Psychotherapy in Adjustment Disorders.

Roger Peele, M.D., Vicenzio H. Perkins, M.D., Mozhdeh Roozegar, M.D., Maryam Razavi, M.D.

E Teaching Supportive Psychotherapy to Psychiatric Residents

Carolyn J. Douglas, M.D.

Discussant: Peter J. Buckley, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.

Room 31 B, Upper Level, San Diego Convention Center

FIRST BREAK SCHIZOPHRENIA IN FRANCOPHONE AND ANGLOPHONE COUNTRIES: TREATMENT AND NEUROIMAGING: VIVE LA DIFFERENCE

French Psychiatric Association

Chp.: John A. Talbott, M.D.

Co-Chp.: Francois C. Petitjean, M.D.

A Early Intervention in Psychosis: An Evidence-Based Reform

Patrick D. McGorry, M.D.

B Cannabis Use and Past Treatment in First Psychotic Episode

Olivier J. Canceil, Psy.D., Fayçal Mouaffak, M.D., Yannick Morvan, Psy.D., Marie-Odile Krebs, Ph.D.

C Preventing Schizophrenia: An International Initiative

Thomas H. McGlashan, M.D.

D Evaluation of Hospital-Based Care for Schizophrenia

Karen A. Ritchie, Ph.D.

E Treatment of First Episode Psychosis: Importance of Drug Selection and Early Intervention

Jeffrey A. Lieberman, M.D.

F Neuroimaging in Patients With First Psychotic Episode

Olivier Maiza, M.D., Annick Razafimandimby, Ph.D., Pascale Abadie, Laurent Lecardeur, Bernard Mazoyer, M.D., Nathalie Tzourio-Mazoyer, M.D., Sonia Dollfus, M.D.

Discussants: Alexandra B. McLean, M.D., Robert Rosenheck, M.D.

THIS SESSION WILL BE AUDIOTAPED.

MONDAY

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.

Room 31 C, Upper Level, San Diego Convention Center

CHALLENGES AND NEW DEVELOPMENTS IN THE PSYCHIATRIC EDUCATION OF MEDICAL STUDENTS

Chp.: Jonathan E. Alpert, M.D.

Co-Chp.: Eric R. Marcus, M.D.

A Psychiatric Stigma in Medical Student Education
Steven C. Schlozman, M.D., Mary Anne Badaracco, M.D.

B The Latent Curriculum and The Emotional Development of Medical Students
Eric R. Marcus, M.D.

C Ambulatory Experiences in the Psychiatry Clerkship
Tamara L. Gay, M.D.

D Interdisciplinary and Longitudinal Integration During Clinical Training

Adam M. Brenner, M.D., Derri Shtasel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.

Room 32 A, Upper Level, San Diego Convention Center

INNOVATIVE WAYS IN PSYCHOTHERAPY SUPERVISION: THE SHORT TERM DYNAMIC THERAPY EXPERIENCE

Chp.: Manuel Trujillo, M.D.

Co-Chp.: Waguih W. IsHak, M.D.

A Innovative Ways in Psychotherapy Supervision: The Short Term Dynamic Therapy Experience
Amir E. Ettkeal, M.D.

Discussants: Manuel Trujillo, M.D., Waguih W. IsHak, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.

Room 32 B, Upper Level, San Diego Convention Center

ALEXITHYMIA AND EMOTIONAL DYSREGULATION: FROM THEORY TO CLINICAL PRACTICE

Chp.: Maurice Corcos, M.D.

Co-Chp.: Gwenole Loas, M.D.

A Depression and Alexithymia in Eating Disorders
Maurice Corcos, M.D., Gwenole Loas, M.D., Jean-Luc Venisse, M.D., Paul Bizouard, M.D.

B Relationships Between Alexithymia, Depression, and Dependent Personality Disorder
Gwenole Loas, M.D.

C BPD and Emotional Dysregulation
Alexandra Pham-Scottet, M.D., Marion Robin, M.D.

D Alexithymia and Self-Injurious Behavior : A Core Dimension? A Study on 692 Subjects
Ludovic Gicquel, M.D., Bruno Falissard, Ph.D., Maurice Corcos, M.D.

E Alexithymia in Infertile Women
Claire Lamas, M.D., Isabelle Nicolas, M.D., Maurice Corcos, M.D., René Frydman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

ADVANCES IN TREATMENTS OF PSYCHIATRIC DISORDERS

2:00 p.m.-5:30 p.m.

Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Glen O. Gabbard, M.D.

A Advances in Treatment of Psychiatric Disorders
Katharine A. Phillips, M.D.

B Advances in Treatment of Psychiatric Disorders, Antisocial Personality Disorders, and Psychopathy
Reid Meloy, Ph.D.

C Advances in Treatment of Psychiatric Disorders: Combined Medication and Psychotherapy for Mood Disorders
Jan Fawcett, M.D.

D Advances in Treatment of Psychiatric Disorders
Charles Marmar, M.D.

E Histrionic Personality Disorder
Glen O. Gabbard, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 3

3:00 p.m.-5:00p.m.

Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

5:30 p.m. Sessions

CONVOCAATION OF DISTINGUISHED FELLOWS

5:30 p.m.-6:30 p.m.

Ballroom 20, Upper Level,
San Diego Convention Center

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, Fellows, members, and registered guests are invited.

(Continued next page)

Presiding: Pedro Ruiz, M.D., President

Grand Marshals: Joseph R. Mawhinney, M.D., Marc A. Schuckit, M.D.

Marshals: Dilip V. Jeste, M.D., Kenneth L. Campos, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS

Carolyn B. Robinowitz, M.D., *President-Elect*

INDUCTION OF DISTINGUISHED FELLOWS

Carolyn B. Robinowitz, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS

Pedro Ruiz, M.D.

INTRODUCTION OF FELLOWS

Pedro Ruiz, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS

Pedro Ruiz, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS

Pedro Ruiz, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS

Pedro Ruiz, M.D.

PRESENTATION OF AWARDS

Pedro Ruiz, M.D.

APA/Lilly Resident Research Awards

Human Rights Awards

Blanche F. Ittleson Award for Research in Child Psychiatry

APIRE/Kempf Fund Awards for Research

Development in Psychobiological Psychiatry

Agnes Purcell McGavin Awards

Isaac Ray Award

Jack Weinberg Memorial Award for Geriatric

Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE

Professor John F. Nash, Jr.

LECTURE 12

5:30 p.m.-6:30 p.m.

Ballroom 20 Lobby, Upper Level,
San Diego Convention Center

**WILLIAM C. MENNINGER
MEMORIAL LECTURE**

Professor John F. Nash, Jr.

Nobel laureate John Nash Jr., Ph.D., at the age of 30, descended into the debilitating blackness of severe paranoid schizophrenia. Despite the odds, however, his perseverance and genius eventually led to his winning the 1994 Nobel Prize for Economics for landmark work he had begun in the 1950s on the mathematics of game theory. His inspiring story was adapted in the movie "A Beautiful Mind," which won the best-picture Oscar for 2001. Mr. Nash was born in Bluefield, WV, in 1928. Early on he excelled at mathematics and won a scholarship to Carnegie Mellon University. He did so well that upon graduation in 1948 he was awarded a master's degree in addition to his bachelor's degree, and went on to earn a Ph.D. from Princeton University in 1950. From 1951 until his resignation in 1959, he was a faculty member at M.I.T. As an undergraduate, he began work on what is now regarded as the basic building block of the theory of games. His reputation as a mathematical genius was firmly established by his ability to solve major problems in pure mathematics using original methodology. In 1957 Nash married a woman he had met while she was a student at M.I.T. During his wife's pregnancy in 1959, he became increasingly delusional and was forcibly hospitalized on several occasions. He eventually refused to take medication and for years was a ghostly figure on the Princeton campus, believing he was engaging in research. It was in the early 1990s that acquaintances noticed that he appeared to be recovering from his illness. According to his autobiography, "When I had been long enough hospitalized... I would finally renounce my delusional hypotheses and revert to thinking of myself as a human of more conventional circumstances and return to mathematical research. In these interludes of, as it were, enforced rationality, I did succeed in doing some respectable mathematical research... But after my return to the dream-like delusional hypotheses in the later 60s, I became a person of delusionally influenced thinking but of relatively moderate behavior and thus tended to avoid hospitalization and the direct attention of psychiatrists. Thus further time passed. Then gradually I began to intellectually reject some of the delusionally influenced lines of thinking which had been characteristic of my orientation. This began, most recognizably, with the rejection of politically oriented thinking as essentially a hopeless waste of intellectual effort." Despite having divorced his wife for her role in having him hospitalized, in 1970 she took him in to save him from homelessness, and they remarried in 1991. Three years later, he won the Nobel Prize. This is no fairytale ending; it provides powerful support for the growing movement within psychiatry to help patients with severe mental illness focus on recovery, not pathology.

THIS SESSION WILL BE AUDIOTAPED.

7:00 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 25-28

INDUSTRY SUPPORTED SYMPOSIUM 25

7:00 p.m.-10:00 p.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

**IMPROVING OUTCOMES IN SCHIZOPHRENIA:
PRODROME TO REMISSION**

Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Christoph U. Correll, M.D.

**A Early Intervention in the Psychotic Prodrome: Has Its
Time Come?**

Christoph U. Correll, M.D.

**B The Course of Brain Abnormalities in Schizophrenia:
Can We Modify Them?**

Rene S. Kahn, M.D.

**C Improving Rates of Response and Remission in
Schizophrenia? How Do We Get Where We Need to Be?**

John M. Kane, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 26

7:00 p.m.-10:00 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

**NAVIGATING THE COMPLEX MAZE OF BIPOLAR
DISORDER**

Supported by Pfizer Inc.

Chp.: Prakash S. Masand, M.D.

A Diagnostic Pitfalls in Patients With Bipolar Disorder

Prakash S. Masand, M.D.

**B Managing the Bipolar Patient With Medical
Comorbidities**

Andrea Fagiolini, M.D.

**C Tailoring Antipsychotic Treatment to the Complex
Patient With Bipolar Disorder**

Paul E. Keck, M.D.

**D Bringing Research to the Clinician: Lessons From
STEP-BD**

Gary S. Sachs, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 27

7:00 p.m.-10:00 p.m.

Elizabeth Ballroom A/B/C/D/E, Second Level,
Manchester Grand Hyatt

**WHEN ENDOCRINOLOGY AND PSYCHIATRY
COLLIDE: WHAT THE CLINICIAN NEEDS TO
KNOW ABOUT ANTIPSYCHOTIC-INDUCED
ENDOCRINE DISTURBANCES**

Supported by AstraZeneca Pharmaceuticals

Chp.: Peter F. Buckley, M.D.

**A Increasing Global Burden of Cardiovascular Disease in
General Populations and Patients With Schizophrenia**

Charles H. Hennekens, M.D.

**B Diabetes and the Metabolic Syndrome: From
Soup to Nuts**

Ramachandiran Cooppan, M.B.Ch.B.

**C Antipsychotics and Metabolic Risk: What's the
Problem and What's the Solution?**

John W. Newcomer, M.D.

**D Prolactin Elevation and Antipsychotic Therapy: What
to Tell Patients About Risks to Bones and Sexual
Functioning**

Meera Narasimhan, M.D.

**E Guidelines for the Management of Metabolic and
Endocrine Side Effects: Confusion or Consensus?**

Peter F. Buckley, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 28

7:00 p.m.-10:00 p.m.

Manchester Ballroom, Second Level, Manchester Grand Hyatt

**IMPROVING DEPRESSION TREATMENTS:
BRIDGING THE GAP BETWEEN RESEARCH AND
CLINICAL PRACTICE**

Supported by Eli Lilly and Company

Chp.: Jonathan E. Alpert, M.D.

Co-Chp.: Timothy Petersen, Ph.D.

**A Follow-Up Care After Initiating Antidepressant
Treatment: An Empirically Informed Approach**

Mark Zimmerman, M.D.

**B Achieving and Maintaining Optimal Therapeutic
Outcomes in Old-Age Depression**

Charles F. Reynolds III, M.D.

**C Optimizing Care for Depression During the
Menopausal Transition: The Interface Between
Psychiatry and Gynecology**

Hadine Joffe, M.D.

**D Management of Depressed Patients With Chronic
Medical Conditions**

Gregory E. Simon, M.D.

E The STAR*D Study: Lessons Learned

Timothy Petersen, M.D.

TUESDAY, MAY 22, 2007

160TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 22-24

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 22, PART 2

7:00 a.m.-8:30 a.m.

Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS: THE MANAGEMENT OF ALLOSTATIC LOAD, METABOLIC SYNDROME, AND CO-OCCURRING DISORDERS

Supported by Solway-Wyeth

Chp.: Mark H. Rapaport, M.D.

- A **Issues in the Assessment and Management of Overweight and Obesity in Psychiatric Patients**
Alicia Ruelaz, M.D.
- B **Integrating Alternative Health Approaches Into the Care of Our patients: Evidence About the Actions of Exercise, Massage, and Acupuncture**
Mark H. Rapaport, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 23, PART 2

7:00 a.m.-8:30 a.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

HOW DO ATYPICALS AND ANTIPSYCHOTICS WORK? FROM RECEPTORS TO REALITY

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

- A **Managing Patients With Psychotic Disorders: From Efficacy to Effectiveness**
John Lauriello, M.D.
- B **Pharmacologic Predictability of Antipsychotic-Related Adverse Effects: An Opportunity for Improving Outcomes**
Prakash S. Masand, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 24, PART 2

7:00 a.m.-8:30 a.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

TREATING THE SPECTRUM OF BIPOLAR DISORDERS: AN INTERACTIVE CASE DISCUSSION

Supported by AstraZeneca Pharmaceuticals

Chp.: Michael E. Thase, M.D.

A **Beyond Antidepressants: Treatment Options for Bipolar Depression**
Roger S. McIntyre, M.D.

B **Treating and Preventing Mania**
Lauren B. Marangell, M.D.

8:00 a.m. Sessions



COURSES 55-61

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 55 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 56 8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: Renato D. Alarcon, M.D., John L. Black, M.D.

COURSE 57 8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfeld, M.D.

COURSE 58 8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Stephen V. Faraone, Ph.D., Michele T. Pato, M.D.

COURSE 59 8:00 a.m.-12 noon
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

TUESDAY

COURSE 60 8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

COURSE 61 8:00 a.m.-12 noon
Randle Ballroom B, Fourth Level, Manchester Grand Hyatt

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: INTRODUCTORY COURSE

Co-Directors: Charles J. Rainey, M.D., Richard A. Montgomery, M.D.
Faculty: Carlyle H. Chan, M.D., Steven I. Altchuler, M.D.,
Raymond J. Kloss, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 2
9:00 a.m.-12 noon
Room 23 a/b, Upper level, San Diego Convention Center

COGNITIVE THERAPY FOR DEPRESSION


Moderator: Judith Beck, Ph.D.
Presenters: Jesse H. Wright III, M.D., Donna M. Sudak, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.**

**ADVANCES IN ASSESSMENT AND
MANAGEMENT OF SUICIDE**
9:00 a.m.-12:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Robert I. Simon, M.D.

- A Suicide and Gender**
Liza H. Gold, M.D.
- B Suicide in Children and Adolescents**
Peter Ash, M.D.
- C Psychiatrists' Reactions to Patient Suicides**
Michael Gitlin, M.D.



COURSES 62-69

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 62 9:00 a.m.-4:00 p.m.
Edward Room C/D, Second Level, Manchester Grand Hyatt

**A PSYCHODYNAMIC APPROACH TO TREATMENT
REFRACTORY MOOD DISORDERS**

Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 63 9:00 a.m.-4:00 p.m.
Gregory Room A/B, Second Level, Manchester Grand Hyatt

**UNDERSTANDING THE PERSON BEHIND THE
ILLNESS: AN APPROACH TO PSYCHODYNAMIC
FORMULATION**

Director: William H. Campbell, M.D.

COURSE 64 9:00 a.m.-4:00 p.m.
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn C. Shea, M.D.

COURSE 65 9:00 a.m.-4:00 p.m.
Madeleine Room A/B, Third Level, Manchester Grand Hyatt

**PERSONNEL MANAGEMENT FOR CLINICIAN-
ADMINISTRATORS**

Director: Stephen M. Soltys, M.D.
Faculty: Joseph J. Parks, M.D., Kay H. Titchenal, S.P.H.R.

COURSE 66 9:00 a.m.-4:00 p.m.
Del Mar Room A/B, Third Level, Manchester Grand Hyatt

**STEPS* TREATMENT PROGRAM FOR
BORDERLINE PERSONALITY DISORDER**

Co-Directors: Donald W. Black, M.D., Bruce M. Pfohl, M.D.
Faculty: Nancee Blum, M.S.W.

COURSE 67 9:00 a.m.-4:00 p.m.
Annie Room A/B, Third Level, Manchester Grand Hyatt

**THE ASSESSMENT AND TREATMENT OF CHILD
SEXUAL ABUSERS**

Co-Directors: Gene G. Abel, M.D., John M. Bradford, F.R.C.P.C.
Faculty: Candice A. Osborn, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.

Windsor Room, Third Level, Manchester Grand Hyatt

SPIRITUALITY IN PSYCHIATRY

Director: Michael D. McGee, M.D.

COURSE 69 9:00 a.m.-4:00 p.m.

Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

BASIC CONCEPTS IN PALLIATIVE CARE FOR PSYCHIATRISTS

Co-Directors: Scott A. Irwin, M.D., Frank D. Ferris, M.D.

Faculty: Charles F. von Gunten, M.D., Gary T. Buckholz, M.D., Laurel H. Herbst, M.D., Steven Oppenheim, M.D., Kimberly A. Bower, M.D., Sidney Zisook, M.D., Rodrigo A. Munoz, M.D.

LECTURES 13-15

LECTURE 13

9:00 a.m.-10:30 a.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center

**APA RESEARCH IN PSYCHIATRY
AWARD LECTURE**

A. John Rush, M.D.

**What Patients and Clinicians Need to Know: The
Case for Patient-Focused Research**

Chp.: Stuart C. Yudofsky, M.D.

Dr. A. John Rush, holds two named positions at the University of Texas Southwestern Medical Center at Dallas, Professor of Psychiatry and Vice Chair in the Department of Clinical Sciences. Following his B.A. at Princeton University (1964), and his M.D. at the Columbia College of Physicians and Surgeons (1968), he completed a general medical internship at Passavat hospital, Northwestern University, and a psychiatric residency at the University of Pennsylvania (1975). His research has focused on the development and testing of innovative treatments for mood disorders including medications, medication combinations, somatic treatments and psychotherapy, as well as disease management protocols (treatment algorithms) for severe and persistent mental illnesses. He has authored more than 470 papers and chapters and 10 books and has received continuous NIMH research support for 30 years. Dr. Rush's past awards include the Mood Disorders Research Award from the American College of Psychiatrists, the Paul Hoch Award from the American Psychopathological Association, the Edward J. Sachar Visiting Scholar Award from Columbia, the American Psychiatric Association Award for Research in Psychiatry, and the Gold Medal Award from the Society of Biological Psychiatry. He is past president of the Society of Biological Psychiatry and Society for Psychotherapy Research.

**Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 14

9:00 a.m.-10:30 a.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

John H. Krystal, M.D.

**Glumate, the Prefrontal Cortex, and Schizophrenia:
Capturing the Angel in Angel Dust**

Chp.: Anu A. Matorin, M.D.

Dr. Krystal is the Robert L. McNeil, Jr., Professor of Clinical Pharmacology and Deputy Chairman for Research for the Department of Psychiatry, Yale University School of Medicine and the VA Connecticut Healthcare System. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Department of Psychiatry Residency Training Program. He has published over 300 papers and chapters on the neurobiology and treatment of alcoholism, schizophrenia, and post-traumatic stress disorder. In this work, he is best known for studies of the contributions of amino acid neurotransmission to behavior, cognition, psychopathology, and treatment. His research program unites psychopharmacology, neuroimaging, and molecular genetics. He is principal investigator of the NIAAA Center for the Translational Neuroscience of Alcoholism, VA Alcohol Research Center, and Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal received the Joel Elkes Award of the American College of Neuropsychopharmacology (ACNP), the Han Jönas Weitbrecht Scientific Award from Bayer, the APIRE/Kempf Fund Award of the American Psychiatric Association, Most Highly Cited Investigator Award from Thomson-ISI, and other awards. He is Chairman of the NIMH Board of Scientific Counselors (2004-2007). He also serves on the NARSAD Scientific Advisory Board and the boards of directors of the ACNP and the Research Society on Alcoholism. He was a managing editor for the journal, Psychopharmacology (1999-2006) and is currently editor of Biological Psychiatry.

**Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 15

9:00 a.m.-10:30 a.m.

Room 33 A/B/C, Upper Level,
San Diego Convention Center

Apisamai Srirangson, M.D.

**Thailand's Recent Experience: Community
Mental Health and Destigmatization**

Chp.: Kathryn Connor, M.D.

(Continued next page)

Apisamai Srirangson, MD, known as Dr. Birth works for the Thai Department of Mental Health, Ministry of Public Health and practices psychiatry at Srithanya public Psychiatric Hospital in Nonthaburi Thailand. In addition to her work as a psychiatrist Dr. Birth also appears as the anchor of the national evening news and appears on several other regular TV segment. She has used her public profile to advance the cause of the mentally ill and has written a best selling book *Stories by Dr. Birth: Welcome to Srithanya Psychiatric Hospital*. Her primary interests lie in the areas of community mental health and de-stigmatization. She has also played important roles in the development and implementation of a new community mental health initiative, Family Link. This program is designed to promote advocacy and education to the public. She was Co-chair in the initiative project 'Destigmatization' in 2002-2005. Additionally she has been a member of the committee for the national de-stigmatization campaign that involves the families and enlists media and political support to reduce stigma. As a medical student she won the Award for Excellence in Community Health for Medical Student. In 1999 she was named Miss Thailand and represented Thailand in the Miss Universe pageant in Trinidad and Tobago. More recently she was awarded the *Tep Tong* Award for Best Practice News Anchor and the *Prav* Award for Women Role Models. Dr. Birth received her medical degree from Khon Kaen University in 1999 and her diploma from the Thai Board of General Psychiatry from Mahidol University in 2002. She currently resides in Nontaburi Thailand, a suburb of Bangkok. In her spare time she enjoys, writing, reading, scuba diving, studying piano, painting and travel as well as running a coffee retail shop, Coffee with Dr. Birth.

International Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 8-9

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 8 **Jon E. Grant, M.D.**, on Men's Mental Health (*Meet the Author*)
Room 27 B, Upper Level, San Diego Convention Center
- 9 **Howard E. Book, M.D.**, on Why Leadership Skills Benefit Residents (*Residents Only*)
Room 31 C, Upper Level, San Diego Convention Center

WORKSHOPS

COMPONENTS 23-29

COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m.

Room 3, Upper Level, San Diego Convention Center

EVALUATING COMPETENCY IN PSYCHOSOMATIC MEDICINE

APA Council on Psychosomatic Medicine

Co-Chps.: Mary J. Massie, M.D., Thomas N. Wise, M.D.

Participants: Lawson R. Wulsin, M.D., David F. Gitlin, M.D., Angel A. Caraballo, M.D.

COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m.

Room 4, Upper Level, San Diego Convention Center

CULTURE MATTERS: A MULTICULTURAL PERSPECTIVE ON THE IMMIGRANT EXPERIENCE

APA/AstraZeneca Minority Fellows

Co-Chps.: Alejandra Postlethwaite, M.D., Natalie D. Weder, M.D.

Participants: Liwei L. Hua, M.D., Jacqueline Henschke, M.D., Navdeep K. Dhaliwal, Rascha Dughly, M.D.

COMPONENT WORKSHOP 25 9:00 a.m.-10:30 a.m.

Room 5 A, Upper Level, San Diego Convention Center

SWEET CHILD OF MINE: PREGNANCY AND PARENTAL LEAVE DURING RESIDENCY

APA/GlaxoSmithKline Fellows

Co-Chps.: Vishal Madaan, M.D., Keith R. Stowell, M.D.

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m.

Room 5 B, Upper Level, San Diego Convention Center

THE APA WEB SITE: POTENTIAL FUTURE DIRECTIONS AND OPPORTUNITY FOR DIALOGUE

APA Ad Hoc Work Group on Information Systems

Chp.: Robert C. Hsiung, M.D.

Participant: William Bruce

COMPONENT WORKSHOP 27 9:00 a.m.-10:30 a.m.

Room 7 B, Upper Level, San Diego Convention Center

UPDATE ON PSYCHIATRY AND LAW

APA Council on Psychiatry and Law

Chp.: Paul S. Appelbaum, M.D.

Participants: Steven K. Hoge, M.D., Howard V. Zonana, M.D.

COMPONENT WORKSHOP 28 9:00 a.m.-10:30 a.m.

Room 7 A, Upper Level, San Diego Convention Center

LEARNING DISORDERS UPDATE FOR MENTAL HEALTH PROFESSIONALS

APA Corresponding Committee on Mental Health and Schools

Chp.: Marcia J. Slattery, M.D.

Participants: Jodi E. Star, M.D., Hong Shen, M.D., Lina M. Lopez, M.D.

COMPONENT WORKSHOP 29 9:00 a.m.-10:30 a.m.

Room 30 B, Upper Level, San Diego Convention Center

THE NATIONAL HEALTH INFORMATION NETWORK AND PSYCHIATRY: HOW WILL ELECTRONIC HEALTH RECORDS IMPACT OUR PATIENTS AND OUR PRACTICE?

APA Corresponding Committee on Electronic Health Records

Chp.: Farrell H. Brazier, M.D.

Participants: Peter F. Fore, M.D., Zebulon Taintor, M.D., Robert M. Plovnick, M.D.

ISSUES 28-39**ISSUE WORKSHOP 28** 9:00 a.m.-10:30 a.m.

Room 11 B, Upper Level, San Diego Convention Center

**PSYCHIATRY IN THE PRIMARY CARE SETTING:
MAKING IT WORK FOR PATIENTS AND DOCTORS****Chp.:** John C. Urbaitis, M.D.**Participants:** Jonathan S. Davine, M.D., David A. Pollack, M.D., Shauna P. Reinblatt, M.D.**ISSUE WORKSHOP 29** 9:00 a.m.-10:30 a.m.

Room 23 C, Upper Level, San Diego Convention Center

**THE UTILITY OF COMPUTER-ASSISTED
PSYCHOEDUCATION FOR RESIDENTIAL
TREATMENT OF VETERANS WITH PTSD****Co-Chps.:** Daniella David, M.D., Gary S. Kutcher, Ph.D.**Participant:** Maria D. Llorente, M.D.**ISSUE WORKSHOP 30** 9:00 a.m.-10:30 a.m.

Room 24 A, Upper Level, San Diego Convention Center

**HOW DOES CULTURE MAKE A DIFFERENCE IN
AMERICAN MENTAL HEALTH CARE?
CULTURALLY-SPECIFIC CARE IN CHANGING
CONTEXTS****Co-Chps.:** Lawrence T. Park, M.D., Mary Jo Good, Ph.D.**Participants:** Roberto Lewis-Fernandez, M.D., Sadeq Rahimi, Ph.D., Lisa Stevenson, Ph.D., Ken Vickery, Ph.D.**ISSUE WORKSHOP 31** 9:00 a.m.-10:30 a.m.

Room 24 C, Upper Level, San Diego Convention Center

**THE PROVIDER'S PURSUIT OF CULTURAL
COMPETENCE: A BIOPSYCHOSOCIAL QUEST****Chp.:** Richard K. Harding, M.D.**Participants:** Nioaka N. Campbell, M.D., Meera Narasimhan, M.D., Eric R. Williams, M.D.**ISSUE WORKSHOP 32** 9:00 a.m.-10:30 a.m.

Room 25 A, Upper Level, San Diego Convention Center

**1: 1 OBSERVATION IN A GENERAL HOSPITAL
SETTING: ISSUES AND RECOMMENDATIONS.****Co-Chps.:** Nyapati Rao, M.D., Kamil Jaghab, M.D.**Participants:** Tanveer Padder, M.D., Jacob E. Sperber, M.D.**ISSUE WORKSHOP 33** 9:00 a.m.-10:30 a.m.

Room 25 B, Upper Level, San Diego Convention Center

**RECOGNITION AND MANAGEMENT OF
NEUROLEPTIC MALIGNANT SYNDROME****Co-Chp.:** Andrew J. Francis, M.D., Stephan C. Mann, M.D.**Participants:** Stanley N. Caroff, M.D., Sanjay Gupta, M.D., Dora D. Kohen, M.D., Perminder Sachdev, M.D.**ISSUE WORKSHOP 34** 9:00 a.m.-10:30 a.m.

Room 25 C, Upper Level, San Diego Convention Center

**INVOLUNTARY HOSPITALIZATION OF MEDICAL
PATIENTS WHO LACK DECISIONAL CAPACITY: AN
UNRESOLVED ISSUE****Chp.:** Nancy Byatt, D.O.**Participants:** Debra A. Pinals, M.D., Patrick Smallwood, M.D.**ISSUE WORKSHOP 35** 9:00 a.m.-10:30 a.m.

Room 28 A, Upper Level, San Diego Convention Center

**HOW TO INVOLVE YOUR PATIENTS WITH BIPOLAR
DISORDER IN THEIR TREATMENT PLAN: A
GUIDELINE FOR CLINICIANS****Chp.:** Heinz Grunze, M.D.**Participants:** Francesc Colom, Ph.D., Eduard Vieta, M.D.**ISSUE WORKSHOP 36** 9:00 a.m.-10:30 a.m.

Room 28 B, Upper Level, San Diego Convention Center

**MAINTENANCE OF CERTIFICATION FOR
DIPLOMATES OF THE AMERICAN BOARD OF
PSYCHIATRY AND NEUROLOGY****Chp.:** Larry R. Faulkner, M.D.**Participants:** Victor I. Reus, M.D., Naleen N. Andrade, M.D., Christopher C. Colenda, M.D., Burton V. Reifler, M.D., Daniel K. Winstead, M.D.**ISSUE WORKSHOP 37** 9:00 a.m.-10:30 a.m.

Room 29 C/D, Upper Level, San Diego Convention Center

**HOW TO LAUNCH A SUCCESSFUL PRIVATE
PRACTICE: PART 1****Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.**Participants:** Martin G. Tracy, J.D., Marynell Hinton, M.A.**ISSUE WORKSHOP 38** 9:00 a.m.-10:30 a.m.

Room 30 C, Upper Level, San Diego Convention Center

**INTERPRETING AND DISSEMINATING FINDINGS
FROM AN EVIDENCE-BASED DRUG REVIEW:
ANTIEPILEPTIC DRUGS FOR MOOD DISORDERS****Chp.:** John M. Oldham, M.D.**Participants:** Cathy Melvin, Ph.D., William D. Evans, Ph.D., John Byrd, M.B.A.

ISSUE WORKSHOP 39 9:00 a.m.-10:30 a.m.

Room 31 A, Upper Level, San Diego Convention Center

PLANNED CARE FOR DEPRESSION: A PROGRAM FOR THE MANAGEMENT OF DEPRESSION IN PRIMARY CARE

Chp.: Robert C. Joseph, M.D.

Participants: Laureen Gray, M.S.N., Carleen A. Riselli, M.S.N., Laura Ncvill, M.S.N., Claire Pierre, M.D.

MEDIAS 3-4

MEDIA WORKSHOP 3 9:00 a.m.-12 noon

Room 10, Upper Level, San Diego Convention Center

WHEN THE LEVEES BROKE: A REQUIEM IN FOUR ACTS BY SPIKE LEE: THE PSYCHIATRIC DIMENSIONS OF HURRICANE KATRINA

APA Council on Minority Mental Health and Health Disparities

Co-Chps.: Francis G. Lu, M.D., Anthony T. Ng, M.D.

Participants: Annelle Primm, M.D., David E. Post, M.D.

MEDIA WORKSHOP 4 9:00 a.m.-12 noon

Room 11 A, Upper Level, San Diego Convention Center

THIRTEEN: PARENTING AND TREATING THE ADDICTED TEENAGER

APA Corresponding Committee on Treatment Services for Patients With Addictive Disorders

Co-Chps.: Petros Levounis, M.D., Alvaro Camacho, M.D.

Participants: Marjorie E. Waldbaum, M.D., Milagros Demandante, M.D., Varinder Rathore, M.D.

11:00 a.m. Sessions

ADVANCES IN MEDICINE 2

MEDICINE IN REVIEW: A JOURNAL ROUNDUP FOR 2006

11:00 a.m.-12:30 p.m.

Room 2, Upper Level, San Diego Convention Center

Chp.: Robert J. Boland, M.D.

Participant: Monique Yohanan, M.D.

LECTURES 16-18

LECTURE 16

11:00 a.m.-12:30 p.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center

Norman H. Sartorius, M.D.

The Future of Psychiatry: International Perspectives

Chp.: Anand Pandya, M.D.

Dr Norman Sartorius obtained his M.D. in Zagreb (Croatia). He specialized in neurology and psychiatry and subsequently obtained a Masters Degree and a Doctorate in psychology (Ph.D.). Dr Sartorius joined the World Health Organization (WHO) in 1967 and soon assumed charge of the programme of epidemiology in social psychiatry. He was also principal investigator of several major international studies on schizophrenia, on depression, and on health service delivery. In 1977, he was appointed Director of the Division of Mental Health of WHO, a position which he held until mid-1993. Dr Sartorius has served as the President of the World Psychiatric Association (WPA, President of the Association of European Psychiatrists (AEP), President of the International Association for the Promotion of Mental Health Programmes, and President of the Board of the Prize of Geneva Foundation. Dr Sartorius holds professorial appointments at the Universities of London, Prague and Zagreb and at several other universities in the USA and China. Dr Sartorius has published more than 300 articles in scientific journals, authored or co-authored several books and edited a number of others. The main areas of his interest are psychosocial aspects of health and development, public health aspects of neurology and psychiatry, cross-cultural psychiatry, scientific methodology and science policy. Dr Sartorius is an Honorary Fellow of the Royal College of Psychiatrists of the United Kingdom of Great Britain, of the Royal Australian and New Zealand College of Psychiatrists and of the American College of Psychiatry. He is a Distinguished Fellow of the American Psychiatric Association. He is a Corresponding Member of the Spanish Royal Academy of Medicine and of the Medical Academy of Mexico, Croatia and Peru. He has received the degree of Doctor of Medicine Honoris Causa of the Universities of Umea and of Prague and of Doctor of Science Honoris Causa of the University of Bath. He is an honorary fellow or member of numerous professional associations and advisory boards, both national and international.

**International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 17

11:00 a.m.-12:30 p.m.

Ballroom 6 C/D/E/F,

Upper Level, San Diego Convention Center

Nora Volkow, M.D.

**The Neurobiology of Free Will in Addictive Disorders
Collaborative Session With the National Institute on Drug Abuse**

Chp.: Herbert D. Kleber, M.D.

Co-Chp.: Eric C. Strain, M.D.

Nora D. Volkow, M.D., was appointed Director of the National Institute on Drug Abuse (NIDA) in May 2003. She is recognized as one of the world's leading experts on drug addiction and brain imaging. Dr. Volkow's work has been pivotal in demonstrating that drug addiction is a disease of the brain. She pioneered the use of brain imaging to investigate the toxic effects of drugs and the

effects of drugs responsible for their addictive properties in the human brain. In addition, she has made important contributions to the neurobiology of obesity, to the neurobiology of the behavioral changes that occur with aging, and to the treatment of ADHD. Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. Dr. Volkow spent most of her professional career at the Department of Energy's Brookhaven National Laboratory (BNL) in Upton, New York where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook. Dr. Volkow has published more than 330 peer-reviewed articles, more than 50 book chapters and non-peer reviewed manuscripts, and also edited three books on the use of neuroimaging in studying mental and addictive disorders. Dr. Volkow has been the recipient of numerous awards for significant scientific and public service achievements, is a member of the Institute of Medicine of the National Academy of Sciences, and was named "Innovator of the Year" in 2000 by US News and World Report.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 18

11:00 a.m.-12:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Fred H. Gage, Ph.D.

New Neurons in the Adult Brain

Chp.: Tara Grady-Weliky, M.D.

Fred H. Gage, Ph.D. is a professor in the Laboratory of Genetics at the Salk Institute in La Jolla, CA. Gage studies degeneration and regeneration in the central nervous system, with an eye on possible future treatments for devastating neurological damages resulting from disease or injury. Gage is a leader in the neuroscience field, consistently one of its most original thinkers and productive researchers. He achieved national renown in 1998 for his groundbreaking experiments demonstrating that neurons are constantly being born in the brain, a process called neurogenesis. The study forced a paradigm shift in beliefs about how the brain functions. His data removed many barriers in neuroscience research, creating, virtually overnight, the

possibility of brain repair. Gage is currently working to understand how new brain cells can be induced to become mature functioning nerve cells in the adult brain and spinal cord. He has shown that environmental enrichment and physical exercise can enhance the growth of these cells. He is studying the underlying cellular and molecular mechanisms that may be harnessed to repair the aged and damaged brain and spinal cord. Gage recently has focused his efforts on Rett Syndrome, a devastating childhood neurological disorder. In addition to substantive research, Gage has helped to define new forms in the practice of scientific research, including private funding and free market competition. In 1988 he co-founded StemCells, Inc., a small, publicly-traded company engaged in the discovery and commercialization of stem cells to treat diseases of the central nervous system, liver and pancreas. In 2000, Gage was named one of the Top 100 Innovators of the 21st Century by TIME magazine. He is a fellow of the National Academy of Sciences, American Association for the Advancement of Science, American Academy of Arts and Sciences and the Institute of Medicine and has been president of the Society for Neuroscience. Gage has received the Charles A. Dana Award for Pioneering Achievements in Health and Education, the Christopher Reeve Research Medal, the Max Planck Research Prize, and the MetLife Award for Medical Research. Dr. Gage has a B.S. degree from the University of Florida and a Ph.D. at The Johns Hopkins University.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 10-18

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.

Room 3, Upper Level, San Diego Convention Center

MEDICAL AND METABOLIC CONSEQUENCES OF PSYCHIATRIC TREATMENT

Chp.: Mitchel A. A. Kling, M.D.

Co-Chp.: Joel Dimsdale, M.D.

11:00 a.m.

29 Metabolic Abnormalities in Psychiatric Inpatients

John W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F. Caley, Pharm.D.

11:30 a.m.

30 Neuroleptic Malignant Syndrome Induced by Low Dose Aripiprazole in First Episode Psychosis

Harun Evcimen, M.D., Yesne Alici-Evcimen, M.D., Irakli Mania, M.D., Maju Mathews, M.D.

12 noon

31 Metabolic Abnormalities in Patients With Major Depressive Disorder

Karen Blank, M.D., Bonnie L. Szarek, R.N., John W. Goethe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11

11:00 a.m.-12:30 p.m.

Room 4, Upper Level, San Diego Convention Center

ACCESS, AVAILABILITY, AND UTILIZATION OF PSYCHIATRIC SERVICES

Chp.: Eduardo Lopez-Gibson

Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

32 Recurrent Psychiatric Hospitalization

Christine Dunn, M.A., William H. Sledge

11:30 a.m.

33 Reducing the Medical and Financial Burden of Depressive Illness: A Plan for Improving Health Care Services

Lawrence W. Adler, M.D.

12 noon

34 Psychiatric Hospital Bed Numbers and Economic Factors in the XIX and XX Centuries: New Analyses

Alfonso Ceccherini-Nelli, M.D., Stefan Priebe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.-12:30 p.m.

Room 5 A, Upper Level, San Diego Convention Center

INTERNATIONAL STUDIES IN SCHIZOPHRENIA

Chp.: Amir Kalali, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

35 Brain Morphology in Schizophrenia Within the Northern Finland 1966 Birth Cohort

Matti K. Isohanni, M.D., Päivikki Tanskanen, M.D., Jouko Miettunen, Ph.D., Graham Murray, M.D., Peter B. Jones, M.D., Ed T. Bullmore, M.D.

11:30 a.m.

36 The ADHES Project in Israel: New Insights in Adherence in Schizophrenia

Yoram Barak, M.D., Dov Aizenberg, M.D., Avi Bleich, M.D.

12 noon

37 Schizophrenia in the Offspring of Antenatally Depressed mothers and Familial Risk- Follow-Up of the Northern Finland 1966 Birth Cohort

Pirjo H. Maki, M.D., Juha M. Veijola, M.D., Jouko Miettunen, Ph.D., Jari Jokelainen, M.S.C., Paula Rantakallio, M.D., Peter B. Jones, M.D., Matti K. Isohanni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13

11:00 a.m.-12:30 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

THEORETICAL AND RESEARCH APPROACHES IN THE STUDY OF VIOLENCE

Chp.: Saul Levine, M.D.

Co-Chp.: Igor Koutsenok, M.D.

11:00 a.m.

38 Beyond the Clash of Civilizations

David A. Rothstein, M.D.

11:30 a.m.

39 Phases of Trauma Recovery

Herbert L. Campbell, M.D.

12 noon

40 Predicting Unresolved PTSS in Earthquake Survivors: A Comparison Between Decision Analysis and Logistics Regression

Keng Shin Lin, Sr., D.M., Kuan-Yi Tsai, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 14

11:00 a.m.-12:30 p.m.

Room 9, Upper Level, San Diego Convention Center

DIAGNOSTIC ISSUES

Chp.: Krauz Ganadjian

Co-Chp.: Derya I. Akbiyik, M.D.

11:00 a.m.

41 Beyond Bipolar I and II: Evidence for the Validity of the "Softer" Bipolar Spectrum

Camilo J. Ruggero, Ph.D., Mark Zimmerman, M.D., Iwona Chelminski, Ph.D., Diane D. Young, Ph.D.

11:30 a.m.

42 A Proposal for a New Multiaxial Model of Psychiatric Diagnosis: A Continuum Patient Model Based On Evolutionary Developmental Gene-Environment Interaction

Hoyle Leigh, M.D.

12 noon

43 Improving the Understanding of Causality in Psychiatric Research

Stephen B. Shanfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15

11:00 a.m.-12:30 p.m.

Room 11 B, Upper Level, San Diego Convention Center

GENETICS

Chp.: Dhatt Ajinder, M.D.

Co-Chp.: Austina Cho, M.D.

11:00 a.m.

44 CYP Genotyping in Patients Treated for Depression

Gualberto Ruano, M.D., John W. Goethe, M.D., Andreas Windemuth, Ph.D., Umme Salema Rahim, M.D.

11:30 a.m.

45 An Association Between the EPAC-1 Gene and Neuroticism and Anxiety

Christel M. Middeldorp, M.D., Xiangning Chen, Ph.D., Jacqueline M. Vink, Ph.D., Kenneth S. Kendler, M.D., Dorret I. Boomsma, Ph.D.

12 noon

- 46 **Circadian System Polymorphisms and Bipolar Disorder**
Daniel F. Kripke, M.D., Caroline M. Nievergelt, Ph.D., John R. Kelsoe, M.D., Thomas B. Barrett, M.D., Nicholas J. Schork, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16

11:00 a.m.-12:30 p.m.

Room 24 C, Upper Level, San Diego Convention Center

CROSS CULTURAL PSYCHIATRY

Chp.: Andres Sciolla, M.D.

Co-Chp.: Jana Cook

11:00 a.m.

- 47 **Similar Depressive Symptom Patterns in a Population Based Study of Immigrants From Turkey and Morocco and Dutch Natives**
Agnes Schrier, Matty de Wit, Jack Dekker, Ralph Kupka, Aartjan Beekman

11:30 a.m.

- 48 **Prevalence and Correlates of PMDD Among Arab Primary Care Patients in The United Arab Emirates**
Ossama Tawakol Osman, M.D., Sufyan Sabri, Ph.D., Hanan Alraeesi, Amal Shamsan, M.D., Diaa Rizk, M.D.

12 noon

- 49 **Effectiveness of Culturally Sensitive Collaborative Treatment for Treating Chinese Americans With Depression in a Primary Care Setting: A Six-Month Follow-Up Study**
Albert Yeung, M.D., Lauren Fisher, B.A., Anna M. Agoston, B.A., Wan-Chen Weng, M.A., Yantao, M.D., Shamsah Sonawalla, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17

11:00 a.m.-12:30 p.m.

Room 25 A, Upper Level, San Diego Convention Center

TREATMENT OF PSYCHIATRIC DISORDERS IN MEDICALLY ILL PATIENTS

Chp.: Nitin Gupta, M.D.

Co-Chp.: Mustafa M. Husain, M.D.

11:00 a.m.

- 50 **Pilot Trial of Modafinil for Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors**
Thomas A. Kaleita, Ph.D., David K. Wellisch, Ph.D., Timothy F. Cloughesy, M.D.

11:30 a.m.

- 51 **Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients**
Thomas S. Zaubler, M.D., James P. Slater, M.D., Rami T. Bustami, Ph.D., Theresa Guarino, R.N., Jessica Stack, Kateki Vinod, Kenneth Freundlich, Ph.D., Grant V.S. Parr, M.D.

12 noon

- 52 **Mood and Anxiety Disorders in Patients With Cancer: A Case Series**
Catherine L. Mancini, M.D., Andrew Cooper, B.S.C.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18

11:00 a.m.-12:30 p.m.

Room 27 A, Upper Level, San Diego Convention Center

EVIDENCE-BASED AND GUIDELINE APPROACHES TO PSYCHIATRIC TREATMENTS

Chp.: Rajnish Mago, M.D.

Co-Chp.: Richard Buccigross, M.D.

11:00 a.m.

- 53 **Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience**
Jennifer P. Wisdom, Ph.D., David A. Pollack, M.D., Ann Hamer, Pharm.D., Sarann Bielavitz

11:30 a.m.

- 54 **Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder**
Thomas F. Smith, M.D., Stewart B. Levine, M.D., Judith Hampel, R.N.

12 noon

- 55 **Stepped Care for Anxiety, Depressive and Stress-Related Disorders: A Randomized Controlled Trial in Primary Care and Mental Health Care**
Desiree Oosterbaan, Ph.D., Anton van Balkom, Ph.D., Marc Verbraak, Ph.D., Roelof ten Doesschate, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 10-11

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 10 **Mark S. George, M.D., on TMS** (*Meet the Author*)
Room 27 B, Upper Level, San Diego Convention Center
- 11 **Nyapati Rao, M.D., on The International Medical Graduate: Issues in Training, Issues in Practice**
Room 31 C, Upper Level, San Diego Convention Center

TUESDAY

WORKSHOPS

COMPONENTS 30-36

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.
Room 5 B, Upper Level, San Diego Convention Center

PASSAGEWAYS: PSYCHOLOGICAL ROUTES TO DELINQUENCY AND THERAPEUTIC OPTIONS OUT OF THE JUVENILE JUSTICE SYSTEM
APA Corresponding Committee on Juvenile Justice Issues

Co-Chps.: Camilla Lyons, M.D., Stephen B. Billick, M.D.
Participants: Eraka Bath, M.D., Louis J. Kraus, M.D.

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.
Room 7 A, Upper Level, San Diego Convention Center

DEMENTIA IN DOWN SYNDROME: RISK FACTORS, BIOMARKERS, DIAGNOSIS, AND TREATMENT
APA Council on Aging

Chp.: John M. De Figueiredo, M.D.
Participants: Ramakrishnan Shenoy, M.D., Leo O. Noragbon, M.D.

COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m.
Room 7 B, Upper Level, San Diego Convention Center

SPIRITUS CONTRA SPIRITUM: THE STRANGE CASE OF SPIRITUALITY AND ADDICTION: DISCUSSION OF THE 2007 OSKAR PFISTER AWARD LECTURE
APA Corresponding Committee on Religion, Spirituality, and Psychiatry

Chp.: William R. Miller, Ph.D.
Participant: George Vaillant, M.D.

COMPONENT WORKSHOP 33 11:00 a.m.-12:30 p.m.
Room 8, Upper Level, San Diego Convention Center

SHOULD THE COMMUNITY REPLACE THE ASYLUM IN THE 21ST CENTURY?
APA Lifers

Co-Chps.: Sheila Hafter Gray, M.D., Edward Hanin, M.D.
Participants: Alan Q. Radke, M.D., Roger Peele, M.D., David L. Huang, M.D., Helen MacLeod Thomson

COMPONENT WORKSHOP 34 11:00 a.m.-12:30 p.m.
Room 23 C, Upper Level, San Diego Convention Center

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY
APA Committee on Women

Chp.: Melva I. Green, M.D., Kimberley Bogan, M.D.
Participants: Gail H. Manos, M.D., Barbara S. Schneidman, M.D., Gabriela Cora-Locatelli, M.D., Janet Taylor, M.D.,

COMPONENT WORKSHOP 35 11:00 a.m.-12:30 p.m.
Room 24 A, Upper Level, San Diego Convention Center

FOCUSING ON ASIA: A REVIEW OF DISASTERS, INTERVENTION AND PREVENTION PROGRAMS
APA Council on Global Psychiatry

Co-Chps.: Pedro Ruiz, M.D., Bruce S. Singh, M.D.
Participants: Pichet Udomratn, M.D., M. Parameshavara Deva, M.D., Tsuyoshi Akiyama, M.D.

COMPONENT WORKSHOP 36 11:00 a.m.-12:30 p.m.
Room 28 A, Upper Level, San Diego Convention Center

HIV AND METABOLIC SYNDROME
APA Committee on AIDS

Chp.: Marshall Forstein, M.D.

ISSUES 40-50

ISSUE WORKSHOP 40 11:00 a.m.-12:30 p.m.
Room 25 C, Upper Level, San Diego Convention Center

SECOND OPINION CONSULTATION ON ONGOING PSYCHOTHERAPY TREATMENTS

Co-Chps.: Mardi Horowitz, M.D., Marc Jacobs, M.D.
Participants: Martina Smit, M.D., Jennifer Cummings, M.D., Jason Bermak, M.D.

ISSUE WORKSHOP 41 11:00 a.m.-12:30 p.m.
Room 28 C, Upper Level, San Diego Convention Center

PRIVACY AND CONFIDENTIALITY CONCERNS IN SHARED ELECTRONIC HEALTH RECORDS

Chp.: Benjamin Liptzin, M.D.
Participants: Ruth A. Barron, M.D., Mary A. Sullivan, M.D., Rohn S. Friedman, M.D., Edward Zuzarte, M.D.

ISSUE WORKSHOP 42 11:00 a.m.-12:30 p.m.
Room 28 D/E, Upper Level, San Diego Convention Center

METHAMPHETAMINE ABUSE AND ADDICTION: PREVALENCE AND TREATMENT.
Collaborative Session With the National Institute on Drug Abuse

Co-Chps.: Ahmed M. Elkashef, M.D., Frank Vocci, Jr., Ph.D.
Participants: James Colliver, Ph.D., William F. Haning III, M.D., Trevor Robbins, Ph.D.

ISSUE WORKSHOP 43 11:00 a.m.-12:30 p.m.
Room 29 C/D, Upper Level, San Diego Convention Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 2

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 44 11:00 a.m.-12:30 p.m.

Room 30 A, Upper Level, San Diego Convention Center

PSYCHIATRY IN THE AMERICAS: UPDATE FROM THE WORLD PSYCHIATRIC ASSOCIATION

Co-Chps.: Michelle B. Riba, M.D., Rodrigo A. Munoz, M.D.
Participants: Roger M. Montenegro, M.D., Julio E. Arboleda-Florez, M.D., Enrique R. Camarena, M.D., Edgard Belfort, M.D.

ISSUE WORKSHOP 45 11:00 a.m.-12:30 p.m.

Room 30 B, Upper Level, San Diego Convention Center

ASSESSING VIOLENCE RISK AMONG PERSONS WITH MENTAL ILLNESSES

Co-Chps.: Steven K. Hoge, M.D., Paul S. Appelbaum, M.D.

ISSUE WORKSHOP 46 11:00 a.m.-12:30 p.m.

Room 30 C, Upper Level, San Diego Convention Center

PSYCHIATRIC EXPERT TESTIMONY: INCREASED SCRUTINY, INCREASED LIABILITY

Chp.: Philip Merideth, M.D.
Participants: Renee L. Binder, M.D., Donna Vanderpool, J.D.

ISSUE WORKSHOP 47 11:00 a.m.-12:30 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

QUALITY OF LIFE OF PATIENTS WITH MAJOR DEPRESSION IN A NATURAL CLINICAL SETTING

Co-Chps.: Waguih W. IsHak, M.D., Mark H. Rapaport, M.D.

ISSUE WORKSHOP 48 11:00 a.m.-12:30 p.m.

Room 31 A, Upper Level, San Diego Convention Center

ARE SEX OFFENDERS CRIMINALLY RESPONSIBLE?

Chp.: Renee M. Sorrentino, M.D.
Participants: Susan H. Friedman, M.D., Joy E. Stankowski, M.D.

ISSUE WORKSHOP 49 11:00 a.m.-12:30 p.m.

Room 31 B, Upper Level, San Diego Convention Center

IMPACT OF PATIENT SUICIDE ON PSYCHIATRY RESIDENTS: A WORKSHOP DISCUSSION

Chp.: Christina Mangurian, M.D.
Participants: Francine Cournos II, M.D., Carolyn J. Douglas, M.D., Elizabeth Harre, M.D., Edmund Griffin, M.D., Aaron Reliford, M.D., Andrew Booty, M.D.

ISSUE WORKSHOP 50 11:00 a.m.-12:30 p.m.

Room 32 A, Upper Level, San Diego Convention Center

PHYSICAL TRAUMA AS A RESULT OF WAR OR NATURAL DISASTER: PSYCHIATRIC INTERVENTIONS

Co-Chps.: Harold J. Wain, Ph.D., Geoffrey M. Gabriel, M.D.

12 noon Sessions**FORUMS 6-8****FORUM 6**

12 noon-1:30 p.m.

Ballroom 6 E, Upper Level, San Diego Convention Center

ONGOING MENTAL HEALTH NEEDS FOLLOWING THE DEVASTATION OF HURRICANE KATRINA

Chp.: Howard Osofsky, M.D.

Presenters: Joy Osofsky, Ph.D., Robert S. Pynoos, M.D., Robert J. Ursano, M.D., Betty Pfefferbaum, M.D.

FORUM 7

12 noon-1:30 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

MOVING NATIONAL HEALTH INFORMATION TECHNOLOGY AGENDA FORWARD

Chp.: Robert Kolodner, M.D.

FORUM 8

12 noon-1:30 p.m.

Room 29 A/B, Upper Level, San Diego Convention Center

SHOCK: THE HEALING POWER OF ELECTROCONVULSIVE THERAPY: DOCUMENTARY AND DISCUSSION

Co-Chps.: Larry Tye, Kitty Dukakis

NEW RESEARCH POSTER SESSION 4

12 noon-2:00 p.m.

Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m Sessions**COURSES 70-75**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 70

1:00 p.m.-5:00 p.m.

Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

DRUG THERAPY AND SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.

Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.

COURSE 71 1:00 p.m.-5:00 p.m.
Edward Room A/B, Second Level, Manchester Grand Hyatt

CBT BOOTCAMP FOR PRACTICING PSYCHIATRISTS

Director: Anton C. Trinidad, M.D.
Faculty: Stephen P. McDermott, M.D., Robert Leahy, Ph.D.

COURSE 72 1:00 p.m.-5:00 p.m.
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

COURSE 73 1:00 p.m.-5:00 p.m.
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

HOW TO PRACTICE BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

COURSE 74 1:00 p.m.-5:00 p.m.
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 75 1:00 p.m.-5:00 p.m.
Randle Ballroom B, Fourth Level, Manchester Grand Hyatt

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: ADVANCED COURSE

Co-Directors: Charles J. Rainey, M.D., John Luo, M.D.
Faculty: John D. Wynn, M.D., Steven I. Althuler, Carlyle H. Chan, M.D., Robert C. Hsiung, M.D., Richard A. Montgomery, M.D.

2:00 p.m Session

LECTURE 19

2:00 p.m.-3:30 p.m.
Ballroom 6 B, Upper Level,
San Diego Convention Center

APA'S ADOLF MEYER AWARD LECTURE

Jeffrey A. Lieberman, M.D.

The Three Stages of Schizophrenia: Can Early Detection and Intervention Change Illness Course and Prevent Disability?

Chp.: Christine E. Marx, M.D.

Jeffrey A. Lieberman, M.D. currently is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair and Directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia. Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent's Hospital and Medical Center of New York Medical College, he was on the faculties of the Albert Einstein College of Medicine and Mount Sinai School of Medicine, and served as Director of Research at the Hillside Hospital of Long Island Jewish Medical Center. Prior to moving to Columbia he was the Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina, School of Medicine in Chapel Hill. Dr. Lieberman's research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia, and the pharmacology and clinical effectiveness of antipsychotic drugs. He currently serves as the Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the NIMH. He is also the Director of an NIMH Silvio O. Conte Center for the Neuroscience of Mental Disorders. His work has been reported in more than 400 articles in the scientific literature and he has edited or co-edited eight books. He currently chairs the APA Council of Research.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3

2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

REVIEW OF GERIATRIC PSYCHIATRY: CURRENT ISSUES

Chp.: Christopher C. Colenda, M.D.
Co-Chp.: Pedro Ruiz, M.D.

- A Late Life Addiction: Rapidly Changing Needs**
David D. Oslin, M.D.
- B Health Services Research in Geriatric Psychiatry**
Mark Snowden, M.D.
- C Training and Workforce Issues in geriatric Psychiatry**
Paul D. Kirwin, M.D.
- D Diversity Issues in Geriatric Psychiatry**
Warachal E. Faison, M.D.
- E Ethical Issues in Geriatric Psychiatry Research**
Scott Y. Kim, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 4

2:00 p.m.-5:00 p.m.

Ballroom 6 E, Upper Level, San Diego Convention Center

CURRENT RESEARCH ADVANCES:**APA/NIMH/NIDA/NIAAA/NAMI PERSPECTIVES***APA Council on Global Psychiatry***Chp.:** Pedro Ruiz, M.D.**Co-Chp.:** Darrel A. Regier, M.D.**Discussants:** Nora D. Volkow, M.D., Thomas R. Insel, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIA 27-51****SYMPOSIUM 27**

2:00 p.m.-5:00 p.m.

Room 2, Upper Level, San Diego Convention Center

BULLYING IN THE WORKPLACE: ASSOCIATED HEALTH PROBLEMS**Chp.:** Jorge C. Srabstein, M.D.**Co-Chp.:** Liza H. Gold, M.D.**A Bullying, Basic Assumptions, and Symptoms of PTSD**

Eva Mikkelsen, Ph.D., Ståle Einarsen, Ph.D.

B Morbidity Associated With Workplace Bullying Among Hospital Staff

Marianna Virtanen, Ph.D., Jussi Vahtera, Ph.D., Marko Elovainio, Ph.D., Mika Kivimäki, Ph.D.

C Patterns of Workplace Bullying and Psychopathology

Jose L. González de Rivera, M.D., Manuel J. Rodríguez-Abuin, Ph.D.

D Psychosocial Rehabilitation of Victims of Bullying and Emotional Abuse at Work

Eva Mikkelsen, Ph.D., Ståle Einarsen, Ph.D.

E Regulatory Responses to Workplace Bullying: A Global Law and Public Policy Perspective

David Yamada, J.D.

Discussant: Liza H. Gold, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 28**

2:00 p.m.-5:00 p.m.

Room 3, Upper Level, San Diego Convention Center

NEW PERSPECTIVES IN PSYCHODYNAMIC TREATMENTS FOR BPD**Chp.:** Lois W. Choi-Kain, M.D.**Co-Chp.:** John G. Gunderson, M.D.**A Mentalization: A Review of the Origins and Applications of the Concept in the Treatment of BPD**

Lois W. Choi-Kain, M.D.

B Is Mentalization Based Therapy More Effective Than Structured Supportive Psychotherapy for BPD: A Randomized Controlled Trial

Anthony Bateman, M.D., Peter Fonagy, M.D.

C Transference Focused Psychotherapy

Otto F. Kernberg, M.D.

D The Role of Reflective Functioning in Affect Regulation and Psychotherapy

John F. Clarkin, Ph.D.

E A Psychotherapy Case Study on Alternative Perspectives

John G. Gunderson, M.D.

Discussant: Glen O. Gabbard, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 29**

2:00 p.m.-5:00 p.m.

Room 4, Upper Level, San Diego Convention Center

AGGRESSIVE BEHAVIORAL DISTURBANCES IN GEROPSYCHIATRIC PATIENTS**Chp.:** Helen H. Kyomen, M.D.**A Neurobiology of Aggression**

Randy J. Nelson, Ph.D.

B Gene-Environment Interactions and Aggression

Brian C. Trainor, Ph.D.

C Epidemiology of Aggressive Behaviors in Geropsychiatric Patients

Nhi-Ha T. Trinh, M.D.

D Evaluation and Management of Aggressive Behaviors in Geropsychiatric Patients

Helen H. Kyomen, M.D., Theodore H. Whitfield, Sc.D.

Discussant: Barry D. Lebowitz, Ph.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 30**

2:00 p.m.-5:00 p.m.

Room 5 A, Upper Level, San Diego Convention Center

FORMATION OF MODERN LESBIAN AND GAY IDENTITIES: PERSONAL, HISTORICAL, AND MENTAL HEALTH PERSPECTIVES**Chp.:** Gene A. Nakajima, M.D.**Co-Chp.:** Carolyn B. Robinowitz, M.D.**A Gertrude Stein's Medical Education, Her Evolving Feminism, and Lesbian Identity**

Gene A. Nakajima, M.D.

B Superior Guinea Pig: Bryher and Psychoanalysis

Maggie Magee, Psy.D.

C *I Didn't Want to Be Queer*: Virgil Thomson's Adaptation to His Homosexual Identity

Anthony Tommasini, D.M.A.

D From the Closet to the Table: A 40 Year History of Gays and the APA

David R. Kessler, M.D.

Discussants: Clayton M. Bullock, M.D., Robert P. Cabaj, M.D.**THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.

Room 5 B, Upper Level, San Diego Convention Center

RESEARCH UPDATE ON ADOLESCENTS WITH SCHIZOPHRENIA: IMPLICATIONS FOR PRODROMAL RESEARCH

Chp.: Sanjiv Kumra, M.D.

- A Early-Stage Neurocognitive Functioning in Adolescent Psychosis: An Examination of Illness Course and Implications for Intervention**
Jeffrey R. Wozniak, Ph.D.
- B Clozapine and Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison**
Harvey Kranzler, M.D.
- C Efficacy and Tolerability of Atypical Antipsychotics in Adolescents with Psychosis**
Joel Oberstar, M.D.
- D Anomalies in White Matter Microstructure in Occipital-Temporal Pathways in Adolescents With Schizophrenia**
Sanjiv Kumra, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.

Room 7 A, Upper Level, San Diego Convention Center

MIRROR NEURONS, EMPATHY, INTUITION AND INTERPRETATION: UNDERSTANDING THE MINDS OF OTHERS

Chp.: Regina Pally, M.D.

- A From Mirror Neurons to Empathy**
Christian Keysers, Ph.D.
- B How is the Mirror Neuron Discovery Relevant to Psychoanalysis and Psychotherapy?**
Morris N. Eagle, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.

Room 7 B, Upper Level, San Diego Convention Center

PTSD, BPD, AND MOTHERHOOD: EARLY RELATIONS, RECOGNITION, AND INTERVENTION

Chp.: Gisele Apter, M.D.

- A Personal and Other Terrorism Toward Women Worldwide**
Leah J. Dickstein, M.D.
- B Violence Turned Against the Victim**
Nada L. Stotland, M.D.
- C Early Interactions Between Borderline Mothers and Their Infants: Why More Intervention Could Mean Less Repetition Trauma and Distortion**
Gisele Apter, M.D.

- D The Therapeutic Use of Videotape in Working With Parents of Children With Psychiatric Disorders**
Alexandra M. Harrison, M.D.

Discussant: Carol C. Nadelson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.

Room 8, Upper Level, San Diego Convention Center

UNEASY PARTNERS: THE PHARMACEUTICAL INDUSTRY AND THE PSYCHIATRIC PROFESSION

Chp.: Nassir Ghaemi, M.D.

Co-Chp.: David N. Osser, M.D.

- A The Pharmaceutical Industry, Evidence-Based Medicine, and Psychiatric Practice**
Howard I. Kushner, Ph.D.
- B Disease Mongering**
David Healy, M.D.
- C Cleaning up Evidence-Based Medicine**
David N. Osser, M.D.
- D Data, Dollars, and Drugs: The Dilemmas of Practice and Research**
Nassir Ghaemi, M.D.
- E Conflict of Interest in Psychiatry: How Much Disclosure Is Enough?**
Daniel J. Carlat, M.D.

Discussant: Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.

Room 9, Upper Level, San Diego Convention Center

STALKING OFFENDERS AND VICTIMS

Chp.: Gail E. Robinson, M.D.

- A Stalking: An Overview of the Problem**
Gail E. Robinson, M.D.
- B Stalking Victims: A Comprehensive Treatment Approach**
Karen M. Abrams, M.D.
- C The Recon Typology of Stalking**
J. Reid Meloy, Ph.D.
- D Stalking: Threat Management by Professional Cooperation**
Werner Tschan, M.D.
- E Stalking: Threat Assessment and Management**
Jeff Dunn

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.

Room 10, Upper Level, San Diego Convention Center

Humane Aspects of Private Practice**Chp.:** Rodrigo A. Munoz, M.D.**Co-Chp.:** Roger Peele, M.D.**A Comprehensive Psychiatry in Private Practice, 2007**

Brian Crowley, M.D.

B Private Practice: The Very Model of Humane Care

Ronald Abramson, M.D.

C Comprehensive Psychiatry in a Community Hospital and Medical Center Provides Ready Access for Least Restrictive Treatment

John C. Urbaitis

Discussant: Donna M. Norris, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 37** 2:00 p.m.-5:00 p.m.

Room 11 A, Upper Level, San Diego Convention Center

EATING DISORDERS UPDATE**Chp.:** Hans W. Hoek, M.D.**Co-Chp.:** Walter H. Kaye, M.D.**A Alterations of Neurocircuits and Symptoms in Anorexia and Bulimia Nervosa**

Walter H. Kaye, M.D., Ursula F. Bailer, M.D., Guido K. Frank, M.D., Angela Wagner, M.D.

B Epidemiology of Eating Disorders

Hans W. Hoek, M.D.

C Psychological Treatments of Eating Disorders: Status Quo and New Developments

Ulrike Schmidt, M.D.

D Pharmacological Treatment of Eating Disorders

B. Timothy Walsh, M.D.

E Children and Adolescents With Eating Disorders

Annemarie A. van Elburg, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 38** 2:00 p.m.-5:00 p.m.

Room 11 B, Upper Level, San Diego Convention Center

LUMPING VERSUS SPLITTING IN PSYCHIATRIC NOSOLOGY**Chp.:** Ahmed M. Okasha, M.D.**Co-Chp.:** Rodrigo A. Munoz, M.D.**A The Controversy Over Lumping vs. Splitting in Psychiatric Nosology**

Ahmed Okasha, M.D.

B Lumping vs. Splitting: Psychopathology and the Rest of Medicine

G. Scott Waterman, M.D.

C Splitting in Order to Better Lump

Hagop Akiskal, M.D.

D Lumping in Order to Better Split

Juan J. López-Ibor Jr., Ph.D.

E The Need for an Eclectic Approach to the Classification of Mental Disorders

Norman H. Sartorius, M.D.

Discussant: Darrel A. Regier, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 39** 2:00 p.m.-5:00 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE**Chp.:** Herbert D. Kleber M.D.**A Cocaine Dependence: Choosing the Right Treatment**

Adam Bisaga, M.D.

B Choosing the Best Treatment: Marijuana and Club Drugs

David M. McDowell, M.D.

C Treatment of Comorbid Conditions

Frances R. Levin, M.D.

D Integrating Psychosocial Interventions With Medications in the Treatment of Substance Dependence

Edward V. Nunes Jr., M.D.

E Choosing the Right Treatment for Opioid Dependence

Herbert D. Kleber, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 40** 2:00 p.m.-5:00 p.m.

Room 28 C, Upper Level, San Diego Convention Center

ETHICAL ISSUES IN PSYCHIATRIC GENETICS**Chp.:** Paul S. Appelbaum, M.D.**Co-Chp.:** Laura B. Dunn, M.D.**A What Can Psychiatric Genetics Tell The Clinician?**

John R. Kelsoe, M.D., Thomas B. Barrett, M.D., Xianjin Zhou, Ph.D., Nicholas Schork, Ph.D.

(Continued next page)

B Ethical Issues Involved in Decision Making About Genetic Testing, Disclosure, and Reproductive Choices Among Individuals at Risk for Huntington's Disease
Robert L. Klitzman, M.D.

C Disclosure of Genetic Information: Patients, Third Parties, Employers, and Insurers
Paul S. Appelbaum, M.D.

D Presenter Ethical Issues Related to the Use of Genetic Information in the Workplace: APA Symposium on Ethics of Psychiatric Genetics
Laura W. Roberts, M.D.

E Training Psychiatrists in Psychiatric Genetics: Views of Program Directors and Residents
Laura B. Dunn, M.D., Jinger G. Hoop, M.D., Sidney Zisook, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.

Room 28 D/E, Upper Level, San Diego Convention Center

WOMEN AND PSYCHIATRY AROUND THE WORLD: THE IMPORTANCE OF GENDER AND CULTURE

Chp.: Nigel Bark, M.D.
Co-Chp.: Hamid Ghodse, M.D.

A Gender Issues in Psychiatry in Pakistan
Haroon R. Chaudhry, M.D., Saima Niaz, M.D., Mirrat G. Butt, Nadia Arshad, Amara Shabir, Khalid A. Mufti

B The African Woman in Health and Disease: Cultural Issues in the Mental Health of Women
Frank G. Njenga, M.B.Ch.B.

C Stress and Mental Disorder Among Mexican Females
Maria Asuncion Lara, Ph.D., Maria E. Medina-Mora, M.D.

D Women and Psychiatry Around the World: The Impact of Gender and Culture in the Middle Eastern Culture
Nasser F. Loza, Nacl M. Hasan, M.B.Ch.B.

E Changing Patterns of Self Harm Behaviour Among Women in Trinidad and Tobago: The Emergence of Self Mutilation
Gerard Hutchinson, M.D.

G Gender Differences in Psychiatry: A Biopsychosocial Approach From Australia
Jayashri Kulkarni, M.B.B.S.

Discussant: Sheila C. Hollins, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.

Room 29 A/B, Upper Level, San Diego Convention Center

PSILOCYBIN AND PSYCHIATRY: RECENT RESEARCH

Chp.: Thomas M. Brod, M.D.

A Psilocybin in Late-Stage Cancer Anxiety
Charles S. Grob, M.D.

B Safety and Efficacy of Psilocybin in OCD
Francisco A. Moreno, M.D.

C Psilocybin can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance: 14-Month Follow-Up
Roland R. Griffiths, Ph.D., William A. Richards, Una D. McCann, M.D., Robert Jessc

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.

Room 29 C/D, Upper Level, San Diego Convention Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 3

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success
William E. Callahan, Jr., M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.

Room 30 B, Upper Level, San Diego Convention Center

THE HIV AND AIDS PANDEMIC: CHANGES IN POPULATIONS, PERCEPTIONS, PRACTICES, AND PROMISES

Chp.: Francisco Fernandez, M.D.

A New Clinical Developments and Opportunities in Combating HIV
Milton L. Wainberg

B The Changing Face of AIDS and HIV Disease
Francine Cournos, M.D.

C The Role of the Psychiatrist: Changing With the Epidemic
Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.

Room 30 B, Upper Level, San Diego Convention Center

DSM-V: OBSESSIVE-COMPULSIVE RELATED DISORDERS

Chp.: Eric Hollander, M.D.
Co-Chp.: Joseph Zohar, M.D.

A Overview and Autism

Eric Hollander, M.D., Ting Wang, Ph.D., Daphne Simeon, Evdokia Anagnostou, M.D., Jennifer Bartz, Ph.D., Latha Soorya, Ph.D., Andrea Allen, Ph.D.

B OCD and the Link With Schizophrenia

Joseph Zohar, M.D., Michael Poyurovsky

C Are the Impulse Control Disorders Related to OCD?

Lorin M. Koran, M.D.

D Genetics of OCD

Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Mark A. Riddle, M.D., Marco Grados, M.D., Bernadette Cullen, M.D., O. Joseph Bienvenu, M.D., Yin Shugart, Ph.D., Ying Wang

E Neuroimaging in Obsessive-Compulsive Related Disorders

Sanjaya Saxena, M.D.

Discussant: Katharine A. Phillips, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46

2:00 p.m.-5:00 p.m.

Room 30 C, Upper Level, San Diego Convention Center

LEADERSHIP DISCOURSE: AGENTS OF CHANGE IN MENTAL HEALTH

American Association of Psychiatric Administrators

Chp.: Yad M. Jabbarpour, M.D.

A Overview of Agents of Change in Mental Health Transformation

Yad M. Jabbarpour, M.D.

B Law as an Agent of Change in the Mental Health System

Paul S. Appelbaum, M.D.

C Federal Perspective: Government as an Agent of Change

Anita S. Everett, M.D.

D How to Lose Friends and Influence People: Challenges in Transforming a State Mental Health Agency

James S. Reinhard, M.D.

E Research, Evidence, Practice, and Policy: New Frontiers in Re-Alignments?

Junius J. Gonzales, M.D.

Discussant: Steven S. Sharfstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47

2:00 p.m.-5:00 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

DEPRESSION AND ANXIETY, CONTINUOUS OR CATEGORICAL? A VIEW FROM DIFFERENT ANGLES

Chp.: Robert Schoevers

A Epidemiology of Mood and Anxiety Disorders in a Multicultural European City

Wilco Tuinebreijer, M.D., Matty de Wit, Ph.D.

B Is Comorbidity Between Anxiety and Depression Caused by Shared Genes? A Genome Wide Linkage Analysis

Christel M. Middeldorp, Jouke-Jan Hottenga, Eline Slagboom, Patrick F. Sullivan, Leo Beem, Gonneke Willemsen, Dorret I. Boomsma

C Differential Neural Patterns in Major Depressive Disorder and Obsessive-Compulsive Disorder: An Affective Activation Neuroimaging Experiment

Peter L. Remijnse, M.D.

D Optimizing Treatment Strategies in Depressed Patients With Comorbid Anxiety Symptoms

Henricus Van, M.D.

E The Relationship Between Generalized Anxiety Disorder, Depression, and Mortality in Old Age

Tjalling Jan Holwerda III, M.D., Robert A. Schoevers, Sr., Ph.D.

F Managing the Patient With Comorbid Depression and an Anxiety Disorder

Robert Schoevers, Ph.D., Henricus Van, Simone Kool, M.D., Jack J. Dekker, Ph.D.

Discussant: Aartjan T.F. Beekman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48

2:00 p.m.-5:00 p.m.

Room 31 A, Upper Level, San Diego Convention Center

FROM CLINICAL TRIALS TO REAL WORLD OUTCOMES

Chp.: Naveed Iqbal, M.D.

Co-Chp.: Zafar Sharif, M.D.

A Schizophrenia With Comorbid Conditions in Clinical Trials: Clinical Applicability

Michael Y. Hwang, M.D.

B Gaining a Better Understanding of Clinical Trial Applicability Through the Use of Outcome Measures and Adverse Event Rating Scales

Gabe Goldfeder, M.A.

C Clinical Implications of Randomized Clinical Trial Designs

Naveed Iqbal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49

2:00 p.m.-5:00 p.m.

Room 31 B, Upper Level, San Diego Convention Center

INVENTORY OF STIGMATIZING EXPERIENCES

Chp.: Roumen V. Milev, M.D.

A Stigma of Mental Illness: From Theory to Practice

Julio E. Arboleda-Florez, Ph.D.

B The Inventory of Stigma Experiences: Development and Reliability

Michelle Koller, M.A., Heather Stuart, Ph.D., Roumen V. Milev, M.D.

C Stigma and Discrimination in Patients With Depression and Bipolar Disorders as Captured by the Inventory of Stigmatizing Experiences

Roumen V. Milev, M.D., Heather Stuart, Ph.D.

(Continued next page)

TUESDAY

D Stigma and Recovery

Heather Stuart, Ph.D., Roumen V. Milev, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50

2:00 p.m.-5:00 p.m.

Room 31 C, Upper Level, San Diego Convention Center

CONSUMER PROVIDER TRAINING: INCORPORATING INDIVIDUALS IN RECOVERY INTO THE BEHAVIORAL WORKFORCE

Chp.: Lori Ashcraft, Ph.D.

**A The University of Kansas Consumers as Providers
Program: Overview of the National Award Winning
Training, Internship, and Research Program Utilizing
Best Practices**

Diane McDiarmid

**B The Implementation and Benefits of Incorporating Self-
Identified Client Employees in the South Carolina
Department of Mental Health**

Katherine M. Roberts, M.P.H.

**C Developing Needed Competencies to Meet Workforce
Demands: The Role of Training, Supervision, and
Mentoring**

Cheryl Gagne, Sc.D

**D Adding People in Recovery to the Behavioral Health
Workforce**

Lori Ashcraft, Psy.D.

**E CPSA's Recovery Support Specialist Initiative:
Evaluation Results of a Consumer Provider Training
Program**

Jason Malfait, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51

2:00 p.m.-5:00 p.m.

Room 32 A, Upper Level, San Diego Convention Center

WHEN USUAL TREATMENTS FAIL: AUGMENTATION STRATEGIES FOR REFRACTORY SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.

Co-Chp.: Joseph I. Friedman, M.D.

**A New Treatment of Schizophrenia by Enhancing N-
methyl-D-Aspartate Neurotransmission**

Guochuan E. Tsai, M.D.

**B Treatment-Refractory Schizophrenia: Use of High
Doses of Antipsychotics**

Peter F. Buckley, M.D.

C Natural and Alternative Treatments in Schizophrenia

Richard P. Brown, M.D.

D Clozapine Augmentation Strategies

Joseph I. Friedman, M.D.

Discussants: Jean-Pierre Lindenmayer, M.D., Joseph I.
Friedman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

ADVANCES IN NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

2:00 p.m.-5:30 p.m.

Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Stuart C. Yudofsky, M.D.

**A Update on Functional Brain Imaging in
Neuropsychiatry**

Robin Hurley

B Update on Diagnostic Testing in Neuropsychiatry

Florence Kim

C Update on the Neuropsychiatry of Delirium

Paula Trepacz, M.D.

D Update on the Neuropsychiatry of Mood Disorders

Helen S. Mayberg, M.D.

E Update on the Neuropsychiatry of Stroke

Robert G. Robinson, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5

3:00 p.m.-5:00p.m.

Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

7:00 p.m Sessions

INDUSTRY SUPPORTED SYMPOSIA 29-32

INDUSTRY SUPPORTED SYMPOSIUM 29

7:00 p.m.-10:00 p.m.

Ballroom 20, Upper Level, San Diego Convention Center

CIGARETTE SMOKING, SMOKING CESSATION, AND PSYCHIATRIC ILLNESS

Supported by Pfizer Inc.

Chp.: Alexander H. Glassman, M.D.

A Reward Systems Underlying Motivation and Addiction
Peter W. Kalivas, M.D.

**B Animal Modeling and Integrative Neurocircuitry of
Addiction Vulnerability in Mental Illness**
R. Andrew Chambers, M.D.

**C What Makes Smoking Cessation Unique in Patients
With a History of Depression**
Alexander H. Glassman, M.D.

D Pharmacological Treatment of Nicotine Dependence in Schizophrenia: The Devil Is in the Details
Tony P. George, M.D.

E Pharmacotherapies for Smoking Cessation
Cheryl A. Oncken, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 30

7:00 p.m.-10:00 p.m.

Marina Ballroom, South Tower, Level Three, Marriott

AM I A PSYCHIATRIST... OR AN ENDOCRINOLOGIST? COPING WITH METABOLIC DISTURBANCES DURING THE TREATMENT OF SCHIZOPHRENIA

Supported by Pfizer & Solway-Wyeth

Chp.: Peter F. Buckley, M.D.

A The Increasing Global Burden of Cardiovascular Disease in General Populations and in Patients With Schizophrenia
Charles H. Hennekens, M.D.

B Antipsychotics and Metabolic Risk: A Clinical Issue at the Forefront of Contemporary Psychiatry
Dan Haupt, M.D.

C Antipsychotic-Induced Hyperprolactinemia: A Neglected Issue in Psychiatry
Robert Conley, M.D.

D Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus
Peter F. Buckley, M.D.

E Consumer Perspective on Tolerability and Safety of Antipsychotic Medications
Frederick J. Frese, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 31

7:00 p.m.-10:00 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

MONOAMINE OXIDIZE INHIBITORS TODAY: A 21ST CENTURY VIEW ON THE TREATMENT OF DEPRESSION

Supported by Bristol-Myers Squibb Company and Otsuka

Chp.: Philip R. Muskin, M.D.

A Everything You Always Wanted to Know About Evidence-Based Psychiatry: But Were Afraid to Ask
Sharon A. Mozier, M.D.

B MAOI's Revisited: The Facts and The Myths
Philip R. Muskin, M.D.

C Diet and MAOI's: Where We Went Wrong and Where We Need to Go?
Kenneth I. Shulman, M.D.

D Treatment of Mood Disorders in the 21st Century: The Best of Applied Neuroscience
Charles B. Nemeroff, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 32

7:00 p.m.-10:00 p.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

UNDERSTANDING THE COMPLEXITY OF BIPOLAR MIXED EPISODES

Supported by Eli Lilly and Company

Chp.: Susan L. McElroy, M.D.

A Diagnostic Dilemmas of Mixed States in Bipolar Disorder
Mark A. Frye, M.D.


B Comorbidity and Consequences of Bipolar Mixed Episodes
Joseph F. Goldberg, M.D.

C The Acute Treatment of the Patient With Mixed Bipolar Episodes
Roger S. McIntyre, M.D.

D Improving Long-Term Outcomes in Patients With Bipolar Mixed Episodes
Susan L. McElroy, M.D.

Wednesday sessions are over ...now what are you going to do?

Join the San Diego Psychiatric Society for a tour of the U.S.S. Midway aircraft carrier.



The flight deck of the U.S.S. Midway, now a floating museum and education center, spans four acres and offers impressive views of San Diego Harbor and the city skyline.

Courtesy of San Diego Aircraft Carrier Museum

APA members and their guests can take guided tours of the ship during the reception, to be held on the ship's flight deck, which spans four acres. The reception will feature hors d'oeuvres and a cash bar. APA members are also invited to attend a dinner aboard ship, in Hangar Bay 1, for the installation of new district branch officers and an awards ceremony to salute members of the media, legislators, and advocacy groups.

The reception and tours of the **Midway** will be held from 5 p.m. to 7:30 p.m., followed by dinner from 7:30 p.m. to 9:30 p.m. Tickets for the reception are \$10 per APA member and spouse or one guest and \$15 for non-APA members. Tickets for the reception and dinner are \$65 per APA member and spouse or one guest and \$75 for non-APA members. The charge for children aged 12 and under is \$35 for the reception and dinner.

The U.S.S. **Midway** San Diego Aircraft Carrier Museum is about a mile from the San Diego Convention Center at 910 North Harbor Drive.

More information is available from Paula Marguiles, executive director of the San Diego Psychiatric Society, by phone at (858) 279-4586. Reservations can also be made through Marguiles. Information about the U.S.S. Midway is posted at www.midway.org. ■

WEDNESDAY, MAY 23, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 76-82

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 76 8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

MULTIDISCIPLINARY TREATMENT OF LOW SEXUAL DESIRE IN WOMEN

Director: Nancy C. Raymond, M.D.
Faculty: Jamie Feldman, M.D., Karin Larsen, Ph.D., Beatrice E. Robinson, Ph.D., Meg I. Striepe, Ph.D.

COURSE 77 8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

PSYCHIATRIC ROLES IN ASSESSING AND TREATING ADULT AND ADOLESCENT SEX OFFENDERS

Co-Directors: Bradley R. Johnson, M.D., Judith V. Becker, Ph.D.

COURSE 78 8:00 a.m.-12 noon
Edward Room C/D, Second Level, Manchester Grand Hyatt

PSYCHIATRIC CARE OF THE HEPATITIS C PATIENT

Co-Directors: Muhamad Aly Rifai, M.D., Peter Hauser, M.D.
Faculty: David Indest, M.D.

COURSE 79 8:00 a.m.-12 noon
Madeleine Room A/B, Third Level, Manchester Grand Hyatt

HOW TO USE YOUR POCKET PC PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE

Co-Directors: Robert J. Boland, M.D., Joshua L. Straus, M.D.
Faculty: Roger L. McRoberts, M.D., Elizabeth V. Getter, M.D.

COURSE 80 8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

REEL PSYCHIATRY

Co-Directors: Luis F. Ramirez, M.D., David J. Robinson, M.D.,

COURSE 81 8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 82 8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY FOR DEPRESSION

Director: Henricus Van, M.D.
Faculty: Robert Schoevers, Ph.D., Gerda van Aalst, M.D., Simone Kool, M.D.

9:00 a.m. Sessions

ADVANCES IN GERIATRIC PSYCHIATRY

9:00 a.m.-12:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Dan Blazer, M.D.

A Depression in Late Life: Complicating Factors and the Role of Medical Illness
Harold W. Goforth, M.D.

B Anxiety Disorders in Late Life
John L. Beyer, M.D.

C Psychotic Disorders in Late Life
Dilip V. Jeste, M.D.

D Psychopharmacological Treatment of Late Life Psychiatric Disorders
Bruce G. Pollock, M.D.

CASE CONFERENCE 3

9:00 a.m. - 12:00 p.m.
Room 23 A/B, Upper Level, San Diego Convention Center

FROM MATERNAL BLISS TO MATERNAL BLUES: A CASE OF INFANTICIDE

Moderator: Nicole F. Wolfe, M.D.

Presenters: John J. Worthington, M.D., Alyson Kuroski-Mazzei, M.D., Jeffrey Childers, M.D.



COURSES 83-87

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 83 9:00 a.m.-4:00 p.m.
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

PSYCHOTHERAPY FOR BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 84 9:00 a.m.-4:00 p.m.

Gregory Room A/B, Second Level, Manchester Grand Hyatt

NAVIGATING THE MINEFIELDS OF MANAGED CARE CONTRACTING: WHAT PSYCHIATRISTS NEED TO KNOW

Director: William H. Campbell, M.D.

COURSE 85 9:00 a.m.-4:00 p.m.

Ford Room A/B/C, Third Level, Manchester Grand Hyatt

EEG FEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS

Director: Thomas M. Brod, M.D.

Faculty: Gary J. Schummer, Ph.D., Harold L. Burke, Ph.D., William C. Scott, B.S.W., Stephen E. Buie, M.D.

COURSE 86 9:00 a.m.-4:00 p.m.

Annie Room A/B, Third Level, Manchester Grand Hyatt

INTERPERSONAL AND SOCIAL RHYTHM THERAPY FOR BIPOLAR DISORDER

Co-Directors: Ellen Frank, Ph.D., Holly A. Swartz, M.D.

COURSE 87 9:00 a.m.-4:00 p.m.

Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

MOOD AND ANXIETY DISORDERS IN LATER LIFE

Co-Directors: James M. Ellison, M.D., Brent P. Forester, M.D.

Faculty: E. Yusuf Sivrioglu, M.D., Donald A. Davidoff, Ph.D., Francesca C. Antognini Ph.D., M. Cornelia Cremens, M.D.

LECTURE 20

LECTURE 20

9:00 a.m.-10:30 a.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

APA'S JOHN FRYER AWARD LECTURE

Lawrence Hartmann, M.D.

HOMOSEXUALITY AND IGNORANCE

Chp.: Serena Y. Volpp, M.D.

Co-Chp.: Dan H. Karasic, M.D.

Lawrence Hartmann, M.D., is a Past President of the American Psychiatric Association; a psychoanalytic and pragmatic child, adolescent, and adult psychiatrist in Cambridge, Massachusetts; and a long-term member of the Harvard Medical School faculty (in his words "a rather minor clinical professor of psychiatry"). Born in Vienna, he

grew up in New York City, went to Harvard College and then Oxford University as a Rhodes Scholar. He returned to Harvard for Medical School, went to the University of California at San Francisco for a pediatric internship, and returned to Harvard again (Massachusetts Mental Health Center) for a residency on psychiatry and a fellowship in child and adolescent psychiatry. He went on to teach child, adolescent, and adult psychiatry at Harvard for over 35 years. He ran a prominent child and adolescent psychiatry clinic and a school consultation and treatment program, and wrote on psychotherapy, play, language, human rights, homosexuality, torture, apartheid, humane values and biopsychosocial integration. Dr. Hartmann's interest in dynamic and social psychiatry, in biopsychosocial integration, in women, children, minorities, homosexuality, and human rights led him to much activity and several leadership positions in both child and adult psychiatric organizations. This included serving on or leading several AACAP Task Forces and Committees and serving on or leading many APA committees and components. He helped to reform the APA in the 1970's, helped the APA remove homosexuality from its Diagnostic Manual in 1973, and has been part of many subsequent APA studies, decisions, and position statements. He served as President of the New England Council on Child and Adolescent Psychiatry, and recently as President of the American Association for Social Psychiatry, in addition to serving in APA over the years as Speaker of the Assembly, Area I Trustee, and Vice President before being elected APA President. He helped organize and lead several APA Human Rights missions (Chile, South Africa, The Soviet Union) and led a post-iron-curtain Travelling University of Psychiatry to Poland, Czechoslovakia, and Hungary. He continues actively to attend APA Board of Trustees meetings, and to teach, and he enjoys seeing patients of all ages in Cambridge, Massachusetts.

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 12-13

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

12 Eric Hollander, M.D., on New Treatment Developments For Autism and Impulse Control Disorders (*Meet the Author*) Room 28 C, Upper Level, San Diego Convention Center

13 Michael Schwartz, on The Recovery Movement in Mental Health: 2007 and Beyond Room 28 D, Upper Level, San Diego Convention Center

WORKSHOPS

COMPONENTS 37-45

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.

Room 3, Upper Level, San Diego Convention Center

CAREER ADVANCEMENT IN ADMINISTRATIVE PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS*APA Assembly Committee of Early Career Psychiatrists***Chp.:** Dimitri D. Markov, M.D.**Participants:** Arthur L. Lazarus, M.D., Thomas S. Newmark, M.D., Shivkumar Hatti, M.D., Joannette A. Sorokin, M.D.**COMPONENT WORKSHOP 38** 9:00 a.m.-10:30 a.m.

Room 5 A, Upper Level, San Diego Convention Center

THE SACRED HERB AND ADDICTION SCIENCE: A STUDY OF NICOTINE DEPENDENCE AND AXIS I COMORBIDITIES AMONG AMERICAN INDIANS*APA Committee of American Indian, Alaska Native, and Native Hawaiian Psychiatrists***Chp.:** Daniel L. Dickerson, D.O.**Participants:** Joseph J. Westermeyer IV, M.D., David A. Gilder, M.D.**COMPONENT WORKSHOP 39** 9:00 a.m.-10:30 a.m.

Room 5 B, Upper Level, San Diego Convention Center

TRANSCULTURAL ARAB PSYCHIATRY WITH A FOCUS ON WOMEN'S MENTAL HEALTH*APA Arab American Psychiatric Association***Co-Chp.:** Ossama T. Osman, M.D., Mahmoud S. Taman, M.D.**Participants:** Mona H. Al-Sawaf, M.D., Naser F. Loza, M.D.,**COMPONENT WORKSHOP 40** 9:00 a.m.-10:30 a.m.

Room 7 A, Upper Level, San Diego Convention Center

SUICIDE ICON: THE GOLDEN GATE BRIDGE*APA Northern California Psychiatric Society***Chp.:** Mel Blaustein, M.D.**Participant:** Anne Fleming, M.D.**COMPONENT WORKSHOP 41** 9:00 a.m.-10:30 a.m.

Room 7 B, Upper Level, San Diego Convention Center

LESSONS LEARNED FROM BUSINESS PRACTICES: HOW CAN PSYCHIATRISTS INCREASE THEIR PRACTICE OPPORTUNITIES BY IMPLEMENTING SUCCESSFUL BUSINESS STRATEGIES*APA Committee on APA/Business Relations***Chp.:** Gabriela Cora-Locatelli, M.D.**Participants:** Dauda A. Griffin, M.D., Alan Langlieb, M.D., Kenneth C. Nash, M.D.**COMPONENT WORKSHOP 42** 9:00 a.m.-10:30 a.m.

Room 8, Upper Level, San Diego Convention Center

SOCIAL DIMENSIONS OF DISASTERS AND COMMUNITY RECOVERY*APA Committee on Psychiatric Dimensions of Disasters***Co-Chps.:** Jacqueline Henschke, M.D., Sonali Sharma, M.D.**COMPONENT WORKSHOP 43** 9:00 a.m.-10:30 a.m.

Room 31 A, Upper Level, San Diego Convention Center

THE ISMS: HOW RACISM, SEXISM, CLASSISM, AND HETEROSEXISM AFFECT MENTAL HEALTH CARE*APA/SAMHSA Minority Fellows***Co-Chps.:** K. Ron-Li Liaw, M.D., Nisba F. Husain, M.D.**Participants:** Alphonso E. Nichols III, M.D., Tracee Burroughs, M.D., Eugene Lee, M.D., Jennifer D. Pender, M.D.**COMPONENT WORKSHOP 44** 9:00 a.m.-10:30 a.m.

Room 31 B, Upper Level, San Diego Convention Center

MANAGED CARE, PSYCHIATRISTS, AND EMPLOYERS: COLLABORATING EFFECTIVELY TO ENSURE PATIENT CARE*APA Committee on Managed Care***Chp.:** Paul H. Wick, M.D.**Participants:** David K. Nace, M.D., Alan Axelson, M.D., George D. Santos, M.D., Joel P. Johnson, M.D.**COMPONENT WORKSHOP 45** 9:00 a.m.-10:30 a.m.

Room 32 A, Upper Level, San Diego Convention Center

RACISM, RACIAL DISCRIMINATION, AND XENOPHOBIA: HOW PSYCHIATRY CAN REDUCE THEIR ADVERSE EFFECTS ON MENTAL HEALTH*APA Council on Minority Mental Health and Health Disparities***Chp.:** Francis G. Lu, M.D.**Participants:** Sandra C. Walker, M.D., Michele Reid, M.D., Andres J. Pumariega, M.D., Rahn K. Bailey, M.D., Napoleon B. Higgins Jr., M.D.

ISSUES 51-65

ISSUE WORKSHOP 51 9:00 a.m.-10:30 a.m.

Room 11 B, Upper Level, San Diego Convention Center

BIOPSYCHOSOCIAL AND SPIRITUAL ASPECTS OF TREATING OUR PHYSICIAN COLLEAGUES**Co-Chps.:** Syed S. A. Naqvi, M.D., Monisha R. Vasa, M.D.**Participants:** Michael F. Myers, M.D., Amir Ettekal, M.D., Tara Klein, M.D.

ISSUE WORKSHOP 52 9:00 a.m.-10:30 a.m.

Room 23 C, Upper Level, San Diego Convention Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.

Participants: Edward R. Shapiro, M.D., Jane G. Tillman, Ph.D.

ISSUE WORKSHOP 53 9:00 a.m.-10:30 a.m.

Room 24 A, Upper Level, San Diego Convention Center

DEVELOPING RESEARCH TRAINING OPPORTUNITIES WITHIN A PSYCHIATRIC RESIDENCY TRAINING PROGRAM: GOALS, MOTIVATIONS, BARRIERS, AND SOLUTIONS

Chp.: Robert J. Love, D.O.

Participants: Vanessa Wong, M.D., Julianne Flynn, M.D., Thomas L. Matthews, M.D., Pedro L. Delgado, M.D.

ISSUE WORKSHOP 54 9:00 a.m.-10:30 a.m.

Room 24 B, Upper Level, San Diego Convention Center

THE ADHD/PEDIATRIC BIPOLAR INTERFACE: SAILING THROUGH TROUBLED WATERS?

Co-Chps.: Vishal Madaan, M.D., Kiki D. Chang, M.D.

ISSUE WORKSHOP 55 9:00 a.m.-10:30 a.m.

Room 24 C, Upper Level, San Diego Convention Center

ORAL BOARDS BOOT CAMP: 2007

Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 56 9:00 a.m.-10:30 a.m.

Room 25 A, Upper Level, San Diego Convention Center

NEUROIMAGING RESEARCH: IMPLICATIONS FOR THE TREATMENT OF SUBSTANCE ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Steven J. Grant, Ph.D.

Participants: Anna R. Childress, Ph.D., Martin P. Paulus, M.D., Clinton D. Kilts, Ph.D., Christopher deCharms, Ph.D., Cameron Carter, M.D.

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.

Room 25 B, Upper Level, San Diego Convention Center

PROJECT MATCH: A RESIDENT CURRICULUM OF MENTORSHIP, ADVOCACY, TEACHING, CAREER ISSUES, AND HEALTH

Co-Chps.: Heather J. Flett, M.D., Jillian Sussman, M.D.

Participant: Bruce Ballon, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.

Room 25 C, Upper Level, San Diego Convention Center

THE RESIDENT EXPERIENCES A PATIENT SUICIDE: STRATEGIES THAT CAN HELP

Co-Chps.: Joan M. Anzia, M.D., Surinder S. Nand, M.D.

Participants: Janet L. Kemp, Arshdeep S. Jawandha, M.D.

ISSUE WORKSHOP 59 9:00 a.m.-10:30 a.m.

Room 26 A/B, Upper Level, San Diego Convention Center

TELEPSYCHIATRY IN ACTION: IMPLEMENTING AND SUSTAINING A SUCCESSFUL TELEPSYCHIATRY PROGRAM

Chp.: Susan Stabinsky, M.D.

Participants: Richard A. Silverman, M.D., Maria L.A. Tiamson-Kassab, M.D., James Varrell, M.D.

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.

Room 27 A, Upper Level, San Diego Convention Center

RESEARCH TRAINING FOR ALL PSYCHIATRIC RESIDENTS: A PROBLEMATIC ENDEAVOR

Chp.: Milton Kramer, M.D.

Participants: Jerald Kay, M.D., Mantosh J. Dewan, M.D., Michele T. Pato, M.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.

Room 27 B, Upper Level, San Diego Convention Center

DETECTING BIPOLAR DISORDER

Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.

Room 30 A, Upper Level, San Diego Convention Center

CAN WE DO BETTER AT PREVENTING THE CHRONIC COURSE OF MOOD DISORDERS?

Co-Chps.: Alina Marin, M.D., Irene Patelis-Siotis, M.D.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.

Room 30 B, Upper Level, San Diego Convention Center

SAFETY TRAINING FOR MEDICAL STUDENTS DURING THEIR PSYCHIATRY CLERKSHIP

Chp.: Erica Z. Shoemaker, M.D.

ISSUE WORKSHOP 64 9:00 a.m.-10:30 a.m.

Room 30 C, Upper Level, San Diego Convention Center

THE ROLE OF *DSM-IV* RATING SCALES IN PSYCHIATRY

Co-Chps.: Joyce Sprafkin, Ph.D., Kenneth D. Gadow, Ph.D.

Participant: Margaret D. Weiss, M.D.

ISSUE WORKSHOP 65 9:00 a.m.-10:30 a.m.

Room 32 B, Upper Level, San Diego Convention Center

**COMPLEXITIES OF POST TERMINATION
RELATIONSHIPS****Chp.:** Malkah T. Notman, M.D.**Participants:** Elissa P. Benedek, M.D., Carl P. Malmquist, M.D.,
Linda M. Jorgenson, J.D.**MEDIAS 5-7****MEDIA WORKSHOP 5** 9:00 a.m.-12 noon

Room 10, Upper Level, San Diego Convention Center

**ROCK BOTTOM: UNDERSTANDING THE
METHAMPHETAMINE EXPERIENCE AND THE
STRUGGLE FOR SOBRIETY****Chp.:** Steven J. Lee, M.D.**Participants:** Petros Levounis, M.D., Colin A. Weil, B.A., Jay
Corcoran, Ubaldo Leli, M.D.**MEDIA WORKSHOP 6** 9:00 a.m.-12 noon

Room 11 A, Upper Level, San Diego Convention Center

**WE ARE DAD: HIV-POSITIVE CHILDREN AND
LESBIAN, GAY, BISEXUAL, OR TRANSGENDER
PARENTING****Chp.:** R. Kaan Ozbayrak, M.D.**Participants:** Marshall Forstein, M.D., Warren Y.K. Ng, M.D.**MEDIA WORKSHOP 7** 9:00 a.m.-12 noon

Room 29 C/D, Upper Level, San Diego Convention Center

**PSYCHIATRIC RESIDENTS' PERSPECTIVE OF
COUPLES AND FAMILY THERAPY TRAINING****Chp.:** Ian E. Alger, M.D.**Participant:** Anita Menfi, R.N.**11:00 a.m. Sessions****ADVANCES IN MEDICINE 3**

11:00 a.m.-12:30 p.m.

Room 2, Upper Level, San Diego Convention Center

**ADVANCES IN THE CAUSE, TREATMENT, AND
PSYCHOLOGY OF HYPERTENSION****Chp.:** Daniella David, M.D.**Participant:** Michael G. Ziegler, M.D.**LECTURES 21-22****LECTURE 21**

11:00 a.m.-12:30 p.m.

Ballroom 6 B, Upper Level,
San Diego Convention Center**APA'S JUDD MARMOR AWARD LECTURE**

Nancy C. Andreasen, M.D.

The Creating Brain: The Neuroscience of Genius**Chp.:** Stuart C. Yudofsky, M.D.

Dr. Andreasen holds positions as Chair of Psychiatry, University of Iowa, Director of the Iowa Neuroimaging Center, and Director of the Mental Health Clinical Research Center, University of Iowa; since 2001 she has also assumed the position of Adjunct Professor of Psychiatry and Neurology, University of New Mexico MIND Institute, a new imaging center dedicated to understanding mental illness. Although Dr. Andreasen is best known to APA as the Editor in Chief, American Journal of Psychiatry, she is an internationally renowned neuropsychiatrist, researcher, educator, and mentor. One of the world's foremost authorities on schizophrenia, Dr. Andreasen was an early pioneer in applying neuroimaging techniques to study the neural basis of major mental illness. Her work was among the first to suggest that schizophrenia was linked to abnormal brain development and that a decrease in the size of the brain's frontal lobe was associated with the negative symptoms of the disorder, including impaired cognitive function. Dr. Andreasen's research has also provided significant insight into the brain mechanisms underlying language, emotion, and the creative process. She led the first extensive empirical study of creativity and was the first to recognize the association between creativity and manic-depressive illness. In 2006 Dr. Andreasen was selected as the recipient of the first "Vanderbilt Prize in Biomedical Science," an award established by Vanderbilt University School of Medicine to honor women who have made significant advances in the biological and biomedical sciences and have contributed positively to the mentorship of other women in science. This major new award carries a \$25,000 prize and establishes a scholarship in the name of the awardee; the scholarship supports a M.D./Ph.D. candidate at Vanderbilt University School of Medicine. Dr. Andreasen was elected a member of the Institute of Medicine (National Academy of Sciences) and of the American Academy of Arts and Sciences. In 2000 she was awarded the National Medal of Science by President Clinton.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 22

11:00 a.m.-12:30 p.m.

Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

William T. Carpenter, Jr., M.D.

A Paradigm Shift for Schizophrenia Discovery

Chp.: Christine E. Marx, M.D.

William T. Carpenter, Jr., M.D., is a Professor of the University of Maryland School of Medicine and the Director of the Maryland Psychiatric Research Center. He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Medical Center. He began his research career with the National Institute of Mental Health Intramural Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. He has also been a collaborating investigator with the World Health Organization's International Pilot Study of Schizophrenia. Dr. Carpenter is the Editor-in-Chief for *Schizophrenia Bulletin*, has served on the several editorial boards, along with authoring over 300 publications. Dr. Carpenter is President of the American College of Neuropsychopharmacology and his major professional interest has been severe mental illness, especially schizophrenia, including phenomenology of the psychoses, the etiology, pathophysiology, anatomy, and treatment of schizophrenia. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics. His special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and National Institutes of Health on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Plan Committee on Treatment Research. Dr. Carpenter is the only scientist to direct both an NIMH-funded Clinical Research Center (now Advanced Centers for Interventions and Services Research) and an NIMH-funded Center for Neuroscience and Schizophrenia. He provided expert testimony in the cases of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He has been the recipient of national and international research awards. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 19-27SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.

Room 3, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY AND SCHIZOPHRENIA

Chp.: Harry Sekhon

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

56 **Number Needed to Treat and Number Needed to Harm: Making Sense of CATIE**

Leslie L. Citrome, M.D., T. Scott Stroup, M.D.

11:30 a.m.

57 **Switching From Long-Acting Typical Antipsychotic Drugs to the Second Generation Antipsychotics: Olanzapine and Risperidone in the Treatment of Patients With Chronic Schizophrenia**

Marnina Swartz-Vanetik, M.D., Ella Lavun, M.D., Yehuda Baruch, M.D., Yoram Barak, M.D.

12 noon

58 **Zolpidem in Treatment Resistant Catatonia: Two-Case Reports and Literature Review**

Cristinel M. Coconcea, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20

11:00 a.m.-12:30 p.m.

Room 4, Upper Level, San Diego Convention Center

MANAGING VIOLENCE

Chp.: Britta Ostermeyer, M.D.

Co-Chp.: Jason R. Kornberg, M.D.

11:00 a.m.

59 **Variables Affecting Violence That Required Physical Restraint Among Psychiatric Inpatients During The First Week Of Hospitalization**

Pinkhas Sirota, M.D., Yuri Markman, Nuc.E., Rachel R. Rosenberg, M.A.

11:30 a.m.

60 **Decreasing the Use of Restraint and Seclusion Among Psychiatric Inpatients**

David J. Hellerstein, M.D., Amy B. Staub, M.B.A., Elizabeth LeQuesne, M.D.

12 noon

61 **CES Reduces Aggression in Violent Neuropsychiatric Patients**

Allen Childs, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21

11:00 a.m.-12:30 p.m.

Room 5 A, Upper Level, San Diego Convention Center

CONTINUATION AND DISCONTINUATION OF SSRIS**Chp.:** Rajnish Mago, M.D.**Co-Chp.:** Aysegul Yildiz-Yesiloglu, M.D.

11:00 a.m.

62 Comparison of the Prophylactic Efficacy of Antidepressants-Factors Associated With Better Outcome

Sabrina J. Khan, M.D., Eric D. Peselow, M.D., Barbara Orłowski, Ph.D.

11:30 a.m.

63 How Often Do SSRIs Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate is True Tachyphylaxis During Continuation Treatment is Low

Mark Zimmerman, M.D.

12 noon

64 Discontinuation of SSRI's After Five Years Stability

Tara M. Pundiak, M.D., Eric D. Peselow, M.D., Loretta Mulcare, Brady G. Case, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 22**

11:00 a.m.-12:30 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

SEX, ATTRACTION, AND INTIMACY**Chp.:** Waguih W. IsHak, M.D.**Co-Chp.:** Daniel Sewell, M.D.

11:00 a.m.

65 An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial of PDE5I Sildenafil Treatment of SRI-Antidepressant-Associated Sexual Dysfunction in Women With MDD in Remission: Identifying a Hormone Endophenotype Associated With Treatment

H. George Nurnberg, Paula L. Hensley

11:30 a.m.

66 Breakthrough Intimacy: Treating Personality

Yukio Ishizuka

12 noon

67 A Link Between Oxytocin and Anxiety of Romantic Attachment

Donatella Marazziti, M.D., Mario Catena, M.D., Stefano Baroni, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 23**

11:00 a.m.-12:30 p.m.

Room 9, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY AND BIPOLAR DISORDER**Chp.:** Vivek Singh, M.D.**Co-Chp.:** Igor Elman, M.D.

11:00 a.m.

68 Effect of Comorbid Anxiety on Antidepressant Use in a Community Sample of Bipolar Subjects

Ayal Schaffer, M.D., John Cairney, Ph.D., Scott Veldhuizen, Amy H. Cheung, M.D., Anthony J. Levitt, M.D.

11:30 a.m.

69 Difficult to Treat Patients: The Role of Quetiapine in the Management of Acute Bipolar Depression With a Focus on Bipolar II Patients

Michael E. Thase, M.D.

12 noon

70 Indirect Comparison of the Safety and Tolerability of Antipsychotics in Patients With Bipolar Disorder and Schizophrenia

Kemeng Gao, M.D., Stephen J. Ganocy, Ph.D., Joseph R. Calabrese, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 24**

11:00 a.m.-12:30 p.m.

Room 11 B, Upper Level, San Diego Convention Center

TREATMENT ISSUES IN COLLEGE AND MEDICAL STUDENTS**Chp.:** Joel Dimsdale, M.D.**Co-Chp.:** Suzanna Parker, M.D.

11:00 a.m.

71 Subjective Sleep Quality and Suicidal Ideation Among College Students

Shamsah B. Sonawalla, M.D., Amy H. Farabaugh, Ph.D., Maribeth Pender, Ph.D., Timothy J. Petersen, Ph.D., Albert Yeung, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.

72 Prevalence and Attitudes Concerning ADHD Diagnosis and Use of Stimulant Medications in Medical Students

Jeffrey Tuttle, M.D., Neil Scheurich, M.D., John Ranssen, Ph.D.

12 noon

73 Prevalence and Symptom Patterns of Depression Among College Students: Findings From a Cross-Cultural Study Across Boston and Bombay

Rajesh M. Parikh, M.D., Shamsah Sonawalla, M.D., Santvana Sharma, M.D., Amy H. Farabaugh, Ph.D., Albert Yeung, M.D., Steve Safren, Ph.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Room 24 C, Upper Level, San Diego Convention Center

FUNCTIONING AND DISEASE BURDENS IN MOOD DISORDERS

Chp.: Kenneth Silk, M.D.

Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.

74 Disease Burden of Bipolar and Schizoaffective Disorder in an Australian Cohort

Jayashri Kulkarni, M.B.B.S., Michael Berk, Paul Fitzgerald, Anthony de Castella, Sectal Dodd, Meg Smith, William Montgomery

11:30 a.m.

75 Days Missed From Work in Patients With MDD With or Without a Personality Disorder

Daniela A. Boerescu, M.D., Mark Zimmerman, M.D., Iwona Chelminski, Ph.D.

12 noon

76 The Relationship Between Global Functioning, Depression, and Painful Somatic Symptoms in Patients With MDD

Thomas N. Wise, Adam L. Meyers, Durisala Desaiyah, Craig H. Mallinckrodt, Michael J. Robinson, Daniel Kajdasz

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Room 25 A, Upper Level, San Diego Convention Center

STIGMA AND DISCRIMINATION

Chp.: Sonja Randle, M.D.

Co-Chp.: Jana Cook

11:00 a.m.

77 How Dangerous is Stigma? Perceived Stigma and HIV Risk Among Women With Severe Mental Illness

Pamela Y. Collins, Patricia Zyberty, Ph.D., Annika Sweetland, M.S.W.

11:30 a.m.

78 Comparison of Public's Stigma Attitude Between Mental Illness and Physical Handicap

Chih-Wei Yang, M.D., Chih-Yu Yang, Ph.D., Pi-Fem Hsu, Ph.D., Li-Min Su, M.S.

12 noon

79 Obsessions About Homosexuality and the Y-BOCS Lessons From a Anti-Discrimination Case in Sweden

Christian Rück, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m.-12:30 p.m.

Room 27 A, Upper Level, San Diego Convention Center

SUICIDE AND SELF DESTRUCTION

Chp.: Austina Cho, M.D.

Co-Chp.: Derya I. Akbiyik, M.D.

11:00 a.m.

80 The 10-Year Course of Physically Self-destructive Acts of Patients With Borderline Personality Disorder

Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., D. Bradford Reich, M.D.

11:30 a.m.

81 Indicators of Treatment Refractory Illness and Risk of Suicide

Bonnie S. Szarek, R.N., John W. Goethe, M.D., Stephen B. Woolley, D.Sc

12 noon

82 Personality Traits as Prospective Predictors of Suicide Attempts: Negative Affectivity/Temperament and Disinhibition in a Personality Disorder Sample

M. Tracie Shea, Ph.D., Shirley Yen, Ph.D., Charles A. Sanislow, Ph.D., Andrew E. Skodol II, M.D., Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSION 14

11:00 a.m.-12:30 p.m.

Susan L. McElroy, M.D., on Metabolic Syndrome

(Meet the Author)

Room 27 B, Upper Level, San Diego Convention Center

WORKSHOPS

COMPONENTS 46-54

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.

Room 5 B, Upper Level, San Diego Convention Center

LEADERSHIP CHALLENGES: BREAKING BARRIERS TO SUCCESS

APA Committee on International Medical Graduates

Co-Chps.: Antony Fernandez, M.D., Annelie B. Primm, M.D.

Participants: Francis M. Sanchez, M.D., Emilio F. Romero, M.D., Marie-Claude Rigaud, M.D., Alejandra Postlethwaite, M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.

Room 7 A, Upper Level, San Diego Convention Center

PUBLIC POLICY, HIV AND MENTAL HEALTH: POLITICS, IDEOLOGY OR SCIENCE

APA New York County District Branch's AIDS Committee

Chp.: Mary Ann Cohen, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.

Room 7 B, Upper Level, San Diego Convention Center

CPT CODING AND DOCUMENTATION UPDATE

APA Committee on RBRVS, Codes, and Reimbursements

Co-Chps.: Ronald M. Burd, M.D., David Nace, M.D.

Participants: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D., Allan A. Anderson, M.D., Edward Gordon, M.D.

COMPONENT WORKSHOP 49 11:00 a.m.-12:30 p.m.

Room 8, Upper Level, San Diego Convention Center

ETHICS AND ETIQUETTE: KEEPING OUT OF TROUBLE*APA Ethics Committee***Chp.:** Wade C. Myers**Participants:** William Arroyo, M.D., Richard D. Milone, M.D., Burton V. Reifler, M.D., Harriet C. Stern, M.D., Lawrence Hartmann, M.D.**COMPONENT WORKSHOP 50** 11:00 a.m.-12:30 p.m.

Room 23 C, Upper Level, San Diego Convention Center

MANAGING OPIATE DETOXIFICATION WITH BUPRENORPHINE/NALOXONE*APA Council on Addiction Psychiatry***Chp.:** John A. Renner, Jr., M.D.**Participants:** Eric C. Strain, M.D., Herbert D. Kleber, M.D., Ray C. Hsiao, M.D.**COMPONENT WORKSHOP 51** 11:00 a.m.-12:30 p.m.

Room 24 A, Upper Level, San Diego Convention Center

NEW APA PRACTICE GUIDELINES ON DEMENTIA, PANIC DISORDER, AND OCD*APA Steering Committee on Practice Guidelines***Chp.:** Jack S. McIntyre, M.D.**Participants:** Lon S. Schneider, M.D., Murray B. Stein, M.D., Lorrin M. Koran, M.D., Laura J. Fochtmann, M.D.**COMPONENT WORKSHOP 52** 11:00 a.m.-12:30 p.m.

Room 25 C, Upper Level, San Diego Convention Center

MISSION POSSIBLE: RECLAIMING AMERICA'S STATE HOSPITAL BEDS*APA Council on Social Issues and Public Psychiatry***Co-Chps.:** Jagannathan Srinivasaraghavan, M.D., Jeffrey L. Geller, M.D.**Participants:** Tracee Burroughs, M.D., Terri L. Randall, M.D., Ruth S. Shim, M.D.**COMPONENT WORKSHOP 53** 11:00 a.m.-12:30 p.m.

Room 28 A, Upper Level, San Diego Convention Center

EARLY COGNITIVE DEVELOPMENT AND PSYCHIATRIC PRESENTATION: IMPLICATIONS FOR ETIOLOGIC UNDERSTANDING AND INTERVENTION*APA Corresponding Committee on Infancy and Early Childhood***Co-Chps.:** Jean M. Thomas, M.D., Irene Chatoor, M.D.**Participant:** Penny Glass, Ph.D.**COMPONENT WORKSHOP 54** 11:00 a.m.-12:30 p.m.

Room 32 B, Upper Level, San Diego Convention Center

MENTORING OF WOMEN IN ACADEMIC PSYCHIATRY*APA Central California Psychiatric Society***Chp.:** Linda L.M. Worley, M.D.**Participants:** Tracy H. McCarthy, M.D., Andreea L. Seritan, M.D., Donald M. Hilty, M.D.**ISSUES 66-76****ISSUE WORKSHOP 66**

11:00 a.m.-12:30 p.m.

Room 24 B, Upper Level, San Diego Convention Center

ETHNICITY, CULTURE, AND PSYCHOPHARMACOLOGY: RECENT ADVANCES**Chp.:** Pedro Ruiz, M.D.,**Participants:** William B. Lawson, M.D., Ph.D., Edmond H. Pi, M.D., Tarek A. Okasha, M.D.**ISSUE WORKSHOP 67**

11:00 a.m.-12:30 p.m.

Room 28 B, Upper Level, San Diego Convention Center

COGNITIVE BEHAVIOUR THERAPY FOR PSYCHOSIS IN PRACTICE: BASIC TECHNIQUES FOR PSYCHIATRISTS**Chp.:** Shanaya Rathod, M.D.**Participants:** David G. Kingdon, M.D., Douglas Turkington, M.D.**ISSUE WORKSHOP 68**

11:00 a.m.-12:30 p.m.

Room 28 C, Upper Level, San Diego Convention Center

PROMISING MEDICATIONS FOR THE TREATMENT OF COCAINE ADDICTION*Collaborative Session With the National Institute on Drug Abuse***Co-Chps.:** Ahmed Elkashef, M.D., Frank Vocci, Jr., Ph.D.**Participants:** Kyle M. Kampman, M.D., Bankole Johnson, M.D., George F. Koob, Ph.D.**ISSUE WORKSHOP 69**

11:00 a.m.-12:30 p.m.

Room 28 D, Upper Level, San Diego Convention Center

PSYCHIATRISTS WHO HAVE BEEN IN TREATMENT. AN INTERACTIVE DISCUSSION**Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.**Participants:** Elizabeth A. Baxter, M.D., Francine Courmos, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.

ISSUE WORKSHOP 70 11:00 a.m.-12:30 p.m.
Room 30 A, Upper Level, San Diego Convention Center

ELECTRIFYING DISCOURSES: PRESENTATION AND COMMUNICATION SKILLS FOR PSYCHIATRISTS AND TRAINEES

Chp.: Shyam K. Bhat, M.D.
Participants: David S. Resch, M.D., Thomas O. Osinowo, M.D., Anjan Bhattacharyya, M.D.

ISSUE WORKSHOP 71 11:00 a.m.-12:30 p.m.
Room 30 B, Upper Level, San Diego Convention Center

AIR FORCE SUICIDE PREVENTION PROGRAM: A COMMUNITY AND ORGANIZATIONAL APPROACH TO PREVENTION

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 72 11:00 a.m.-12:30 p.m.
Room 30 C, Upper Level, San Diego Convention Center

DAY-TO-DAY VARIABILITY IN BIPOLAR DISORDER

Co-Chps.: Jan L. Scott, M.D., Michael Bauer, M.D.
Participants: Mark S. Bauer, M.D., Tasha Glenn, Ph.D.

ISSUE WORKSHOP 73 11:00 a.m.-12:30 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

FROM THE MISSISSIPPI TO THE GANGES: UNDERSTANDING THE CROSS CULTURAL CONTEXT OF TREATMENT FROM THE PERSPECTIVE OF THE SOUTH ASIAN PSYCHIATRIST IN AMERICA

Indo-American Psychiatric Association

Co-Chps.: Asha S. Mishra, M.D., Sudeepta Varma, M.D.
Participants: Surinder Nand, M.D., Nalini Juthani, M.D.

ISSUE WORKSHOP 74 11:00 a.m.-12:30 p.m.
Room 31 A, Upper Level, San Diego Convention Center

RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., James L. Griffith, M.D.
Participant: Christina M. Puchalski, M.D.

ISSUE WORKSHOP 75 11:00 a.m.-12:30 p.m.
Room 31 B, Upper Level, San Diego Convention Center

FROM EVIDENCE TO CLINICAL METHODS IN INTEGRATIVE MENTAL HEALTH CARE

Chp.: James Lake, M.D.

ISSUE WORKSHOP 76 11:00 a.m.-12:30 p.m.
Room 32 A, Upper Level, San Diego Convention Center

GAY MEN AND CRYSTAL METHAMPHETAMINE: A REVIEW

Co- Chp.: Eugene Lee, M.D., Waguih W. Ishak, M.D.
Participants: Douglas Braun-Harvey, Jeffery N. Wilkins, M.D.

12 noon Sessions

FORUMS 9-10

FORUM 9
12 noon-1:30 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

CATASTROPHE MANAGEMENT: PSYCHIATRY RESPONSE TO HURRICANES KATRINA AND RITA IN LOUISIANA

Chp.: David E. Post, M.D.
Presenters: Kathleen A. Crapanzano, M.D., Rochelle Head-Dunham, M.D., Jacquelyn A. Robinson, M.D.

FORUM 10
12 noon-1:30 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

WALLY: A FILM BY BOB FINK, M.D.

Chp.: Robert Fink, M.D.

NEW RESEARCH POSTER SESION 6
12 noon-2:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m Sessions

**COURSES 88-91**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 88 1:00 p.m.-5:00 p.m.
 Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

THE WAY OF YOGA AND HERBS IN TREATMENT OF STRESS, DEPRESSION, AGGRESSION, AND MASS TRAUMA

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg M.D.

COURSE 89 1:00 p.m.-5:00 p.m.
 Madeleine Room A/B, Third Level, Manchester Grand Hyatt

MOTIVATIONAL THERAPY FOR PATIENTS WITH CONCURRENT DISORDERS

Director: Shimi Kang, M.D.
 Faculty: Steve Mathias, M.D., Jennifer Toomey, R.P.N., Tristin Wayte, Ph.D.

COURSE 90 1:00 p.m.-5:00 p.m.
 Madeleine Room C/D, Third Level, Manchester Grand Hyatt

PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY

Director: Roy O. Resnikoff, M.D.

COURSE 91 1:00 p.m.-5:00 p.m.
 Emma Room A/B/C, Third Level, Manchester Grand Hyatt

CORRECTIONAL PSYCHIATRY: A SKILLS BUILDING COURSE

Director: Melissa P. Piasecki, M.D.
 Faculty: Keith Courtney, M.D., Steven J. Zuchowski, M.D., Ole J. Thienhaus, M.D.

2:00 p.m Sessions

ADVANCES IN ADVANCES IN C-L PSYCHIATRY AND PSYCHOSOMATIC MEDICINE

2:00 p.m.-5:30 p.m.
 Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: James L. Levenson, M.D.

- A Legal Issues at the Interface of Psychiatry and Medicine**
 James L. Levenson, M.D.
- B Somatization and Somatoform Disorders**
 Steven A. Epstein, M.D.
- C Depression in the Medically Ill**
 Gary Rodin, M.D.
- D Psychosis in the Medically Ill**
 Prakash S. Masand, M.D.
- E Deception Syndromes**
 Charles V. Ford, M.D.

LECTURES 23-24

LECTURE 23

2:00 p.m.-3:30 p.m.
 Ballroom 6 B, Upper Level,
 San Diego Convention Center

Tanya Luhrmann, Ph.D.

Psychosis on the Streets: An Ethnography of Chicago's Netherworld

Chp.: Deborah Spitz, M.D.

Tanya Luhrmann is the Max Palevsky Professor in the Committee on Human Development. She trained at the University of Cambridge (PhD 1986), taught for many years at the University of California San Diego, and joined the University of Chicago faculty in 2000. Her work focuses on the social construction of psychological experience, and the way that social practice alters psychological mechanism, particularly in the domain of what some would call the "irrational". Her first project is a detailed study of the way apparently reasonable people come to believe apparently unreasonable beliefs (*Persuasions of the Witch's Craft*, Harvard, 1989). Her second project explored the apparently irrational self-criticism of a postcolonial India elite, the result of colonial identification with the colonizers (*The Good Parsi*, Harvard 1996). Her third book identified two cultures with the American profession of psychiatry and examined the way these different cultures encouraged two different experiences of empathy and two different understandings of mental illness (*Of Two Minds*, Knopf, 2000). Her current work looks at the experience of voices and visions both in the new style of American religion and among psychiatric clients, and the way the interpretation of these phenomena may affect the experience of God (on the one hand) and the identification, experience and outcome of psychiatric illness (on the other). She is a director of the Clinical Ethnography project in the Committee on Human Development.

Frontiers of Science Award Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 24

2:00 p.m.-3:30 p.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Leah Dickstein, M.D.

Keys to Effective Mentoring for All in Psychiatry

Chp.: Kathryn Connor, M.D.

Co-Chp.: Christine E. Marx, M.D.

Leah J. Dickstein, M.D., earned her undergraduate and master's degrees in elementary education at Brooklyn College, taught in an inner city school for almost seven years and earned her M.D. from the University of Louisville. She joined the faculty in 1975 to found the University Student Mental Health Section of the University Student Health Service, and became School of Medicine Associate Dean for Student Affairs in 1981, then Associate Dean for Faculty and Student Advocacy in 1989, was associate chair for academic affairs, and became Professor Emerita in 2002. She established a number of medical school health promotion programs. Dr. Dickstein has edited/co-edited a number of books and has served in various positions of leadership with numerous associations. In addition she initiated the first APA named lecture for a woman: Alexandra Symonds, M.D., the Nancy C.A. Roeske, M.D. Teaching Award at every medical school, The AWP Man of Good Conscience Award (Martin Symonds, M.D.), the AWP Marian Butterfield, M.D. Early Career Leadership Award, and proposed the Irma Bland Award. She created the medical student physicians and the arts elective (and awards). Her research has focused on health promotion among medical students and residents, interviews of over 200 Catholic and Jewish Women & Men Nazi Concentration Camp Survivors related to gender, spiritual, and coping differences. Her publications exceed 100, she is a reviewer for several journals, and has given over 500 national and international lectures. Currently, Dr. Dickstein is Professor Emerita, and continues to lecture, write, and mentor students, trainees, and young faculty nationwide.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 5-7

PRESIDENTIAL SYMPOSIUM 5

2:00 p.m.-5:00 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

HEALTH INEQUALITIES FOR PERSONS WITH MENTAL HEALTH PROBLEMS AND DEVELOPMENTAL DISABILITIES

Royal College of Psychiatrists

Chp.: Pedro Ruiz, M.D.

Co-Chp.: Sheila Hollins, M.D.

A Health Care Delivery Systems in the United Kingdom
Dinesh Bughra, M.D.

B The Role of Organized Medicine and Psychiatry in the United Kingdom
Sue Bailey, M.D.

C The Provision of Care for Persons With Intellectual Disabilities in the United Kingdom
Helen Miller, M.B.

D Health Care Delivery Systems in the U.S.
Roger Peele, M.D.

E The Role of the Professional Society (Organized Psychiatry) in Addressing Health Care in the U.S.
James H. Scully Jr., M.D.

F The Provision of Care for Persons With Intellectual Disabilities in the U.S.
Stephen Ruedrich

Discussants: Greg Richardson, M.D., Sidney Weissman, M.D.

PRESIDENTIAL SYMPOSIUM 6

2:00 p.m.-5:00 p.m.

Ballroom 6 E, Upper Level, San Diego Convention Center

FOCUSING ON EUROPEAN PSYCHIATRY

APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.

Co-Chp.: Cyril Hoschl, M.D.

A European Psychiatry: Between Neuroscience and Medical Humanities
Michael Musalek, M.D.

B Current European Perspectives on the Concept of Schizophrenia
Mario Maj, M.D.

C Green Paper and Limits of Psychiatry as a Medical Discipline
Cyril Hoschl, M.D.

Discussant: Norman H. Sartorius, M.D.

PRESIDENTIAL SYMPOSIUM 7

2:00 p.m.-5:00 p.m.

Room 33 A/B/C, Upper Level, San Diego Convention Center

GLOBALIZATION AND MENTAL HEALTH: ROLE OF SPANISH-SPEAKING PSYCHIATRY**Chp.:** Renato D. Alarcon, M.D.**Co-Chp.:** Cesar M. Mejias

- A Globalization and its Discontents: The Spanish-Speaking Perspective**
Renato D. Alarcon, M.D.
- B Psychiatry in Ibero-America: Historical Perspective**
Pedro Ruiz, M.D.
- C Globalization and Psychiatry in Latin America: A Role for Professional Prudence**
Fernando Lolas, M.D.
- D A Global Psychiatry for a Globalized World**
Jose Lazaro

Discussant: Manuel Trujillo, M.D.**SYMPOSIA 52-74****SYMPOSIUM 52**

2:00 p.m.-5:00 p.m.

Room 2, Upper Level, San Diego Convention Center

BEHAVIORAL AND SUBSTANCE ADDICTIONS IN MINORITY POPULATIONS**Chp.:** Jon E. Grant, M.D.

- A Implications of Black/African American Race, Ethnicity, and Culture for Addiction**
Marc N. Potenza, M.D., Marvin Steinberg, Ph.D., Ran Wu, M.S., Declan Barry, Ph.D.
- B Native American and Hispanic Veterans With Addictive Disorders: Comorbidity With Internalizing and Externalizing Disorders**
Joseph J. Westermeyer, M.D.
- C Asian-Americans, Addictions, and Barriers to Treatment**
Timothy W. Fong, M.D.
- D Addictions Within the Gay and Lesbian Community**
Jon E. Grant, M.D.
- E Clinical Challenges to Addiction Treatment Within the Latino Community**
Carlos Blanco-Jerez

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 53**

2:00 p.m.-5:00 p.m.

Room 3, Upper Level, San Diego Convention Center

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL: AN UPDATE FROM RECENT CLINICAL TRIALS**Chp.:** François Lespérance, M.D.

- A The Create Trial: Background and Design of a 2 by 2 Factorial Randomized Trial of Citalopram and IPT for Major Depression in Patients with Coronary Artery Disease**
Nancy Frasure-Smith, François Lespérance, M.D., Diana Koszycki, Ph.D., John R. Swenson, M.D., Brian Baker, M.B.Ch.B., Louis T. van Zyl, M.D., Marc-André Laliberté, M.D., Beth L. Abramson, M.D., Marie-Claude Guertin
- B The Create Trial: Results of a 2 by 2 Factorial Randomized Trial of Citalopram and IPT for Major Depression in Patients With Coronary Artery Disease**
François Lespérance, M.D., Nancy Frasure-Smith, Ph.D., Diana Koszycki, Marc-André Laliberté, M.D., Louis T. vanZyl, M.D., Brian Baker, M.D., John R. Swenson, M.D., Kayhan Ghatavi, M.D., Beth L. Abramson, M.D.
- C Randomized Controlled Trial of Treatments for Depression After Coronary Bypass Surgery**
Kenneth E. Freedland, Ph.D.
- D Cost-Effectiveness or Improving Depression Outcomes in Patients With Diabetes and Depression**
Wayne J. Katon, M.D., Gregory E. Simon, M.D., Jurgen Unutzer, M.D., Ming-Yu Fan, Ph.D., Michael Schoenbaum, Ph.D., Michael Von Korff, Sc.D, John W. Williams, Jr., M.D., Carolyn Rutter, Ph.D., Paul S. Ciechanowski, M.D.
- E Efficacy of Sertraline for Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes**
Patrick J. Lustman, Ph.D., Ray E. Clouse, M.D., Billy D. Nix, Monique M. Williams, M.D.

Discussant: Craig B. Taylor, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 54**

2:00 p.m.-5:00 p.m.

Room 4, Upper Level, San Diego Convention Center

DRUG ABUSE TREATMENT WITHIN THE CRIMINAL JUSTICE SYSTEM: ADDRESSING OUR NATION'S PUBLIC HEALTH NEEDS*Collaborative Session With the National Institute on Drug Abuse***Chp.:** Timothy Condon Ph.D.**Co-Chp.:** Redonna K. Chandler Ph.D.

- A Findings From a National Survey of Correctional Agencies on Substance Abuse Treatment and Health Services: Who Can Get Served?**
Faye S. Taxman, Ph.D.

(Continued next page)

B The Long-Term Effectiveness of Corrections-Based Treatment for Drug-Involved Offenders

James A. Inciardi, Ph.D.

C Mental Health and Co-occurring Treatment Needs of Individuals in the Criminal Justice System

Roger H. Peters, Ph.D.

D Meeting the Medical Needs of Offenders

Peter D. Friedmann, M.D., Jennifer G. Clarke, M.D., Lynn E. Taylor, M.D., Michael Poshkus, M.D., Josiah D. Rich, M.D.

E Pharmacotherapy in Correctional Settings for Addictive and Other Mental Disorders

Robert P. Schwartz, M.D.

Discussant: Redonna K. Chandler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.

Room 5 A, Upper Level, San Diego Convention Center

IMPROVING CROSS-CULTURAL COMPETENCY IN PSYCHIATRIC PRACTICE

Chp.: Maria Lujan, M.D.

A South Asian Psychiatrist-Providing Culturally Sensitive Treatment

R. Rao Gogineni, M.D.

B Cultural Competency in Psychiatry and African-Americans

Altha J. Stewart, M.D.

C Filipino Families and Mental Health: Understanding Their Perspectives

Consuelo Cagande, M.D.

D Latinos in the United States, Cross-Cultural Issues

Maria Velazquez, M.D.

Discussant: Andres Pumariega, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.

Room 5 B, Upper Level, San Diego Convention Center

EATING BEHAVIOR IN SCHIZOPHRENIA: BIOLOGICAL AND CLINICAL IMPLICATIONS

Chp.: Michael Y. Hwang

Co-Chp.: Katherine A. Halmi, M.D.

A Obesity and Metabolic Disorders in Schizophrenia

Naveed Iqbal, M.D.

B Eating Disorders in Schizophrenia: Conceptual and Clinical Issues

Michael Y. Hwang, M.D.

C Phenomenological and Clinical Profiles of Eating Behavior in Schizophrenia

Sun Y. Yum, M.D., Michael Y. Hwang, M.D.

D Effect of Atypical Antipsychotics on Obesity and Metabolism in Schizophrenia

Palmiero Monteleone, M.D., Michele Fabrazzo, M.D., Alfonso Tortorella, M.D., Mario Maj, M.D.

Discussant: Katherine A. Halmi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57 2:00 p.m.-5:00 p.m.

Room 7 A, Upper Level, San Diego Convention Center

SIMPLE TECHNOLOGIES TO IMPROVE PSYCHOTHERAPY

Chp.: Mantosh J. Dewan, M.D.

A Web-Based Learning in Psychotherapy: A Demonstration

Priyanthy Wecrasekera, M.D.

B Seeing Is Believing: Web-Cams in Psychotherapy Supervision

John Manring, M.D.

C Evidence for Measuring, Monitoring, and Feeding Back Progress Information to Providers: Technology in the Service of Improving Patient Outcome

Michael J. Lambert, Ph.D.

D Using Technology in Cognitive Therapy

Judith Beck, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.

Room 7 B, Upper Level, San Diego Convention Center

PSYCHIATRIC TRAINING ACROSS THE CONTINENTS: INTERNATIONAL YOUNG PSYCHIATRIST PERSPECTIVES

Chp.: Julian Beezhold, M.B.Ch.B.

Co-Chp.: Allan Tasman, M.D.

A From the Old to the New: Changes to Postgraduate Psychiatric Training in the UK

Amit Malik, M.B.B.S.

B Psychiatric Training in Kenya: An African Perspective

Violet A. Okech, M.Med.

C The Specialist Training in Psychiatry in Bolivia and Latin America

Guillermo C. Rivero Arroyo, Sr., Ph.D.

D Psychiatric Training Program in Japan

Atsuo Nakagawa, M.D., Ryoko Sato, M.D.

E The Interface Between East and West: Psychiatric Training in Turkey

Ozgur Ozturk, M.D.

F A Review of Psychiatric Training in the United States

Abigail L. Donovan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.

Room 8, Upper Level, San Diego Convention Center

AMERICAN PSYCHIATRY VIEWED FROM THE OUTSIDE: A GLOBAL PERSPECTIVE ON THE DSM5 AND PSYCHOPHARMACOLOGY**Chp.:** Nassir Ghaemi, M.D.**Co-Chp.:** Eduardo A. Correa, M.D.**A A The View from South America: A Chilean Perspective**

Eduardo A. Correa, M.D.

B U.S. Influence on the Evolution of European Psychiatry

Athanasios Koukopoulos

C The View From the Middle East

Kemal Sayar, M.D.

D The Rise and Fall of American Psychiatry

Nassir Ghaemi, M.D.

Discussant: P.R. McHugh**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 60** 2:00 p.m.-5:00 p.m.

Room 9, Upper Level, San Diego Convention Center

THE END, MIDDLE, AND BEGINNING OF THE AFFAIR: INFIDELITY IN FILM AND TELEVISION**Chp.:** Robert J. Boland, M.D.**Co-Chp.:** Anton C. Trinidad, M.D.**A Do Married People Have Affairs Because They Can't Help It? Lessons From the History of Marriage**

Anton C. Trinidad, M.D.

B Why We Think People Cheat

Robert J. Boland, M.D.

Discussant: Josepha A. Cheong, M.D., S.D. Haltzman**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 61** 2:00 p.m.-5:00 p.m.

Room 11 A, Upper Level, San Diego Convention Center

CONNECTIONS TO MEDICAL INFORMATION**Chp.:** John Luo, M.D.**Co-Chp.:** Carlyle H. Chan, M.D.**A Medical Information Devices: The Technology to Connect**

John Luo, M.D.

B Connectivity and Interactivity

Britton A. Arey, M.D.

C Information Resources

Carlyle H. Chan, M.D.

D Connections: The Present and the Future

Robert Kennedy, M.D., Britton A. Arey, M.D., Carlyle H. Chan, M.D., John Luo, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 62** 2:00 p.m.-5:00 p.m.

Room 11 B, Upper Level, San Diego Convention Center

PRESCRIBING PATTERNS, PREDICTORS, AND COSTS FOR ANTIDEPRESSANT MEDICATIONS:**Chp.:** Ronald J. Diamond, M.D.**Co-Chp.:** Marion A. Becker, Ph.D.**A Changes in Prescribing When Antidepressants Become Generic**

Ronald J. Diamond, M.D., Michael Mergener, Pharm.D., Theodore M. Collins, Pharm.D.

B Patterns of Pharmacotherapy for MDD

Marion A. Becker, Ph.D.

C Retrospective Analysis of Public Payer Healthcare Costs Associated With Specific Types of Antidepressant Treatment for MDD

Paul Stiles, Ph.D.

D Recent Patterns and Predictors of Antidepressant Medication Regimens Used to Treat MDD

M. Scott Young, Ph.D., Marion A. Becker, Ph.D., Lodi Rohrer, M.P.H.

Discussant: James W. Jefferson, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 63** 2:00 p.m.-5:00 p.m.

Room 26 A/B, Upper Level, San Diego Convention Center

NEUROBIOLOGY OF THE UNCONSCIOUS: IMPLICATIONS FOR PSYCHOTHERAPEUTIC UNDERSTANDING AND TECHNIQUE**Chp.:** Barton J. Blinder, M.D.**A Historical Overview of the Concept Unconscious**

Barton J. Blinder, M.D.

B Mapping the Unconscious in the Brain

George I. Viamontes, M.D.

C The Mirror Neuron System

Marco Iacoboni, M.D.

D Unconscious Enactments in Psychotherapy

Glen O. Gabbard, M.D.

E Metacommunication, Psychotherapy and the Brain

Bernard D. Beitman, M.D., Jessica R. Nittler, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 64** 2:00 p.m.-5:00 p.m.

Room 28 C, Upper Level, San Diego Convention Center

UPDATE ON THE BIOLOGY OF PERSONALITY DISORDERS**Chp.:** Kenneth R. Silk, M.D.**Co-Chp.:** Larry J. Siever, M.D.*(Continued next page)*

- A New Developments in Neurocircuits and Neurotransmitters in the Personality Disorders**
Larry J. Siever, M.D.
 - B Biology and Treatment of Impulsive Aggression in Personality Disorder**
Emil F. Coccaro, M.D.
 - C NMDA Neurotransmission and the Neurobiology of BPD**
Bernadette M. Grosjean, M.D.
 - D Pain Processing in BPD**
Christian Schmahl, Anja Jochims, M.A., Petra Ludaescher, M.A., Martin Bohus, M.D.
 - E 5HT_{2a} Receptor Binding in BPD**
Paul H. Soloff, M.D., Julie C. Price, Ph.D., Carolyn C. Meltzer, M.D., Anthony Fabio, Ph.D., Guido Frank, M.D., Walter H. Kaye, M.D.
 - F A Neurodevelopmental Model of BPD**
Kenneth R. Silk, M.D., Katherine Putnam, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.
Room 29 A/B, Upper Level, San Diego Convention Center

A PICTURE OF THE DEVELOPMENT OF THE ADOLESCENT BRAIN: A STRUCTURAL AND FUNCTIONAL ASSESSMENT

Collaborative Session With the National Institute on Drug Abuse

Chp.: David Shurtleff, Ph.D.,
Co-Chp.: Laurence R. Stanford, Ph.D.

- A Mapping Adolescent Brain Maturation with Structural Magnetic Resonance Imaging**
Elizabeth R. Sowell, Ph.D.
- B The Usefulness of Diffusion Tensor Imaging for the Study of Brain Development in Children**
Michael J. Rivkin, M.D.
- C Magnetic Resonance Spectroscopy Studies of Human Brain Development**
Perry F. Renshaw, M.D., Young Hoon H. Sung, M.D.
- D Risk Taking and the Adolescent Brain: Who Is at Risk?**
B.J. Casey, Ph.D.

Discussant: Linda C. Mayes, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
Room 29 C/D, Upper Level, San Diego Convention Center

AN UPDATE ON CROSS-CULTURAL, ETHNIC, AND ETHNOPSYPHARMACOLOGICAL ASPECTS OF MOOD DISORDERS

Chp.: Shamsah B. Sonawalla, M.D.
Co-Chp.: Rajesh M. Parikh, M.D.

- A Ethnopsychopharmacology**
David C. Henderson, M.D.
 - B Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology**
David Mischoulon, M.D.
 - C Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans in Primary Care**
Albert S. Yeung, Lauren Fisher, Anna M. Agoston, Wan-Chen Weng, M.A., Yantao Ma, M.D., Shamsah B. Sonawalla, M.D., Maurizio Fava, M.D.
 - D Cultural Considerations in the Diagnosis and Treatment of Mood Disorders in the Asian-Indian Population**
Rajesh M. Parikh, M.D.
 - E A Cultural Perspective on the Diagnosis and Treatment of Mood Disorders in Women**
Shamsah B. Sonawalla, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 67 2:00 p.m.-5:00 p.m.
Room 30 A, Upper Level, San Diego Convention Center

ETHICS OF TREATING SUBSYNDROMAL PSYCHIATRIC DISORDERS

Chp.: Ahmed M. Okasha, M.D.

- A Should We Treat Subsyndromal Psychiatric Disorders?**
Ahmed M. Okasha, M.D.
- B Subthreshold Mood States Are Not Subclinical**
Hagop S. Akiskal, M.D.
- C Treating Subsyndromal Schizophrenia: Why the Uproar?**
Thomas H. Mc Glashan, M.D.
- D Defining the Threshold for the Diagnosis of Mental Disorder: Some Current Approaches**
Mario Maj, M.D.

Discussant: Pedro Ruiz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.
Room 30 B, Upper Level, San Diego Convention Center

INNOVATIONS IN THE TREATMENT OF ADOLESCENT SUBSTANCE USE DISORDERS

Collaborative Session With the National Institute on Drug Abuse

Chp.: Marc Galanter, M.D.
Co-Chp.: Yifrah Kaminer, M.D.

- A Fluoxetine in Adolescents With Comorbid Major Depressive Disorder and an Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial**
Jack R. Cornelius, M.D.

B Evidence for Adolescent Participation in Alcoholics Anonymous and Narcotics Anonymous: Further Steps Needed

John F. Kelly, Ph.D.

C Does Smoking Cessation Intervention Influence Adolescent Alcohol and Other Drug Abuse Treatment Outcome?

Mark G. Myers, Ph.D.

D Aftercare for Adolescent Alcohol Use Disorders

Yifrah Kaminer, M.D.

Discussants: Frances R. Levin, M.D., Wilson M. Compton, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.

Room 30 C, Upper Level, San Diego Convention Center

SEXUALITY IN LONG-TERM CARE FACILITY RESIDENTS

Chp.: Helen H. Kyomen, M.D.

A Normal Aging and Sexuality in Later Life

Shunda McGahee, M.D.

B The Impact of Psychiatric Illness on Sexual Function in Elderly Long Term Care Facility Residents

Robert K. Dolgoff, M.D.

C Assessment and Management of Inappropriate Sexual Behavior in the Long Term Care Setting

David D. Myran, M.Ed.

D Sexuality and Rights of Residents in Long-Term Care Facilities

Ken Schwartz, M.D.

Discussant: Helen H. Kyomen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

THE SEXUALLY VIOLENT OFFENDER

Chp.: Jean-Pierre Lindenmayer, M.D.

Co-Chp.: Samuel J. Langer, M.D.

A Civil Commitment of Sex Offenders

Howard V. Zonana, M.D.

B The Civil Facility Experience With a Program for SVPs

Samuel J. Langer

C Risk Assessment and Treatment Issues Related to Paraphilic Sex Offenders

Fabian M. Saleh

D The Role of Treatment Outcome in the SVP Courtroom

Howard E. Barbaree, Ph.D.

E Treatment of Sex Offenders in a Prison Setting

Lawrence A. Siegel, M.D.

Discussant: Ruichard B. Krueger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71

2:00 p.m.-5:00 p.m.

Room 31 A, Upper Level, San Diego Convention Center

PRENATAL NICOTINE EXPOSURE: HOW DOES IT RELATE TO DEVELOPMENTAL VULNERABILITIES?

Collaborative Session With the National Institute on Drug Abuse

Chp.: Nicollete Borek, Ph.D.

Co-Chp.: Allison Chausmer, Ph.D.

A Beyond Diagnosis: Unpacking the Association of Prenatal Smoking and Exposure Across Developmental Periods

Kimberly A. Espy, Ph.D., Bennett L. Leventhal, M.D., Gretchen Biessecker, Ph.D., Kate Pickett, Ph.D., Daniel Pine, M.D.

B Neuroimaging Evidence of Altered Medial Temporal Lobe Function in Adolescent Tobacco Smokers With Prenatal Exposure to Maternal Smoking

Leslie K. Jacobsen, M.D., Theodore A. Slotkin, Ph.D., Michael Westerveld, Ph.D., W. Einar Mencl, Ph.D., Kenneth R. Pugh, Ph.D.

C Gestational Nicotine Alters Brain Nicotinic Cholinergic Receptor Expression in Dopaminergic Regions of Adolescents and Adults

Burt Sharp, M.D., H. Chen, S.L. Parker, J.M. McIntosh, S G. Matta

D Prenatal Nicotine Exposure Induces Sex-Dependent Changes in Dopamine Pathways in Adolescent Brain

Frances Leslie, Ph.D., Ryan Franke, Anita Lakatos, Ph.D., James D. Belluzzi, Ph.D.

Discussant: Bennett L. Leventhal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72

2:00 p.m.-5:00 p.m.

Room 31 B, Upper Level, San Diego Convention Center

THE IOM INFORMS, NAMI STORMS, AND AACP TRANSFORMS: HOW TO MAKE THE GRADE IN RESPONSE TO THE U.S. MENTAL HEALTH'S BAD REPORT CARD

Chp.: David A. Pollack, M.D.

Co-Chp.: Neal H. Adams MD

A Can Community Psychiatry Cross the Quality Chasm? The Institute of Medicine Report on Improving Care for Mental and Substance-Use Conditions

Harold A. Pincus, M.D.

B What Families and Consumers See and Want in Americas Mental Health Service System

Kenneth S. Duckworth, M.D.

C Leadership and Collaboration: Transforming Community Psychiatry

Wesley E. Sowers, M.D.

(Continued next page)

D Getting the Word Out: How to Synthesize, Disseminate, Implement, and Support the IOM's Recommendations

Neal H. Adams, M.D.

Discussants: Pedro Ruiz, M.D., Wilma L. Townsend, M.S.W.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.

Room 32 A, Upper Level, San Diego Convention Center

HIV UPDATE FOR PSYCHIATRIC CARE

Chp.: Marshall Forstein, M.D.

A HIV Medical Update: What Every Psychiatrists Needs to Know

Diane Pennesi

B Evidence-Based Treatments in HIV Psychiatric Care

Stephen Ferrando, M.D.

C HIV as a Lifelong Illness

Karl Goodkin

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.

Room 32 B, Upper Level, San Diego Convention Center

DISSOCIATIVE DISORDERS: MEETING THE CHALLENGE OF THE *DSM-V*

Chp.: Daphne Simeon, M.D.

A Dissociative Disorders: History, Conceptual Issues, Diagnosis, and Research

Richard J. Loewenstein, M.D.

B DID and DID-Like Cases of Dissociative Disorder Not Otherwise Specified

Paul F. Dell, Ph.D.

C Depersonalization Disorder and Dissociative Amnesia

Daphne Simeon, M.D.

D Conversion Disorder, Dissociative Psychosis, and Childhood Dissociative Disorder

Vedat Sar, M.D.

Discussant: Michael B. First, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00p.m.

Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

7:00 p.m. Session

INDUSTRY SUPPORTED SYMPOSIUM 33

7:00 p.m.-10:00 p.m.

Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

FIBROMYALGIA: NEW INSIGHTS INTO THE PATHOPHYSIOLOGY AND TREATMENT

Supported by Pfizer Inc.

Chp.: Lesley M. Arnold, M.D.

A The Pathophysiology of Pain in Fibromyalgia and Related Syndromes

Daniel J. Clauw, M.D.

B The Role of Disordered Sleep in Fibromyalgia

Lesley M. Arnold, M.D.

C New Developments in the Pharmacological Treatment of Fibromyalgia

Leslie J. Crofford, M.D.

D Exercise as a Treatment for Fibromyalgia

Dina Dadabhoy, M.D.

THURSDAY, MAY 24, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 92-94

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 92 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

CONNECTIONS

Co-Directors: Robert S. Kennedy, M.D., John Luo, M.D.
Faculty: Carlyle H. Chan, M.D.

COURSE 93 8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

JUDGING JUDGMENT: PSYCHIATRIST'S GUIDE TO DECISION MAKING

Co-Directors: Ansar M. Haroun, M.D., Paul J. Zak, Ph.D.
Faculty: Martin P. Paulus, M.D.

COURSE 94 8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

DECONSTRUCTING SOCIAL PHOBIA: FOCUS ON SHAME AND NEUROTICISM

Director: Paul B. Bohn, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 4
9:00 a.m.-12 noon
Room 23 A/B, Upper Level, San Diego Convention Center

TRANSFERENCE FOCUSED PSYCHOTHERAPY FOR BORDERLINE PATIENTS

Moderator: Otto F. Kernberg, M.D.
Presenters: Glen O. Gabbard, M.D., John M. Oldham, M.D., Frank E. Yeomens, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

ISSUES 77-94

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Room 24 A, Upper Level, San Diego Convention Center

USING AUDIOVISUAL TECHNOLOGY TO TEACH BEHAVIORAL SCIENCES

Chp.: Jonathan S. Davine, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
Room 24 B, Upper Level, San Diego Convention Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Room 24 C, Upper Level, San Diego Convention Center

INNOVATIVE CHILD PROGRAMS DESIGNED TO INCREASE ACCESS TO CARE IN DIVERSE SETTINGS

Chp.: Radmila Bogdanich, M.A.
Participants: Mary I. Dobbins, M.D., Deborah E. Seale, M.A.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.
Room 25 A, Upper Level, San Diego Convention Center

CONFIDENTIALITY IN OVERSEAS SETTINGS: THE PRIORITIZATION OF THE INDIVIDUAL VERSUS THE INSTITUTION VERSUS THE COMMUNITY

Chp.: Herbert L. Campbell, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.
Room 25 B, Upper Level, San Diego Convention Center

SPIRITUALLY AUGMENTED WELL-BEING COGNITIVE-BEHAVIOR THERAPY

American Psychiatric Association and the World Psychiatric Association

Co-Chps.: Russell F. D'Souza, M.D., Jack S. McIntyre, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Room 25 C, Upper Level, San Diego Convention Center

PSYCHIATRIC ISSUES IN ARGENTINA

Co-Chps.: Rodolfo D. Fahrner, Sr., M.D., Michelle B. Riba, M.D.
Participants: Salvador M. Guinjoan, M.D., Alfredo O. Fragola, Sr., M.D., Alicia B. Vittone, M.D.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.

Room 27 B, Upper Level, San Diego Convention Center

**BUDDHIST TEACHINGS AND TECHNIQUES
APPLIED TO DISASTER RELIEF: A 2 YEAR FOLLOW-
UP ON SRI LANKAN TSUNAMI VICTIMS**

Chp.: Syed S.A. Naqvi, M.D.

Participants: Viet Bui, M.D., Amy R. Dewar, M.D., Norana
Caivano, M.D.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.

Room 28 A, Upper Level, San Diego Convention Center

**MINORITY MENTAL HEALTH POLICY TRAINING:
DEVELOPING PSYCHIATRIC LEADERS FOR
CAREERS ABOUT CULTURAL COMPETENCE AND
DISPARITIES REDUCTION**

Chp.: Francis G. Lu, M.D.

Participants: Joan Y. Recede, M.D., Octavio N. Martinez, Jr.,
M.D., Richard J. Nunes, M.D., Katherine G. Ruiz-Mellott, M.D.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.

Room 28 B, Upper Level, San Diego Convention Center

**RESEARCH ON PROCEDURAL MEMORY:
PRACTICAL APPLICATIONS IN DEMENTIA CARE**

Co-Chps: Sheila M. Loboprabhu, M.D., Theron C. Bowers, Jr., M.D.

Participants: Ellen F. Barr, L.C.S.W., Victor A. Molinari, Ph.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.

Room 28 C, Upper Level, San Diego Convention Center

**VIETNAM VETERANS AND THE IRAQ WAR: IS THE
PAST EVER THE PAST?**

Co-Chps.: Laura C. Kordon, M.D., Eric Glessner, L.C.S.W.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.

Room 30 A, Upper Level, San Diego Convention Center

**A ROLE FOR SELF-AWARENESS, MINDFULNESS,
AND MEDITATION IN PSYCHIATRIC EDUCATION**

Chp.: Robert S. Marin, M.D.

ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.

Room 30 B, Upper Level, San Diego Convention Center

**FRONTIER PSYCHIATRY: WORKING WITH
STREET-INVOLVED YOUTH**

Co-Chps.: Seena S. Grewal, M.D., John H. Langley, M.D.

ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m.

Room 30 C, Upper Level, San Diego Convention Center

**FIBROMYALGIA: CURRENT UNDERSTANDING
AND FUTURE DIRECTIONS**

Co-Chps.: Alan Z.A. Manevitz, M.D., James P. Halper, M.D.

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.

Room 31 A, Upper Level, San Diego Convention Center

PERCEPTION AND COLOR IN AFFECTIVE STATES

Co-Chps.: Lina I. Augius, M.D., Suzanne Silverstein, M.A.

Participant: Nima A. Fahimian, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.

Room 31 B, Upper Level, San Diego Convention Center

**MEDICAL BOARD OF CALIFORNIA MEDICAL
EXPERT WITNESS TRAINING**

Chp.: Matthew F. Carroll, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.

Room 31 C, Upper Level, San Diego Convention Center

**RACIST REALITY: AN ASSESSMENT OF
REPRESENTATIONS OF MINORITIES IN REALITY
TELEVISION PROGRAMMING**

Chp.: Curley L. Bonds II, M.D.

Participants: Austina Cho, M.D., Eve Maremont, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.

Room 32 A, Upper Level, San Diego Convention Center

**THE FOUR A'S OF COLLABORATIVE MENTAL
HEALTH CARE: ACCESSIBLE, ACCOUNTABLE,
APPROPRIATE, AND AFFABLE**

Chp.: John M. Haggarty, M.D.

Participants: Jennifer Lehto, R.N., James Goertzen, M.D.,
Randy B. Goossen, F.R.C.P.C., Tammy E. McKinnon, M.S.W.,
Jatinder Takhar, M.D.

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.

Room 32 B, Upper Level, San Diego Convention Center

**REFRACTORY SCHIZOPHRENIA:
TREATMENT ISSUES**

American Association of Practicing Psychiatrists

Co-Chps: Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.

Participants: Jean-Pierre Lindenmayer, M.D., Naveed Iqbal, M.D.

11:00 a.m. Sessions**ADVANCES IN MEDICINE 4**

11:00 a.m.-12:30 p.m.

Room 2, Upper Level, San Diego Convention Center

CONGESTIVE HEART FAILURE: ADVANCES IN DIAGNOSIS AND MANAGEMENT

Chp.: Julio Licinio, M.D.

Presenter: Alan S. Maisel, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35**SCIENTIFIC AND CLINICAL REPORT SESSION 28**

11:00 a.m.-12:30 p.m.

Room 3, Upper Level, San Diego Convention Center

PHARMACOTHERAPY AND PERSONALITY DISORDERS

Chp.: Kenneth Silk, M.D.

Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.

- 83 Personality Traits and Prophylactic Treatment With Selective Serotonin Reuptake Inhibitors**
Sabrina J. Khan, M.D., Eric D. Peselow, M.D., Barbara Orłowski, Ph.D.

11:30 a.m.

- 84 Olanzapine for the Treatment of BPD: A Flexible-Dose 12-Week Randomized Double-Blind Placebo-Controlled Study**
S. Charles Schulz, M.D., Mary C. Zanarini, Ed.D., Holland C. Detke, Ph.D., Quynh Trzaskoma, M.S., Daniel Lin, Ph.D., Walter Deberdt, M.D., Sara Corya, M.D.

12 noon

- 85 A Dose Comparison of Olanzapine for the Treatment of BPD: A 12-Week Randomized Double-Blind Placebo-Controlled Study**
Mary C. Zanarini, Ed.D., S. Charles Schulz, M.D., Holland C. Detke, Ph.D., Yoko Tanaka, Ph.D., Fangyi Zhao, Ph.D., Walter Deberdt, M.D., Sara Corya, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 29**

11:00 a.m.-12:30 p.m.

Room 4, Upper Level, San Diego Convention Center

LONG-TERM OUTCOMES OF SCHIZOPHRENIA

Chp.: Brian P. Miller, M.D.

Co-Chp.: Austina Cho, M.D.

11:00 a.m.

- 86 Relationship Between Neurocognitive Performance and Instrumental Work Functioning in Schizophrenia and Other Disorders: A 20-Year Prospective Longitudinal Study**
Linda S. Grossman, Ph.D., Martin Harrow, Cherise Rosen, Ph.D., Henry W. Dove, M.D., Robert Faull, B.S.

11:30 a.m.

- 87 A 20-Year Multi-Followup Study of Persecutory Delusions in Schizophrenia**
Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Dennis D. Beedle, M.D., Joseph F. Goldberg, M.D.

12 noon

- 88 Neurocognition, Complex Social Cognition, and Functional Outcome in Schizophrenia**
Joseph Ventura, Ph.D., Michael F. Green, Ph.D., Mark J. Sergi, Ph.D., Kimmy S. Kee, Ph.D., Sarah A. Wilson, M.A., Keith H. Nuechterlein, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 30**

11:00 a.m.-12:30 p.m.

Room 5 A, Upper Level, San Diego Convention Center

NOVEL APPROACHES TO WELLNESS

Chp.: Julio Licinio, M.D.

Co-Chp.: Richard Buccigross, M.D.

11:00 a.m.

- 89 A New Kind of Psychiatry: Information Theory in the 21st Century**
David A. Rothstein, M.D.

11:30 a.m.

- 90 Spirituality and Recovery From Panic Attacks**
Caroline B. Williams, M.D., Eric D. Peselow, M.D., Barbara Orłowski, Ph.D.

12 noon

- 91 Fostering Spiritual Values and Well-Being: The Need in Psychiatry**
Russell F. D'Souza, M.D., Pedro Ruiz, M.D., Jack S. McIntyre, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31

11:00 a.m.-12:30 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

METHODOLOGICAL ISSUES IN PSYCHIATRIC DISORDERS

Chp.: Rajnish Mago, M.D.

Co-Chp.: Donna Mancuso, M.D.

11:00 a.m.

92 Joint Crisis Plans for People With Psychosis: Economic Evaluation of an RCT

Claire Henderson, M.D., Sarah Byford, Ph.D., Chris Flood, M.S.C., Morven Leese, Ph.D., Graham Thornicroft, M.B.B.S., George Szumukler, M.B.B.S.

11:30 a.m.

93 LOCF (Last Observation Carried Forward) and Distortion of Findings in a Psychotropic Drug Clinical Study

Alex A. Cardoni, M.S., Stephen B. Woolley, D.Sc, John W. Goethe, M.D.

12 noon

94 Comparison of Depression and Personality Ratings by a Patient and Informant Regarding the Patient's Psychopathology

Gavi Hollander, D.O., Eric D. Peselow, Barbara Orłowski, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32

11:00 a.m.-12:30 p.m.

Room 9, Upper Level, San Diego Convention Center

TRAUMA, AGGRESSION, AND PSYCHOPATHOLOGY

Chp.: Britta Ostermeyer, M.D.

Co-Chp.: Igor Elman, M.D.

11:00 a.m.

95 Clinical Differences Between Patients With PTSD With and Without Psychotic Symptoms

Brian P. Mika, M.D., Anu Asnaani, Iwona Chelminski, Ph.D., Diane Young, Ph.D., Mark Zimmerman, M.D.

11:30 a.m.

96 A Controlled Comparison Study of a Yoga Breath-Based Program and a Client-Centered Exposure Therapy for PTSD and Depression in Survivors of Tsunami Disaster

Patricia L. Gerbarg, M.D., Richard P. Brown, M.D., Teresa Descilo, M.S.W., A. Vedamurthachar, Ph.D., R. Damodoran, Ph.D., B.N. Gangadhar, M.D.

12 noon

97 Exploratory Factor Analysis of Borderline Personality Disorder Criteria in Hispanic Men and Women With Substance Use Disorders

Daniel F. Becker, M.D., Luiz Miguel Anez, Psy.D., Manuel Paris, Psy.D., Carlos M. Grilo, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33

11:00 a.m.-12:30 p.m.

Room 11 B, Upper Level, San Diego Convention Center

GENDER ISSUES IN PSYCHIATRIC DISORDERS

Chp.: Andres Sciolla, M.D.

Co-Chp.: James Merikangas, M.D.

11:00 a.m.

98 Suicide Among Female Veterans in the General U.S. Population

Bentson Mc Farland, M.D., Mark Kaplan, D.P.H., Nathalie Huguet, Ph.D., Jason Newsom, Ph.D.

11:30 a.m.

99 Diagnostic and Gender Differences in Schizophrenia and Other Psychotic Disorders in First Episode Psychosis

Robert W. Marvin, M.D., Cherise Rosen, Ph.D., James L. Reilly, Ph.D., Hugo A. Solari, M.D., John A. Sweeney, Ph.D.

12 noon

100 Comparison of Longitudinal Course of Illness Between Women and Men: A 25-Year Multi-Followup Study of Schizophrenia, Other Psychotic Disorders, and Nonpsychotic Depression

Cherise Rosen, Ph.D., Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Robert Faull, B.S.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.-12:30 p.m.

Room 24 C, Upper Level, San Diego Convention Center

NEUROSCIENCE AND NEUROPSYCHIATRY IN MOOD DISORDERS

Chp.: Peter Thompson, M.D.

Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

101 Brain-Derived Neurotrophic Factor Levels in Depressed Patients During Antidepressant Treatments

Armando Piccinni, M.D., Mario Catena, M.D., Donatella Marazziti

11:30 a.m.

102 Information Processing in Bipolar Disorder During Remission

Camilo J. Ruggero, Ph.D., Sheri L. Johnson, Ph.D.

12 noon

103 Mitochondrial Function in the Anterior Cingulate and Treatment Response in MDD

Dan V. Iosifescu, M.D., J. Eric Jensen, Ph.D., Andrew A. Nierenberg, M.D., Nicolas R. Bolo, Ph.D., Dana Charles, B.A., Maurizio Fava, M.D., Perry F. Renshaw, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.-12:30 p.m.

Room 25 A, Upper Level, San Diego Convention Center

**ANTIDEPRESSANTS AND MOOD DISORDERS:
OUTCOME STUDIES****Chp.:** Waguih W. IsHak, M.D.**Co-Chp.:** Nitin Gupta, M.D.

11:00 a.m.

**104 Impact of Study Design on the Results of Continuation
Studies of Antidepressants**Mark Zimmerman, M.D., Michael A. Posternak, M.D.,
Camilo J. Ruggero, Ph.D.

11:30 a.m.

**105 The Effectiveness of Venlafaxine and its Metabolite in
Refractory Depressed Patients**Patrick S. Mbaya, Faouzi Alam, M.D., Aung Tint, M.D.,
Edgar Specer, Ph.D.

12 noon

**106 Discontinuation of Antidepressant Prophylaxis: Are
There Predictors**Tara M. Pundiak, M.D., Eric D. Peselow, M.D., Loretta
Mulcare, B.S., Brady G. Case, M.D.**THIS SESSION WILL BE AUDIOTAPED.****WORKSHOPS****ISSUES 95-107****ISSUE WORKSHOP 95** 11:00 a.m.-12:30 p.m.

Room 24 A, Upper Level, San Diego Convention Center

**CAREGIVERS IN BIPOLAR FAMILIES: PATIENTS
AND PARTNERS IN TREATMENT****Co-Chps.:** Igor I. Galynker, M.D., Susan Tross, Ph.D.**Participants:** Nancy C. Maruyama, M.D., Ramin Mojtabai,
M.D., Lucy Lamphere, B.A., Katherine DuHamel, Ph.D.**ISSUE WORKSHOP 96** 11:00 a.m.-12:30 p.m.

Room 25 B, Upper Level, San Diego Convention Center

GENDER BENDERS IN FORENSIC PSYCHIATRY**Chp.:** Susan J. Hatters-Friedman, M.D.**Participants:** Renee M. Sorrentino, M.D., Joy Stankowski,
M.D., Charles Scott, M.D.**ISSUE WORKSHOP 97** 11:00 a.m.-12:30 p.m.

Room 25 C, Upper Level, San Diego Convention Center

**A STIGMA OF MUCH SUBSTANCE: EDUCATIONAL
SKILLS TO ENHANCE TRAINEES ATTITUDES AND
APPROACHES TO SUBSTANCE USE AND
CONCURRENT DISORDERS****Chp.:** Heather Flett, M.D.**ISSUE WORKSHOP 98** 11:00 a.m.-12:30 p.m.

Room 28 A, Upper Level, San Diego Convention Center

**ADAPTING THE ACT MODEL FOR THE NEEDS OF
DIFFERENT COMMUNITIES: A COMPARATIVE
CASE STUDY OF TWO JAPANESE AND CANADIAN
ACT TEAMS****Co-Chps.:** Wendy S. Chow, M.S.W., Melyn Leszcz, M.D.**Participants:** Joel Sadavoy, M.H.S.C., Miyuki Shiida, M.S.W.**ISSUE WORKSHOP 99** 11:00 a.m.-12:30 p.m.

Room 28 B, Upper Level, San Diego Convention Center

**CLINICAL PATHWAYS FOR MOOD AND ANXIETY
DISORDERS****Chp.:** Waguih W. IsHak, M.D.**ISSUE WORKSHOP 100** 11:00 a.m.-12:30 p.m.

Room 30 A, Upper Level, San Diego Convention Center

**FINDING BALANCE; THE APPLICATION OF YOGA
TO MENTAL HEALTH****Co-Chps.:** Syed S.A. Naqvi, M.D., Tara A. Klein, M.D.**Participants:** Monisha Vasa, M.D., Carla Mandili, M.D.**ISSUE WORKSHOP 101** 11:00 a.m.-12:30 p.m.

Room 30 B, Upper Level, San Diego Convention Center

AKATHISIA: AN ELUSIVE PHENOMENON**Co-Chps.:** Naveed Iqbal, M.D., Peter Weiden, M.D.**Participant:** Gabe Goldfeder, M.A.**ISSUE WORKSHOP 102** 11:00 a.m.-12:30 p.m.

Room 30 C, Upper Level, San Diego Convention Center

A MALPRACTICE LAWSUIT PRIMER**Co-Chps.:** Eugene Lowenkopf, M.D., Abe M. Rychik, J.D.**ISSUE WORKSHOP 103** 11:00 a.m.-12:30 p.m.

Room 31 A, Upper Level, San Diego Convention Center

**MULTIDISCIPLINARY TREATMENT OF CHRONIC
PAIN****Chp.:** Vladimir Bokarius, MD, Ph.D.**Participants:** Steven Richeimer, M.D., Ali Nemat, M.D., Lisa
Victor, Ph.D., Yogi Matharu, D.P.T., Mary Kay Wolfe, O.T.D.

ISSUE WORKSHOP 104 11:00 a.m.-12:30 p.m.

Room 31 B, Upper Level, San Diego Convention Center

ADDRESSING THE NEEDS OF COMMUNITY DWELLING OLDER SCHIZOPHRENIC PERSONS

Chp.: Carl I. Cohen, M.D.

Participants: Colin Depp, Ph.D. Ipsit Vahia, M.D., Azziza O. Bankole, M.D., Shilpa P. Diwan, M.D., Pia N. Reyes, M.D., John Kasckow, M.D.

ISSUE WORKSHOP 105 11:00 a.m.-12:30 p.m.

Room 31 C, Upper Level, San Diego Convention Center

FROM LAB TO CLINICAL PRACTICE: BIOLOGY AND TREATMENT OF DEPRESSION AND PTSD

Co-Chps.: Meera Narasimhan, M.D., Marlene A. Wilson, Ph.D.

Participants: Travis O. Bruce, M.D., Lawrence P. Reagan, Ph.D.

ISSUE WORKSHOP 106 11:00 a.m.-12:30 p.m.

Room 32 A, Upper Level, San Diego Convention Center

THE ULTIMATE GOAL: A MODULAR APPROACH TO PSYCHOSIS?

Chp.: Wolfgang Gaebel, M.D.

Participants: Juergen Zielasek, M.D., Franz Müller-Spahn, M.D.

ISSUE WORKSHOP 107 11:00 a.m.-12:30 p.m.

Room 32 B, Upper Level, San Diego Convention Center

CASE STUDIES USING VIDEO PLAYBACK IN COUPLES THERAPY

Chp.: Anita Menfi, R.N.

Participant: Ian E. Alger, M.D.

2:00 p.m Sessions

SYMPOSIA 75-89

SYMPOSIUM 75 2:00 p.m.-5:00 p.m.

Ballroom 6 D, Upper Level, San Diego Convention Center

CULTURE AS A RATIONALIZATION FOR VIOLENCE AGAINST WOMEN

Chp.: Gail E. Robinson, M.D.

A Finding a Firm Base in a Sea of Cultural Relativism
Sarah E. Romans, M.D.

B Culture as a Rationalization for Violence Against Women-Pakistani Perspective
Unaiza Niaz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.

Room 2, Upper Level, San Diego Convention Center

The COMBINE Trial: Treatment of Alcohol Dependence From Bench to Bedside

Chp.: Mark L. Willenbring, M.D.

A Adapting the COMBINE Trial Findings for Clinical Practice: The 2006 NIAAA Clinicians Guide
Mark L. Willenbring, M.D.

B Primary Results From Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study
Raymond F. Anton, M.D.

C Relationship Between Patient Adherence and Treatments Outcomes in the COMBINE Study
Allen Zweben, D.S.W.

D Cost and Cost-Effectiveness of the COMBINE Study
Gary Zarkin, Ph.D.

E Predicting Drinking Outcomes in the COMBINE Study
Dennis M. Donovan, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.

Room 3, Upper Level, San Diego Convention Center

DEPRESSION AS INDICATOR AND FOCUS OF TREATMENT IN PRIMARY CARE CLINICS

Chp.: Rodrigo A. Munoz, M.D.

Co-Chp.: Nancy Bryant-Wallis, D.P.H.

A From Dreaming to Doing: Essential Infrastructure Supports for Successful Mental Health/Primary Care Integration
Nancy Bryant-Wallis, D.P.H.

B Addressing the Behavioral Health Needs of the Medically Underserved: Integrating Mental Health Services Into the Primary Care Setting
Nora Cole, M.Ed.

C Depression Treatment from a Primary Care Physician Perspective
Paul E. Hubble MD

D A Psychiatry Perspective on Mental Health/Primary Care Integration
Claudio O. Cabrejos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.

Room 4, Upper Level, San Diego Convention Center

THE PSYCHOPATHOLOGY OF PERSONALITY: PERSPECTIVES FROM THE COLLABORATIVE LONGITUDINAL PERSONALITY DISORDERS STUDY

Chp.: Andrew F. Skodol, M.D.

Co-Chp.: Donna S. Bender, Ph.D.

A Longitudinal Course and Validity of Schizotypal Personality Disorder
Thomas H. Mc Glashan, M.D.

B Life Events and Relapse in Personality Disorders
M. Tracie Shea, R.Ph., John G. Gunderson, M.D., Shirley Yen, Psy.D., Robert L. Stout, Ph.D.

C Clinical Course and Impact of Avoidant Personality Disorder
Andrew E. Skodol, M.D., Donna S. Bender, Ph.D., Maria E. Pagano, Ph.D.

D A Multidimensional Model of Obsessive-Compulsive Personality Disorder
Anthony Pinto, Ph.D., Emily Ansell, Ph.D., Carlos M. Grilo, Ph.D., M. Tracie Shea, Ph.D.

E New Episodes and New Onsets of Major Depression in Borderline and Other Personality Disorders
John G. Gunderson, M.D.

Discussant: Paul S. Links, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.

Room 5 A, Upper Level, San Diego Convention Center

EXPANDING NEW YORK STATE PRISON PSYCHIATRY

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Henry C. Weinstein, M.Div.

A Prison Psychiatric Care: Access, Parity, and Humane Care
Zebulon C. Taintor, M.D.

B Forensic Mental Health Triage & Admission Services: The Operations of the NYS-OMH Forensic Diagnostic Unit Within a Maximum Security Correctional Environment
Mike Hill, M.S. Ed.

C Therapy, Advocacy, and Staff Burnout
Al Shimkunas, Ph.D.

D Inmates With Serious Mental Illness and Significant Disciplinary Issues
Bruce B. Way, Ph.D.

E The Evolution of New York State's Civil Commitment for Sex Offenders
Bezalel Wurzbarger, M.D.

Discussant: Steven S. Sharfstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.

Room 5 B, Upper Level, San Diego Convention Center

NEURAL CORRELATES OF PSYCHODYNAMIC CONSTRUCTS

Chp.: Harold W. Koenigsberg, M.D.

A Neural Correlates of Psychodynamic Constructs
Georg Northoff, M.D.

B Neural Correlates of Cognitive Reappraisal in BPD
Harold W. Koenigsberg, M.D., Jin Fan, Ph.D., Kevin Ochsner, Ph.D., Scott Pizzarello, Antonia S. New, M.Div., Marianne S. Goodman, M.D., Larry J. Siever, M.D.

C Brain-Behavior Relationship in the Process of Establishing a Trusting Relationship in Individuals With a Diagnosis of BPD
Peter Fonagy, Ph.D., Brooks King-Casas, Ph.D., Carla Sharp, Ph.D., Laura Lomax, Ph.D., Read P. Montague, Jr., Ph.D.

D Neuroimaging of the Role of the Self and Identification in Emotion Regulation
Philippe Fossati, M.D.

Discussant: Larry J. Siever, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.

Room 8, Upper Level, San Diego Convention Center

ADDRESSING PATIENT'S NEEDS: PATIENT CENTERED DIAGNOSIS

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: G. Scott Waterman, M.D.

A Recording Multiple Psychiatric Diagnoses in an Individual Patient: Does It Lead to a More Comprehensive and Targeted Approach to Treatment?
Mario Maj, M.D.

B Biopsychosocial Thinking: Friend or Foe?
G. Scott Waterman, M.D.

C Therapeutic Diagnosing
Roger Peele, M.D.

D Patient Centered Practice Guidelines: The Challenge
Jack S. McIntyre, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.

Room 11 A, Upper Level, San Diego Convention Center

OPTIMUM TREATMENT DURATION IN EARLY PSYCHOSIS

Chp.: Wolfgang Gaebel, M.D.
Co-Chp.: Patrick D. McGorry, M.D.

A Early Intervention in the Initial Prodromal Phase: Results From the German Research Network on Schizophrenia
Joachim Klosterkötter, M.D., Andreas Bechdolf, M.D., Stephan Ruhrmann, M.D.

B Intervention in Ultra-High Risk Patients: The Pace Experience
Patrick D. McGorry, M.D.

C Are Antidepressants an Alternative for the Early Treatment of the Schizophrenia Prodrome?
Barbara A. Cornblatt, Ph.D.

(Continued next page)

THURSDAY

D Duration of Long-Term Treatment in First Episode Schizophrenia: Results From the German Research Network on Schizophrenia
Wolfgang Gaebel, M.D.

E Treatment Strategies in Remitted First Episode Psychosis: The Mesifos Trial
Durk Wiersma, Ph.D., Lex Wunderink, M.D., Fokko Nienhuis, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.

Room 11 B, Upper Level, San Diego Convention Center

MODEL PSYCHIATRY RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY

Chp.: Francis G. Lu, M.D.

A Baylor College of Medicine Educational Programs in Psychiatry and Spirituality
Linda B. Andrews, M.D.

B The George Washington University Curriculum in Psychiatry and Spirituality
James L. Griffith, M.D.

C The University of California, Irvine, Psychiatry and Spirituality Curriculum for Resident Training
Aaron Kheriaty, M.D.

Discussants: Allan M. Josephson, M.D., Christina M. Puchalski, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84 2:00 p.m.-5:00 p.m.

Room 29 A/B, Upper Level, San Diego Convention Center

SUICIDE: PRACTICAL PATIENT SAFETY FOR THE DOCTOR FROM RISK ASSESSMENT TO RISK REDUCTION

Chp.: Yad M. Jabbarpour, M.D.

A Suicide: Practical Patient Safety for the Doc From Risk Assessment to Risk Reduction
Helena C. Kraemer, Ph.D.

B Assessing and Overcoming the Failure Modes to Improve Suicide Risk Assessment and Risk Reduction
Yad M. Jabbarpour, M.D.

C Opportunities and Obstacles to Implementing Treatment Practice Guidelines
Rory P. Houghtalen, M.D.

Discussant: Alfred Herzog, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.

Room 29 C/D, Upper Level, San Diego Convention Center

COMBINED TREATMENT WITH PSYCHOTHERAPY AND MEDICATIONS: RESEARCH AND CLINICAL ISSUES

Chp.: Bret R. Rutherford, M.D.
Co-Chp.: Steven P. Roose, M.D.

A Making the Choice: Medication or Psychotherapy
Ellen Frank, Ph.D.

B Integrating Pharmacotherapy With Psychodynamic Psychotherapy.
Steven P. Roose, M.D.

C Research on Combined Treatment of Mood Disorders
Michael E. Thase, M.D.

D Specific and Nonspecific Treatment Factors in Clinical Trials for Depression
Bret R. Rutherford, M.D.

Discussant: A. John Rush, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.

Room 30 A, Upper Level, San Diego Convention Center

CHILDREN AND WAR: EMOTIONAL AND PSYCHIATRIC CONSEQUENCES OF WAR AND TERROR ON CHILDREN AND ADOLESCENTS

Council for Global Psychiatry

Chp.: Siham Muntasser, M.D.
Co-Chp.: Rodrigo A. Munoz, M.D.

A Overview: The Impact of War and Terror on Middle Eastern Children and Adolescents
Siham Muntasser, M.D.

B Treatment of Children in War
Elie G. Karam, M.D., John Fayyad, M.D., Aimee N. Karam, Ph.D., Caroline C. Tabet, M.A., Zeina Mneimneh, M.P.H., Hani Dimassi, Ph.D., Nadine Melhem, Ph.D.

C Dealing With Children's Anxiety and Fears During Wartime
Alan Apter, M.D.

D War Trauma and Child Mental Health in Iraqi Kurdistan
Abdulbaghi Ahmad, Ph.D.

E Considerations in Developing Therapeutic Services for Children Traumatized by War
Dennis J. Hunt, Ph.D.

Discussant: Anthony T. Ng, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87 2:00 p.m.-5:00 p.m.

Room 30 B, Upper Level, San Diego Convention Center

THE PSYCHOCULTURAL FOUNDATIONS OF CONTEMPORARY TERRORISM**Chp.:** Jerrold M. Post, M.D.**Co-Chp.:** Stevan M. Weine, Ph.D.**A Killing for a Cause: An Integrated Social Science and Social Psychological Approach**

Dipak K. Gupta, Ph.D.

B Understanding the Girls' Madrasas in Pakistan

Farhana Ali, M.A.

C Why we Are Losing the War on Terrorism

George Everly, Ph.D.

D Crimes of Obedience

Jerrold M. Post, M.D.

E Migrant Youth and the Risk for Terrorism

Stevan M. Weine, M.D.

Discussant: David A. Rothstein, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 88** 2:00 p.m.-5:00 p.m.

Room 30 C, Upper Level, San Diego Convention Center

WORK OUTCOME IN SCHIZOPHRENIA: ADVANCES IN PREDICTION AND INTERVENTION**Chp.:** Keith H. Nuechterlein, Ph.D.**Co-Chp.:** Joseph Ventura, Ph.D.**A Functional Capacity and Work Outcomes: Are There any Specific Relationships?**

Philip D. Harvey, Ph.D.

B Improving Work Outcome in Recent-Onset Schizophrenia: Supported Employment and Education, Workplace Skills Training, and Neurocognition

Keith H. Nuechterlein, Ph.D., Kenneth L. Subotnik, Ph.D., Joseph Ventura, Ph.D., Michael J. Gitlin, Denise Gretchen-Doorly, Ph.D., Michael Green, Charles J. Wallace, Ph.D., Deborah R. Becker, M.A., Robert P. Liberman, M.D.

C Work Outcome in Schizophrenia: Advances in Prediction and Intervention

Jean-Pierre Lindenmayer, M.D.

D Neurocognitive Enhancement Therapy and Work Therapy: Productivity Outcomes at 6- and 12- Months

Joanna Fiszdon, Ph.D., Morris D. Bell, Ph.D., Bruce E. Wexler, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 89** 2:00 p.m.-5:00 p.m.

Room 30 D/E, Upper Level, San Diego Convention Center

PASSAGES: PERSPECTIVES OF WOMEN PSYCHIATRISTS NEGOTIATING CAREER TRANSITIONS**Chp.:** Asha S. Mishra, M.D.**Co-Chp.:** Stephanie S. Durruthy, M.D.**A Retirement as a Life Passage**

Leah J. Dickstein, M.D.

B The Juggling Act: Balancing the Scales at Mid-Career

Carol A. Bernstein, M.D.

C Career Transitions for Women in Psychiatry

Joan A. Lang, M.D.

D Pursuing Different Paths in Academic Psychiatry

Laura W. Roberts, M.D.

E To Thine Own Self Be True

Melva I. Green, M.D.

F Passages: Navigating Career Changes Within the Health Care Industry

Kathy M. Vincent, M.D.

G Passages: The Perspective of a Female MIT Navigating Through the Medical School and Residency Years

Navdeep K. Dhaliwal, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 90** 2:00 p.m.-5:00 p.m.

Room 31 A, Upper Level, San Diego Convention Center

STUCK IN THE BLACK BOX: PRESCRIBING ANTIDEPRESSANTS: A PATIENT SAFETY APPROACH**Chp.:** Geetha Jayaram, M.D.**Co-Chp.:** Alfred Herzog, M.D.**A Assessing Suicide Risk in Prescribing Antidepressant Medications**

Geetha Jayaram, M.D.

B From Obstetrics to Pediatrics to Geriatrics: Safe Antidepressant Prescribing Across the Years

Yad M. Jabbarpour, M.D.

C Making It to Morning: A Resident's Perspective

Jason G. Roof, M.D.

D Educating Residents in Patient Safety

Carl B. Greiner, M.D.

E Stuck in the Black Box: Safe Prescribing of Antidepressants Using A Patient-Safety Approach

Alfred Herzog, M.D.

THIS SESSION WILL BE AUDIOTAPED.



American Psychiatric Association
161st Annual Meeting • May 3-8, 2008 • Washington, D.C.

CALL FOR PAPERS

PRESIDENT'S THEME:

Our Voice in Action: Advancing Science, Care, and the Profession

*Carolyn B. Robinowitz, M.D.
President*

*Robert W. Guynn, M.D., Chairperson
Scientific Program Committee*

THE SUBMISSION SCHEDULE

<u>Format</u>	<u>Deadline</u>
Industry-Supported Symposia	August 9, 2007
Courses Scientific & Clinical Reports Symposia Workshops (Issue & Media)	September 6, 2007
Component Workshops	September 20, 2007
New Research Posters	December 6, 2007

Submissions are accepted ONLINE ONLY!

For format descriptions, instructions, guidelines, and to submit your program or poster proposal, consult the 2008 Annual Meeting information available on the APA home page (www.psych.org).

Paper submissions, as well as incomplete submissions, will not be accepted or considered.

If you would like to volunteer to chair a session, please send a letter to the attention of Dr. Guynn, at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

2007 ANNUAL MEETING

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

Addiction Psychiatry
AIDS and HIV-Related Disorders
Alcohol and Drug-Related Disorders
Anxiety Disorders
Attention Spectrum Disorders
Behavior and Cognitive Therapies
Biological Psychiatry and Neuroscience
Brain Imaging
Child and Adolescent Psychiatry and Disorders
Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
Community and Social Psychiatry
Computers
Consultation/Liaison Psychiatry
Couple and Family Therapies
Creativity and the Arts
Cross-Cultural and Minority Issues
Diagnostic Issues
Dissociative Disorders
Eating Disorders
Electronic Medical Records
Emergency Psychiatry
Epidemiology
Ethics and Human Right
Forensic Psychiatry
Gender Issues
Genetics
Geriatric Psychiatry
Group Therapy
Health Services Research
Historical Issues
Individual Psychotherapies
Information Technology
Internet
Lesbian/Gay/Bisexual/Transgender Issues
Managed Care and Health Care Funding
Men's Issues
Mental Retardation (Child/Adolescent/Adult)

Mood Disorders
National Institute on Drug Abuse
Neuropsychiatry
Other Somatic Therapies
Pain Management
Patient Safety
Personal Digital Assistants (PDAs)
Personality Disorders
Pharmacotherapy and Psychotherapy
Political Questions
Premenstrual Dysphoric Disorder
Presidential Theme: "Addressing Patient Needs: Access, Parity, and Humane Care"
Professional and Personal Issues
Psychiatric Administration and Services: Public, Private, and University
Psychiatric Education
Psychiatric Rehabilitation
Psychoanalysis
Psychoimmunology
Psychopharmacology
Religion, Spirituality, and Psychiatry
Research Issues
Resident and Medical Student Issues
Schizophrenia and Other Psychotic Disorders
Sexual and Gender Identity Disorders
Sleep Disorders
Somatoform Disorders
Stigma/Advocacy
Stress
Suicide
Telepsychiatry
Treatment Techniques and Outcome Studies
Violence, Trauma, and Victimization
Virtual Reality
Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. Under each topic listed above, you will find a list of formats (types of sessions) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number that the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

	Page#		Page #
ADDICTION PSYCHIATRY		19 the Relationship Between Functional Outcomes and Treatment of Anxious and Painful Somatic Symptoms in Patients With Generalized Anxiety Disorder	26
COURSES		52 Mood and Anxiety Disorders in Patients With Cancer: A Case Series	49
41 Office-Based Buprenorphine Treatment of Opioid-Dependent Patients	18	99 Clinical Differences Between Patients With PTSD With and Without Psychotic Symptoms	82
51 Street Drugs and Mental Disorder: Overview and Treatment	30		
INDUSTRY SUPPORTED SYMPOSIA		SYMPOSIUM	
9 Still Sleepy After All these Cures: Hypersonmia in Psychiatry	10	47 Depression and Anxiety, Continuous or Categorical? A View From Different Angles	57
29 Cigarette Smoking, Smoking Cessation, and Psychiatric Illness	58		
COMPONENT WORKSHOP		COMPONENT WORKSHOP	
38 The Sacred Herb and Addiction Science: A Study of Nicotine Dependence and Axis I Comorbidities Among American Indians	63	51 New APA Practice Guidelines on Dementia, Panic Disorder, and OCD	69
ISSUE WORKSHOP			
11 Practical Pharmacotherapy for the Treatment of Alcohol Dependence	23	ATTENTION SPECTRUM DISORDERS	
MEDIA WORKSHOP		COURSES	
4 "Thirteen": Parenting and Treating the Addicted Teenager	46	14 ADD in Adults	5
		55 Advanced Assessment and treatment of ADD	41
AIDS AND HIV-RELATED DISORDERS		INDUSTRY SUPPORTED SYMPOSIA	
SCIENTIFIC AND CLINICAL REPORT		1 Clinical Management of ADHD	2
77 How Dangerous is Stigma? Perceived Stigma and HIV Risk among Women With Severe Mental Illness	68	10 Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management	6
COMPONENT WORKSHOPS		18 How Comorbid is ADHD? Results from Epidemiological and Clinical Studies	9
36 HIV and Metabolic Syndrome	50	SCIENTIFIC AND CLINICAL REPORTS	
47 Public Policy, HIV, and Mental Health: Politics, Ideology, or Science	68	21 Is Comorbid Adult ADHD Prevalent in Psychiatric Outpatients?	27
		22 Extended Duration of Action of SPD465, a 16-Hour Mixed Amphetamine Salts Formulation, in the Treatment of Adults With ADHD	27
ALCOHOL AND DRUG-RELATED DISORDERS			
SCIENTIFIC AND CLINICAL REPORT		BEHAVIOR AND COGNITIVE THERAPIES	
6 Paternal Alcoholism Predicts Alcohol Dependence But Not Recovery After 40 Years	25	CASE CONFERENCE	
SYMPOSIA		1 Cognitive Therapy for Chronic Depression	46
9 CRF-Antagonism for Treatment of Alcoholism and Affective Disorders	34	SCIENTIFIC AND CLINICAL REPORT	
76 The COMBINE Trial: Treatment of Alcohol Dependence From Bench to Bedside	84	66 Breakthrough Intimacy: Treating Personality	67
MEDIA WORKSHOP		BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE	
5 "Rock Bottom": Understanding the Methamphetamine Experience and the Struggle for Sobriety	65	COURSES	
ANXIETY DISORDERS		3 The Evaluation, Identification, and Treatment of the Major Dementias	1
ADVANCES IN		9 Neuroanatomy of Emotions: From Brain to Clinical Practice	1
Advances in Treatment of Psychiatric Disorders	38	27 EEG in Clinical Practice: Indications and Limitations	7
COURSE		37 Behavioral Neuroanatomy: An Introduction	18
94 Deconstructing Social phobia: Focus on Shame and Neuroticism	79	42 Advances in Neuropsychiatry	18
		44 Traumatic Brain Injury: Neuropsychiatric Assessment	18
SCIENTIFIC AND CLINICAL REPORTS		SCIENTIFIC AND CLINICAL REPORT	
8 Capsulotomy in Refractory OCD: Long-Term Outcome in 25 Patients	26	66 CES Reduces Aggression in Violent Neuropsychiatric Patients	66
9 Trichotillomania in Youth: A Naturalistic Outcome Study	26	SYMPOSIA	
17 Treatment Outcome of Panic Disorder and Agoraphobia in a Naturalistic Clinical Setting	26	18 Impulsivity: From Neurophenomenology to Treatment Options	36
18 Panic Disorder With Social Anxiety Disorder Comorbidity: Difference of Response to Low Versus High Doses of Clonazepam	26	42 Psilocybin and Psychiatry: Recent Research	56
		63 Neurobiology of the Unconscious: Implications for Psychotherapeutic Understanding and Technique	75

	Page#		Page #
ISSUE WORKSHOP		ISSUE WORKSHOPS	
105 From Lab to Clinical Practice: Biology and Treatment of Depression and PTSD	84	79 Innovative Child Programs Designed to Increase Access to Care In Diverse Settings.	79
		88 Frontier Psychiatry: Working With Street-Involved Youth	80
BRAIN IMAGING		MEDIA WORKSHOP	
COURSES		3 "When the Levees Broke: A Requiem In Four Acts by Spike Lee": The Psychiatric Dimensions of Hurricane Katrina	46
11 Introduction to Transcranial Magnetic Stimulation	2		
28 Vagus Nerve Stimulation	7	CONSULTATION/LIAISON PSYCHIATRY	
SYMPOSIUM		COURSES	
80 Neural Correlates of Psychodynamic Constructs	85	1 Dynamic Psychotherapy for Cancer Patients and their Spouses	1
ISSUE WORKSHOP		40 Families Coping With Medical Illness: A Treatment Approach for Psychiatry	18
90 Perception and Color in Affective States	80	69 Basic Concepts in Palliative Care for Psychiatrists	43
		78 Psychiatric Care of the Hepatitis C Patient	61
CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS		INDUSTRY SUPPORTED SYMPOSIUM	
COURSE		33 Fibromyalgia: New Insights Into the Pathophysiology and Treatment	78
33 ADD in Children and Adolescents	17	SCIENTIFIC AND CLINICAL REPORT	
SCIENTIFIC AND CLINICAL REPORTS		50 Pilot Trial of Modafinil for Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors	49
23 Quality of Care for Children and Adolescents: Access to Psychotherapy	27	SYMPOSIA	
24 Adolescent Depression and Its Relationship to School Dropouts and Accidents on University Campus	27	8 How to Practice Sport Psychiatry: A Demonstration	34
		53 Treatment of Depression in the Medically Ill: An Update From Recent Clinical Trials	73
SYMPOSIUM		COMPONENT WORKSHOPS	
86 Children and War: Emotional and Psychiatric Consequences of War and Terror on Children and Adolescents	86	23 Evaluating Competency in Psychosomatic Medicine	44
COMPONENT WORKSHOPS		41 Lessons Learned From Business Practices: How can Psychiatrists Increase their Practice Opportunities by Implementing Successful Business Strategies	63
28 Learning Disorders Update for Mental Health Professionals	44	ISSUE WORKSHOPS	
30 Passageways: Psychological Routes to Delinquency and Therapeutic Options out of the Juvenile Justice System	50	1 Assessment of Capacity: A Multimedia Approach to Enhancing Clinical Skills In Different Cultural and Legal Settings	23
53 Early Cognitive Development and Psychiatric Presentation: Implications for Etiologic Understanding and Intervention	69	28 Psychiatry In the Primary Care Setting: Making It Work for Patients and Doctors	45
ISSUE WORKSHOP		32 1:1 Observation in A General Hospital Setting: Issues and Recommendations	45
54 The ADHD/Pediatric Bipolar Interface: Sailing Through Troubled Waters?	64	34 Involuntary Hospitalization of Medical Patients Who Lack Decisional Capacity: An Unresolved Issue	45
		39 Planned Care for Depression: A Program for the Management of Depression In Primary Care.	46
COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)		93 The 4 A's of Collaborative Mental Health Care: Accessible, Accountable, Appropriate and Affable.	80
COURSES		COUPLE AND FAMILY THERAPIES	
13 Cognitive Therapy for Severe Mental Disorders	3	COURSE	
25 Introduction to Cognitive-Behavioral Therapy	7	35 Family Skills for the General Psychiatrist	18
31 Cognitive Therapy for Schizophrenia	8	ISSUE WORKSHOPS	
46 Cognitive Therapy on the Fly	18	95 Caregivers In Bipolar Families: Patients and Partners In Treatment	83
71 CBT Bootcamp for Practicing Psychiatrists	52	107 Case Studies Using Video Playback in Couples' Therapy	84
SCIENTIFIC AND CLINICAL REPORT		CREATIVITY AND THE ARTS	
51 Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients	49	SYMPOSIUM	
		60 The End, Middle, and Beginning of the Affair: Infidelity in Film and Television	75
COMMUNITY AND SOCIAL PSYCHIATRY			
COMPONENT WORKSHOPS			
2 Reentry After Prison: Rejoining the Community	21		
42 Social Dimensions of Disasters and Community Recovery	63		
52 Mission Possible: Reclaiming America's State Hospital Beds	69		

	Page#		Page #
ISSUE WORKSHOPS			
5 Psychiatry and the Medical Humanities	22		
78 The Portrayal of Psychiatry In Recent American Film	79		
MEDIA WORKSHOP			
1 Personal Transformation Through an Encounter With Death: Akira Kurosawa's "Ikiru"	23		
CROSS-CULTURAL AND MINORITY ISSUES			
COURSE			
2 <i>DSM-IV-TR</i> Cultural Formulations: Diagnosis and Treatment	1		
SCIENTIFIC AND CLINICAL REPORTS			
4 Dealing With Disaster Mental Health	25		
47 Similar Depressive Symptom Patterns in a Population Based Study of Immigrants From Turkey and Morocco and Dutch Natives	49		
49 Effectiveness of Culturally Sensitive Collaborative Treatment for Treating Chinese Americans With Depression in a Primary Care Setting: A Six-Month Follow-Up Study	49		
SYMPOSIA			
4 Suicide Across the Life Cycle: A Spanish Language Update (Manejo y Tratamiento del Paciente Suicida en las Distintas Etapas de la Vida)	33		
10 The California Mental Health Systems Act: Transforming Systems of Care to Reduce Mental Health Disparities	34		
21 Children of Immigrants in the Changing Mosaic of the U.S.	37		
23 First Break Schizophrenia in Francophone and Anglophone Countries: Treatment and Neuroimaging: Vive la Difference	37		
41 Women and Psychiatry Around the World: The Importance of Gender and Culture	56		
52 Behavioral and Substance Addictions in Minority Populations	73		
55 Improving Cross-Cultural Competency in Psychiatric Practice	74		
59 American Psychiatry Viewed From the Outside: a Global Perspective on the DSMs and Psychopharmacology	75		
66 An Update on Cross-Cultural, Ethnic, and Ethnopsychopharmacological Aspects of Mood Disorders	76		
COMPONENT WORKSHOPS			
14 Uncovering the Secret: Intimate Partner Violence Among Asian-Americans	28		
17 How to Teach Cultural Competence in Geriatric Psychiatry: Addressing Unmet Patient Needs	28		
20 The Impact of Violence in Latino Communities	28		
24 Culture Matters: A Multicultural Perspective on the Immigrant Experience	44		
39 Transcultural Arab Psychiatry With a Focus on Women's Mental Health	63		
43 The Isms: How Racism, Sexism, Classism, and Heterosexism Affect Mental Health Care	63		
45 Racism, Racial Discrimination, and Xenophobia: How Psychiatry can Reduce Their Adverse Effects on Mental Health	63		
46 Leadership Challenges: Breaking Barriers to Success	68		
ISSUE WORKSHOPS			
30 How Does Culture Make a Difference in American Mental Health Care? Culturally-Specific Care in Changing Contexts	45		
31 The Provider's Pursuit of Cultural Competence: A Biopsychosocial Quest	45		
66 Ethnicity, Culture, and Psychopharmacology: Recent Advances	69		
73 From the Mississippi to the Ganges: Understanding the Cross Cultural Context of Treatment From the Perspective of the South Asian Psychiatrist in America	70		
82 Psychiatric Issues in Argentina	79		
84 Minority Mental Health Policy Training: Developing Psychiatric Leaders for Careers About Cultural Competence and Disparities Reduction	80		
92 Racist Reality: An Assessment of Representations of Minorities In Reality Television Programming.	80		
		98 Adapting the ACT Model for the Needs of Different Communities: A Comparative Case Study of Two Japanese and Canadian ACT Teams	83
DIAGNOSTIC ISSUES			
COURSES			
5 A Practical Approach to Risk Assessment			1
32 Web-Based CADI, Behavioral Healthcare, and CMHCs			32
85 EEG Feedback in Psychiatry: Clinical Applications			62
93 Judging Judgment: Psychiatrist's Guide to Decision Making			79
SCIENTIFIC AND CLINICAL REPORTS			
10 OCD in Psychiatric Outpatients: Prevalence, Comorbidity, and Demographic and Clinical Characteristics			26
41 Beyond Bipolar I and II: Evidence for the Validity of the Softer Bipolar Spectrum			48
42 A Proposal for a New Multiaxial Model of Psychiatric Diagnosis: A Continuum Patient Model Based On Evolutionary Developmental Gene-Environment Interaction			48
94 Comparison of Depression and Personality Ratings by a Patient and Informant Regarding the Patient's Psychopathology			82
SYMPOSIA			
19 The "Hidden" Diagnoses in Psychiatry: Implications for Training, Clinical Care, and Outcomes			36
38 Lumping Versus Splitting in Psychiatric Nosology			55
45 DSM-V: Obsessive-Compulsive Related Disorders			56
ISSUE WORKSHOP			
64 The Role of <i>DSM-IV</i> Rating Scales In Psychiatry			64
DISSOCIATIVE DISORDERS			
SYMPOSIUM			
74 Dissociative Disorders: Meeting the Challenges of the <i>DSM-V</i>			78
EATING DISORDERS			
COURSE			
21 Therapeutic Interventions in Eating Disorders: Basic Principles			6
SCIENTIFIC AND CLINICAL REPORT			
7 Self-Loathing and Perfectionism: Linking Eating Disorders and Compulsive Exercise			25
SYMPOSIA			
12 Eating Disorders 2007: Expanding Biological and Clinical Perspectives			35
37 Eating Disorders Update			55
COMPONENT WORKSHOP			
5 Obesity in our Youth: the Weight of Mental Illness			21
ELECTRONIC MEDICAL RECORDS			
ISSUE WORKSHOPS			
29 The National Health Information Network and Psychiatry: How Will Electronic Health Records Impact our Patients and our Practice?			44
41 Privacy and Confidentiality Concerns In Shared Electronic Health Records			50

	Page#		Page #
EPIDEMIOLOGY		GENDER ISSUES	
SCIENTIFIC AND CLINICAL REPORT		SCIENTIFIC AND CLINICAL REPORT	
40 Predicting Unresolved PTSD in Earthquake Survivors: A Comparison Between Decision Analysis and Logistics Regression	48	100 Comparison of Longitudinal Course of Illness Between Women and Men: A 25-Year Multi-Followup Study of Schizophrenia, Other Psychotic Disorders, and Nonpsychotic Depression	82
ETHICS AND HUMAN RIGHT		COMPONENT WORKSHOP	
COURSES		10 Gender and Culture in Academic Leadership: Improving the Current State for Women	22
30 Bioethics 2007	8	ISSUE WORKSHOP	
38 The Evaluation and Treatment of Physicians Involved in Sexual Misconduct and/or Sexual Harassment	18	17 The Dilemma of Women's Professional Garments and Professionalism	28
PRESIDENTIAL SYMPOSIUM		GENETICS	
1 The Role of Ethics in World Psychiatry	32	COURSE	
SYMPOSIA		56 Psychiatric Genomics: Applications for Clinical Practice	41
3 Physical Illness in People With Severe Mental Disorders	33	FOCUS LIVE	
11 Ethics, Human Rights and Dynamic Psychiatry	35	1 Genetics and Psychiatry	31
40 Ethical Issues in Psychiatric Genetics	55	SCIENTIFIC AND CLINICAL REPORTS	
67 Ethics of Treating Subsyndromal Psychiatric Disorders	76	44 CYP Genotyping in Patients Treated for Depression	48
COMPONENT WORKSHOPS		45 An Association Between the EPAC-1 Gene and Neuroticism and Anxiety.	48
16 Multi-National Perspectives of Psychiatric Ethics	28	46 Circadian System Polymorphisms and Bipolar Disorder	49
49 Ethics and Etiquette: Keeping out of Trouble	69	GERIATRIC PSYCHIATRY	
ISSUE WORKSHOP		ADVANCES IN	
65 Complexities of Post Termination Relationships	65	Geriatric Psychiatry	61
FORENSIC PSYCHIATRY		COURSES	
COURSES		6 Updates in Geriatric Psychiatry 2007	1
39 The Detection of Malingered Mental Illness	18	17 Psychiatric Consultation in Long Term Care: Basic	5
54 The Psychiatrist as Expert Witness	30	53 Psychiatric Consultation in Long Term Care: Advanced	30
60 Child Murder by Parents	42	87 Mood and Anxiety Disorders in Later Life	62
77 Psychiatric Roles in Assessing and Treating Adult and Adolescent Sex Offenders	61	INDUSTRY SUPPORTED SYMPOSIUM	
81 Insanity Defense Evaluations	61	2 Expert Dialogue on Alzheimer's Disease: Diagnostic and Referral Issues, Treatment of the Cognitive Deficits, Ameliorating the Behavior Complications, and Comprehensive Multidisciplinary Care	2
91 Correctional Psychiatry: A Skills Building Course	71	PRESIDENTIAL SYMPOSIUM	
SCIENTIFIC AND CLINICAL REPORTS		3 Review of Geriatric Psychiatry: Current Issues	52
14 Understanding Filicide	26	SMALL INTERACTIVE SESSION	
16 Correctional Mental Health Care in a Large, Urban Jail: Challenges and Opportunities	26	4 Issues in Geriatric Psychiatry	21
SYMPOSIUM		SYMPOSIA	
79 Expanding New York State Prison Psychiatry	85	20 Psychiatric Practice in the Nursing Home	37
COMPONENT WORKSHOPS		29 Aggressive Behavioral Disturbances in Geropsychiatric Patients	53
3 Committing Occupational Suicide: A Psychiatric Emergency	21	69 Sexuality in Long-Term Care Facility Residents	77
18 Providing Services to Mentally Ill Inmates Returning to the Community	28	COMPONENT WORKSHOPS	
27 Update on Psychiatry and Law	44	15 Controversies in the Management of Behavioral Disturbance in Dementia	28
ISSUE WORKSHOPS		31 Dementia in Down Syndrome: Risk Factors, Biomarkers, Diagnosis, and Treatment	50
14 Internet Child Pornography and Mental Illness: the Psychiatrist's Role	23	ISSUE WORKSHOPS	
26 Detection of Malingering	29	9 Prevention of Burden and Burnout in Caregivers at Home and Healthcare Workers in Long-Term Care Settings	23
46 Psychiatric Expert Testimony: Increased Scrutiny, Increased Liability	51	85 Research on Procedural Memory: Practical Applications In Dementia Care	80
48 Are Sex Offenders Criminally Responsible?	51	104 Addressing the Needs of Community Dwelling Older Schizophrenic Persons	84
91 Medical Board of California Medical Expert Witness Training	80		93
96 Gender Benders in Forensic Psychiatry	83		
102 A Malpractice Lawsuit Primer	83		

	Page#		Page #
GROUP THERAPY		SYMPOSIA	
COURSE		14 Brief Therapies: An Update for Clinicians	35
66 STEPPS* Treatment Program for BPD	42	22 Update on Supportive Psychotherapy	37
LECTURE		57 Simple Technologies to Improve Psychotherapy	74
13 What Patients and Clinicians Need to Know: The Case for Patient-Focused Research	43	ISSUE WORKSHOP	
HEALTH SERVICES RESEARCH		18 Dynamic Therapy With Self-Destructive Borderlines	29
SCIENTIFIC AND CLINICAL REPORTS		INFORMATION TECHNOLOGY	
33 Reducing the Medical and Financial Burden of Depressive Illness: A Plan for Improving Health Care Services	48	COURSES	
53 Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience	49	61 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Introductory Course	42
54 Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder.	49	75 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Advanced Course	52
55 Stepped Care for Anxiety, Depressive and Stress-Related Disorders. A Randomized Controlled Trial in Primary Care and Mental Health Care	49	79 How to Use Your Pocket PC Personal Digital Assistant in Psychiatric Practice	61
62 Comparison of the Prophylactic Efficacy of Antidepressants-Factors Associated With Better outcome	67	92 Connections	79
92 Joint Crisis Plans for People With Psychosis: Economic Evaluation of an RCT	82	SCIENTIFIC AND CLINICAL REPORT	
106 Discontinuation of antidepressant prophylaxis: Are There Predictors	83	89 A New Kind of Psychiatry: Information Theory in the 21st Century	81
HISTORICAL ISSUES		INTERNET	
SCIENTIFIC AND CLINICAL REPORTS		COMPONENT WORKSHOP	
15 Testimonies of APA and ANA Presidents in the Harry Thaw Brain Storm Defense: Temporary Insanity One Hundred Years Ago in 1907	26	26 The APA Web Site: Potential Future Directions and Opportunity for Dialogue	44
34 Psychiatric Hospital Bed Numbers and Economic Factors in the XIX and XX Centuries: New Analyses	48	LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES	
INDIVIDUAL PSYCHOTHERAPIES		LECTURE	
CASE CONFERENCE		20 Homosexuality and Ignorance	62
4 Transference Focused Psychotherapy for Borderline Patients	79	SCIENTIFIC AND CLINICAL REPORT	
COURSES		79 Obsessions about homosexuality and the Y-BOCS: Lessons From A Anti-Discrimination Case in Sweden	68
15 Using Boundary Crossings as Creative therapy Instead of Slippery Slopes	5	SYMPOSIUM	
18 Interpersonal Psychotherapy	5	30 Formation of Modern Lesbian and Gay Identities: Personal, Historical, and Mental Health Perspectives	53
23 Achieving Psychotherapy Effectiveness: Practical Approaches for Clinicians	7	COMPONENT WORKSHOP	
34 Engaging Resistant and Difficult-to-Treat Patients in Collaborative Treatment	17	9 Mental Health and Men who Have Sex With Men in the African-American Community: Controversies About the Down Low	22
47 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice	19	MEDIA WORKSHOPS	
59 Treating Medical Students and Physicians	41	2 "Brokeback Mountain": The Myth, the Reality, and the Controversy	23
62 A Psychodynamic Approach to Treatment Refractory Mood Disorders	42	6 "We Are Dad": HIV-Positive Children and Lesbian, Gay, Bisexual, or Transgender Parenting	65
64 Advanced Interviewing Techniques	42	MANAGED CARE AND HEALTH CARE FUNDING	
73 How to Practice Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method	52	COURSES	
82 Short-Term Psychodynamic Supportive Psychotherapy for Depression	59	50 Current CPT Coding and Documentation Requirements	30
86 Interpersonal and Social Rhythm therapy for Bipolar Disorder	61	84 Navigating the Minefields of Managed Care Contracting: What Psychiatrists Need to Know	62
89 Motivational therapy for Patients With Concurrent Disorders	71	SYMPOSIUM	
90 Personality Disorders: Combining Relational therapy and Psychopharmacology	71	62 Prescribing Patterns, Predictors, and Costs for Antidepressant Medications:	75

	Page#		Page #
COMPONENT WORKSHOPS			
21 Conceptualizing Access to Psychiatric Care	28	71 Subjective Sleep Quality and Suicidal Ideation Among College Students	67
44 Managed Care, Psychiatrists, and Employers: Collaborating Effectively to Ensure Patient Care	63	73 Prevalence and Symptom Patterns of Depression Among College Students: Findings From A Cross-Cultural Study Across Boston and Bombay	67
48 CPT Coding and Documentation Update	68	74 Disease burden of bipolar and schizoaffective disorder in an Australian cohort.	68
MEN'S ISSUES			
SCIENTIFIC AND CLINICAL REPORT			
28 The Effect of Sildenafil on Erectile Function and Depression: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies in Men With ED and Treated or Untreated Depression	27	76 the Relationship Between Global Functioning, Depression and Painful Somatic Symptoms in Patients With Major Depressive Disorder	68
SMALL INTERACTIVE SESSION			
8 Men's Mental Health	44	102 Information Processing in Bipolar Disorder During Remission	82
MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)			
COMPONENT WORKSHOP			
4 Providing Optimum Care for Patients With Mental Retardation and Developmental Disabilities in the Psychiatric Emergency Room	21	103 Mitochondrial Function in the Anterior Cingulate and Treatment Response In MDD	82
MOOD DISORDERS			
INDUSTRY SUPPORTED SYMPOSIA			
4 Insights from STAR*D: Are Our Patients' Needs Being Met?	3	104 Impact of Study Design on the Results of Continuation Studies of Antidepressants	83
7 The Prevailing Predominant Pole of Bipolar Depression	4	105 The Effectiveness of Venlafaxine and its Metabolite in Refractory Depressed Patients	83
16 Rethinking Bipolar Disorder: Implications of Comorbidities	8	SYMPOSIUM	
17 Caring for our most challenging patients With depression: an interactive forum on novel treatments	9	2 Biological Foundations of Bipolar Disorder: New Insights and Prospects for Treatment	33
21 STAR*D Findings: Implications for Patients, Clinicians, and Other Stakeholders	10	COMPONENT WORKSHOP	
24 Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion: Part 1	17	11 Optimizing Depression Treatment: Clinical Applications of Measurement-Based Care	22
24 Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion: Part 2	41	ISSUE WORKSHOPS	
28 Improving Depression Treatments: Bridging the Gap Between Clinical Trials and Community Practice	40	19 First Episode Mood Disorders: What Have We Learned and Where Do We Go From Here?	29
LECTURE			
5 A Neurotrophic Hypothesis of Depressions and Antidepressant Response	20	35 How to Involve Your Patients With Bipolar Disorder In their Treatment Plan: A Guideline for Clinicians	45
OTHER SOMATIC THERAPIES			
ADVANCES IN MEDICINE			
1 New Integrative Treatments for PTSD and Chronic Fatigue, Disorders of Autonomic Function	24	47 Quality of Life of Patients With Major Depression in A Natural Clinical Setting	51
2 Medicine in Review: A Journal Roundup for 2006	46	61 Detecting Bipolar Disorder	64
SCIENTIFIC AND CLINICAL REPORTS			
31 Metabolic Abnormalities in Patients With Major Depressive Disorder	47	62 Can We Do Better At Preventing the Chronic Course of Mood Disorders?	64
63 How Often Do SSRIs Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate is True Tachyphylaxis During Continuation Treatment is Low	67	72 Day-to-Day Variability In Bipolar Disorder	70
68 Effect of Comorbid Anxiety on Antidepressant Use in a Community Sample of Bipolar Subjects	67	75 From Evidence to Clinical Methods in Integrative Mental Health Care	70
69 Difficult to Treat Patients: the Role of Quetiapine in the Management of Acute Bipolar Depression (With a Focus on Bipolar II Patients)	67	NATIONAL INSTITUTE ON DRUG ABUSE	
70 Indirect Comparison of the Safety and Tolerability of Antipsychotics in Patients With Bipolar Disorder and Schizophrenia	67	FORUM	
		4 Substance Abuse in Your Patients: Beyond What is Taught in Your Residency	30
		LECTURE	
		4 The Road to Equity: Marching Towards a Just Treatment of Mental Illness and Addiction in America	20
		6 Spiritus Contra Spiritum: The Strange Case of Spirituality and Addiction	24
		8 Stress Responsivity, Gene Variants, and the Persistence of Addictions	25
		17 The Neurobiology of Free Will in Addictive Disorders	46
		PRESIDENTIAL SYMPOSIUM	
		4 Current Research Advances: APA/NIMH/NIDA/NIAAA/NAMI Perspectives	53
		SCIENTIFIC AND CLINICAL REPORT	
		5 Association of Cannabis Use With Prodromal Features of Psychosis and Behavioral Problems in Adolescents	25
		SYMPOSIUM	
		5 Insights on Obesity and Drug Addiction From Brain Imaging	33
		15 What Is the Directionality of the Onset of Comorbid Substance Use and Other Psychiatric Disorders?	35
		16 Categories and Dimensions in Clinical and Research Contexts of Diagnostic Classification for DSM-V	36
		39 Choosing the Right Treatment for Substance Abuse	55
			95

	Page#		Page #
54 Drug Abuse Treatment Within the Criminal Justice System: Addressing Our Nation's Public Health Needs	73	SCIENTIFIC AND CLINICAL REPORTS	
65 A Picture of the Development of the Adolescent Brain: A Structural and Functional Assessment	76	75 Days Missed from Work in Patients With Major Depressive Disorder With or Without a Personality Disorder.	68
68 Innovations in the Treatment of Adolescent Substance Use Disorders	76	80 The 10-Year Course of Physically Self-destructive Acts of Patients With BPD	68
71 Prenatal Nicotine Exposure: How Does It Relate to Developmental Vulnerabilities?	77	83 Personality Traits and Prophylactic Treatment With Selective Serotonin Reuptake Inhibitors	81
COMPONENT WORKSHOP		84 Olanzapine for the Treatment of BPD: A Flexible-Dose 12-Week Randomized Double-Blind Placebo-Controlled Study	81
50 Managing Opiate Detoxification With Buprenorphine/Naloxone	69	85 A Dose Comparison of Olanzapine for the Treatment of BPD: A 12-Week Randomized Double-Blind Placebo-Controlled Study	81
ISSUE WORKSHOPS		97 Exploratory Factor Analysis of BPD Criteria in Hispanic Men and Women With Substance Use Disorders	82
6 Grantwriting Workshop: Research Funding Opportunities From the National Institute on Drug Abuse	22	SYMPOSIA	
7 Gene-Environment-Development Interactions: Implications for Psychiatric and Substance Abuse Disorders	23	6 Treatments for Maladaptive Personality Traits With Some Empirical Support	33
42 Methamphetamine Abuse and Addiction: Prevalence and Treatment.	50	28 New Perspectives in Psychodynamic Treatments for Borderline Personality Disorder	53
56 Neuroimaging Research: Implications for the Treatment of Substance Abuse	64	64 Update on the Biology of Personality Disorders	75
68 Promising Medications for the Treatment of Cocaine Addiction	69	78 The Psychopathology of Personality: Perspectives From the Collaborative Longitudinal Personality Disorders Study (CLPS)	84
76 Gay Men and Crystal Methamphetamine: A Review	70	PHARMACOTHERAPY AND PSYCHOTHERAPY	
NEUROPSYCHIATRY		SYMPOSIUM	
ADVANCES IN		85 Combined Treatment With Psychotherapy and Medications: Research and Clinical Issues	86
Neuropsychiatry and Clinical Neurosciences	58	ISSUE WORKSHOP	
INDUSTRY SUPPORTED SYMPOSIA		16 Achieving Medication Adherence by Understanding Recovery	23
12 Dark Horizons: Depression and Cognitive Impairment	6	POLITICAL QUESTIONS	
23 How do Atypicals and Antipsychotics Work? From Receptors to Reality: Part 1	17	41	
23 How do Atypicals and Antipsychotics Work? From Receptors to Reality: Part 2	41	COURSE	
26 Navigating the Complex Maze of Bipolar Disorder	40	43 Personality and Political Behavior	18
27 When Endocrinology and Psychiatry Collide: What the Clinician Needs to Know About Antipsychotic-Induced Endocrine Disturbances	40	PREMENSTRUAL DYSPHORIC DISORDER	
SYMPOSIUM		SCIENTIFIC AND CLINICAL REPORTS	
7 Neuroscience and Phenomenology of Schizophrenia	34	48 Prevalence and Correlates of PMDD Among Arab Primary Care Patients in the United Arab Emirates	49
PAIN MANAGEMENT		PRESIDENTIAL THEME: "ADDRESSING PATIENT NEEDS: ACCESS, PARITY, AND HUMANE CARE"	
ISSUE WORKSHOP		LECTURE	
103 Multidisciplinary Treatment of Chronic Pain	83	16 The Future of Psychiatry: International Perspectives	46
PATIENT SAFETY		PRESIDENTIAL SYMPOSIA	
SCIENTIFIC AND CLINICAL REPORTS		5 Health Inequalities for Persons With Mental Problems and Intellectual Disabilities	72
29 Metabolic Abnormalities in Psychiatric Inpatients	47	7 Globalization and Mental Health: Role of Spanish-Speaking Psychiatry	73
60 Decreasing the Use of Restraint and Seclusion Among Psychiatric Inpatients	66	SCIENTIFIC AND CLINICAL REPORTS	
SYMPOSIUM		2 The Discourse of Health Care Economics	25
84 Suicide: Practical Patient Safety for the Doctor From Risk Assessment to Risk Reduction	86	32 Recurrent Psychiatric Hospitalization	48
PERSONALITY DISORDERS		36 The ADHES Project in Israel: New Insights in Adherence in Schizophrenia	48
COURSE			
83 Psychotherapy for Borderline Personality			

	Page#		Page #
SYMPOSIA			
36 Humane Aspects of Private Practice	55	SYMPOSIUM	
72 The IOM Informs, NAMI Storms, and AACP Transforms: How to Make the Grade in Response to the U.S. Mental Health's Bad Report Card	77	46 Leadership Discourse: Agents of Change in Mental Health	57
77 Depression as Indicator and Focus of Treatment in Primary Care Clinics	84	COMPONENT WORKSHOPS	
81 Addressing Patient's Needs: Patient Centered Diagnosis	85	8 Mental Health Transformation: Is It for Real?	22
COMPONENT WORKSHOP		33 Should the Community Replace the Asylum in the 21st Century?	50
35 Focusing on Asia: A Review of Disasters, Intervention and Prevention Programs	50	37 Career Advancement In Administrative Psychiatry for Early Career Psychiatrists	63
ISSUE WORKSHOPS			
44 Psychiatry In the Americas: Update From the World Psychiatric Association	51	PSYCHIATRIC EDUCATION	
80 Confidentiality in Overseas Settings: The Prioritization of the Individual Versus the Institution Versus the Community	79	ADVANCES IN	
PROFESSIONAL AND PERSONAL ISSUES		Treatments of Psychiatric Disorders	38
PRESIDENTIAL SYMPOSIUM		COURSES	
2 Women Leaders in the APA and Beyond	32	7 the Conceptual Basis of Psychiatry	1
SYMPOSIA		16 How to Give a More Effective Lecture: Punch, Passion, and Polish	5
17 The Disruptive Physician: Rehabilitate or Retaliate?	36	20 Seeing the Forest and the Trees: A Biopsychosocial Approach to the Oral Board Examination	6
34 Uneasy Partners: The Pharmaceutical Industry and the Psychiatric Profession	54	36 Teaching Psychiatry? Let Hollywood Help!	18
43 How to Launch a Successful Private Practice: Part 3	56	63 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation	42
89 Passages: Perspectives of Women Psychiatrists Negotiating Career Transitions	87	72 Improving Your Presentation Skills: A Coaching Approach	52
COMPONENT WORKSHOPS		80 Reel Psychiatry	61
12 Reaching Out: Approaches to Suicide Amongst the Physician Population	22	LECTURE	
22 Pearls and Pitfalls in Negotiating Your First Job	28	9 The American Board of Psychiatry and Neurology: Impact on Psychiatric Education: Past, Present, and Future	31
34 Novel Careers in Psychiatry: Women who Have Made Their own Way	50	SCIENTIFIC AND CLINICAL REPORT	
54 Mentoring of Women in Academic Psychiatry	69	72 Prevalence and Attitudes Concerning ADHD Diagnosis and Use of Stimulant Medications in Medical Students	67
ISSUE WORKSHOPS			
3 Risk Management Issues in Psychiatric Practice	22	SYMPOSIA	
4 Children of Psychiatrists	22	24 Challenges and New Developments in the Psychiatric Education of Medical Students	38
21 American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification In Psychiatry and Its Subspecialties	29	25 Innovative Ways in Psychotherapy Supervision: The Short Term Dynamic Therapy Experience	38
36 Maintenance of Certification for Diplomates of the American Board of Psychiatry and Neurology	45	58 Psychiatric Training Across the Continents: International Young Psychiatrist Perspectives	74
37 How to Launch a Successful Private Practice: Part 1	45	COMPONENT WORKSHOPS	
43 How to Launch a Successful Private Practice: Part 2	50	1 A Model Curriculum for Teaching the Working Alliance as a Core Process Across Psychotherapies	21
51 Biopsychosocial and Spiritual Aspects of Treating our Physician Colleagues	63	6 How to Become a More Creative Teacher: Winning Strategies for Residents and Faculty	21
69 Psychiatrists Who Have Been In Treatment. An Interactive Discussion	69	ISSUE WORKSHOPS	
PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY			
COURSES			
8 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management	1	2 Headspace Theatre: An Innovative Method for Experiential Learning of Psychiatric Symptomatology Using Modified Role-Playing and Improvisational Theatre Techniques Association for Academic Psychiatry	22
24 Basic Concepts in Administrative Psychiatry II	7	6 Lessons From Teaching Interviewing to International Residents: Integrating Cultural Competency From the Start of Training	22
65 Personnel Management for Clinician-Administrators	42	20 Teaching Cognitive Behavior Therapy to Child and Adult Residents	29
PRESIDENTIAL SYMPOSIUM			
20 Current European perspectives on the concept of schizophrenia	72	57 Project Match: A Resident Curriculum of Mentorship, Advocacy, Teaching, Career Issues, and Health	64
		58 The Resident Experiences a Patient Suicide: Strategies That can Help	64
		63 Safety Training for Medical Students During Their Psychiatry Clerkship	64
		70 Electrifying Discourses: Presentation and Communication Skills for Psychiatrists and Trainees	70
		77 Using Audiovisual Technology to Teach Behavioral Sciences	79
		87 A Role for Self-Awareness, Mindfulness, and Meditation in Psychiatric Education	80
		97 A Stigma of Much Substance: Educational Skills to Enhance Trainees Attitudes and Approaches to Substance Use and Concurrent Disorders	83
			97

MEDIA WORKSHOP

- 7 Psychiatric Residents' Perspective of Couples and Family Therapy Training 65

PSYCHIATRIC REHABILITATION

COURSE

- 19 Improving Clinical Outcomes: A Practical Guide to Evidence-Based Employment and Recovery Practices 5

SMALL INTERACTIVE SESSION

- 5 American Psychoanalysis Today 27

SYMPOSIUM

- 50 Consumer Provider Training: Incorporating Individuals in Recovery Into the Behavioral Workforce 40

ISSUE WORKSHOP

- 29 The Utility of Computer-Assisted Psychoeducation for Residential Treatment of Veterans With PTSD 45

PSYCHOANALYSIS

SYMPOSIUM

- 32 Mirror Neurons, Empathy, Intuition, and Interpretation: Understanding the Minds of Others 58

ISSUE WORKSHOPS

- 10 Going to the Heart of the Matter in Patient Interviews: A Further Exploration 23

PSYCHOPHARMACOLOGY

COURSES

- 70 Drug Therapy and Schizophrenia 51

INDUSTRY SUPPORTED SYMPOSIUM

- 31 Monamine Oxidase Inhibitors Today: A 21st Century View on the Treatment of Depression 59

LECTURE

- 19 The Three Stages of Schizophrenia: Can Early Detection and Intervention Change Illness Course and Prevent Disability? 52

SCIENTIFIC AND CLINICAL REPORTS

- 3 Medicare Part D Prescription Drug Benefits: Impact on Medication Access and Continuity Among Dual Eligible Patients With Psychiatric Conditions 25
- 11 Second-Generation Antipsychotics and Diabetes Mellitus: Risk, Number Needed to Harm, and Clinical Impact 26
- 30 Neuroleptic Malignant Syndrome Induced by Low Dose Aripiprazole in First Episode Psychosis 47
- 64 Discontinuation of SSRI's after 5 years stability 67
- 93 LOCF and Distortion of Findings in a Psychotropic Drug Clinical Study 82

SMALL INTERACTIVE SESSIONS

- 6 Treatment of Dementia with Behavioral Disturbance: If Not an Antipsychotic, Then What? 27
- 12 New Treatment Developments For Autism and Impulse Control Disorders 62

ISSUE WORKSHOPS

- 33 Recognition and Management of Neuroleptic Malignant Syndrome 45
- 38 Interpreting and Disseminating Findings From An Evidence-based Drug Review: Antiepileptic Drugs for Mood Disorders 45

RELIGION, SPIRITUALITY, AND PSYCHIATRY

COURSES

- 22 Kundalini Yoga Meditation Techniques for Mental Health 7
- 49 Spirituality and Worldview in Clinical Practice 30
- 68 Spirituality in Psychiatry 43
- 88 The Way of Yoga and Herbs in Treatment of Stress, Depression, Aggression, and Mass Trauma 71

SCIENTIFIC AND CLINICAL REPORTS

- 90 Spirituality and Recovery From Panic Attacks 81
- 91 Fostering Spiritual Values and Well-being : the need in psychiatry 81

SYMPOSIUM

- 83 Model Psychiatry Residency Programs on Religion and Spirituality 86

COMPONENT WORKSHOP

- 32 Spiritus Contra Spiritum: The Strange Case of Spirituality and Addiction: Discussion of the 2007 Oskar Pfister Award Lecture 50

ISSUE WORKSHOPS

- 74 Religious and Spiritual Assessment In Clinical Practice 70
- 81 Spiritually Augmented Well-Being Cognitive-Behavior Therapy 79
- 83 Buddhist Teachings and Techniques Applied to Disaster Relief; A 2 Year Follow-up On Sri Lankan Tsunami Victims 80
- 100 Finding Balance; the Application of Yoga to Mental Health 83

RESEARCH ISSUES

COURSES

- 29 Clinician Administered Rating Scales for Mood and Anxiety Disorders 7
- 58 Research on a Shoestring Budget 41

SCIENTIFIC AND CLINICAL REPORTS

- 43 Improving the Understanding of Causality in Psychiatric Research 48
- 67 A link between oxytocin and anxiety of romantic attachment 67
- 101 Brain-Derived Neurotrophic Factor Levels in Depressed Patients during Antidepressant Treatments 82

SYMPOSIUM

- 48 From Clinical Trials to Real World Outcomes 38

RESIDENT AND MEDICAL STUDENT ISSUES

SMALL INTERACTIVE SESSION

- 9 Why Leadership Skills Benefit Residents [Residents Only] 44

COMPONENT WORKSHOP

- 25 Sweet Child of Mine: Pregnancy and Parental Leave During Residency 44

ISSUE WORKSHOPS

- 24 Women Residents' Needs During Psychiatric Training 29
- 53 Developing Research Training Opportunities Within a Psychiatric Residency Training Program: Goals, Motivations, Barriers, and Solutions 64
- 55 Oral Boards Boot Camp: 2007 64
- 60 Research Training for all Psychiatric Residents: A Problematic Endeavor 64

	Page#		Page #
SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS		SEXUAL AND GENDER DISORDERS	
COURSES		COURSE	
52 Assessing Positive and Negative Symptoms With the Positive and Negative Syndrome Scale	30	48 Love, Desire, Intimacy, and Infidelity	19
INDUSTRY SUPPORTED SYMPOSIA		SLEEP DISORDERS	
6 Clinical Skills to Clinical Scales: Practical Tools in the Management of Patients with Schizophrenia	4	COURSES	
8 The Ongoing Debate Surrounding Atypicals: Are The Benefits Worth the Risks?	5	12 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders	2
11 Long-term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models	6	26 Sleep Medicine Review and Update for Psychiatrists	7
13 Planning for Success in Schizophrenia Management	8	INDUSTRY SUPPORTED SYMPOSIUM	
20 Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?	20	3 Recognition and Management of Restless Legs Syndrome in Psychiatric Practice	2
25 Improving Outcomes in Schizophrenia: Prodrome to Remission	40	5 Insomnia: Primary Diagnosis or Secondary Symptoms?	3
32 Understanding the Complexity of Bipolar Mixed Episodes	59	9 Still Sleepy After All these Cures: Hypersomnia In Psychiatry	5
LECTURES		14 Making Every Sheep Count: Evidence-Based Approaches to Treating Insomnia	8
14 Glutamate, the Prefrontal Cortex, and Schizophrenia: Capturing the Angel in "Angel Dust"	43	SCIENTIFIC AND CLINICAL REPORTS	
22 A Paradigm Shift for Schizophrenia Discovery	66	20 Circadian Rhythm Disturbances in ADHD	27
23 Psychosis on the Streets: An Ethnography of Chicago's Netherworld	71	27 Modafinil Improves Behavioral Alertness in Patients With Residual Excessive Sleepiness Following Nasal Continuous Positive Airway Pressure (nCPAP)-Treated Obstructive Sleep Apnea	27
SCIENTIFIC AND CLINICAL REPORTS		ISSUE WORKSHOP	
12 Metabolic Risks of Psychosis in Sweden	26	22 Assessing Capacity to Drive: A Practical Approach to the Psychiatrist's Role and Responsibilities	29
13 Effect of Body Weight and Metabolic Complications on Health Related Quality of Life in Swedish Outpatients With Schizophrenia.	26	SOMATOFORM DISORDERS	
25 Insulin Resistance in Adolescent Subjects at Risk for Psychosis	27	SYMPOSIUM	
35 Brain Morphology in Schizophrenia Within the Northern Finland 1966 Birth Cohort	48	26 Alexithymia and Emotional Dysregulation: From Theory to Clinical Practice	38
56 Number Needed to Treat and Number Needed to Harm: Making Sense of CATIE	66	ISSUE WORKSHOP	
58 Zolpidem in Treatment Resistant Catatonia: Two Case Reports and Literature Review	66	89 Fibromyalgia: Current Understanding and Future Directions	80
86 Relationship Between Neurocognitive Performance and Instrumental Work Functioning In Schizophrenia and Other Disorders: A 20-Year Prospective Longitudinal Study	81	STIGMA/ADVOCACY	
87 A 20-Year Multi-Followup Study of Persecutory Delusions in Schizophrenia	81	LECTURES	
88 Neurocognition, Complex Social Cognition, and Functional Outcome in Schizophrenia	81	11 The Healing Power of Electroconvulsive Therapy	32
99 Diagnostic and Gender Differences in Schizophrenia and Other Psychotic Disorders in First Episode Psychosis	82	15 Thailand's Recent Experience: Community Mental Health and De-Stigmatization	43
SYMPOSIA		SCIENTIFIC AND CLINICAL REPORT	
1 Schizophrenia With Comorbid Conditions: Clinical Issues	32	78 Comparison of Public's Stigma Attitude Between Mental Illness and Physical Handicap	68
13 Deconstructing Psychosis: Research planning for DSM-V	35	SYMPOSIUM	
31 Research Update on Adolescents With Schizophrenia: Implications for Prodromal Research	54	49 Inventory of Stigmatizing Experiences	57
51 When Usual Treatments Fail: Augmentation Strategies for Refractory Schizophrenia	58	COMPONENT WORKSHOP	
56 Eating Behavior in Schizophrenia: Biological and Clinical Implications	74	13 Advocacy Training for Early Career Psychiatrists With a Focus on Parity Legislation	28
82 Optimum Treatment Duration in Early Psychosis	86	STRESS	
88 Work Outcome in Schizophrenia: Advances in Prediction and Intervention	87	SYMPOSIUM	
ISSUE WORKSHOPS		27 Bullying in the Workplace: Associated Health Problems	53
13 Metabolic Screening of Patients On Antipsychotic Medications: Implementation of A Quality Improvement Program In An Urban Training Clinic	23	ISSUE WORKSHOP	
67 Cognitive Behaviour therapy for Psychosis In Practice: Basic Techniques for Psychiatrists	69	25 The Earliest Environment: Prenatal Stress, Anxiety, and Depression and Child Outcome	29
94 Refractory Schizophrenia: Treatment Issues	80		
101 Akathisia: An Elusive Phenomenon	83		
106 The Ultimate Goal: A Modular Approach to Psychosis?	84		

	Page#		Page #
SUICIDE		VIOLENCE, TRAUMA, AND VICTIMIZATION	
ADVANCES IN		COURSES	
Assessment and Management of Suicide	42	4 Psychiatric Interventions in Disaster and Public Health Emergencies: Theory to Practice	1
SCIENTIFIC AND CLINICAL REPORTS		57 Disaster Psychiatry: Terrorism, Trauma, and Things to Do	41
26 Severe Headaches and the Risk of Subsequent Suicidal Thoughts or Behaviors	27	67 The Assessment and Treatment of Child Sexual Abusers	42
81 Indicators of Treatment Refractory Illness and Risk of Suicide	68	74 Risk Assessment for Violence	52
82 Personality Traits as Prospective Predictors of Suicidal Attempts: Negative Affectivity/Temperament and Disinhibition in a Personality Disorder Sample	68	FORUM	
98 Suicide Among Female Veterans in the General U.S. Population	82	3 On the Frontline in America: Treating Violent Patients and the Ethics of Providing Care	30
COMPONENT WORKSHOPS		SCIENTIFIC AND CLINICAL REPORTS	
40 Suicide Icon: The Golden Gate Bridge	63	38 Beyond the Clash of Civilizations	48
ISSUE WORKSHOPS		39 Phases of Trauma Recovery	48
49 Impact of Patient Suicide on Psychiatry Residents: A Workshop Discussion	51	59 Variables Affecting Violence That Required Physical Restraint Among Psychiatric Inpatients During the First Week of Hospitalization.	66
52 Responding to the Impact of Suicide on Clinicians	64	96 A Controlled Comparison Study of a Yoga Breath-Based Program and a Client-Centered Exposure Therapy for PTSD and Depression in Survivors of Tsunami Disaster	82
71 Air Force Suicide Prevention Program: A Community and Organizational Approach to Prevention	70	SYMPOSIUM	
TELEPSYCHIATRY		35 Stalking Offenders and Victims	54
COMPONENT WORKSHOP		70 The Sexually Violent Offender	77
7 Beyond Powerpoint: How Technology can Improve Mental Health Training	21	87 The Psychocultural Foundations of Contemporary Terrorism	87
ISSUE WORKSHOPS		ISSUE WORKSHOPS	
15 Challenging the Status Quo: Centralized Assessments In Psychiatric Clinical Trials	23	12 the Trauma of War: Understanding Interventions In A Developmental Context.	23
23 Implementing A Telepsychiatry Program In the Kern County Mental Health System In Rural California	29	27 Music As A Means of Survival: the Significance of Music In Surviving the Holocaust	29
59 Telepsychiatry in Action: Implementing and Sustaining a Successful Telepsychiatry Program	64	45 Assessing Violence Risk Among Persons With Mental Illnesses	51
TREATMENT TECHNIQUES AND OUTCOME STUDIES		50 Physical Trauma as a Result of War or Natural Disaster: Psychiatric Interventions	51
ADVANCES IN		86 Vietnam Veterans and the Iraq War: Is the Past Ever the Past?	80
Treatments of Psychiatric Disorders	38	WOMEN'S HEALTH ISSUES	
ADVANCES IN MEDICINE		COURSES	
3 Advances in the Cause, Treatment, and Psychology of Hypertension	65	10 Management of Psychiatric Disorders in Pregnant and Postpartum Women	2
SCIENTIFIC AND CLINICAL REPORT		76 Multidisciplinary Treatment of Low Sexual Desire in Women	60
57 Switching From Long-Acting Typical Antipsychotic Drugs to the Second Generation Antipsychotics: Olanzapine and Risperidone in the Treatment of Patients With Chronic Schizophrenia	66	SCIENTIFIC AND CLINICAL REPORTS	
ISSUE WORKSHOPS		37 Schizophrenia in the Offspring of Antenatally Depressed mothers and Familial Risk- Follow-Up of the Northern Finland 1966 Birth Cohort	48
40 Second Opinion Consultation on Ongoing Psychotherapy Treatments	50	65 An 8-Week Randomized, Double-blind, Placebo-controlled Trial of PDE5I Sildenafil Treatment of SRI-Antidepressant-Associated Sexual Dysfunction in Women With Major Depression Disorder in Remission: Identifying a Hormone Endophenotype Associated With Treatment	67
99 Clinical Pathways for Mood and Anxiety Disorders	83	SYMPOSIUM	
COMPONENT WORKSHOPS		33 PTSD, Borderline Personality Disorder and Motherhood: Early Relations, Recognition and Intervention	54
19 Boot Camp for Burnout	28	75 Culture as a Rationalization for Violence Against Women	84

PARTICIPANT INDEX

APA 160TH ANNUAL MEETING

A

Abadie, Pascale.....	37
Abdulla, Amina.....	26
Abel, Gene G.....	18, 42
Abrams, Karen M.....	54
Abramson, Beth L.....	73
Abramson, Ronald.....	55
Adams, Neal H.....	77, 78
Addario, Dominick.....	26
Adler, Lawrence W.....	48
Adler, Lenard A.....	27
Agoston, Anna M.....	76
Aguilar-Gaxiola, Sergio.....	34
Ahmad, Abdulbaghi.....	87
Ahmed, Iqbal.....	21
Aizenberg, Dov.....	48
Ajinder, Dhatt.....	48
Akiskal, Hagop S.....	55, 76
Akiyama, Tsuyoshi.....	50
Akselson, Soren.....	26
Alam, Faouzi.....	83
Alarcon, Renato D.....	41, 73
Alger, Ian E.....	65, 84
Ali, Farhana.....	87
Alici-Evcimen, Yesne.....	47
Allen, Andrea.....	57
Allen, Michael H.....	4
Alpert, Jonathan E.....	38, 40, 67
Al-Sawaf, Mona H.....	63
Altchuler, Steven I.....	42, 52
Anagnostou, Evdokia.....	57
Anderson, Allan A.....	8, 30
Andrade, Naleen N.....	29, 45
Andreasen, Nancy C.....	65
Andrews, Linda B.....	86
Andrus, Jason.....	25
Anez, Luiz M.....	82
Ansell, Emily.....	85
Antognini, Francesca C.....	62
Anton, Raymond F.....	84
Anzia, Joan M.....	21, 64
Apfeldorf, William J.....	35
Appelbaum, Paul S.....	30, 44, 51, 55, 56, 57
Apter, Alan.....	87
Apter, Gisele.....	54
Arboleda-Florez, Julio E.....	51, 57
Arey, Britton A.....	75
Arias, Albert J.....	10
Arnold, Lesley M.....	78
Arntz, Arnoud.....	33
Arora, Sanjay.....	27
Arroyo, William.....	21, 28, 69
Arshad, Nadia.....	56
Ash, Peter.....	42
Ashcraft, Lori.....	58
Ashley, Kenneth.....	23
Asnaani, Anu.....	82
Atkins, Robert W.....	7
Augius, Lina I.....	80
Aviram, Ron.....	37
Axelson, Alan.....	63
B	
Badaracco, Mary Anne.....	38
Bailer, Ursula F.....	55
Bailey, Rahn K.....	63
Bailey, Sue.....	72
Bak, Mina.....	28
Baker, Brian.....	73
Balkom, Anton V.....	49
Ballon, Bruce.....	22, 64
Bankole, Azziza O.....	84
Barak, Yoram.....	48, 66
Barbaree, Howard F.....	77
Bark, Nigel.....	56
Barr, Christina S.....	34
Barr, Ellen F.....	80
Barrett, Thomas B.....	49, 55
Barron, Ruth A.....	50
Barry, Declan.....	73
Bartlett, Selena.....	34
Bartz, Jennifer.....	36, 57
Basco, Monica R.....	3
Bateman, Anthony.....	53
Bates, Dorothy.....	30
Bath, Eraka.....	50
Bauer, Mark S.....	70
Bauer, Michael.....	70
Baum, Antonia I.....	34
Baxter, Elizabeth A.....	69
Bechdorf, Andreas.....	86
Beck, Judith S.....	29, 35, 42, 74
Becker, Daniel F.....	82
Becker, Deborah R.....	87
Becker, Judith V.....	61
Beeber, Alan R.....	19
Beedle, Dennis D.....	81
Beekman, Aartjan.....	49, 57
Beem, Leo.....	57
Beezhold, Julian.....	23, 74
Beitman, Bernard D.....	21, 75
Belfort, Edgard.....	51
Bell, Morris D.....	87
Belluzzi, James D.....	77
Benca, Ruth M.....	3, 8
Bender, Donna S.....	85
Benedek, Elissa P.....	65
Bergeson, Susan R.....	12
Berk, Michael.....	68
Berlin, Heather.....	36
Bermak, Jason.....	50
Bernardi, Silvia.....	36
Bernstein, Carol A.....	18, 87
Bernstein, David P.....	33
Beyer, John L.....	61
Bhat, Shyam K.....	5, 70
Bhattacharyya, Anjan.....	70
Biederman, Joseph.....	9
Bielavitz, Sarann.....	49
Biesecker, Gretchen.....	77
Billick, Stephen B.....	50
Binder, Renee J.....	51
Bisaga, Adam.....	55
Bizamcer, Aurelia N.....	23
Bizouard, Paul.....	38
Black, Donald W.....	33, 42
Black, Jed E.....	2, 27
Black, John I.....	41
Blanco-Jerez, Carlos.....	73
Blank, Karen.....	47
Blaustein, Mel.....	63
Blazer, Dan.....	61
Bleich, Avi.....	13, 48
Blinder, Barton J.....	75
Bloom, Hy.....	36
Blum, Nancee.....	42
Blumenfeld, Michael.....	7, 41
Bober, Daniel I.....	21
Boerescu, Daniela A.....	68
Bogan, Kimberley.....	50
Bogdanich, Radmila.....	79
Bogunovic, Olivcra J.....	37
Bohn, Paul B.....	79
Bohus, Martin.....	76
Bokarius, Vladimir.....	83
Boland, Robert J.....	46, 61, 75
Bolo, Nicolas R.....	82
Bonci, Antonello.....	34
Bonds, Curley L.....	80
Book, Howard E.....	5, 36, 44, 52
Boomsma, Dorret L.....	48, 57
Booty, Andrew.....	51
Boutros, Nashaat N.....	7, 18
Bowers Jr., Theron C.....	80
Bradford, John M.....	42
Brady, Kathleen T.....	17, 36
Braun-Harvey, Douglas.....	70
Bregman, Joel.....	21
Brendel, David H.....	1
Brenner, Adam M.....	38
Brenner, Ronald.....	37
Brod, Thomas M.....	56, 62
Bromley, Elizabeth.....	5
Brooks, Beth Ann.....	29
Brown, Richard P.....	24, 58, 71, 82
Brown, Thomas E.....	5, 17, 41
Bruce, Travis O.....	84
Bruce, William.....	44
Buccigross, Richard.....	49, 81
Buchanan, Alec.....	28
Buckholz, Gary T.....	43
Buckley, Peter F.....	11, 37, 40, 58, 59
Bughra, Dinesh.....	72
Bui, Viet.....	80
Buie, Stephen E.....	62
Bullock, Clayton M.....	54
Bullmore, Fd T.....	36, 48
Burd, Ronald M.....	30, 68
Burke, Harold L.....	62
Burrroughs, Tracee.....	63, 69
Bursztajn, Harold J.....	23
Bush, George.....	6
Bustami, Rami T.....	49
Butler, Jeremy R.....	18
Buyse, Daniel J.....	5, 8
Byatt, Nancy.....	45
Byford, Sarah.....	82
C	
Cabaj, Robert P.....	54
Cabrejos, Claudio O.....	84
Cagande, Consuelo C.....	37, 74
Cairney, John.....	67
Caivano, Norana.....	80
Caligor, Eve.....	61
Callahan, William E.....	45, 50, 56
Camacho, Alvaro.....	46
Camarena, Enrique R.....	51
Campbell, Herbert L.....	48, 79
Campbell, Nioaka N.....	45
Campbell, William H.....	1, 6, 28, 42, 62
Campo, Ana F.....	21
Cancel, Olivier J.....	37

PARTICIPANT INDEX

- Cappelleri, Joseph.....27
 Caraballo, Angel A.....44
 Cardish, Robert.....33
 Cardoni, Alex A.....82
 Carlat, Daniel J.....54
 Carli, Vladimir.....32
 Caroff, Stanley N.....45
 Carpenter, William T.....35, 66
 Carroll, Matthew F.....80
 Carter, Cameron.....64
 Carter, Diana.....2
 Case, Brady G.....67, 83
 Casey, Daniel E.....6
 Casey, David A.....28
 Castellanos, Daniel.....28
 Catena, Mario.....67, 82
 Ceccherini-Nelli, Alfonso.....48
 Chamberlain, Samuel.....36
 Champagne, Frances A.....23
 Chan, Carlyle H.....42, 52, 75, 79
 Chandler, Redonna K.....73
 Chang, Jacquelyn.....28
 Chang, Kiki D.....4, 64
 Chapman, Daniel P.....48
 Charles, Dana.....82
 Chatoor, Irene.....69
 Chaudhry, Haroon R.....56
 Chausmer, Allison.....77
 Chelminski, Iwona.....26, 68, 82
 Chen, H.....77
 Chen, Tai-Jui.....27
 Chen, Xiangning.....48
 Cheong, Josepha A.....31, 75
 Cheung, Amy H.....67
 Childers, Jeffrey.....61
 Childress, Anna R.....64
 Childs, Allen.....66
 Cho, Austina.....48, 68, 80, 81
 Choi-Kain, Lois W.....18, 53
 Chow, Wendy S.....83
 Choy, Yujuan.....28
 Chung, Henry.....22
 Ciechanowski, Paul S.....73
 Citrome, Leslie L.....26, 66
 Clark, Connie.....5
 Clark, David.....18
 Clarke, Jennifer G.....74
 Clarkin, John F.....53, 61
 Clauw, Daniel J.....78
 Cloughesy, Timothy F.....49
 Clouse, Ray E.....73
 Coccaro, Emil F.....76
 Coconcea, Cristinel M.....66
 Cohen, Carl L.....84
 Cohen, Judith A.....1
 Cohen, Mary Ann.....68
 Cole, Nora.....84
 Colenda, Christopher C.....45, 52
 Collins, Pamela Y.....68
 Collins, Theodore M.....75
 Colom, Francesc.....45
 Compton, Wilson M.....36, 77
 Conant-Norville, David O.....34
 Condon, Timothy.....73
 Conley, Robert.....59
 Connor, Daniel F.....36
 Connor, Kathryn.....20, 43, 72
 Conway, Kevin P.....35
 Cook, Jana.....49, 68
 Cooper, Andrew.....49
 Cooper, Arnold.....27
 Cora-Locatelli, Gabriela.....50, 63
 Corcoran, Jay.....65
 Corcos, Maurice.....38
 Coric, Vladimir.....23
 Cornblatt, Barbara A.....86
 Cornelius, Jack R.....76
 Corral, Maria R.....2
 Correa, Eduardo A.....75
 Correll, Christoph U.....40
 Corya, Sara.....81
 Cottler, Joan.....50
 Cournos, Francine.....51, 56, 69
 Courtney, Keith.....71
 Crapanzano, Kathleen A.....70
 Crofford, Leslie J.....78
 Crowley, Brian.....55
 Cullen, Bernadette.....57
 Cummings, Jeffrey L.....8, 18
 Cummings, Jennifer.....50
- D**
- Dadabhoy, Dina.....78
 Dagher, Alain.....33
 Damodoran, R.....82
 David, Daniella.....45, 65
 Davidoff, Donald A.....62
 Davine, Jonathan S.....45, 79
 Davis, Lori L.....8
 Dawe, Ian.....33
 Day, Max.....23
 de Castella, Anthony.....68
 de Figueiredo, John M.....21, 50
 de Francisci Lis, Lea E.....28, 35
 de Wit, Matty.....49, 57
 Deberdt, Walter.....81
 deCharms, Christopher.....64
 Dekker, Jack.....49
 del Rosario, Salvador R.....29
 Delgado, Pedro L.....33, 64
 Dell, Paul F.....78
 Demandante, Milagros.....46
 de-Melo-Neto, Valfrido L.....26
 Desai, Abhilash K.....5, 30
 Desai, Durisala.....68
 Derke, Holland C.....81
 Deva, M. Parameshavara.....50
 Devanand, Davangere P.....6
 Dewan, Mantosh J.....35, 41, 64, 74
 Dewar, Amy R.....80
 Dhaliwal, Navdeep K.....44, 87
 Diamond, Ronald J.....75
 Diaz, Esperanza.....28
 Dickerson, Daniel L.....30, 63
 Dickstein, Leah J.....22, 28, 30, 41, 54, 69, 72, 87
 Diller, Katherine.....23
 Dimassi, Hani.....87
 Dimsdale, Joel.....29, 47, 67
 Dingess, David F.....27
 Diwan, Shilpa P.....84
 Dobbins, Mary I.....79
 Dodd, Seetal.....68
 Doerr Zegers, Otto F.....34
 Doghramji, Karl.....8
 Dolgoff, Robert K.....77
 Dollfus, Sonia.....37
 Dominguez, Lourdes M.....22
 Donovan, Abigail I.....74
 Donovan, Dennis M.....84
 Dorer, David J.....35
 Douglas, Carolyn J.....37, 51
 Dove, Henry W.....81
 Draeger, John H.....25
 Drake, Christopher L.....5
 Drazinic, Carolyn M.....36
 Drescher, Jack.....35
 Drury, Laura M.....18
 D'Souza, Russell F.....25, 79, 81
 Duckworth, Kenneth S.....77
- Duffy, Farifitch F.....22, 27
 Dughly, Rascha.....44
 DuHamel, Katherine.....83
 Dukakis, Kitty.....32, 51
 Duman, Ronald S.....20
 Dunn, Christine.....48
 Dunn, Jeff.....54
 Dunn, Laura B.....55, 56
 Durruthy, Stephanie S.....87
- E**
- Eagle, Morris N.....54
 Eddy, Kamryn T.....35
 Einarson, Stalc.....53
 Eist, Harold I.....55
 Elkashaf, Ahmed M.....50, 69
 Elliott, Katherine.....34
 Ellison, James M.....62
 Elman, Igor.....26, 67, 82
 Elovainio, Marko.....53
 England, Mary Jane.....32
 Epstein, Steven A.....71
 Ernst, Monique.....36
 Escobar, Javier I.....33
 Espy, Kimberly A.....77
 Fith, Spencer.....35
 Fttekal, Amir F.....38, 63
 Fvcimen, Harun.....47
 Everett, Anita S.....57
 Everly, George.....87
 Exum, Kelvin.....22
- F**
- Faber, Raymond A.....1
 Fabio, Anthony.....76
 Fabrazzo, Michele.....74
 Fagiolini, Andrea.....40
 Fahimian, Nima A.....80
 Fahrer, Rodolfo D.....79
 Faision, Warachal E.....2, 28, 52
 Falcone, Tatiana.....28
 Falissard, Bruno.....38
 Fan, Jin.....85
 Fan, Ming-Yu.....73
 Farabaugh, Amy H.....3, 67
 Faraone, Stephen V.....41
 Faulkner, Larry R.....29, 45
 Faull, Robert.....81, 82
 Fava, Maurizio.....3, 23, 49, 67, 76, 82
 Fawcett, Jan A.....38, 42
 Fayyad, John.....87
 Feldman, Jamie.....61
 Feldmann, Theodore.....21
 Fernandez, Antony.....68
 Fernandez, Francisco.....3, 56
 Ferrando, Stephen.....78
 Ferris, Frank D.....43
 Fidler, Donald C.....22
 Fineberg, Naomi A.....36
 Fink, Robert.....70
 First, Michael B.....18, 78
 Fisher, Lauren.....49, 76
 Fiszdon, Joanna.....87
 Fleming, Anne.....63
 Flett, Heather L.....64, 83
 Flynn, Julianne.....64
 Fochtman, Laura J.....69
 Folsom, David P.....8, 84
 Fonagy, Peter.....53, 85
 Fong, Timothy W.....30, 73
 Ford, Charles V.....71
 Ford, Julian D.....36

- Fore, Peter F.44
 Forcster, Brent P.62
 Forstein, Marshall 50, 56, 65, 78
 Fossati, Philippe85
 Fowler, Joanna S.33
 Francis, Andrew J.45
 Frank, Ellen 62, 86
 Frank, Guido76
 Franke, Ryan77
 Frankenburg, Frances R.68
 Frankle, Gordon17
 Franko, Debra L.35
 Frascella, Joseph 22, 33
 Frasure-Smith, Nancy73
 Fredman, Lisa27
 Freedland, Kenneth E.73
 Freedman, Robert22
 Freeman, Marlene P.10
 Freire, Rafael C.26
 Freundlich, Kenneth49
 Fricks, Larry58
 Fried, Ronna6
 Friedberg, Robert D.29
 Friedman, Joseph I.58
 Friedman, Rohn S.50
 Friedman, Susan II.51
 Friedmann, Peter D.74
 Frydman, René38
 Frye, Mark A. 4, 59
- G**
- Gabbard, Glen O.18, 38, 53, 75, 79
 Gabriel, Geoffrey M.51
 Gabrielli Jr., William F.25
 Gadow, Kenneth D.64
 Gaebel, Wolfgang 72, 84, 86
 Gage, Fred H.47
 Gagne, Cheryl58
 Galanter, Marc76
 Galynker, Igor I.83
 Ganadjian, Krauz 26, 48
 Ganguli, Rohan17
 Ganocy, Stephen J.67
 Gao, Keming67
 Garza, Daniel23
 Gay, Tamara L.38
 Geller, Jeffrey L.69
 George, Mark S. 18, 49
 George, Tony P.59
 Gerberg, Patricia L. 71, 82
 Gergen, John A.27
 Getter, Elizabeth V.61
 Ghaemi, Nassir 1, 54, 75
 Ghatavi, Kayhan73
 Ghodse, Hamid56
 Gicquel, Ludovic38
 Gilder, David A.63
 Gill, Mona H.28
 Gitlin, David F.44
 Gitlin, Michael J. 42, 87
 Glass, Penny69
 Glassman, Alexander H.58
 Glenn, Tasha70
 Glessner, Eric80
 Glick, Ira D.34
 Gnam, William33
 Godejahaun, John26
 Goertzen, James80
 Goethe, John W. 27, 47, 68, 78
 Goff, Donald C.10
 Goforth, Harold W.61
 Gogineni, R. Rao 37, 74
 Goin, Jessica22
 Goisman, Robert M.7
- Gold, Liza H. 42, 53
 Goldberg, David A.21
 Goldberg, Joseph F.59
 Goldfeder, Gabe 57, 83
 Goldman, Morris B.51
 Goldstein, Michael37
 Gonzales, Junius J. 10, 57
 Gonzalez, Gerardo18
 Gonzalez-Lima, Francisco1
 Good, Mary Jo45
 Goodkin, Karl78
 Goodman, Marianne S.85
 Goodwin, Frederick K.54
 Goossen, Randy B.80
 Gordon, Edward68
 Gordy, Tracy R. 30, 50, 68
 Gottlieb, Diane B.23
 Grados, Marco57
 Grady-Weliky, Tana A.28
 Granacher, Robert P.18
 Grant, Jon F. 44, 73
 Grant, Steven J.64
 Gray, Kevin F.1
 Gray, Lauren46
 Grebb, Jack A.23
 Green, Melva I. 28, 50, 87
 Green, Michael F. 81, 87
 Green, Stephen A.35
 Greenberg, Roger P.35
 Gretchen-Doorly, Denise87
 Grewal, Seena S.80
 Griffin, Edmund51
 Griffith, James L. 30, 70, 86
 Griffiths, Roland R.56
 Grilo, Carlos M.82
 Grob, Charles S.56
 Grosjean, Bernadette M.76
 Gross, Cornelius T.23
 Grossberg, George T. 2, 5, 30
 Grossman, Linda S. 81, 82
 Grunze, Heinz45
 Guarino, Theresa49
 Gudeman, Jon E.24
 Guertin, Marie-Claude73
 Guinjoan, Salvador M.79
 Gunderson, John G. 18, 53, 85
 Gupta, Dipak K.87
 Gupta, Nitin 27, 49, 83
 Gupta, Sanjay 37, 45
 Gur, Raquel F.35
 Guthrie, Thomas G. 23, 30
- H**
- Hafta Gray, Sheila50
 Haggarty, John M.80
 Hales, Deborah J. 19, 24, 31
 Hales, Robert F. 17, 41
 Halmi, Katherine A. 6, 35, 74
 Halper, James P.80
 Haltzman, S.D.75
 Hamarman, Stephanie21
 Hamer, Ann49
 Hamilton, Roy H.6
 Hamilton, Tom21
 Hammerness, Paul G.2
 Hanin, Edward50
 Haning III, William F.50
 Harding, Richard K.45
 Harmon, Larry J.36
 Haroun, Ansar M.79
 Harre, Elizabeth51
 Harris, Toi B.29
 Harrison, Alexandra M.54
 Harrow, Martin81
- Hartman, David E. 29
 Hartmann, Lawrence 62, 69
 Harvey, Philip D.87
 Hasan, Nacl M.56
 Hatters-Friedman, Susan J.83
 Hatti, Shivkumar S. 1, 7, 63
 Haupt, Dan59
 Hauser, Peter61
 Head-Dunham, Rochelle70
 Healy, David54
 Heath, Jennifer68
 Heeren, Timothy27
 Heilig, Markus34
 Hellerstein, David J. 22, 37, 66
 Henderson, Claire82
 Henderson, David C. 19, 76
 Hennekens, Charles H.40, 59
 Henschke, Jacqueline44, 63
 Hensley, Paula L.67
 Hepburn, Brian M.22
 Herbst, Laurel H.43
 Herman, Barry K.1
 Hery, Alison M.18
 Herzog, David B.35
 Hesselbrock, Victor36
 Higgins Jr., Napoleon B. 22, 63
 Hill, Mike85
 Hilty, Donald M.69
 Hinton, Marynell 22, 45
 Hirsch, Alan R.29
 Hirschowitz, Max 7, 27
 Hoek, Hans W.55
 Hollander, Eric 29, 36, 56, 57, 62
 Hollander, Gavi82
 Hollins, Sheila 14, 56, 72
 Holzheimer, Paul9
 Holwerda, Tjalling J.57
 Hoop, Jinger G.56
 Horowitz, Mardi50
 Hoschl, Cyril72
 Hottenga, Jouke-Jan57
 Houghtalen, Rory P.86
 Howe, Edmund G.8
 Hsiao, Ray C.69
 Hsiung, Robert C. 44, 52
 Hsu, Pi-Fem68
 Hu, Rona4
 Hua, Liwei L.44
 Huang, David L.50
 Huang, Yueqin36
 Hubley, Paul E.84
 Huey, Leighton Y.36
 Huff-Musgrove, Robbin34
 Huguet, Nathalie82
 Hunt, Dennis J.87
 Hunt, Justin B.28
 Hunter, Jon7
 Hurley, Robin58
 Hurwitz, Thomas D.7
 Husain, Mustafa M. 27, 49
 Husain, Nisba F.63
 Hutchinson, Gerard56
 Hwang, Michael Y. 32, 57, 74, 80
 Hyler, Steven F.18
- I**
- Iacoboni, Marco 54, 75
 Iheagwara, Chioma23
 Inciardi, James A.74
 Indest, David61
 Insel, Thomas R. 13, 53
 Iosifescu, Dan V.82
 Iqbal, Naveed 57, 74, 80, 83
 Iren Akbiyik, Derya 48, 68

PARTICIPANT INDEX

Irwin, Scott A.....43
 Isbey, JoAnne.....30
 Ishak, Waguih W.....38, 51, 67, 70, 83
 Ishizuka, Yukio.....67
 Isohanni, Matti K.....48

J

Jabbarpour, Yad M.....57, 86,, 87
 Jacobs, Marc.....50
 Jacobsen, Leslie K.....77
 Jacobson, Sandra.....27
 Jaghab, Kamil.....45
 Jain, Vivek.....5
 Janicak, Philip G.....51
 Jawandha, Arshdeep S.....64
 Jayaram, Geetha.....32
 Jefferson, James W.....75
 Jensen, J. Eric.....82
 Jensen, Per.....25
 Jesse, Robert.....56
 Jeste, Dilip V.....8, 39, 61
 Jimerson, David C.....6
 Jobe, Thomas H.....81
 Jochims, Anja.....76
 Joffe, Hadine.....40
 Johnson, Bankole.....69
 Johnson, Bradley R.....61
 Johnson, Joel P.....63
 Johnson, Kyle P.....27
 Johnson, Shaneek.....23
 Johnson, Sheri L.....82
 Jokelainen, Jari.....48
 Jones, Lynne M.....23
 Jones, Peter B.....48
 Jorgenson, Linda M.....5, 65
 Joseph, Robert C.....46
 Josephson, Allan M.....30
 Juthani, Nalini.....70

K

Kajdasz, Daniel.....68
 Kalali, Amir.....48
 Kalita, Thomas A.....49
 Kalivas, Peter W.....58
 Kaminr, Yifrah.....76, 77
 Kamm, Ronald L.....34
 Kampman, Kyle M.....69
 Kane, John M.....4, 11, 23, 40
 Kang, Shimi.....71
 Kaplan, Gabriel.....33
 Kaplan, Mark.....82
 Kapur, Shitij.....17
 Karam, Elie G.....87
 Karasic, Dan H.....62
 Kaspert, Siegfried.....32
 Katon, Wayne J.....73
 Katzelnick, David J.....22
 Kaufmann, Michael.....36
 Kay, Jerald.....21, 64
 Kaye, Walter H.....35, 55, 76
 Kearley, Bob.....28
 Keck, Paul E.....40
 Kee, Kimmy S.....81
 Keith, Samuel J.....5
 Kelly, John F.....77
 Kelsoe, John R.....31, 49, 55
 Kemp, Janet L.....64
 Kendler, Kenneth S.....48
 Kennedy, Patrick J.....20
 Kennedy, Robert S.....75, 79
 Kerfoot, Karin.....1
 Kernberg, Otto F.....27, 53, 61, 79
 Keshavan, Matcheri.....35

Kessler, David R.....53
 Kessler, Ronald C.....9, 35
 Keyzers, Christian.....54
 Khan, Sabrina J.....67, 81
 Kheriati, Aaron.....86
 Kilts, Clinton D.....64
 Kim, Jieun.....23
 Kim, Scott Y.....52
 Kim, Thomas J.....21
 Kim-Cohen, Julia.....23
 King-Casas, Brooks.....85
 Kingdon, David G.....8, 69
 Kirkby, Kenneth.....25
 Kirwin, Paul D.....52
 Kivimäki, Mika.....53
 Kleber, Herbert D.....46, 55, 69
 Klein, Tara A.....63, 83
 Kling, Mitchel A.....26, 47
 Klitzman, Robert L.....56
 Kloss, Raymond J.....42
 Klosterkötter, Joachim.....86
 Knop, Joachim.....25
 Koenigsberg, Harold W.....85
 Kogan, Richard.....30
 Kohen, Dora D.....45
 Koller, Michelle.....57
 Kolodner, Robert.....51
 Koob, George F.....34, 69
 Kool, Simone.....33, 57, 61
 Koponen, Hannu J.....27
 Koran, Lorrin M.....36, 57, 69
 Kordon, Laura C.....80
 Korman, Lorne.....33
 Kornberg, Jason.....66
 Kosten, Thomas R.....24
 Koszycki, Diana.....73
 Kotov, Kimberly.....37
 Koukopoulos, Athanasios.....75
 Koutsenok, Igor.....25, 48
 Kovaszny, Beatrice.....28
 Kraemer, Helena C.....29, 35, 36, 86
 Krahn, Lois E.....7
 Kramer, Milton.....22, 64
 Kranzler, Harvey.....54
 Kratochvil, Christopher J.....2
 Kraus, Louis J.....50
 Krebs, Marie-Odile.....37
 Kreek, Mary J.....25
 Kripke, Daniel F.....49
 Krueger, Richard B.....18, 77
 Krueger, Robert F.....36
 Kystal, John H.....43
 Kulkarni, Jayashri.....56, 68
 Kumra, Sanjiv.....54
 Kunkel, Elisabeth J.S.....29
 Kupfer, David J.....29
 Kupka, Ralph.....49
 Kuroski-Mazzei, Alyson.....61
 Kushner, Howard I.....54
 Kutcher, Gary S.....45
 Kwon, Alyssa S.....37
 Kyomen, Helen H.....53, 77

L

Ladavac, April S.....23
 Laitinen, Jaana.....27
 Lakatos, Anita.....77
 Lake, James.....70
 Laliberté, Marc-André.....73
 Lamas, Claire.....38
 Lamb, H. Richard.....21
 Lambert, Michael J.....74
 Lamphere, Lucy.....83
 Lam-Po-Tang, John K.....26

Land, Alisa J.....23
 Lang, Joan A.....87
 Langer, Samuel J.....77
 Langley, John H.....80
 Langlieb, Alan.....63
 Larsen, Karin.....61
 Lauriello, John.....41
 Lauronen, Erika.....25
 Lauterbach, Edward C.....18
 Lauterbach, Margo.....21
 Lavun, Ella.....66
 Lawson, William B.....69
 Layne, Christopher M.....23
 Lazaro, Jose.....73
 Lazarus, Arthur L.....1, 7, 63
 Le Melle, Stephanie.....28
 Lebowitz, Barry D.....53
 Lecardeur, Laurent.....37
 Lee, Eugene.....28, 63, 70
 Lee, Hochang B.....2
 Lee, Karen L.....5
 Lee, Steven J.....23, 65
 Leese, Morven.....82
 Lehto, Jennifer.....80
 Leigh, Hoyle.....48
 Leli, Ubaldo.....65
 Leon, Andrew C.....23
 LeQuesne, Elizabeth.....66
 Leslie, Frances.....77
 Lespérance, François.....73
 Lester, Patricia.....23
 Leszcz, Molynd.....7, 83
 Leucht, Stefan.....33
 Levendusky, Philip G.....7
 Levenson, Hanna.....35
 Levenson, James L.....71
 Leventhal, Bennett J.....77
 Levin, Frances R.....55, 77
 Levine, Saul.....25, 48
 Levine, Stephen B.....19
 Levine, Stewart B.....49
 Levitan, Robert D.....27
 Levitin, Teresa.....22
 Levitt, Anthony J.....67
 Levounis, Petros.....46, 65
 Lewis-Fernandez, Roberto.....1, 45
 Lewy, Alfred J.....2, 27
 Liaw, K. Ron-Li.....63
 Liberman, Robert P.....87
 Licinio, Julio.....81
 Lieberman, Jeffrey A.....24, 37, 52
 Lim, Russell F.....1, 21
 Lin, Daniel.....81
 Lin, Keng S.....48
 Lincoln, Alisa.....27
 Lindelius, Birgitta.....26
 Lindenmayer, Jean-Pierre.....58, 77, 80, 87
 Links, Paul.....33
 Liptzin, Benjamin.....50
 Livesley, W. John.....36
 Llorente, Maria D.....28, 45
 Loas, Gwenole.....38
 Loboprabhu, Sheila M.....80
 Loewenstein, Richard J.....78
 Lolas, Fernando.....73
 Lomax, Laura.....85
 Lopes, Fabiana L.....26
 Lopez, Lina M.....29, 44
 Lopez-Gibson, Eduardo.....48
 Lopez-Ibot Jr., Juan J.....32, 72
 Losonczy, Miklos F.....80
 Löthman, Anna.....26
 Love, Robert J.....64
 Lowenkopf, Eugene.....83
 Loza, Nasser F.....56, 63

Ju, Francis G. 1, 23, 34, 46, 63, 70, 80, 86
 Luhmann, Tanya 71
 Lujan, Maria 74
 Lundt, Leslie P. 5
 Luo, John 52, 75, 79
 Lusskin, Shari I. 2
 Lustman, Patrick J. 73
 Lyons, Camilla 50

M

Ma, Yantao 76
 Macdonald, Kathryn J. 29
 MacLeod Thomson, Helen 50
 Madaan, Vishal 27, 44, 64
 Madhusoodanan, Subramoniam 37
 Magee, Maggie 53
 Mago, Rajnish 49, 67, 82
 Maisel, Alan S. 81
 Maiza, Olivier 37
 Maj, Mario 13, 32, 33, 35, 72, 74, 76, 85
 Maki, Pirjo H. 25, 27, 48
 Malaspina, Dolores 31
 Malfait, Jason 58
 Malik, Amir 74
 Mallinckrodt, Craig H. 26
 Malmquist, Carl P. 9, 65
 Malone, Matthew T. 1
 Mancini, Catherine T. 26, 49
 Mandili, Carla 83
 Mangurian, Christina 28, 51
 Mann, Stephan C. 45
 Manneclid, Deanne 26
 Manos, Gail H. 50
 Manring, John 74
 Manzardo, Ann M. 25
 Marangell, Lauren B. 8, 41
 Marazziti, Donatella 26, 67
 Marcus, Eric R. 38
 Marder, Stephen R. 4, 5, 51
 Maremont, Eve 80
 Marin, Alina 64
 Marin, Humberto 33
 Marin, Robert S. 80
 Markle, Sondra 26
 Markman, Yuri 66
 Markov, Dimitri D. 29, 63
 Markowitz, John C. 5
 Marks, Tracy I. 18
 Martin, Michael J. 5
 Martinez, Moises 28
 Martinez, Octavio N. 80
 Maruyama, Nancy C. 83
 Marvin, Robert W. 82
 Marx, Christine E. 52, 66, 72
 Masand, Prakash S. 40, 41, 71
 Matharu, Yogi 83
 Mathews, Maju 47
 Mathias, Steve 71
 Matorin, Anu A. 29, 43
 Matthews, Thomas L. 64
 Mayberg, Helen S. 9, 58
 Mayes, Linda C. 76
 Mayeux, Richard 6
 Mazoyer, Bernard 37
 McFarland, Bentson 82
 McGlashan, Thomas H. 76, 85
 McAllister, Thomas W. 18
 McBurnett, Keith 2
 McCarthy, Tracy H. 69
 McDiarmid, Diane 58
 McDowell, David M. 55
 McElroy, Susan L. 4, 59, 68
 McGahee, Shunda 28, 77
 McGee, Michael D. 43

McGlashan, Thomas H. 37, 84
 McGorry, Patrick D. 37, 86
 McHugh, P.R. 75
 McIntyre, Jack S. 22, 25, 69, 79, 81, 85
 McIntyre, Roger S. 41, 59
 McKinnon, Tammy E. 80
 McLean, Alexandra 37
 McMain, Shelley 33
 McNaughton, Nancy I. 7
 McNicholas, Laura 18
 McRoberts, Roger I. 61
 Medina-Mora, Maria F. 56
 Mednick, Sarnoff 25
 Mee-Lee, David 17
 Mellman, Lisa 21, 28
 Melonas, Jacqueline M. 22
 Meloy, Reid 4, 38
 Melvin, Cathy 45
 Mencl, W. Finar 77
 Menfi, Anita 65, 84
 Menza, Matthew A. 18
 Menzies, Lara 36
 Mergener, Michael 75
 Merideth, Philip 51
 Merikangas, Kathleen R. 23
 Merlino, Joseph P. 35
 Messing, Robert O. 34
 Meyers, Adam I. 26, 68
 Meyers, Barnett S. 24
 Mezzasalma, Marco A. 26
 Michaeli, Danni 23
 Mick, Thomas 36
 Middeldorp, Christel M. 48, 57
 Miettunen, Jouko 25, 48
 Mika, Brian P. 82
 Mikkelsen, Eva 53
 Milad, Roseann 26
 Milev, Roumen V. 57, 58
 Miller, Brian P. 81
 Miller, Gary E. 64
 Miller, Paul R. 8
 Miller, William R. 24, 50
 Milone, Richard D. 69
 Miner, Lucinda L. 22
 Mintz, David L. 42
 Mintzer, Jacobo F. 2, 33
 Mischoulon, David 76
 Mishra, Asha S. 13, 70, 87
 Misri, Shaila 2
 Mitchell, James E. 6, 35
 Mobley, David 23
 Moilanen, Irma 25, 27
 Mojtabei, Ramin 83
 Molander, Rachel C. 21
 Molinari, Victor A. 80
 Monk, Catherine 29
 Montague, Read P. 85
 Monteleone, Palmiero 74
 Montgomery, Richard A. 42, 52
 Montoya, Ivan D. 35
 Montplaisir, Jacques 2
 Monuteaux, Mike 10
 Moreno, Francisco A. 56
 Morvan, Yannick 37
 Moss, Quinton E. 10
 Mouaffak, Fayçal 37
 Moussaoui, Driss 28
 Mrazek, David A. 29, 41
 Mufti, Khalid A. 56
 Müller-Spahn, Franz 84
 Munoz, Rodrigo A. 43, 51, 55, 84, 85, 86
 Muntasser, Siham 86
 Murray, Graham 48
 Muskin, Philip R. 59
 Muszynski, Irvin L. 25

Myers, Mark G. 77
 Myers, Michael F. 22, 41, 63, 69
 Myers, Wade C. 28, 69
 Myran, David D. 77

N

Nace, David K. 30, 63, 68
 Nadelson, Carol C. 54
 Nahas, Ziad H. 2, 7
 Nahoum-Jaros, Bonita 29
 Nakagawa, Atsuo 74
 Nakajima, Gene A. 53
 Nand, Surinder S. 28, 64, 70
 Napoli, Joseph C. 41
 Naqvi, Syed S.A. 63
 Narashimhan, Meera 8, 40, 45, 84
 Nardi, Antonio E. 26
 Narrow, William E. 25, 27
 Nascimento, Isabella 26
 Nash, John 39
 Nash, Kenneth C. 63
 Nasrallah, Henry A. 5, 10
 Nathaniel, Vernon I. 28
 Ndelela, Johannes C. 1
 Nelson, Randy J. 53
 Nemat, Ali 83
 Nemeroff, Charles B. 9, 59
 Nestadt, Gerald 57
 Nevill, Laura 46
 New, Antonia S. 85
 Newcomer, John W. 10, 40
 Newkirk, Cassandra F. 21
 Newmark, Thomas S. 63
 Newsom, Jason 82
 Ng, Anthony T. 1, 46
 Niaz, Saima 56
 Niaz, Unaiza 84
 Nichols, Alphonso E. 63
 Nickel, Elizabeth J. 25
 Nicolas, Isabelle 38
 Nicrenberg, Andrew A. 82
 Nicvergelt, Caroline M. 49
 Nittler, Jessica R. 75
 Njenga, Frank G. 56
 Noel, Richard L. 64
 Noragbon, Leo O. 50
 Norquist, Grayson S. 10
 Norris, Donna M. 7, 28, 32, 55
 Northoff, Georg 85
 Notman, Malkah T. 22, 65
 Novac, Andrei 29
 Nuechterlein, Keith H. 81, 87
 Nunes, Edward V. 36, 55
 Nunes, Richard J. 80
 Nurnberg, H. George 27, 67
 Nutt, David J. 3

O

Oberstar, Joel 54
 O'Brien, Charles P. 30
 O'Connor, Thomas 29
 Okasha, Ahmed M. 12, 55, 76
 Okasha, Tarek A. 69
 Okech, Violet A. 74
 Oldham, John M. 45, 79
 Oncken, Cheryl A. 59
 Ongur, Dost 33
 Oosterbaan, Desiree 49
 Opler, Lewis A. 30
 Oppenheim, Steven 43
 Oquendo, Maria A. 33
 Osborn, Candice A. 42
 Osby, Urban P. 26

PARTICIPANT INDEX

- Osinowo, Thomas O.....70
 Osman, Ossama T.....49, 63
 Osofsky, Howard.....51
 Osofsky, Joy.....51
 Osser, David N.....54
 Ostacher, Michael J.....8
 Östensson, Claes-Göran.....26
 Ostermeyer, Britta.....66, 82
 Outvey, Eugene A.....5
 Ozbayrak, R. Kaan.....65
 Ozturk, Ozgur.....74
- P**
- Packer, Sharon.....21
 Padder, Tanveer.....45
 Pain, Clare.....7
 Pallanti, Stefano.....36
 Pally, Regina.....54
 Pampaloni, Ilenia.....36
 Pandya, Anand.....46
 Parikh, Rajesh M.....67, 76
 Parikh, Sagar V.....7
 Park, Lawrence T.....45
 Parker, Suzanna.....67
 Parks, Joseph J.....42
 Parr, Grant V.S.....49
 Parelis-Sioris, Irene.....64
 Pato, Michele T.....41, 64
 Patterson, Beth.....26
 Paul, Robindra K.....23
 Paulus, Martin P.....64, 79
 Paz, Rodrigo D.....34
 Peele, Roger.....28, 37, 50, 55, 72, 85
 Pejlare, Anna.....26
 Pender, Jennifer D.....63
 Pender, Maribeth.....67
 Penick, Elizabeth C.....25
 Pennessi, Diane.....78
 Perkins, Vicenzo H.....37
 Perlis, Roy H.....3
 Peselow, Eric D.....64, 67, 81, 82, 83
 Peteet, John R.....24, 30
 Peterkin, Allan D.....7
 Peters, Roger H.....74
 Petersen, Timothy J.....40, 67
 Petitjean, Francois C.....37
 Pfefferbaum, Betty.....51
 Pflanz, Steven E.....11, 21, 70, 79
 Pfohl, Bruce M.....42
 Pham-Scottex, Alexandra.....38
 Phillips, Barbara A.....2
 Phillips, Katharine A.....38, 57
 Pi, Edmond H.....12
 Piasecki, Melissa P.....71
 Piccinni, Armando.....82
 Pickett, Kate.....77
 Pierre, Claire.....46
 Pinals, Debra A.....45
 Pine, Daniel.....77
 Pinta, Emil R.....26
 Pinto, Anthony.....85
 Pizzarello, Scott.....85
 Plakun, Eric M.....21, 29, 42, 64
 Plovnick, Robert M.....44
 Pollack, David A.....45, 49, 77
 Pollock, Bruce G.....61
 Pollock, Jonathan D.....23
 Poshkus, Michael.....74
 Post, David F.....46, 70
 Post, Jerrold M.....18, 87
 Post, Robert M.....4
 Posternak, Michael A.....83
 Postlethwaite, Alejandra.....44, 68
 Potenza, Marc N.....73
- Porter, William Z.....23
 Powsner, Seth.....21
 Poyurovsky, Michael.....57
 Prakash, Apurva.....26
 Preud'Homme, Xavier A.....3
 Price, Julie C.....76
 Price, Marilyn.....21
 Priebe, Stefan.....48
 Primm, Annelle.....46
 Primm, Annelle B.....32, 68
 Prince, Jefferson B.....5, 17, 41
 Puchalski, Christina M.....70
 Puddester, Derek.....22
 Pugh, Kenneth R.....77
 Pumariaga, Andres J.....3, 28, 37, 63, 74
 Pundiak, Tara M.....67, 83
 Putnam, Katherine.....76
 Pynoos, Robert S.....51
- Q**
- Quastel, Adam.....33
- R**
- Radke, Alan Q.....50
 Rae, Donald S.....25, 27
 Rahim, Umme Salema.....48
 Rahimi, Sadeq.....45
 Rainey, Charles J.....42, 52
 Ramchandani, Dilip.....37
 Ramirez, Luis F.....1, 52
 Randall, Terri L.....69
 Randle, Sonja.....68
 Ranseen, John.....67
 Rantakallio, Paula.....48
 Rao, Nyapati.....22, 45, 49
 Rapaport, Mark H.....17, 19, 24, 31, 41, 51
 Rathod, Shanaya.....6, 69
 Rathore, Varinder.....46
 Ravitz, Paula.....7
 Raymond, Nancy C.....61
 Razafimandimby, Annick.....37
 Razavi, Maryam.....37
 Reagan, Lawrence P.....84
 Recupero, Patricia R.....9
 Reede, Joan Y.....80
 Regier, Darrel A.....22, 25, 27, 29, 32, 53, 55
 Reich, D. Bradford.....68
 Reich, James H.....33
 Reichman, William L.....2
 Reid, Michele.....19, 63
 Reid, William H.....7
 Reifler, Burton V.....29, 45, 69
 Reinblatt, Shauna P.....45
 Reinhard, James S.....57
 Reliford, Aaron.....51
 Remijnse, Peter J.....57
 Renner, John A.....69
 Renshaw, Perry F.....76, 82
 Resendez, Cynthia I.....28
 Resnick, Phillip J.....5, 18, 30, 42, 52, 61
 Resnikoff, Roy O.....71
 Reus, Victor I.....45
 Reyes, Raymond M.....69
 Reynisdottir, Signy.....26
 Reynolds, Charles F.....40
 Reznik, Vivian.....22
 Rhea, Karen H.....8
 Riba, Michelle B.....22, 33, 51, 79
 Rich, Josiah D.....74
 Richards, William A.....56
 Richardson, Greg.....72
 Richeimer, Steven.....83
 Riddle, Mark A.....57
- Rifai, Muhamad A.....61
 Rigaud, Marie-Claude.....21, 68
 Riggio, Silvana.....7
 Riggs, Paula D.....30
 Ring, Helena.....26
 Riselli, Carleen A.....46
 Ritchie, Karen A.....37
 Ritvo, Fva C.....36
 Rivera Arroyo, Guillermo C.....74
 Rivkin, Michael J.....76
 Rizk, Diaa.....49
 Robbins, Trevor.....36, 50
 Roberts, Katherine M.....58
 Roberts, Laura W.....56, 87
 Robin, Marion.....38
 Robinowitz, Carolyn B.....9, 17, 39, 53
 Robinson, Beatrice F.....61
 Robinson, David J.....61
 Robinson, Gail E.....5, 28, 54, 84
 Robinson, Jacquelyn A.....70
 Robinson, Michael J.....26, 68
 Robinson, Robert G.....58
 Rocker, Charlotte A.J.....26
 Rodin, Gary.....71
 Rodriguez, Mercedes M.....28
 Rodriguez-Abuin, Manuel J.....53
 Rojewicz, Stephen J.....37
 Rolland, John S.....18
 Romans, Sarah F.....84
 Romero, Emilio F.....68
 Roose, Steven P.....6, 86
 Roozegar, Mozhdeh.....37
 Rosen, Cherise.....82
 Rosenheck, Robert.....37
 Roskes, Erik.....21
 Rothman, Marc.....29
 Rothstein, David A.....25, 48, 81
 Roy, Alec.....32
 Roybal, C. Nathaniel.....35
 Ruano, Gualberto.....48
 Rubio-Stipec, Martiza.....36
 Rück, Christian.....26, 68
 Ruedrich, Stephen.....72
 Ruelaz, Alicia.....41
 Ruggero, Camilo J.....48, 82, 83
 Ruhrmann, Stephan.....86
 Ruiz, Amanda.....25
 Ruiz, Pedro.....7, 9, 25, 32, 39, 50,
52, 53, 69, 72, 73, 76, 78, 81
 Ruiz-Mellott, Katherine G.....34, 80
 Rush, A. John.....10, 43
 Russakoff, L. Mark.....1, 22
 Russell, James.....26
 Rutherford, Bret R.....22, 86
 Rutter, Carolyn.....73
 Ryall, Jo-Ellyn M.....32
 Ryan, Deirdre M.....2
 Rychik, Abe M.....83
- S**
- Sabri, Sufyan.....49
 Sachdev, Perminder.....45
 Sachs, Gary S.....8, 40
 Sadavoy, Joel.....83
 Saeed, Sy A.....1, 22
 Safren, Steven A.....6, 67
 Sahakian, Barbara.....36
 Saleh, Fabian M.....77
 Samuels, Jack P.....57
 Sanchez, Francis M.....68
 Santos, George D.....63
 Sar, Vedat.....78
 Sarchiapone, Marco.....32
 Sartorius, Norman II.....29, 33, 46, 55, 72

- Sato, Ryoko74
 Saunders, Erika33
 Saxena, Sanjaya57
 Saxon, Andrew J.18
 Sayar, Kemal75
 Schaffer, Ayal67
 Schalling, Martin26
 Schatzberg, Alan P.3
 Scheiber, Stephen C.31
 Scheurich, Neil67
 Schiffer, Randolph B.1
 Schlaepfer, Thomas9
 Schlozman, Steven C.38
 Schmahl, Christian76
 Schmidt, Jr., Chester W.30, 50, 68
 Schmidt, Ulrike55
 Schneider, Lon S.69
 Schoenbaum, Michael73
 Schoener, Gary R.5
 Schoevers, Robert A.57, 61
 Schork, Nicholas J.49, 55
 Schrier, Agnes49
 Schubmehl, James Q.19
 Schulz, S. Charles81
 Schumann, Gunter34
 Schummer, Gary J.62
 Schwartz, Ken77
 Schwartz, Michael A.34
 Schwartz, Robert P.74
 Sciolla, Andres49, 82
 Scott, Jan L.70
 Scott, Marcia21
 Scott, William C.62
 Scully, Jr., James H.7, 9, 20, 72
 Seale, Deborah E.79
 Searls, Michael26
 Sekhon, Harry66
 Seligman, Roslyn22
 Seritan, Andrea L.69
 Sewell, Daniel67
 Sexson, Sandra B.29
 Shabir, Amara56
 Shaffer, David29
 Shamsan, Amal49
 Shanfield, Stephen B.48
 Shannahoff-Khalsa, David S.7
 Shapiro, Edward R.29, 42, 64
 Sharfstein, Steven S.11, 35, 57
 Sharif, Zafar57
 Sharma, Santvana67
 Sharma, Sonali63
 Sharp, Burt77
 Shaw, Kaijie31
 Shea, M. Tracie68, 85
 Shea, Shawn C.42
 Shear, M. Katherine36
 Sheehan, David V.26
 Shen, Hong44
 Shenoy, Ramakrishnan21, 50
 Shida, Miyuki83
 Shim, Ruth S.69
 Shimkunas, Al85
 Shoemaker, Erica Z.64
 Shrout, Patrick36
 Shtasel, Derri38
 Shugart, Yin57
 Shulman, Kenneth I.59
 Shurtleff, David76
 Siegel, Lawrence A.77
 Siegel, Richard L.27
 Siever, Larry J.75, 76, 85
 Silk, Kenneth R.33, 68, 75, 76
 Silver, Ivan22
 Silver, Stuart B.1
 Silverman, Richard A.64
 Silverstein, Suzanne80
 Simeon, Daphne36, 57, 78
 Simon, Asher28
 Simon, Gregory F.40, 73
 Simon, Robert I.26, 42
 Singh, Bruce S.25, 50
 Singh, Meeta5
 Singh, Vivek67
 Sirotka, Pinkhas66
 Skodol, Andrew E.36, 68, 85
 Slater, James P.49
 Slattery, Marcia J.44
 Sledge, William H.48
 Slotkin, Theodor C.77
 Small, Dana M.33
 Small, Gary W.6
 Smallwood, Patrick45
 Smit, Martina50
 Smith, Meg68
 Smith, Thomas E.49
 Smoller, Jordan W.33
 Snowden, Mark52
 Solanto, Mary2
 Solari, Hugo A.82
 Soloff, Paul H.76
 Soltys, Stephen M.42
 Sonawalla, Shamsah B.49, 67, 76
 Soorya, Latha57
 Sorel, Eliot28
 Sorkin, Joannette A.63
 Sorrentino, Renee M.51, 83
 Sowell, Elizabeth R.76
 Sowers, Wesley E.77
 Specker, Edgar83
 Spencer, Thomas J.6, 9, 27
 Sperber, Jacob22
 Spitz, Deborah29, 71
 Sprafkin, Joyce64
 Srabstein, Jorge C.53
 Srinivasaraghavan, Jagannathan69
 Srirangson, Apisamai43
 Stabinsky, Harvey26
 Stabinsky, Susan26, 64
 Stack, Jessica49
 Stahl, Stephen M.5, 19
 Stanford, Laurence R.76
 Stankowski, Joy F.51, 83
 Stanley, Barbara H.37
 Star, Jodi E.21, 44
 Stein, Murray B.69
 Steinberg, Marvin73
 Stern, Harriet C.69
 Stevens, Hanna E.29
 Stevenson, Lisa45
 Stewart, Altha J.28, 32, 74
 Stiles, Paul75
 Stolar, Andrea21
 Stone, Alan A.32
 Stotland, Nada L.28, 54
 Stout, Robert L.68, 85
 Stowe, Zachary N.29
 Stowell, Keith R.44, 28
 Strain, Eric C.18, 46, 69
 Straker, Norman L.1
 Strakowski, Stephen M.8
 Stratigos, Katharine A.21, 28
 Straus, Joshua L.61
 Streiner, David33
 Striepe, Meg I.61
 Stroup, T. Scott66
 Stuart, Heather57, 58
 Su, Ii-Min27, 68
 Subotnik, Kenneth I.87
 Sudak, Donna M.21, 29, 42
 Sullivan, Ann Marie T.32
 Sullivan, Patrick F.57
 Sung, Young H.76
 Suomi, Stephen J.23
 Suppes, Patricia36
 Sussman, Jillian64
 Swartz, Holly A.17, 62
 Swartz-Vanetik, Marnina66
 Sweeney, John A.82
 Swenson, John R.73
 Swift, Robert M.10, 23
 Swindle, Ralph W.26
 Szarek, Bonnie J.47
 Szarek, Bonnie S.68
 Szigethy, Fva M.28, 30
 Szmukler, George82
- T**
- Taanila, Anja27
 Tabet, Caroline C.87
 Tahilani, Kavita35
 Taintor, Zebulun C.44, 85
 Takhar, Jatinder80
 Talbott, John A.37
 Tammelin, Tuja27
 Tamminga, Carol A.35
 Tampi, Rajesh R.1
 Tanaka, Yoko81
 Tandon, Rajiv6, 51
 Tanskanen, Päivikki48
 Tariot, Pierre N.2, 8
 Tasman, Allan74
 Taxman, Faye S.73
 Taylor, Craig B.73
 Taylor, Janet50
 Taylor, Lynn E.74
 Taylor, Valerie29
 Temporini, Humberto23
 ten Doesschate, Roelof49
 Thakur, Mugdha E.3
 Thase, Michael E.3, 17, 36, 41, 67, 86
 Thienhaus, Ole J.71
 Thomas, Jean M.69
 Tiamson-Kassab, Maria L.A.64
 Tillman, Jane G.64
 Tint, Aung83
 Titchenal, Kay H.42
 Tommasini, Anthony53
 Tong, Lowell D.21
 Toomey, Jennifer71
 Tormancu, Sari25
 Tortorella, Alfonso74
 Townsend, Wilma L.78
 Tracy, Martin G.22, 45
 Trainor, Brian C.53
 Trimble, Michael R.18
 Trinh, Nhi-Ha T.53
 Trinidad, Anton C.52, 75
 Trippitelli, Carol I.28
 Trivedi, Madhukar H.22
 Tross, Susan83
 Trujillo, Manuel38, 73
 Trzaskoma, Quynh81
 Tsai, Guochuan E.58
 Tsai, Kuan-Yi48
 Tschan, Werner54
 Tsceng, Kuei-Yuan34
 Tsuang, John W.30
 Tsuang, Ming T.22
 Tucker, Phebe M.1
 Tuinebreijer, Wilco57
 Turkington, Douglas8, 69
 Tuttle, Jeffrey67
 Tye, Larry32, 51
 Tyrer, Peter J.33

PARTICIPANT INDEX

Tzourio-Mazoyer, Nathalie.....37

U

Udomratn, Pichet..... 14, 50
 Urbaitis, John C..... 45, 55
 Ursano, Robert J.....51
 Uwakwe, Richard.....33

V

Vahia, Ipsit.....84
 Vahtera, Jussi.....53
 Vaillant, George.....50
 Valença, Alexandre M.....26
 Valles, Rene J.....28
 van Aalst, Gerda.....61
 Van Ameringen, Michael A.....26
 van Elburg, Annemarie A.....55
 Van Os, Jim.....35
 van Zyl, Louis T.....73
 Van, Henricus..... 57, 61
 Vanderpool, Donna..... 22, 51
 Vanyukov, Michael.....35
 vanZyl, Louis T.....73
 Varma, Sudhepta.....70
 Varrell, James.....64
 Vasa, Monisha R..... 63, 83
 Vaswani, Meera..... 25, 48, 66, 82
 Vaswani, Sanjay M..... 23, 27
 Vedamurthachar, A.....82
 Vejola, Juha M..... 25, 27, 48
 Vela, Ricardo M.....1
 Velazquez, Maria.....74
 Veldhuizen, Scott.....67
 Velligan, Dawn I.....8
 Velyvis, Vytas.....7
 Venisse, Jean-Luc.....38
 Ventura, Joseph..... 81, 87
 Verbraak, Marc.....49
 Verduin, Marcia J.....4
 Viamontes, George I.....75
 Vickery, Ken.....45
 Victor, Jisa.....83
 Viera, Eduard..... 33, 45
 Vincent, Kathy M.....87
 Vink, Jacqueline M.....48
 Vinod, Katecki.....49
 Virtanen, Marianna.....53
 Vittone, Alicia B.....79
 Vocci, Frank..... 50, 69
 Vogel-Scibilia, Suzanne E.....69
 Volkow, Nora D..... 13, 20, 30, 33, 46, 53
 Volpp, Serena Y.....62
 von Gunten, Charles F.....43
 Von Korff, Michael.....73

W

Wadhwa, Pathik D.....29
 Wagner, Angela.....55
 Wahlstrom, Carl M.....29
 Wain, Harold J.....51
 Wainberg, Milton I.....56
 Waldbaum, Marjorie F.....46
 Walker, Sandra C..... 22, 63
 Walker-Schmucker, Willadene.....21
 Wall, Chuck.....23
 Wallace, Charles J.....87
 Walsh, B. Timothy.....55
 Wang, Gene-Jack.....33
 Wang, Ting.....57
 Waterman, G. Scott..... 55, 85
 Watson Jr, Clarence.....29
 Way, Bruce B.....85
 Wayne, Tristin.....71
 Weder, Natalie D..... 28, 44
 Weerasakera, Priyanthy.....74
 Weiden, Peter J..... 6, 8, 83
 Weil, Colin A.....65
 Weine, Stevan M..... 23, 87
 Weiner, Flyse D.....64
 Weiner, Richard.....32
 Weinstein, Henry C..... 21, 85
 Weisler, Richard H.....27
 Weiss, Margaret D.....64
 Weiss, Roger D..... 10, 23
 Weisser, Lydia F.....22
 Weissman, Sidney.....72
 Wellisch, David K.....49
 Weng, Wan-Chen..... 49, 76
 West, Joyce C..... 25, 27
 West, Sara G.....26
 Westermeyer, Joseph J..... 63, 73
 Westerveld, Michael.....77
 Wexler, Bruce F.....87
 Whitfield, Theodore H.....53
 Wiersma, Durk.....86
 Wilens, Timothy J..... 2, 6
 Wilfley, Denise.....6
 Wilk, Joshua E.....25
 Wilkins, Jeffery N.....70
 Wilkins, Kirsten M.....1
 Willenbring, Mark L.....84
 Williams, Caroline B.....81
 Williams, Eric R.....45
 Williams, Janet B.W.....23
 Williams, John W.....73
 Williams, Monique M.....73
 Williams, Solomon S.....1
 Wilson, Marlene A.....84
 Wilson, Sarah A.....81
 Wilson, Stephen N.....23
 Winkelman, John W.....2
 Winkler, Dietmar.....32
 Winstead, Daniel K..... 29, 45
 Winston, Arnold.....37
 Wisdom, Jennifer P.....49
 Wisc, Thomas N..... 44, 68


Wolf, Aron S..... 21
 Wolfe, Mary Kay..... 83
 Wolfe, Nicole F..... 61
 Wong, Vanessa..... 64
 Woolley, Stephen B..... 27, 82
 Worley, Jessica L..... 22
 Worley, Linda I.M..... 69
 Worthington, John J..... 61
 Wozniak, Jeffrey R..... 54
 Wright III, Jesse H..... 29, 42
 Wright, Jesse H..... 3, 8, 29, 42
 Wulsin, Lawson R..... 44
 Wunderink, Lex..... 86
 Wurzbeger, Bezalel..... 85
 Wynn, John D..... 52

Y

Yaari, Roy.....8
 Yager, Joel.....6, 21, 35
 Yamada, David..... 53
 Yang, Chih-Wci..... 27, 68
 Yang, Chih-Yu..... 68
 Yang, Yi-Hsin..... 27
 Yates, Alayne.....25
 Yen Jean, Mei-Chu.....27
 Yen, Shirley..... 68
 Ycomans, Frank F..... 61
 Yeung, Albert S..... 49, 76
 Yildiz-Yesiloglu, Aysegul..... 33, 67
 Yohanan, Monique..... 46
 Young, Diane D..... 26, 48, 82
 Young, Jason..... 28
 Young, Keith W..... 45, 50, 56
 Young, M. Scott..... 75
 Yucel, Kaan..... 29
 Yudofsky, Stuart C..... 17, 41, 43, 58, 65
 Yum, Sun Y..... 32, 74
 Yurgelun-Todd, Deborah..... 33

Z

Zak, Paul J..... 79
 Zanarini, Mary C..... 68, 81
 Zaretsky, Ari F..... 18
 Zarkin, Gary..... 84
 Zaubler, Thomas S..... 49
 Zhao, Yangyi..... 81
 Ziegler, Michael G..... 65
 Ziegler, Penelope P..... 22
 Ziclasek, Juergen..... 84
 Zimmerman, Mark..... 26, 40, 48, 67, 68, 82, 83
 Zisook, Sidney..... 43
 Zisook, Stephanie A..... 22
 Zohar, Joseph..... 56, 57
 Zolovska, Beata A..... 23
 Zonana, Howard V..... 44, 7
 Zuchowski, Steven J..... 71
 Zuzarte, Edward..... 50
 Zweben, Allen..... 23, 84
 Zybert, Patricia..... 68



160TH ANNUAL MEETING
AMERICAN PSYCHIATRIC ASSOCIATION
ADDRESSING PATIENT NEEDS
ACCESS, PARITY AND HUMANE CARE

SAN DIEGO, CALIFORNIA, MAY 19-24, 2007

2007 Annual Meeting Online

Your One-Stop Educational Resource library


"APA Annual Meeting Online" is an e-resource for psychiatrists to learn and earn CME credits through the 2007 Annual Meeting Online library - providing audio-visual programs that offer a dynamic learning experience 24/7.

- Special pre-meeting and on-site pricing to access the library
- 70+ hours of new 2007 meeting content
- Vast online, searchable database
- Review presentations from world renowned faculty
- Participate online and earn CME credit
- Free admission for Industry-Supported Symposia and previous meetings content
- DVD-ROMs also available

More information will be available post-meeting. Look for more details to follow.

Visit the APA Annual Meeting Online
www.psych.org/amlibrary

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



THE FIRST AND LAST

Visit the APPI BOOKSTORE at the 2007 APA ANNUAL MEETING IN SAN DIEGO!

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online—including PsychiatryOnline.com.

The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss Author Book Signings or discounts for APA Members—see you there!

APPI Bookstore Hours


Saturday, May 19 10:00 am – 5:00 pm
 Sunday, May 20 10:00 am – 4:30 pm
 Monday, May 21 10:00 am – 5:30 pm
 Tuesday, May 22 10:00 am – 6:00 pm
 Wednesday, May 23 10:00 am – 3:00 pm



Gabbard's Treatments of Psychiatric Disorders, Fourth Edition

Edited by Glen O. Gabbard, M.D.


2007 • 986 pages • ISBN 978-1-58562-216-0 • Hardcover
 \$195.00 • Item #62216



Manual of Clinical Psychopharmacology, Sixth Edition

Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles DeBattista, D.M.H., M.D.

2007 • 720 pages • ISBN 978-1-58562-317-4 • Paperback
 \$79.00 • Item #62317



Introductory Textbook of Psychiatry, Fourth Edition

Nancy C. Andreasen, M.D., Ph.D., and Donald W. Black, M.D.

2006 • 668 pages • ISBN 978-1-58562-223-8 • Hardcover
 \$78.00 • Item #62223

2006 • 668 pages • ISBN 978-1-58562-272-6 • Paperback • \$58.00 • Item #62272



Essentials of Psychosomatic Medicine

Edited by James L. Levenson, M.D.

2007 • 604 pages • ISBN 978-1-58562-246-7 • Paperback
 \$85.00 • Item #62246



The American Psychiatric Publishing Board Prep and Review Guide for Psychiatry

Edited by James A. Bourgeois, O.D., M.D., Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.

2007 • 496 pages • ISBN 978-1-58562-237-5 • Paperback \$75.00 • Item #62237




Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems

A Resource Book of Medication Information Handouts, Third Edition

Edited by Mina K. Dulcan, M.D.

2007 • 759 pages • ISBN 978-1-58562-253-5 • Paperback • \$79.00 • Item #62253



DSM-IV-TR® Casebook, Volume 2

Experts Tell How They Treated Their Own Patients

Edited by Robert L. Spitzer, M.D., Michael B. First, M.D., Janet B. W. Williams, D.S.W., and Miriam Gibbon, M.S.W.

2006 • 483 pages • ISBN 978-1-58562-219-1 • Hardcover • \$62.00 • Item #62219

2006 • 483 pages • ISBN 978-1-58562-220-7 • Paperback • \$42.00 • Item #62220



Essentials of Geriatric Psychiatry

Edited by Dan G. Blazer, M.D., Ph.D., David C. Steffens, M.D., M.H.S., and Ewald W. Busse, M.D.

2007 • 499 pages • ISBN 978-1-58562-247-4 • Paperback
 \$75.00 • Item #62247



The First and Last Word in Psychiatry
 American Psychiatric Publishing, Inc.
 1000 Wilson Boulevard, Suite 1825
 Arlington, VA 22209-3901

Phone: 703-907-7322 or 1-800-368-5777 • Mon.-Fri., 9 am to 5:30 pm, ET
 Fax: 703-907-1091 Email: appi@psych.org Web: www.appi.org

Please reference priority code AH739 when ordering

WORD IN PSYCHIATRY

JANUARY

Managing Metabolic Abnormalities in the Psychiatrically Ill

A Clinical Guide for Psychiatrists

Edited by Richard A. Bermudes, M.D., Paul E. Keck, Jr., M.D., and Susan L. McElroy, M.D.

2007 • 326 pages • ISBN 978-1-58562-241-2
Paperback • \$49.00 • Item #62241

Transcranial Magnetic Stimulation in Clinical Psychiatry

Edited by Mark S. George, M.D., and Robert H. Belmaker, M.D.

2007 • 289 pages • ISBN 978-1-58562-197-2
Paperback • \$55.00 • Item #62197

Complementary and Alternative Treatments in Mental Health Care

Edited by James H. Lake, M.D., and David Spiegel, M.D.

2007 • 504 pages • ISBN 978-1-58562-202-3
Paperback • \$56.00 • Item #62202

Clinical Manual of Psychiatry and Law

Robert I. Simon, M.D., and Daniel W. Shuman, J.D.

2007 • 263 pages • ISBN 978-1-58562-249-8
Paperback • \$47.95 • Item #62249

FEBRUARY

Clinical Manual of Geriatric Psychopharmacology

Sandra A. Jacobson, M.D., Ronald W. Pies, M.D., and Ira R. Katz, M.D., Ph.D.

2007 • 829 pages • ISBN 978-1-58562-252-8
Paperback • \$74.00 • Item #62252

MARCH

Handbook of Dynamic Psychotherapy for Higher Level Personality Pathology

Eve Caligor, M.D., Otto F. Kernberg, M.D., and John F. Clarkin, Ph.D.

2007 • 284 pages • ISBN 978-1-58562-212-2
Hardcover • \$60.00 • Item #62212

Study Guide to Clinical Psychopharmacology

A Companion to The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition

Kelly L. Cozza, M.D., Scott C. Armstrong, M.D., Jessica Oesterheld, M.D., and Neil B. Sandson, M.D.

2007 • 304 pages • ISBN 978-1-58562-301-3
Paperback • \$37.95 • Item #62301

Recognition and Prevention of Major Mental and Substance Use Disorders

Edited by Ming T. Tsuang, M.D., Ph.D., D.Sc., William S. Stone, Ph.D., and Michael J. Lyons, Ph.D.

American Psychopathological Association

2007 • 429 pages • ISBN 978-1-58562-308-2
Hardcover • \$65.00 • Item #62308

APRIL

Gabbard's Treatments of Psychiatric Disorders, Fourth Edition

Edited by Glen O. Gabbard, M.D.

2007 • 986 pages • ISBN 978-1-58562-216-0
Hardcover • \$195.00 • Item #62216

Manual of Clinical Psychopharmacology, Sixth Edition

Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles DeBattista, D.M.H., M.D.

2007 • 720 pages • ISBN 978-1-58562-317-4
Paperback • \$79.00 • Item #62317

Traumatic Dissociation

Neurobiology and Treatment

Edited by Eric Vermetten, M.D., Ph.D., Martin J. Dorahy, Ph.D., and David Spiegel, M.D.

2007 • 416 pages • ISBN 978-1-58562-196-5
Paperback • \$62.00 • Item #62196

MAY

Diagnostic Issues in Dementia

Advancing the Research Agenda for DSM-V

Edited by Trey Sunderland, M.D., Dilip V. Jeste, M.D., Olusegun Baiyewu, M.D., Paul J. Sirovatka, M.S., and Darrel A. Regier, M.D., M.P.H.

2007 • 192 pages • ISBN 978-0-89042-298-4
Paperback • \$45.00 • Item #2298

Clinical Manual of Eating Disorders

Edited by Joel Yager, M.D., and Pauline S. Powers, M.D.

2007 • 512 pages • ISBN 978-1-58562-270-2
Paperback • \$49.00 • Item #62270

psychiatryonline
I belong Learning in Psychiatry™

Subscribe/Renew Help

SEARCH

Home DSM Library >> Textbooks >> Journals >> APA Guidelines A-Z Index

PsychiatryOnline.com — a state-of-the-art website offering access to the most trusted and reliable psychiatric references for patient diagnosis, treatment, research, and professional development and lifelong learning, including

DSM-IV-TR® and *American Journal of Psychiatry*. Featuring search, navigation, and cross-referencing tools custom-designed for psychiatrists. Subscribe now at **www.psychiatryonline.com**.

See a demo at the **APPI Bookstore**.



Join the American Psychiatric Foundation for four special events at the 2007 APA Annual Meeting.

2007 Annual Benefit "Celebrate San Diego!"

Saturday, May 19, 2007

7- 10 p.m.

San Diego Wine & Culinary Center


200 Harbor Drive

San Diego, California

You are invited to an exciting special evening featuring a California wine tasting, regional cuisine, live music and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation's grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable.

Tickets:

\$125 per person. To order tickets on Friday May 18, call (703) 907-8512. For tickets on Saturday May 19, please visit the foundation booth in the Member Center.



"Conversations" featuring Brooke Shields

Tuesday, May 22, 2007

5:30-6:30 p.m.

San Diego Marriott, San Diego Ballroom B/C, Lobby Level

Free to all annual meeting attendees

Don't miss our sixth annual "Conversations" event, an interactive series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Actress and former model Brooke Shields will share her personal story of postpartum depression and recovery and the ensuing media frenzy.

Supported by an unrestricted educational grant from:

Take Me Out to the Ball Game

Field level tickets (\$38 ticket value):

Tuesday, May 22 or Wednesday, May 23, 2007 at 7 p.m. - \$35 per ticket

Thursday, May 24, 2007 - 7p.m. - \$24 per ticket

Upper level tickets:

Tuesday, May 22 or Wednesday, May 23, 2007 at 7 p.m.- \$12 per ticket

Thursday, May 24, 2007 - 7 p.m. \$11 per ticket

Enjoy a spring evening at PETCO Park while supporting the work of the foundation. The San Diego Padres will play the Chicago Cubs in an exciting three-game series. For every ticket sold, \$5 will be contributed to the foundation. To order tickets, log on to www.padres.com/groups. The username is APA and the password is PADRES.

Golfers of the APA 2007 Annual Golf Tournament

Monday, May 21, 2007

8 a.m. with a shotgun start

Maderas Golf Club

Enjoy a round of golf at the Maderas Golf Club. Your \$210 registration fee includes transportation to the course, greens fees, carts, lunch, amenities and prizes. Golf club rental is offered by the course for \$70. Event proceeds will benefit the foundation. For more information on the course, visit www.maderasgolf.com. To enter, please contact Stan Jennings, M.D., at mbears@comcast.net or (804) 320-7881.

INDUSTRY-SUPPORTED SYMPOSIUM 1
 Saturday, May 19, 2007, 12:30 p.m.-3:30 p.m.
 Marina Ballroom, South Tower, Level Three, Marriott

Please join us for an interactive CME Lunch Symposium

Clinical Management of ADHD

ATTENTION SPECTRUM DISORDERS

APA 160th Annual Meeting

May 19, 2007

LUNCH: 12:00PM-12:30PM

SYMPOSIUM: 12:30PM-3:30PM

SAN DIEGO MARRIOTT HOTEL AND MARINA

Marina Ballroom South Tower

CHAIRPERSON

Timothy E. Wilens, MD
 Harvard Medical School,
 Boston

FACULTY

Paul G. Hammerness, MD
 Massachusetts General Hospital,
 Boston

Keith McBurnett, PhD
 University of California,
 San Francisco

Mary Solanto, PhD
 Mount Sinai School of Medicine,
 New York

Christopher J. Kratochvil, MD
 University of Nebraska
 Medical Center, Omaha

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be able to:

- Implement a multifaceted approach to diagnosing children and adults with ADHD, comparing and contrasting the advantages and disadvantages of various diagnostic tools and rating scales
- Describe the special considerations required in the diagnosis and management of preschool children, adults, and other special groups with ADHD
- Understand the role that psychosocial interventions play in the management and treatment of ADHD
- Identify comorbid conditions related to ADHD and make appropriate recommendations for pharmacotherapy
- Understand, evaluate, and appropriately manage the cardiovascular risks associated with the use of medications for ADHD
- Describe the bidirectional overlap between ADHD and substance use disorders that has been observed both statistically and clinically.

12:30PM-12:40PM Welcome and Introductions

12:40PM-1:05PM Office-based Diagnosis

1:05PM-1:30PM Effective Psychosocial Treatments for Adults with ADHD

1:30PM-1:55PM Addressing Comorbidity in ADHD

1:55PM-2:20PM Addressing Treatment of Special Groups

2:20PM-2:45PM Managing Hypertension, Cardiovascular Issues, and SUD in ADHD

2:45PM-3:30PM Question and Answer Session

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association



Supported by an educational grant from Shire Pharmaceuticals Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 2

Saturday, May 19, 2007, 12:30 p.m.-3:30 p.m.

Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

A CME LUNCH SYMPOSIUM

Expert Dialogue on Alzheimer's Disease

Diagnostic and Referral Issues, Treatment of Cognitive Deficits, Ameliorating the Behavioral Complications, and Comprehensive Multidisciplinary Care

Saturday, May 19, 2007 • 12:00 PM – 3:30 PM • Douglas Pavilion C/D • Ground Level • Manchester Grand Hyatt

This interactive symposium will use case-based, moderated dialogue between senior experts who care for patients with Alzheimer's disease. The symposium will allow for active discussion of participants' questions and encourage experts to share their opinions and recommendations.

AGENDA

12:00 LUNCH

12:30 INTRODUCTION

George T. Grossberg, MD (Chair)
 Samuel W. Fordyce Professor
 Saint Louis University School of Medicine

12:45 DIAGNOSTIC AND REFERRAL ISSUES

William E. Reichman, MD
 Professor of Psychiatry and Neurology
 Robert Wood Johnson Medical School

1:15 TREATING COGNITIVE DEFICITS IN PATIENTS WITH ALZHEIMER'S DISEASE

Pierre N. Tariot, MD
 Research Professor of Psychiatry
 University of Arizona College of Medicine

1:45 AMELIORATING THE BEHAVIORAL COMPLICATIONS IN PATIENTS WITH ALZHEIMER'S DISEASE

Jacobo E. Mintzer, MD
 Professor of Psychiatry, Neurology, Physiology,
 and Neuroscience
 Medical University of South Carolina

2:15 COMPREHENSIVE MULTIDISCIPLINARY CARE

Warachal E. Faison, MD
 Assistant Professor of Psychiatry
 Medical University of South Carolina

2:45 QUESTION AND ANSWER SESSION

George T. Grossberg, MD (Chair)

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Sponsored by



Supported by an educational grant from

Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 3
 Saturday, May 19, 2007, 12:30 p.m.-3:30 p.m.
 Manchester Ballroom, Second Level, Manchester Grand Hyatt



RECOGNITION AND MANAGEMENT OF RESTLESS LEGS SYNDROME (RLS) IN PSYCHIATRIC PRACTICE

2007 APA ANNUAL MEETING

SATURDAY, MAY 19, 2007 | 12:00 PM – 3:30 PM
 JOHN W. WINKELMAN, MD, PhD | Activity Chairperson
 Manchester Ballroom | Manchester Grand Hyatt
 San Diego, California



Supported by an educational grant from **Boehringer Ingelheim**

AGENDA

12:00 PM – 12:30 PM	LUNCH
12:30 PM – 12:35 PM	OPENING REMARKS John W. Winkelman, MD, PhD
12:35 PM – 12:45 PM	INTERACTIVE CASE PRESENTATION John W. Winkelman, MD, PhD
12:45 PM – 1:10 PM	UNDERSTANDING RLS: EPIDEMIOLOGY AND CLINICAL FEATURES Barbara A. Phillips, MD
1:10 PM – 1:35 PM	RLS ASSOCIATED PSYCHIATRIC SYMPTOMS Hochang Benjamin Lee, MD
1:35 PM – 1:45 PM	Q & A
1:45 PM – 2:10 PM	TREATMENT OPTIONS FOR RLS Jacques Montplaisir, MD
2:10 PM – 2:35 PM	THE PSYCHIATRIST'S ROLE IN MANAGING RLS Jed E. Black, MD
2:35 PM – 3:25 PM	CLINICAL PATHWAYS: AN INTERACTIVE CASE STUDY John W. Winkelman, MD, PhD <i>Moderator</i>
3:25 PM – 3:30 PM	CLOSING REMARKS John W. Winkelman, MD, PhD

PROGRAM OVERVIEW

Restless legs syndrome (RLS) is a chronic neurological condition characterized by an overwhelming compulsion to move one's legs, usually accompanied by dysesthesias, which are worse during periods of inactivity and at night. A higher prevalence of psychiatric comorbidity, including panic attacks and depression, has been reported in those suffering from RLS. Overlapping symptoms of RLS and psychiatric disorders complicate diagnostic efforts. In particular, sleep disturbance, fatigue, agitation, and diminished concentration are commonly seen in RLS and psychiatric disorders, such as depression. Therefore, it is critical to be aware of diagnostic criteria for RLS and to look for psychological symptoms not commonly associated with RLS. Therapeutic decision making can also be difficult in patients with concurrent RLS and psychiatric disorders. Dopamine receptor agonists are the treatment of choice for RLS; however, antidepressants, which may be required in patients experiencing comorbid depression and anxiety disorders, can worsen RLS. By obtaining a greater understanding of RLS and its associated psychiatric features and comorbidities, psychiatrists can effectively identify patients with RLS and select appropriate treatment strategies, thereby improving patient outcomes. This symposium will include an interactive case-based approach to the diagnosis and management of RLS in patients with psychiatric comorbidities.

LEARNING OBJECTIVES

- After attending this symposium, participants should be better able to:
- Describe prevalence, defining features, and common comorbidities associated with RLS
 - Identify psychiatric symptoms commonly observed in RLS sufferers, and explore the potential causal relationship between these symptoms and RLS
 - Review current treatment strategies for patients with RLS and comorbid psychological symptoms

Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 4
 Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
 Marriott Halls 1-4, North Tower, Lower Level, Marriott

APA 2007 ANNUAL MEETING IN SAN DIEGO

INSIGHTS FROM STAR*D: ARE OUR PATIENTS' NEEDS BEING MET?

LEARNING OBJECTIVES

- At the conclusion of this symposium, the participant should be able to:
- Identify the unmet needs of patients who are unlikely to achieve remission with any one treatment.
 - Evaluate strategies for partial or non-responders that include switching, augmentation, and combination strategies.
 - Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to achieve remission.

Supported by an educational grant from




Saturday, May 19, 2007
6:00-9:00 PM

Marriott San Diego, Marriott Halls 1-4,
 North Tower, Lobby Level

PROGRAM AGENDA

5:30-6:00 PM	Dinner
6:00-6:10 PM	Introduction Maurizio Fava, MD (Chair) Massachusetts General Hospital Harvard Medical School
6:10-6:35 PM	Do Antidepressants Work in the Real World and for Whom? Roy H. Perlis, MD Harvard Medical School Massachusetts General Hospital
6:35-7:00 PM	Polypharmacy to Increase the Chances of Remission Maurizio Fava, MD Massachusetts General Hospital Harvard Medical School
7:00-7:25 PM	Switching Antidepressants: The STAR*D Experience Michael E. Thase, MD University of Pennsylvania
7:25-7:50 PM	Augmentation and Combination Strategies in Treatment-Resistant Depression Alan F. Schatzberg, MD Stanford University School of Medicine
7:50-8:15 PM	The Role of Psychotherapy as Adjunctive Treatment in Depression Amy Farabaugh, PhD Harvard Medical School Massachusetts General Hospital
8:15-9:00 PM	Panel Discussion/Q&A



Sponsored by the
 American Psychiatric Association

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 5
 Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
 Marina Ballroom, South Tower, Level Three, Marriott




6:30 pm - 6:00 pm	Registration/Dinner	
6:00 pm - 6:10 pm	Welcome & Introductions	
6:10 pm - 6:30 pm	David J. Nutt, DSc, FRCP, FRCPsych, FMedSci University of Bristol	
6:30 pm - 6:55 pm	The State of Insomnia: Barriers to Recognition	
6:55 pm - 7:10 pm	North Ravea, MD, PhD University of Wisconsin School of Medicine	
7:10 pm - 7:30 pm	Clinical Correlates	
7:30 pm - 7:45 pm	Madhulika Trivedi, MD, FRCP, FRCPsych, FMedSci Zucker University Medical Center	
7:45 pm - 8:45 pm	Pharmacological Progress in Insomnia	
8:45 pm - 9:00 pm	Panel Discussion Moderated by David Nutt, DSc, FRCP, FRCPsych, FMedSci	
9:00 pm	Adjournment	

At the conclusion of this symposium, the participant should be able to:


- Review the prevalence of insomnia and its link to the consequences of morbidity and mortality in the affected populations
- Recognize patient presentations of primary and secondary insomnia and understand the causal relationship of the psychophysiological factors
- Identify the abnormal sleep components in people with insomnia and discuss how the mechanism of action of current pharmacologic agents address the inherent abnormalities in a patient's sleep cycle
- Discuss future pharmacological and clinical features of GABA_A modulators and how they increase our understanding of the sleep mechanism

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 Category 1 Credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim credit for those activities in which he or she participated. Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, contact the APA Web site at www.psych.org, call toll free at 1-888-357-7324 within the United States or Canada or 703-907-7300.



INDUSTRY-SUPPORTED SYMPOSIUM 6
 Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
 Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

YOU ARE INVITED to Attend a Complimentary Dinner Symposium at the APA 2007 Annual Meeting



Earn Up to 3 *AMA PRA Category 1 Credits*[™]

Saturday, May 19 - 5:30 PM
 Manchester Grand Hyatt, Douglas Pavilion C/D
 San Diego, CA

A complimentary dinner will be served as a part of this program.

PRESENTED BY CHAIRPERSON:
John M. Kane, MD
 The Zucker Hillside Hospital

FACULTY
Michael H. Allen, MD
 Colorado Psychiatric Hospital
Rona Hu, MD
 Stanford University School of Medicine
Stephen R. Marder, MD
 Semel Institute of Neuroscience and Human Behavior at UCLA

OBJECTIVES
 Upon completion of this activity, participants should be able to:

- 1) Identify and implement clinical assessment tools to measure patient health, psychopathology, adverse effects, and functioning
- 2) Increase awareness of underlying medical comorbidities that may impact patient outcomes
- 3) Recognize real-world challenges patients face that impact functioning and long-term outcomes


AGENDA

5:30 PM - Dinner
 6:00 PM - Welcome and Introduction
 6:15 PM - **Monitoring Physical Health** - Stephen R. Marder, MD
 6:50 PM - **Measuring and Managing Agitation** - Michael H. Allen, MD
 7:25 PM - **Measuring Cognitive and Functional Outcomes in Schizophrenia: A Practical Guide for Clinicians** - Rona J. Hu, MD
 8:00 PM - **Measurement-Based Clinical Decision-Making in Patients with Schizophrenia** - John M. Kane, MD
 8:35 PM - Panel Discussion/Q&A
 9:00 PM - Symposium Adjournment

WHO SHOULD ATTEND
 This program will benefit all clinicians who want to increase their knowledge of the assessment and treatment of patients with schizophrenia. This includes psychiatrists, neurologists, family practitioners, internists and other healthcare professionals.

CONTINUING EDUCATION CREDITS
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity of a maximum of 3 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7324 (within the U.S. or Canada) or 703-907-7300.



INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

Saturday, May 19, 2007 || 6:00-9:00 pm || Manchester Grand Hyatt, Manchester Ballroom, Second Level

SAN DIEGO, CA

THE PREVAILING PREDOMINANT POLE OF BIPOLAR DEPRESSION

PROGRAM AGENDA

- 5:30-6:00 pm **Dinner**
- 6:00-6:10 pm **Introduction**
Mark A. Frye, MD (Chair)
Mayo Clinic
Mayo College of Medicine
- 6:10-6:35 pm **Neurobiology of Bipolar Depression: Implications for Treatment**
Robert M. Post, MD
Penn State University College of Medicine
Biological Collaborative Network
- 6:35-7:00 pm **New Treatment Options for Bipolar Depression**
Marcia L. Verduin, MD
Medical University of South Carolina
- 7:00-7:25 pm **Clinical Correlates Associated with Treatment-Emergent Mania**
Mark A. Frye, MD
Mayo Clinic
Mayo College of Medicine
- 7:25-7:50 pm **The Clinical Interface Between Obesity and Bipolar Depression**
Susan L. McElroy, MD
University of Cincinnati
- 7:50-8:15 pm **Clinical Challenges of Diagnosing and Treating Adolescents with Bipolar Depression**
Kiki Chang, MD
Stanford University School of Medicine
- 8:15-9:00 pm **Panel Discussion/Q&A**

LEARNING OBJECTIVES

- At the conclusion of this symposium, the participant should be able to:
1. Describe the neurobiology of bipolar depression.
 2. Discuss current evidence-based medicine for the treatment of bipolar depression.
 3. Realize the impact of obesity and bipolar depression, and the challenges of diagnosing and treating bipolar depression in adolescence.
 4. Integrate these data into clinical practice.

CREDIT DESIGNATION


The APA designates this educational activity for a maximum of 3 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an educational grant from  GlaxoSmithKline

 Sponsored by the American Psychiatric Association

**PRESENTED
 AT THE
 APA 2007
 ANNUAL
 MEETING**



INDUSTRY-SUPPORTED SYMPOSIUM 8
Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

THE ONGOING DEBATE SURROUNDING ATYPICALS
Are the Benefits Worth the Risks?

APA 160th Annual Meeting
 Satellite Symposium

AGENDA AND FACULTY

- 7:30AM *Breakfast*
- 8:00AM *Introductory Remarks/Welcomes*
Stephen R. Marder, MD (Chair)
Semel Institute for Neuroscience and Human Behavior at UCLA
- 8:10AM *Balancing Efficacy and Side Effects*
Samuel J. Keith, MD
University of New Mexico
- 8:50AM *The Effect of Atypicals on Health Outcomes in Light of Pre-Existing Medical Risks*
Henry A. Nasrallah, MD
University of Cincinnati Medical Center
- 9:30AM *The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia*
Elizabeth Bromley, MD
University of California, Los Angeles
- 10:10AM *New Mechanisms and Innovative Pharmacologic Strategies*
Stephen R. Marder, MD
- 10:50AM *Concluding Remarks*
Stephen R. Marder, MD

Each presentation includes time for attendee Q&A


EDUCATIONAL OBJECTIVES

- At the conclusion of this symposium, the participant should be able to:
- 1) Compare and contrast the effectiveness of atypical antipsychotics in terms of symptom control and cognitive functioning in schizophrenia
 - 2) Examine multiple dimensions that contribute to overall functional outcomes of persons with schizophrenia, including health considerations, medication tolerability, and adherence
 - 3) Discuss the rationale for drug selection to achieve optimal mental and physical outcomes
 - 4) Review the risk/benefit ratio of atypicals in early phase schizophrenia

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity of a maximum of 3 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the  American Psychiatric Association

Supported by an educational grant from Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals.

 Solvay Pharmaceuticals

 Wyeth

**Sunday
 May 20, 2007**
Breakfast: 7:30AM
Symposium:
8:00AM-11:00AM
 Marriott Hotel & Marina
 Marriott Hall 1-4
 San Diego, California



INDUSTRY-SUPPORTED SYMPOSIUM 9
 Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
 Marina Ballroom, South Tower, Level Three, Marriott

2007 APA Annual Meeting • Sunday, May 20, 2007


STILL SLEEPY AFTER ALL THESE CURES

HYPERMOMNIA IN PSYCHIATRY

May 20, 2007 • Breakfast • 7:30-8:00 a.m. • Symposium • 8:00-11:00 a.m.
Marina Ballroom, South Tower, Level Three • San Diego Marriott Hotel & Marina

<p>AGENDA</p> <p>7:30-8:00 a.m. Breakfast</p> <p>8:00-8:15 a.m. Welcome and Introduction Stephen M. Stahl, MD, PhD - Chairman Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine</p> <p>8:15-8:40 a.m. The Neurobiology of Hypersomnia Stephen M. Stahl, MD, PhD - Chairman Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine</p> <p>8:40-9:05 a.m. The Clinical Spectrum of Hypersomnia Daniel J. Buysse, M.D. Psychiatry, University of Pittsburgh School of Medicine</p> <p>9:05-9:25 a.m. Measurement of Hypersomnia Meeta Singh, M.D. Sleep Disorders Center, Henry Ford Hospital</p> <p>9:25-9:50 a.m. Strategies for the Management of Hypersomnia Leslie P. Lundt, M.D. Faculty, Idaho State University Director, Foothills Foundation Boise, Idaho</p> <p>9:50-10:15 a.m. Prevalence and Consequences of Hypersomnia Christopher L. Drake, Ph.D. Senior Staff Scientist, Hospital Sleep Center Assistant Professor Psychiatry and Behavioral Neurosciences Wayne State College of Medicine</p> <p>10:15-11:00 a.m. Faculty Panel Question-and-Answer Session</p>	<p>OBJECTIVES</p> <p>At the conclusion of this symposium, the participant should be able to:</p> <ul style="list-style-type: none"> • Discuss the prevalence and most common types of hypersomnia • Describe the most common symptoms and signs of hypersomnia • Choose the best to test for hypersomnia • Recognize the most current evidence-based treatment strategies for hypersomnia <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 <i>AMA PRA category 1 credits</i>[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>Sponsored by the American Psychiatric Association </p> <p>Supported by an educational grant from </p>
---	---

INDUSTRY-SUPPORTED SYMPOSIUM 10
 Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
 Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt



Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

<p>Breakfast 7:30 AM - 8:00 AM</p> <p>Scientific Session 8:00 AM - 11:00 AM</p> <p>Welcome and Preactivity Educational Outcomes Measurement 8:00 AM - 8:10 AM</p> <p>Overview of ADHD 8:10 AM - 8:35 AM</p> <p>Neurocircuitry in ADHD 8:35 AM - 9:00 AM</p> <p>Neuropsychology in ADHD 9:00 AM - 9:25 AM</p> <p>Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults 9:25 AM - 9:50 AM</p> <p>Pharmacologic Treatment of ADHD: Focus on Attention 9:50 AM - 10:10 AM</p> <p>Postactivity Measurement 10:10 AM - 10:15 AM</p> <p>Discussion, Q&A 10:15 AM - 11:00 AM</p>	<p>Thomas J. Spencer, MD</p> <p>Thomas J. Spencer, MD</p> <p>George Bush, MD, MMSc</p> <p>Ronna Fried, PhD</p> <p>Steven A. Safren, PhD</p> <p>Timothy E. Wilens, MD</p> <p>Thomas J. Spencer, MD</p> <p>Thomas J. Spencer, MD and Faculty</p>	<p>Learning Objectives</p> <p>At the conclusion of this symposium, the participant should be able to:</p> <ol style="list-style-type: none"> 1. Describe the neurobiology and clinical presentation of ADHD. 2. Discuss the regions of the brain and neurotransmitters involved in ADHD. 3. Evaluate the various pharmacological treatment options and their effects on the improvement of attention. 4. Recognize the neuropsychological underpinnings of ADHD. 5. Explain ADHD's impact on cognition and executive functioning. <p>Program Chair Thomas J. Spencer, MD Associate Chief Clinical and Research Program in Pediatric Psychopharmacology Massachusetts General Hospital Associate Professor, Psychiatry Harvard Medical School Boston, Massachusetts</p> <p>Distinguished Faculty George Bush, MD, MMSc Director, Cingulate Cortex Research Laboratory Assistant Director, Psychiatric Neuroimaging Research Department of Psychiatry Massachusetts General Hospital Boston, Massachusetts</p> <p>Ronna Fried, EdD Neuropsychologist Director, Paradigm Development Department of Psychiatry Massachusetts General Hospital Clinical Instructor, Psychology Harvard Medical School Boston, Massachusetts</p> <p>Steven A. Safren, PhD Director, Behavioral Medicine Associate Director, Cognitive-Behavioral Therapy Program Department of Psychiatry Massachusetts General Hospital Associate Professor, Psychology (Psychiatry) Harvard Medical School Boston, Massachusetts</p> <p>Timothy E. Wilens, MD Director, Substance Abuse Services Pediatric Psychopharmacology Unit Massachusetts General Hospital Associate Professor, Psychiatry Harvard Medical School Boston, Massachusetts</p>
---	--	--

Sponsored by the American Psychiatric Association. Supported by an educational grant from McNeil Pediatrics, a Division of McNeil-PPC, Inc.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

Registered conference participants and registered guests may attend an industry-supported symposium at the APA meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 11
 Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
 Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Breakfast	7:30 AM - 8:00 AM	
Scientific Session	8:00 AM - 11:00 AM	
Welcome and Preactivity Educational Outcomes Measurement	8:00 AM - 8:10 AM	Thomas J. Spencer, MD
Overview of ADHD	8:10 AM - 8:35 AM	Thomas J. Spencer, MD
Neurocircuitry in ADHD	8:35 AM - 9:00 AM	George Bush, MD, MMSc
Neuropsychology in ADHD	9:00 AM - 9:25 AM	Ronna Fried, PhD
Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults	9:25 AM - 9:50 AM	Steven A. Safren, PhD
Pharmacologic Treatment of ADHD: Focus on Attention	9:50 AM - 10:10 AM	Timothy E. Wilens, MD
Postactivity Measurement	10:10 AM - 10:15 AM	Thomas J. Spencer, MD
Discussion Q&A	10:15 AM - 11:00 AM	Thomas J. Spencer, MD and Faculty

Learning Objectives:	At the conclusion of this symposium, the participant should be able to:
1. Describe the neurobiology and clinical presentation of ADHD.	
2. Discuss the regions of the brain and neurotransmitters involved in ADHD.	
3. Evaluate the various pharmacological treatment options and their effects on the improvement of attention.	
4. Recognize the neuropsychological underpinnings of ADHD.	
5. Explain ADHD's impact on cognition and executive functioning.	

Program Chair: Thomas J. Spencer, MD Associate Chief Clinical and Research Program in Pediatric Psychopharmacology Massachusetts General Hospital Associate Professor, Psychiatry Harvard Medical School Boston, Massachusetts	Steven A. Safren, PhD Director, Behavioral Medicine Associate Director, Cognitive-Behavioral Therapy Program Department of Psychiatry Massachusetts General Hospital Associate Professor, Psychology (Psychiatry) Harvard Medical School Boston, Massachusetts
Distinguished Faculty: George Bush, MD, MMSc Director, Cingulate Cortex Research Laboratory Assistant Director, Psychiatric Neuroimaging Research Department of Psychiatry Massachusetts General Hospital Boston, Massachusetts	Timothy E. Wilens, MD Director, Substance Abuse Services Pediatric Psychopharmacology Unit Massachusetts General Hospital Associate Professor, Psychiatry Harvard Medical School Boston, Massachusetts
Ronna Fried, PhD Neuropsychologist Director, Paradigm Development Department of Psychiatry Massachusetts General Hospital Clinical Instructor, Psychology Harvard Medical School Boston, Massachusetts	

Sponsored by the American Psychiatric Association. Supported by an educational grant from McNeil Pediatrics, a Division of McNeil-PPC, Inc. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA/PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300. Registered conference participants and registered guests may attend an industry-supported symposium at the APA meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 12
 Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
 Manchester Ballroom, Second Level, Manchester Grand Hyatt

Dark Horizons: Depression and Cognitive Impairment

Sunday, May 20, 2007

7:30 - 8:00 AM Scientific Program: 8:00 - 11:00 AM

held at the APA 2007 Annual Meeting

Manchester Grand Hyatt

Manchester Ballroom, Second Level

San Diego, California

Agenda

- 7:30 AM **Breakfast**
- 8:00 **Welcome and Introduction**
Steven P. Roose, MD – Chairman
Columbia University, College of Physicians and Surgeons
New York State Psychiatric Institute
- 8:10 **The Epidemiology and Genetic Studies of Depression and Memory***
Richard Mayeux, MD, MSc
Columbia University, College of Physicians and Surgeons
New York State Psychiatric Institute
- 8:40 **The Biology of Depression and Dementia***
Gary W. Small, MD
David Geffen School of Medicine at UCLA
- 9:10 **Vascular Depression and Vascular Dementia***
K. Ranga R. Krishnan, MB, ChB
Duke University Medical Center
- 9:40 **The Course of Treatment for Patients With Questionable Dementia***
D.P. Devanand, MD
Columbia University, College of Physicians and Surgeons
New York State Psychiatric Institute
- 10:10 **The Course of Treatment for Patients With Depression and Mild Cognitive Impairment***
Roy Hamilton, MD, MS
University of Pennsylvania
- 10:40 **Panel Discussion and Q & A Session**
- 11:00 **Conclusion**

*Each presentation will include 5 minutes for audience questions.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (703) 907-7300.

Educational Objectives:

- Evaluate the data that older adults with depressive symptoms are at a higher risk for the development of dementia.
- Identify the neurochemical and neurobiologic changes that occur in patients with recurrent depression and how these changes may influence the development of dementia.
- Review the concept of vascular depression and poststroke depression and discuss whether patients with these disorders progress to vascular dementia.
- Understand the phenomenology and course of treatment for patients with mild cognitive impairment with no depressive symptoms to determine the phenomenologic fate of this group.
- Identify treatment options available to patients with combined mood and memory disorders, particularly to review whether effective treatments can forestall the devastating impact of these illnesses in a late-life population.

Sponsored by the American Psychiatric Association

Supported by an educational grant from Forest Pharmaceuticals, Inc.



Forest Pharmaceuticals, Inc.
Pharmaceuticals • Therapeutics • Biotech • Clinical • Strategic • Quality • Safety • Team

INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

Planning for Success in **Schizophrenia Management**

A Symposium held at the APA 160th Annual Meeting

Sunday
May 20, 2007

1:30pm-4:30pm

San Diego Marriott
 Hotel and Marina

Marriott Halls 1-4
 North Tower
 (lower level)

Complimentary lunch
 from 1:00pm-1:30pm

- **Introduction** (1:30pm - 1:35pm)
Dilip V. Jeste, MD (Chair) *Estelle and Edgar Levi Chair in Aging; Director, Sam and Rose Stein Institute for Research on Aging; Distinguished Professor of Psychiatry & Neurosciences, University of California, San Diego, California*
- **Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients** (1:35pm-2:10pm)
Peter J. Weiden, MD *Professor of Psychiatry, SUNY Downstate Medical Center, Brooklyn, New York*
- **Strategies for Assessing and Managing Adherence** (2:10pm-2:45pm)
Dilip V. Jeste, MD *Estelle and Edgar Levi Chair in Aging; Director, Sam and Rose Stein Institute for Research on Aging; Distinguished Professor of Psychiatry & Neurosciences, University of California, San Diego, California*
- **Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, Psychosocial Strategies** (2:45pm-3:20pm)
Dawn I. Velligan, PhD *Professor and Co-Director, Division of Schizophrenia and Related Disorders, University of Texas Health Science Center, San Antonio, Texas*
- **Case Presentations of Adherence Dilemmas** (3:20pm-3:55pm)
David P. Folsom, MD *Assistant Clinical Professor of Family and Preventive Medicine, University of California, San Diego, California*
- **General Discussion** (3:55pm-4:30pm)
 Panel

At the end of this session, participants will be able to

- Improve their ability to assess a patient's likelihood of treatment adherence
- Apply major models of adherence to strategies for remaining on antipsychotic medications for schizophrenia
- Incorporate adherence prevalence and risk factor data from studies of patients at various stages of disease, including first-episode and refractory, to the development of practical management strategies for improving treatment adherence among people with schizophrenia in a variety of treatment settings
- Develop individualized management plans, including psychosocial interventions, augmentation strategies, depot or long-acting injectable formulations, and side-effect management strategies, to improve patient outcomes


Attendees must be registered for the APA Annual Meeting to attend this Symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This symposium is supported by an educational grant from Ortho-McNeill Janssen Scientific Affairs, LLC, and is sponsored by the American Psychiatric Association.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity of a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
Marina Ballroom, South Tower, Level Three, Marriott



APA 2007 Annual Meeting sponsored by the American Psychiatry Association

Making Every Sheep Count:

Evidence-Based Approaches to Treating Insomnia

Sunday, May 20, 2007

1:00 – 1:30 PM Lunch
 1:30 – 4:30 PM Symposium
 Marriott San Diego Hotel & Marina
 Marina Ballroom, South Tower, Level 3
 333 West Harbor Drive
 San Diego, California

Educational Objectives

- At the end of this educational activity participants should be able to
1. Summarize the neural circuitry and physiological regulation of sleep, wakefulness, and circadian rhythms in humans. Relate the neurobiology of sleep to insomnia and its daytime consequences
 2. Describe the emerging evidence regarding interactions between sleep, circadian rhythms, and psychiatric disorders
 3. Explain the biological basis for nonpharmacologic treatments of insomnia and nightmare disorders, and apply the basic elements of these treatments in clinical practice
 4. Discuss new developments and new treatment targets for pharmacologic management of insomnia

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity of a maximum of 3 AMA PRA category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.


Registered conference participants and registered guests may attend an industry supported symposium at the APA meeting.

Sponsored by the American Psychiatric Association
 Supported by an educational grant from Takeda Pharmaceuticals North America.

Agenda

- 1:30-1:40 PM **Opening Remarks**
Daniel J. Buysse, MD-Chairman
University of Pittsburgh School of Medicine
- 1:40-2:10 PM **The Clinical Neuroscience of Sleep and Insomnia**
Daniel J. Buysse, MD
- 2:10-2:40 PM **Comorbidity Between Insomnia and Psychiatric Illness**
Meera Narasimhan, MD
University of South Carolina School of Medicine
- 2:40-3:10 PM **Novel Pharmacological Targets for the Management of Insomnia**
Ruth M. Benca, MD, PhD
University of Wisconsin-Madison
- 3:10-3:40 PM **Innovative Behavioral Approaches for Treating Insomnia and Comorbid Psychiatric Illness**
Karl Daghraji, MD
Thomas Jefferson University
- 3:40-4:25 PM **Panel Discussion**
 Faculty Panel

INDUSTRY-SUPPORTED SYMPOSIUM 16
 Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
 Elizabeth Ballroom A/B/C/D/E, Second Level,
 Manchester Grand Hyatt



RETHINKING BIPOLAR DISORDER: IMPLICATIONS OF COMORBIDITIES

SUNDAY, MAY 20, 2007 • Lunch: 1:00-1:30 PM • Symposium: 1:30-4:30 PM

Elizabeth Ballroom A-E, Second Level • Manchester Grand Hyatt San Diego • **SAN DIEGO, CALIFORNIA**

This program will be conducted on May 20, 2007, during the APA 2007 Annual Meeting

AGENDA:

1:00-1:30 PM	Lunch	3:10-3:40 PM	Posttraumatic Stress Disorder and Bipolar Disorder: Critical Overlaps and Possible Links in Pathology and Treatment LORI L. DAVIS, MD VA Medical Center
1:30-1:40 PM	Welcome and Introductions GARY S. SACHS, MD (CHAIRPERSON) Massachusetts General Hospital	3:40-4:10 PM	Neuroimaging of Dual Diagnoses STEPHEN M. STRAKOWSKI, MD University of Cincinnati College of Medicine
1:40-2:10 PM	Medical Comorbidities With Bipolar Disorder GARY S. SACHS, MD	4:10-4:30 PM	Question and Answer Session ALL FACULTY
2:10-2:40 PM	Comorbid Substance Abuse in Bipolar Disorder MICHAEL J. OSTACHER, MD, MPH Massachusetts General Hospital	4:30 PM	Adjourn
2:40-3:10 PM	Suicidality as a Component of Bipolar Disorder LAUREN B. MARANGELL, MD Baylor College of Medicine		

Each presentation will conclude with a 5-minute panel discussion.

LEARNING OBJECTIVES:

- After attending this symposium, participants should be able to:
- Understand the general medical comorbidities associated with bipolar disorder, in particular the association of inflammatory markers in bipolar disorder
 - Understand the significance of high rates of comorbidity between bipolar disorder and alcohol and substance abuse and emerging data on treatment strategies
 - Be aware of the assessment techniques for evaluation of suicide in bipolar disorder and evidence-based treatment options
 - Recognize the many potential relationships between trauma and bipolar disorder and the prognostic significance of posttraumatic stress disorder in bipolar patients
 - Examine the findings in brain regions of interest related to bipolar disorder and common comorbidities

CME STATEMENT

This symposium will be conducted on May 20, 2007, during the APA 2007 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Attendees must be registered for the APA 2007 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

If any participant in this educational activity is in need of accommodations, please call 800-435-1050 by May 1, 2007, in order to receive services.



INDUSTRY-SUPPORTED SYMPOSIUM 17
 Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
 Manchester Ballroom, Second Level, Manchester Grand Hyatt



CARING for OUR MOST CHALLENGING PATIENTS with DEPRESSION: An Interactive Forum on Novel Treatments

PRESENTED AT THE APA 2007 ANNUAL MEETING IN SAN DIEGO, CA

Sunday, May 20, 2007 • 1:30 p.m. - 4:30 p.m.

Manchester Grand Hyatt, Manchester Ballroom, Second Level

PROGRAM AGENDA

1:00 p.m.	Lunch
1:30 p.m.	Introduction Charles B. Nemeroff, MD, PhD (Chair) Emory University School of Medicine
1:45 p.m.	Mechanism of Action of Vagus Nerve Stimulation (VNS) Charles B. Nemeroff, MD, PhD Emory University School of Medicine
2:15 p.m.	Assessing the Efficacy of VNS in Patients with TRD Paul Holtzheimer, MD Emory University School of Medicine
2:45 p.m.	Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) and Magnetic Seizure Therapy (MST) Thomas E. Schlaepfer, MD University of Bern Johns Hopkins Medical School
3:15 p.m.	Mechanism of Action and Efficacy of Deep Brain Stimulation Helen Mayberg, MD Emory University School of Medicine
3:45 p.m.	Panel Discussion/Q&A
4:30 p.m.	Conclusion

LEARNING OBJECTIVES:

At the conclusion of this symposium, the participant should be able to:

1. Identify criteria used to recognize depressed patients who are treatment-resistant.
2. Compare and contrast somatic interventions for treatment-resistant depression (TRD).
3. Recognize the neurobiological substrates of investigational treatments for refractory depression.

REGISTRATION


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



INDUSTRY-SUPPORTED SYMPOSIUM 18
 Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
 Marriott Halls 1-4, North Tower, Lower Level, Marriott

Presented in conjunction with the 2007 Annual Meeting

How Comorbid is ADHD?

Results from Epidemiological and Clinical Studies

Sunday, May 20, 2007

**APA 160th Annual Meeting
 SATELLITE SYMPOSIUM**

MARRIOTT HOTEL AND MARINA
 North Tower, Lower Level, Marriott Halls 1-4, San Diego, California
 Dinner: 6:30 pm-7:00 pm Symposium: 7:00 pm-10:00 pm

CHAIRPERSON

Joseph Biederman, MD
 Massachusetts General Hospital

FACULTY

Ronald C. Kessler, PhD
 Harvard Medical School

Thomas J. Spencer, MD
 Massachusetts General Hospital

Michael Manicavasagar, PhD
 Massachusetts General Hospital

Constance M. Moore, PhD
 Harvard Medical School


7:00 PM - 7:10 PM	Welcome and Introductions
7:10 PM - 7:35 PM	Patterns of Comorbidity in Longitudinal Samples of Boys and Girls with ADHD
7:35 PM - 8:00 PM	Patterns of Comorbidity in a Clinical Sample of Adults with ADHD
8:00 PM - 8:25 PM	Patterns of Comorbidity in a Community Sample of Adults with ADHD: Results from the National Comorbidity Survey
8:25 PM - 8:50 PM	Morphometric Findings in Adults with ADHD with and without Comorbid BPD
8:50 PM - 9:15 PM	Spectroscopic Findings in Children with ADHD and Comorbid BPD
9:15 PM - 10:00 PM	Question and Answer Session

LEARNING OBJECTIVES

At the conclusion of this symposium, the participant should be able to:

- Recognize the patterns of comorbidity associated in longitudinal, clinical, and community samples of both youth and adults with ADHD
- Describe differences in brain structure and brain chemistry associated with comorbidity in those with ADHD

 **Sponsored by the American Psychiatric Association**

 **Shire** Supported by an educational grant from Shire Pharmaceuticals Inc.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity of a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 19
 Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
 Marina Ballroom, South Tower, Level Three, Marriott

2007 APA Annual Meeting

THE ALCOHOL-DEPENDENT PATIENT

IMPROVING OUTCOMES THROUGH ADHERENCE

SUNDAY, MAY 20, 2007 | 6:30 PM - 10:00 PM

Marina Ballroom | San Diego Marriott Hotel and Marina | San Diego, California

Activity Chairperson | **ROBERT SWIFT, MD, PhD**

AGENDA

6:30 PM - 7:00 PM	Dinner
7:00 PM - 7:05 PM	Opening Remarks Robert Swift, MD, PhD
7:05 PM - 7:35 PM	Patient Adherence in the Treatment of Alcohol Dependence: The Journey of Recovery Roger D. Weiss, MD
7:35 PM - 8:05 PM	Pharmacotherapeutic Options for the Management of Alcohol Dependence: Importance of Adherence Robert Swift, MD, PhD
8:05 PM - 8:35 PM	Patient Readiness: Implications for Adherence and Management of Alcohol Dependence Carlo C. DiClemente, PhD
8:35 PM - 9:05 PM	Implementing Adherence-Enhancing Strategies in Clinical Practice: Negotiating Within the Therapeutic Alliance Albert J. Arias, MD
9:05 PM - 9:50 PM	Panel Discussion Moderator: Robert Swift, MD, PhD
9:50 PM - 10:00 PM	Closing Remarks Robert Swift, MD, PhD

PROGRAM OVERVIEW

Alcohol dependence is a chronic disorder associated with significant morbidity and mortality. Although available pharmacologic agents and psychosocial treatments have demonstrated improved outcomes in alcohol-dependent patients, the effectiveness of evidence-based therapies is often limited by patient nonadherence. Alcohol-dependent patients are more likely to have positive therapeutic outcomes when they exhibit readiness and motivation to initiate behavioral change. Psychosocial components, such as fostering motivation for abstinence, developing positive therapeutic relationships, learning coping skills, improving interpersonal functioning, and enhancing social supports, can be used in combination with pharmacotherapy. Strategies for increasing patient adherence to treatment include patient-matching components of psychosocial interventions in combination with pharmacotherapy. There are various oral pharmacologic agents available to treat alcohol dependence, such as disulfiram, oral naltrexone, and acamprosate, which require daily administration. Furthermore, there is a monthly, long-acting agent available that may benefit patient adherence. This symposium will address the factors that hinder treatment adherence in patients with alcohol dependence, describe the stages of behavioral change, and discuss the role of psychosocial and pharmacologic therapies in achieving desired outcomes.

LEARNING OBJECTIVES

After attending this symposium, participants should be better able to:

- Discuss the impact of treatment nonadherence on outcomes in patients with alcohol dependence
- Review factors that facilitate or hinder treatment adherence and assess patient readiness for changing behavior related to alcohol consumption
- Describe pharmacologic and psychosocial interventions that may promote adherence to treatment and improve patient outcomes
- Describe evidence-based treatment-matching strategies for alcohol dependence and approaches to overcoming barriers to treatment adherence


Accreditation Statement



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by 

Supported by an educational grant from  **Allergan** and  **Cephalon**

INDUSTRY-SUPPORTED SYMPOSIUM 20
 Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
 Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

APA 2007 Annual Meeting Sponsored by the American Psychiatric Association

**WEIGHING THE RISKS AND BENEFITS
 OF ATYPICAL ANTIPSYCHOTICS:
 CAN WE HAVE OUR CAKE AND EAT IT TOO?**

SUNDAY, MAY 20, 2007

Dinner: 6:30-7:00 PM
 Symposium: 7:00-10:00 PM

Manchester Grand Hyatt San Diego
 Douglas Pavilion C/D
 One Market Place
 San Diego, California

Agenda

- 7:00 PM **Opening Remarks**
 Henry A. Nasrallah, MD • Chairman • University of Cincinnati College of Medicine
- 7:05 **High Morbidity and Mortality in Schizophrenia and Bipolar Disorder: What, Why, and How?**
 Quinton E. Moos, MD • University of Cincinnati College of Medicine
- 7:35 **Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons from the CATIE Schizophrenia Trial***
 Donald C. Goff, MD • Harvard Medical School
- 8:05 **The Dual Health Jeopardy in Schizophrenia: Highly Prevalent Metabolic Disorders and Low Access to Medical Treatment***
 Henry A. Nasrallah, MD
- 8:35 **Lessons From ATP III, the ADA, and the APA Workgroup on Antipsychotics and Metabolic Risk***
 John W. Newcomer, MD • Washington University School of Medicine
- 9:05 **Patient, Provider, and System Approaches to Reducing Risk of Poor Health in Patients Receiving Antipsychotics***
 Lisa B. Dixon, MD, MPH • University of Maryland School of Medicine
 VA Capital Health Care Network MIRECC
- 9:35 **Question and Answer**
- 10:00 **Closing Remarks**

*Each presentation will include 5 minutes for audience questions.

Educational Objectives

- At the end of this educational activity participants should be able to:
1. Review the epidemiological studies demonstrating high rates of morbidity and mortality in schizophrenia and bipolar disorder patients.
 2. Discuss the high prevalence of the metabolic syndrome in the Clinical Antipsychotic Trials of Intervention-Effectiveness (CATIE) sample and the low rates of treatment for it.
 3. Compare and contrast the metabolic profiles of antipsychotics in the CATIE study.
 4. Identify potential patient, provider and system level interventions to improve metabolic outcomes among patients treated with antipsychotic medications.

Accreditation/Support

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity of a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Registered conference participants and registered guests may attend an industry supported symposium at the APA meeting.

Co-supported by an educational grant from



INDUSTRY-SUPPORTED SYMPOSIUM 21
 Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
 Manchester Ballroom, Second Level, Manchester Grand Hyatt



STAR*D Findings

*Implications for Patients,
 Clinicians, and Other Stakeholders*

Sunday, May 20, 2007
 7:00-10:00 pm

Manchester Grand Hyatt
 Manchester Ballroom, Second Level

PROGRAM AGENDA

- 6:30-7:00 pm **Dinner**
- 7:00-7:15 pm **Introduction**
 Grayson S. Norquist, MD, MSPH (Chair)
 University of Mississippi Medical Center
- 7:15-7:35 pm **Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes**
 Junius J. Gonzales, MD, MBA
 Abt Associates, Inc.
 The George Washington University
- 7:35-7:45 pm **Interactive Panel Discussion**
- 7:45-8:05 pm **Selecting Among First- and Second-Step Acute Treatments: Level 1 and Level 2**
 Marlene Freeman, MD
 University of Arizona Health Sciences Center
- 8:05-8:15 pm **Interactive Panel Discussion**
- 8:15-8:35 pm **Treatments After the First Two Steps, Including Follow-Up: Level 3 and Level 4**
 A. John Rush, MD
 University of Texas Southwestern Medical Center
- 8:35-8:45 pm **Interactive Panel Discussion**
- 8:45-9:05 pm **The Role of Other Treatment Options in the Management of Depression**
 K. Ranga Krishnan, MB, ChB
 Duke University Medical Center
- 9:05-9:15 pm **Interactive Panel Discussion**
- 9:15-10:00 pm **Panel Discussion/Q&A**

LEARNING OBJECTIVES

- At the conclusion of this symposium, the participant should be able to:
1. Apply data from large-scale research studies to clinical practice.
 2. Translate switching, augmentation, and combination data from STAR*D and apply to clinical practice.
 3. Identify augmentation strategies in MDD that may improve patient outcomes.
 4. Evaluate emerging therapies that may help patients achieve remission and improve long-term outcomes.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Supported by an educational grant from **Forest Pharmaceuticals, Inc.**

Presented
 at the
 APA 2007
 Annual
 Meeting in
 San Diego,
 California



Sponsored
 by the
 American
 Psychiatric
 Association

INDUSTRY-SUPPORTED SYMPOSIUM 22
Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS

The Management of Allostatic Load, Metabolic Syndrome, and Co-occurring Disorders

APA 160th Annual Meeting
 Satellite Symposium
Monday, May 21, 2007 (Part I)
Tuesday, May 22, 2007 (Part II)

Breakfast: 6:30 a.m.
 Symposium: 7:00 a.m.-8:30 a.m.

Marriott Hotel & Marina
 Marriott Hall 1-4
 San Diego, California

Part I MONDAY, MAY 21

6:30 AM *Breakfast*
 7:00 AM *Introductory Remarks/Welcomes*
Mark H. Rapaport, MD
 Cedars-Sinai Medical Center
 7:05 AM *The Heart of the Matter: Allostatic Load and Psychiatric Illness*
R. Bruce Lydiard, PhD, MD
 Medical University of South Carolina
 7:25 AM *Co-occurring Disorders: The Complex Interplay Between Psychiatric Syndromes, Substance Use, and Health*
Kathleen T. Brady, PhD, MD
 Medical University of South Carolina
 7:45 AM *Psychotropic Medications, Psychiatric Illness, and Weight Gain*
Rohan Ganguli, MD
 University of Pittsburgh School of Medicine
 8:05 AM *Q&A*
 8:25 AM *Concluding Remarks*

Part II TUESDAY, MAY 22

6:30 AM *Breakfast*
 7:00 AM *Welcome/Recap of Part I*
Mark H. Rapaport, MD
 Cedars-Sinai Medical Center
 7:10 AM *Issues in the Assessment and Management of Overweight and Obesity in Psychiatric Patients*
Alicia Ruelaz, MD
 Cedars-Sinai Center for Weight Loss
 7:35 AM *Integrating Alternative Health Approaches Into the Care of Our Patients: Evidence About the Actions of Exercise, Massage, and Acupuncture*
Mark H. Rapaport, MD
 8:00 AM *Q&A*
 8:25 AM *Concluding Remarks*

Educational Objectives

- After taking part in this educational activity, participants should be able to:
- 1) Describe the postulated bidirectional relationships between allostatic load and psychiatric illness
 - 2) Recognize the complex interaction that occurs between psychotropic medications, weight regulation, and the challenges of metabolic syndrome
 - 3) Discuss the health and mental health implications of the presence of comorbid substance use disorders including tobacco, psychiatric syndromes, and physical health (including HIV risk)
 - 4) Identify treatment interventions possible to help mitigate the effects of allostatic load, medication-induced health complications, and co-occurring disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity of a maximum of 3 AMA PRA Category 1 CreditsSM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association

Supported by an educational grant from Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals.

Solvay Pharmaceuticals



Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 23
Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

PROGRAM OVERVIEW

An increasing appreciation of the pathophysiological mechanisms underlying psychotic disorders has fueled the development of agents with identifiable pharmacologic properties. Current research studies are now incorporating neuroimaging as a critical tool to guide drug development by further elucidating neuronal pathways associated with psychotic disorders and identifying the physiologic effects of pharmacologic therapies. When choosing an atypical antipsychotic for the management of a particular disorder, it is important to consider the different pharmacologic profiles of these agents in order to personalize pharmacotherapy based on patient preferences, prior response to treatment, and overall health vulnerabilities. The distinct receptor-binding profiles and pharmacodynamic properties of the atypical antipsychotics result in unique propensities for causing clinically meaningful effects such as weight gain, diabetes, and other metabolic abnormalities; hyperprolactinemia; and sedation. These adverse effects may lead to nonadherence to antipsychotic therapy. This symposium will review the implications of choice of antipsychotic therapy on functional outcomes and overall patient health in individuals with psychotic disorders.

LEARNING OBJECTIVES

- After attending this symposium, participants should be better able to:
- Review the neurobiologic basis of various psychotic disorders
 - Recognize how neuroimaging may be able to further elucidate the etiology of psychotic disorders and guide drug choice and development
 - Discuss the differential pharmacology of atypical antipsychotics and the clinical implications in patients with psychotic disorders

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 CreditsSM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

2007 APA ANNUAL MEETING HOW DO ATYPICAL ANTIPSYCHOTICS FROM RECEPTORS TO REALITY WORK?

MONDAY, MAY 21, 2007 6:30 AM – 8:30 AM

TUESDAY, MAY 22, 2007 6:30 AM – 8:30 AM

DOUGLAS PAVILION C/D
 MANCHESTER GRAND HYATT
 SAN DIEGO, CALIFORNIA

ACTIVITY CHAIRPERSON: ROBERT E. HALES, MD, MBA
 CO-CHAIRPERSON: STUART C. YUDOFSKY, MD

AGENDA

MONDAY, MAY 21, 2007 – PART A

6:30 AM – 7:00 AM *Breakfast*
 7:00 AM – 7:05 AM *Opening Remarks*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
 7:05 AM – 7:30 AM *Mechanisms of Antipsychotic Efficacy: Linking Pharmacology to Phenomenology*
 Shitij Kapur, MD, PhD, FRCP
 7:30 AM – 7:55 AM *Neurobiology of Schizophrenia: From Basic Science to Clinical Practice*
 Gordon Frankle, MD
 7:55 AM – 8:25 AM *Panel Discussion*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
 8:25 AM – 8:30 AM *Closing Remarks*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD

TUESDAY, MAY 22, 2007 – PART B


6:30 AM – 7:00 AM *Breakfast*
 7:00 AM – 7:05 AM *Opening Remarks*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
 7:05 AM – 7:30 AM *Managing Patients With Psychotic Disorders: From Efficacy to Effectiveness*
 John Lauriello, MD
 7:30 AM – 7:55 AM *Pharmacologic Predictability of Adverse Effects: An Opportunity for Improving Outcomes*
 Prakash S. Masand, MD
 7:55 AM – 8:25 AM *Panel Discussion*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD
 8:25 AM – 8:30 AM *Closing Remarks*
 Robert E. Hales, MD, MBA
 Stuart C. Yudofsky, MD

Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.


Sponsored by

Supported by an educational grant from Bristol-Myers Squibb, Company and

ORION PHARMACEUTICALS, INC.



INDUSTRY-SUPPORTED SYMPOSIUM 24
 Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
 Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt



TREATING THE SPECTRUM OF BIPOLAR DISORDERS:

AN INTERACTIVE CASE DISCUSSION

MONDAY, MAY 21 AND TUESDAY, MAY 22, 2007 • Breakfast: 6:30-7:00 AM • Symposium: 7:00-8:30 AM

Elizabeth Ballroom A-E, Second Level • Manchester Grand Hyatt San Diego • **SAN DIEGO, CALIFORNIA**

This program will be conducted on May 21 and 22, 2007, during the APA 2007 Annual Meeting

AGENDA:

MONDAY, MAY 21, 2007

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
MICHAEL E. THASE, MD (CHAIRPERSON)
University of Pittsburgh
- 7:05-7:20 AM Psychotherapy and Bipolar Depression
HOLLY A. SWARTZ, MD
University of Pittsburgh
- 7:20-7:35 AM Case Scenario Discussion with Audience Interaction
ALL FACULTY
- 7:35-7:50 AM Antidepressants in Bipolar Depression: A Two-Sided Story
MICHAEL E. THASE, MD
- 7:50-8:05 AM Case Scenario Discussion with Audience Interaction
ALL FACULTY
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn

TUESDAY, MAY 22, 2007

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome and Introductions
MICHAEL E. THASE, MD (CHAIRPERSON)
- 7:05-7:20 AM Beyond Antidepressants: Treatment Options for Bipolar Depression
ROGER S. MCINTYRE, MD
University of Toronto
- 7:20-7:35 AM Case Scenario Discussion with Audience Interaction
ALL FACULTY
- 7:35-7:50 AM Treating and Preventing Mania
LAUREN B. MARANGELL, MD
Baylor College of Medicine
- 7:50-8:05 AM Case Scenario Discussion with Audience Interaction
ALL FACULTY
- 8:05-8:30 AM Question and Answer Session
ALL FACULTY
- 8:30 AM Adjourn



Sponsored by the American Psychiatric Association



Supported by an educational grant from AstraZeneca

LEARNING OBJECTIVES:

- After attending this symposium, participants should be able to:
- Examine the role of psychotherapy in the management of patients with bipolar disorder with an emphasis on empirical data demonstrating its efficacy as adjunctive treatment for bipolar depression
 - Review the implications of antidepressants in bipolar depression and the importance of differential diagnosis in patients with bipolar disorder with regard to treatment
 - Identify and evaluate current and future treatment options and the optimal approach in the pharmacotherapy of patients with bipolar depression
 - Formulate management strategies for the treatment of mania and discuss successful methods of intervention aimed at preventing mania

CME STATEMENT

This symposium will be conducted on May 21 and May 22, 2007, during the APA 2007 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Attendees must be registered for the APA 2007 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7974 (within the US or Canada) or 793-907-7900.

If any participant in this educational activity is in need of accommodations, please call 860-434-1650 by May 1, 2007, in order to receive service.

INDUSTRY-SUPPORTED SYMPOSIUM 25
 Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
 Marriott Halls 1-4, North Tower, Lower Level, Marriott

IMPROVING OUTCOMES IN SCHIZOPHRENIA

From Prodrome to Remission

2007 APA ANNUAL MEETING

MONDAY, MAY 21, 2007 | 6:30 PM – 10:00 PM

Marriott Halls 1-4

San Diego Marriott Hotel and Marina | San Diego, California

ACTIVITY CHAIRPERSON | **Christoph U. Correll, MD**


AGENDA

- | | |
|---|--|
| <ul style="list-style-type: none"> 6:30 PM – 7:00 PM Dinner 7:00 PM – 7:05 PM Opening Remarks
Christoph U. Correll, MD 7:05 PM – 7:45 PM Early Intervention in the Psychotic Prodrome: Has Its Time Come?
Christoph U. Correll, MD 7:45 PM – 8:25 PM The Course of Brain Abnormalities in Schizophrenia: Can We Slow Disease Progression?
René S. Kahn, MD, PhD | <ul style="list-style-type: none"> 8:25 PM – 9:05 PM Improving Rates of Response and Remission in Schizophrenia: How Do We Get Where We Need to Be?
John M. Kane, MD 9:05 PM – 9:55 PM Panel Discussion
Moderator:
Christoph U. Correll, MD 9:55 PM – 10:00 PM Closing Remarks
Christoph U. Correll, MD |
|---|--|

REGISTRATION STATEMENT • Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

ACCREDITATION STATEMENT • The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT • The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Sponsored by



Administered by



PROGRAM OVERVIEW

The onset of schizophrenia, whether insidious or acute, is marked with difficulties for patients, families, and clinicians. During the prodromal phase, the severity of symptoms may be masked, the medical nature of behavioral disturbance may be misunderstood, and symptoms are often kept hidden from family and friends by the afflicted person. Patients may remove themselves emotionally and geographically from social support networks, and initial diagnosis of psychosis is often confounded by substance abuse. The gradual development of psychosis, combined with misunderstanding of symptoms, creates a substantial window of time between symptom onset and initiation of diagnosis and treatment. Because treatment effectiveness is greatest when initiated early in a pathologic process, a longer duration of untreated psychosis may be associated with a poorer treatment response. Additionally, schizophrenia may arise from a neurodevelopmental diathesis, although structural changes in the brain over time suggest that the pathophysiology of schizophrenia may be progressive after the onset of illness. There has been much speculation recently regarding the role of medication in contributing to schizophrenia-associated pathomorphologic changes as well as mitigating such changes. Preclinical studies and emerging clinical data have suggested the possibility that specific atypical antipsychotic drugs have pharmacologic properties that could produce neurotrophic, neurogenetic, or neuroprotective effects, and possibly lead to improvement in the illness in the longer term. Remission and recovery have become increasingly prominent goals of therapy for people with schizophrenia, due in part to new understanding of the etiology and the course of the disease, new treatments, and increased interest in improving outcomes among patients, families, advocates, and health care professionals. This symposium will focus on schizophrenia treatment options from the prodromal phase to remission.


LEARNING OBJECTIVES

After attending this symposium, participants should be better able to:

- 1. Identify prodromal symptom criteria and intervene in patients who are considered at high risk for developing psychotic disorders
- 2. Describe brain abnormalities present in schizophrenia and recent attempts to modify the course of specific brain abnormalities with pharmacologic treatments
- 3. Summarize the current goals of long-term treatment in schizophrenia and efforts to better characterize remission



INDUSTRY-SUPPORTED SYMPOSIUM 26
Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt



APA 2007 ANNUAL MEETING SPONSORED BY
 THE AMERICAN PSYCHIATRY ASSOCIATION

**NAVIGATING THE
 COMPLEX MAZE
 OF BIPOLAR DISORDER**

Monday, May 21, 2007

6:30 – 7:00 PM Dinner *Manchester Grand Hyatt San Diego*
 7:00 – 10:00 PM Symposium *Douglas Pavilion C/D
 One Market Place
 San Diego, California*

AGENDA

- 7:00–7:10 PM
Opening Remarks
*Prakash Masand, MD—Chairman
 Duke University Medical Center*
- 7:10–7:40 PM
**Diagnostic Pitfalls in Patients
 with Bipolar Disorder**
Prakash Masand, MD
- 7:40–8:10 PM
**Managing the Bipolar Patient
 with Medical Comorbidities**
*Andrea Fagiolini, MD
 University of Pittsburgh School of Medicine*
- 8:10–8:40 PM
**Tailoring Antipsychotic Treatment
 to the Complex Patient with
 Bipolar Disorder**
*Paul E. Keck, Jr., MD
 University of Cincinnati College of Medicine*
- 8:40–9:10 PM
**Bringing Research to the Clinician:
 Lessons from STEP-BD**
*Gary Sachs, MD
 Massachusetts General Hospital*
- 9:10–9:55 PM
Panel Discussion
Faculty Panel

EDUCATIONAL OBJECTIVES

At the end of this educational activity participants should be able to

- 1) List major obstacles to the diagnosis of bipolar disorder and describe strategies for distinguishing bipolar disorder from depression and agitated depression.
- 2) Describe common psychiatric and medical comorbidities in bipolar patients, and their implications for treatment.
- 3) Outline major findings from STEP-BD and their implications for clinical practice

ACCREDITATION



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Registered conference participants and registered guests may attend an industry-supported symposium at the APA meeting.

Sponsored by the American Psychiatric Association.

Supported by an educational grant from Pfizer, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 27
Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt



**WHEN ENDOCRINOLOGY AND PSYCHIATRY
 COLLIDE: WHAT THE CLINICIAN NEEDS TO KNOW ABOUT
 ANTIPSYCHOTIC-INDUCED ENDOCRINE DISTURBANCES**

MONDAY, MAY 21, 2007 • Dinner: 6:30–7:00 PM • Symposium: 7:00–10:00 PM

Elizabeth Ballroom A–E, Second Level • Manchester Grand Hyatt San Diego • SAN DIEGO, CALIFORNIA

This program will be conducted on May 21, 2007, during the APA 2007 Annual Meeting

AGENDA:

- | | | | |
|--------------|---|---------------|--|
| 6:30–7:00 PM | Dinner | 8:00–8:25 PM | Antipsychotics, Diabetes, and the Metabolic Syndrome: What Is the Strength of These Relationships?
JOHN W. NEWCOMER, MD
Washington University School of Medicine |
| 7:00–7:10 PM | Welcome and Introductions
PETER F. BUCKLEY, MD
(CHAIRPERSON)
Medical College of Georgia | 8:25–8:50 PM | Prolactin Elevation and Antipsychotic Therapy: What to Tell Patients About Risks to Bones and Sexual Functioning
MEERA NARASIMHAN, MD
University of South Carolina School of Medicine |
| 7:10–7:35 PM | Increasing Global Burden of Cardiovascular Disease in General Populations and Patients with Schizophrenia
CHARLES H. HENNEKENS, MD, PHD, MPH, MS
Florida Atlantic University | 8:50–9:15 PM | Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus?
PETER F. BUCKLEY, MD |
| 7:35–8:00 PM | Diabetes and the Metabolic Syndrome: From Soup to Nuts
RAMACHANDIRAN COOPAN, MBChB, FRCP, FACE
Harvard Medical School | 9:15–10:00 PM | Panel Discussion
ALL FACULTY |
| | | 10:00 PM | Adjourn |

LEARNING OBJECTIVES:

- After attending this symposium, participants should be able to:
- Discuss the epidemiologic relationship between cardiovascular disease and schizophrenia, and the importance of the aggressive management of cardiovascular disease risk factors in this population group
 - Employ the current state of medical knowledge about diabetes mellitus and the metabolic syndrome
 - Complete risk analysis for diabetes and the metabolic syndrome during antipsychotic therapy
 - Describe the clinical impact of raised prolactin, both upon sexual functioning and also the longer term risk for osteoporosis during antipsychotic therapy
 - Develop management strategies as well as emergent new lifestyle behavioral approaches to minimize the risk of antipsychotic-induced endocrine adverse effects and to deal with these effectively when they emerge during treatment

CME STATEMENT



This symposium will be conducted on May 21, 2007, during the APA 2007 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Attendees must be registered for the APA 2007 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

If any participants in this educational activity is in need of accommodations, please call 800-434-1650 by May 1, 2007, in order to receive service.

Sponsored by the American Psychiatric Association

Supported by an educational grant from AstraZeneca



INDUSTRY-SUPPORTED SYMPOSIUM 28
 Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
 Manchester Ballroom, Second Level, Manchester Grand Hyatt

<p>IMPROVING DEPRESSION TREATMENTS: BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE</p> <p>Monday, May 21, 2007 6:30 pm – 7:00 pm Dinner 7:00 pm – 10:00 pm Scientific Session Manchester Grand Hyatt • Manchester Ballroom One Market Place • San Diego, California • USA</p>		<p>SCIENTIFIC PROGRAM AGENDA</p> <p>7:00 pm – 7:10 pm Welcome and Announcements <i>Jonathan Alpert, MD, PhD (Symposium Chair)</i> <i>Timothy Petersen, PhD (Co-Chair)</i></p> <p>7:10 pm – 7:35 pm Follow-up Care After Initiating Antidepressant Treatment: An Empirically Informed Approach <i>Mark Zimmerman, MD</i> <i>Brown Medical School</i></p> <p>7:35 pm – 8:00 pm Achieving and Maintaining Optimal Therapeutic Outcomes in Old-Age Depression <i>Chip Reynolds, MD</i> <i>University of Pittsburgh Medical Center</i></p> <p>8:00 pm – 8:25 pm Optimizing Care for Menopausal Symptoms: The Interface Between Psychiatry and Gynecology <i>Hadine Joffe, MD</i> <i>Massachusetts General Hospital</i></p> <p>8:25 pm – 8:50 pm Management of Depression in Patients with Chronic Medical Conditions <i>Gregory Simon, MD</i> <i>Group Health Cooperative Center for Health Studies</i></p> <p>8:50 pm – 9:15 pm The Sequenced Treatment Alternative to Relieve Depression (STAR*D) Study: Lessons Learned <i>Timothy Petersen, PhD</i> <i>Massachusetts General Hospital</i></p> <p>9:15 pm – 10:00 pm Panel Discussion/Question and Answer Session</p>
<p> Supported by an educational grant from Eli Lilly and Company.</p>	<p> Sponsored by the American Psychiatric Association</p>	
<p>OVERALL EDUCATIONAL OBJECTIVES:</p> <p>At the conclusion of this symposium, the participant should be able to:</p> <ul style="list-style-type: none"> recognize factors that limit the generalizability of traditional clinical trials. demonstrate knowledge of effective treatment approaches for depressed patient populations commonly found in community-based practices. 	<p>ACCREDITATION STATEMENT The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>CREDIT DESIGNATION The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>REGISTRATION Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.</p>	
<p align="center">Symposium to be held at the APA 2007 Annual Meeting</p>		

INDUSTRY-SUPPORTED SYMPOSIUM 29
 Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
 Ballroom 20, Upper Level, San Diego Convention Center

PRESENTED AT THE APA 2007 ANNUAL MEETING IN SAN DIEGO, CA

Cigarette Smoking, Smoking Cessation, and Psychiatric Illness
 Tuesday, May 22, 2007 ♦ 7:00–10:00 pm ♦ San Diego Convention Center, Ballroom 20, Upper Level

<p>PROGRAM AGENDA</p> <p>6:30–7:00 pm Dinner</p> <p>7:00–7:10 pm Introduction <i>Alexander H. Glassman, MD (Chair)</i> Columbia University College of Physicians and Surgeons New York State Psychiatric Institute</p> <p>7:10–7:35 pm Reward Systems Underlying Motivation and Addiction <i>Peter W. Kalivas, PhD</i> Medical University of South Carolina</p> <p>7:35–8:00 pm Animal Modeling and Integrative Neurocircuitry of Addiction Vulnerability in Mental Illness <i>R. Andrew Chambers, MD</i> Indiana University School of Medicine</p> <p>8:00–8:25 pm What Makes Smoking Cessation Unique in Patients with a History of Depression? <i>Alexander H. Glassman, MD</i> Columbia University College of Physicians and Surgeons New York State Psychiatric Institute</p> <p>8:25–8:50 pm Pharmacological Treatment of Nicotine Dependence in Schizophrenia: The Devil Is in the Details <i>Tony P. George, MD, FRCP</i> University of Toronto Centre for Addiction and Mental Health</p> <p>8:50–9:15 pm Pharmacotherapies for Smoking Cessation <i>Cheyl Oncken, MD, MPH</i> University of Connecticut Health Center</p> <p>9:15–10:00 pm Panel Discussion/Q&A</p>	<p>LEARNING OBJECTIVES</p> <p>At the conclusion of this symposium, the participant should be able to:</p> <ul style="list-style-type: none"> Recognize the unique risks of cigarette smoking for patients with psychiatric illness. Discuss common neurobiology underlying all addictions. Compare and contrast smoking addiction in patients with depression and schizophrenia. Outline tools and treatments for smoking cessation in patients with and without psychiatric illness. <p>CREDIT DESIGNATION The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>ACCREDITATION STATEMENT The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>REGISTRATION Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.</p>
<p>Supported by an educational grant from </p>	<p>Sponsored by the American Psychiatric Association </p>

INDUSTRY-SUPPORTED SYMPOSIUM 30
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

2007 APA Annual Meeting

AM I A PSYCHIATRIST... OR AN ENDOCRINOLOGIST?

**Coping With Metabolic Disturbances
During the Treatment of Schizophrenia**

Activity Chairperson | Peter F. Buckley, MD

TUESDAY, MAY 22, 2007 | 6:30 PM – 10:00 PM


Marina Ballroom | San Diego Marriott Hotel and Marina
SAN DIEGO, CALIFORNIA

AGENDA

6:30 PM – 7:00 PM	Dinner	8:20 PM – 8:45 PM	Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus Peter F. Buckley, MD
7:00 PM – 7:05 PM	Opening Remarks Peter F. Buckley, MD	8:45 PM – 9:10 PM	Consumer Perspective on Tolerability and Safety of Antipsychotic Medications Frederick J. Frese, PhD
7:05 PM – 7:30 PM	The Increasing Global Burden of Cardiovascular Disease in General Populations and in Patients With Schizophrenia Charles H. Hennekens, MD	9:10 PM – 9:55 PM	Panel Discussion Peter F. Buckley, MD
7:30 PM – 7:55 PM	Antipsychotics and Metabolic Risk: A Clinical Issue at the Forefront of Contemporary Psychiatry Dan Haupt, MD	9:55 PM – 10:00 PM	Closing Remarks Peter F. Buckley, MD
7:55 PM – 8:20 PM	Antipsychotic-Induced Hyperprolactinemia: A Neglected Issue in Psychiatry Robert Conley, MD		


ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Sponsored by 

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from  and Wyeth

PROGRAM OVERVIEW

Endocrinologic disturbances are common in patients taking antipsychotic medications. Amidst growing national concern about the raging epidemic of diabetes and the metabolic syndrome, clinicians have been presented with conflicting information on the relationship between endocrine disturbances and antipsychotic medications. Moreover, despite the absence of clear direction, clinicians are expected to undertake close monitoring for metabolic disturbances during antipsychotic therapy. Available therapeutic agents have unique properties and vary in potential risk of inducing diabetes mellitus and the metabolic syndrome. Approaches to patient risk assessment, symptom documentation, and formulation of treatment strategies designed to offer guidance to clinicians on effectively managing these adverse effects will be reviewed. In addition to the metabolic syndrome, other adverse endocrinologic events such as prolactin elevation have been associated with the use of antipsychotics. Elevated prolactin levels can affect human growth, sexual function, and bone formation. These effects are of particular concern when treating children and adolescents. Antipsychotic adverse event profiles vary and should be considered when individualizing therapy. A discussion on the incidence, consequences, and management of hyperprolactinemia will be presented.

The symposium will conclude with a synthesis of current management approaches, including emergent evidence on the impact of lifestyle modification for patients receiving antipsychotic therapy who develop metabolic complications. The important consideration of patient choice will be discussed and a consumer perspective on decision making and risk appraisal will be highlighted.

LEARNING OBJECTIVES

After attending this symposium, participants should be better able to:

- Discuss the differential risk and risk management of various antipsychotics with respect to metabolic abnormalities such as diabetes mellitus and the metabolic syndrome
- Describe the risk and clinical impact of elevated prolactin on growth, sexual functioning, and bone formation when selecting and monitoring effects of specific antipsychotic agents
- Identify management strategies, including emergent lifestyle-modification approaches, to minimize the risk of antipsychotic-induced endocrinologic disturbances and to deal with these effectively when they present during treatment
- Consider patient preferences and consumer perspectives when making treatment recommendations and monitoring patient progress

Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 31
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

2007 APA ANNUAL MEETING

MONOAMINE OXIDASE INHIBITORS TODAY

A 21st Century View on the Treatment of Depression

Tuesday, May 22 6:30 PM – 10:00 PM | Philip R. Muskin, MD Activity Chairperson

Douglas Pavilion C/D, Manchester Grand Hyatt, San Diego, California

AGENDA

TUESDAY, MAY 22, 2007

6:30 PM – 7:00 PM	DINNER
7:00 PM – 7:05 PM	OPENING REMARKS Philip R. Muskin, MD
7:05 PM – 7:35 PM	EVERYTHING YOU ALWAYS WANTED TO KNOW ABOUT EVIDENCE-BASED PSYCHIATRY (BUT WERE AFRAID TO ASK) Sharon A. Mozian, MD
7:35 PM – 8:05 PM	MAOIs REVISITED: FACTS AND MYTHS Philip R. Muskin, MD
8:05 PM – 8:35 PM	DIET AND MAOIS: WHERE WE WENT WRONG AND WHERE WE NEED TO GO Kenneth L. Shulman, MD
8:35 PM – 9:05 PM	TREATMENT OF DEPRESSION IN THE 21ST CENTURY: THE BEST OF APPLIED NEUROSCIENCE Charles B. Nemeroff, MD, PhD
9:05 PM – 9:55 PM	PANEL DISCUSSION Philip R. Muskin, MD
9:55 PM – 10:00 PM	CLOSING REMARKS Philip R. Muskin, MD

PROGRAM OVERVIEW

Many psychiatrists consider monoamine oxidase inhibitors (MAOIs) an effective class of antidepressants. Although MAOIs have established efficacy in the treatment of depression and atypical depression, they are infrequently prescribed because of safety concerns. One of the safety concerns with MAOIs is the potential for patients to develop hypertensive crisis, which may be precipitated by tyramine-containing foods. Initially, the misunderstanding of diets and inaccurate measures of tyramine concentrations in food required patients to adhere to a broad tyramine-restrictive diet. However, research shows that many foods originally banned from tyramine-restrictive diets actually have very little tyramine content. Information obtained from a critical review of the literature will guide clinicians in formulating treatment strategies that will enable patients to use MAOIs with realistic dietary restrictions. In addition, as a result of innovations in drug delivery systems, an MAOI can now be administered using a transdermal delivery system, providing effective treatment while increasing safety and tolerability. This symposium will review data regarding treatment of depression and atypical depression, discuss treatment with MAOIs, provide perspective on MAOI diets, and explore how the neuroscience of depression, including the delineation of neurochemical pathways, may lead to novel treatment approaches in the future.

LEARNING OBJECTIVES

At the conclusion of this symposium, participants should be better able to:

- Describe the biologic basis for novel therapies and delivery systems used in the management of depression
- Evaluate evidence-based MAOI dietary guideline recommendations
- Discuss how the therapeutic benefits of MAOIs are influenced by dosing and route of administration

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION STATEMENT



Attendees must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by 

Supported by an educational grant from  Bristol-Myers Squibb Company



INDUSTRY-SUPPORTED SYMPOSIUM 32
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level,
Manchester Grand Hyatt

<p>A Dinner Symposium Held During the APA 2007 Annual Meeting</p>		<p>Don't Miss This Important CME Activity!</p>	
<p>Understanding the Complexity of BIPOLAR Mixed Episodes</p>		<p>Tuesday, May 22, 2007 Manchester Grand Hyatt Second Level, Elizabeth Ballroom A-E San Diego, California</p>	
<p>Learning Objectives Upon completion of the activity, participants should be able to:</p> <ol style="list-style-type: none"> 1. Demonstrate knowledge of diagnostic and treatment issues concerning bipolar mixed states, and be able to meet the challenges posed by their recognition and management. 2. Discuss new treatment options available for patients with mixed episodes of bipolar disorder. 3. List essential principles in the clinical assessment of every patient with depression and anxiety, and the differential diagnosis of bipolar mixed episodes. 4. Distinguish common comorbidities in the patient with bipolar mixed episodes. 5. Describe the social and economic costs of bipolar mixed episodes. 6. Prescribe appropriate medication therapy for stabilization and maintenance of the patient with bipolar mixed episodes. 		<p>AGENDA</p> <p>6:30PM Dinner</p> <p>7:00PM Welcome and Introduction Susan L. McElroy, MD Program Chairperson</p> <p>7:15PM Diagnostic Dilemmas of Mixed States in Bipolar Disorder Mark A. Frye, MD</p> <p>7:45PM Comorbidity and Consequences of Bipolar Mixed Episodes Joseph F. Goldberg, MD</p> <p>8:15PM The Acute Treatment of the Patient With Bipolar Mixed Episodes Roger S. McIntyre, MD, FRCP</p> <p>8:45PM Improving Long-Term Outcomes in Patients With Bipolar Mixed Episodes Susan L. McElroy, MD Program Chairperson</p> <p>9:15PM Question and Answer Session</p> <p>10:00PM Adjournment</p>	
<p>Accreditation Statement The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>Credit Designation Statement The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.</p> <p>Faculty Disclosure Statement All faculty are required to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the educational activity. The faculty disclosure statements will be listed in the course syllabus and at the beginning of each slide presentation.</p> <p>Sponsored by the American Psychiatric Association  Supported by an educational grant from Eli Lilly and Company </p>		<p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.</p>	

INDUSTRY-SUPPORTED SYMPOSIUM 33
Wednesday, May 23, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

You Are Invited to Attend a Complimentary Dinner Symposium at the APA 2007 Annual Meeting

Fibromyalgia: New Insights into the Pathophysiology and Treatment

A complimentary dinner will be served as a part of this program.

Wednesday, May 23 6:30 PM
 Manchester Grand Hyatt, Elizabeth Ballroom A-E
 San Diego, CA

Earn Up to 3 AMA PRA Category 1 Credits

<p>Presented by</p> <p>Chairperson Lesley M. Arnold <i>University of Cincinnati</i></p> <p>Faculty Daniel J. Clauw <i>University of Michigan</i> Leslie J. Crofford <i>University of Kentucky</i> Dina Dadaboy <i>University of Michigan</i></p>	<p>Objectives</p> <p>Upon completion of this activity, participants should be able to:</p> <ol style="list-style-type: none"> 1. Recognize the psychiatrist's role in the treatment of patients with fibromyalgia 2. Describe the possible mechanisms involved in the pathophysiology of fibromyalgia 3. Explain the rationale for the selection of treatments for fibromyalgia 4. Discuss pharmacological and nonpharmacological treatment options for fibromyalgia 	<p>Agenda</p> <p>6:30 PM Dinner</p> <p>7:00 PM Welcome and Introduction</p> <p>7:15 PM The Pathophysiology of Pain in Fibromyalgia and Related Syndromes</p> <p>7:45 PM The Role of Disordered Sleep in Fibromyalgia</p> <p>8:15 PM New Developments in the Pharmacological Treatment of Fibromyalgia</p> <p>8:45 PM Exercise as a Treatment for Fibromyalgia</p> <p>9:15 PM Panel Discussion/Q&A</p>